{"qid": "Q1", "query": "5-year-old (18 kg) acute otitis media — calculate amoxicillin dose (mg/kg/day) and volume using 400 mg/5 mL suspension.", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 76.59840151789648, "bm25_max": 78.11511414908531, "bge_top3": 0.7795708974202474, "bge_max": 0.802157461643219, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 49.75949068470944, "bm25_max": 57.43946909678447, "bge_top3": 0.7565899888674418, "bge_max": 0.769795835018158, "title": "Amoxicillin: Drug information", "rep_snippet": "eradication: Children and Adolescents: Oral: 50 mg/kg/day in 2 divided doses for 10 to 14 days; maximum daily dose: 2,000 mg/day. Administer in combination with a proton pump inhibitor or bismuth subsalicylate and at lea…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 52.34409529812856, "bm25_max": 52.34409529812856, "bge_top3": 0.7112074494361877, "bge_max": 0.7112074494361877, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 49.687666382852335, "bm25_max": 51.94210394380498, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG <400 mg/dL), prevention of bacterial infection (off-label use): Note: Increase dose or frequency to maintain IgG concentration >400 mg/dL.  ≤100 da…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 48.88494215541853, "bm25_max": 48.88494215541853, "bge_top3": 0.729423999786377, "bge_max": 0.729423999786377, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Erythromycin and sulfisoxazole (United States: Not available): Pediatric drug information\")  Note: All erythromycin and sulfisoxazole products (brand and generic) have…"}, {"doc_id": "atovaquone-and-proguanil-drug-information", "bm25_top3": 48.22888439188711, "bm25_max": 48.22888439188711, "bge_top3": null, "bge_max": null, "title": "Atovaquone and proguanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atovaquone and proguanil: Pediatric drug information\")  Prevention of malaria: Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the st…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 47.44218949339031, "bm25_max": 47.44218949339031, "bge_top3": null, "bge_max": null, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": 46.942336364969, "bm25_max": 46.942336364969, "bge_top3": 0.7095152139663696, "bge_max": 0.7095152139663696, "title": "Cefuroxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefuroxime: Pediatric drug information\")  Note: Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg bas…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 41.03694780509629, "bm25_max": 44.74998112419146, "bge_top3": 0.7237414121627808, "bge_max": 0.7295401096343994, "title": "Ceftibuten: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftibuten: Pediatric drug information\")  Acute bacterial otitis media:  Infants and Children 6 months to <12 years: Oral: 9 mg/kg/dose once daily (maximum dose: 400 mg…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 44.20346546515212, "bm25_max": 44.20346546515212, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefdinir: Pediatric drug information\")  Infants ≥6 months and Children:  Acute bacterial otitis media, pharyngitis/tonsillitis: Oral: 7 mg/kg/dose twice daily for 5 to…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 41.6175023913377, "bm25_max": 41.6175023913377, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 40.928460865002954, "bm25_max": 40.928460865002954, "bge_top3": null, "bge_max": null, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftaroline: Pediatric drug information\")  Pneumonia, community acquired: IV:  Infants ≥2 months and Children <2 years: 8 mg/kg/dose every 8 hours for 5 to 14 days  Chi…"}, {"doc_id": "ciprofloxacin-otic-drug-information", "bm25_top3": 40.92800423783635, "bm25_max": 40.92800423783635, "bge_top3": 0.7320822775363922, "bge_max": 0.736070454120636, "title": "Ciprofloxacin (otic): Drug information", "rep_snippet": "Dosing: Adult  Acute otitis externa: Otic:  Solution 0.2%: Instill 0.25 mL (0.5 mg) solution (contents of 1 single-dose container) into affected ear twice daily for 7 days  Suspension 6%: Instill 0.2 mL (12 mg) suspensio…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 40.28149014196365, "bm25_max": 40.922433509684396, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 40.645821563070314, "bm25_max": 40.645821563070314, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Hematopoietic radiation injury syndrome (acute): Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after s…"}, {"doc_id": "edrophonium-drug-information", "bm25_top3": 40.45573681967803, "bm25_max": 40.45573681967803, "bge_top3": null, "bge_max": null, "title": "Edrophonium: Drug information", "rep_snippet": "Alternate dosing: Weight-directed dosing: Limited data available: Children and Adolescents: IV, IM, SubQ: Initial: 0.01 to 0.02 mg/kg every 30 to 45 seconds up to the maximum dose (Kliegman 2015; Swaiman 2012). Note: Typ…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 40.24027236478258, "bm25_max": 40.24027236478258, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefpodoxime: Pediatric drug information\")  Usual dosage range:  Infants ≥2 months of age and Children <12 years of age: Oral: 10 mg/kg/day divided every 12 hours (maxim…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 40.16649038975611, "bm25_max": 40.20439846961943, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Extended release suspension (Zmax): Infants ≥6 months and Children: Oral:  <75 lbs (34 kg): 60 mg/kg as a single dose  ≥75 lbs (34 kg): Refer to adult dosing  Disseminated M. avium complex disease in patients with advanc…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 39.93150949022969, "bm25_max": 39.93150949022969, "bge_top3": null, "bge_max": null, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Immune thrombocytopenia, refractory (off-label use): Oral: 5 mg/kg/day in 2 divided doses (every 12 hours) for 6 days, followed by 2.5 to 3 mg/kg/day (titrate to serum levels of 100 to 200 ng/mL); time to response in cli…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 39.56083284701771, "bm25_max": 39.56083284701771, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": 39.38002967679451, "bm25_max": 39.38002967679451, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Pricing: US  Chewable (Almacone Oral)  200-200-25 mg (100): $3.82  Chewable (Gelusil Oral)  200-200-25 mg (100): $6.67  Chewable (Mintox Plus Oral)  200-200-25 mg (100): $2.99  Suspension (Almacone Double Strength Oral)…"}, {"doc_id": "famotidine-drug-information", "bm25_top3": 38.67637218111196, "bm25_max": 38.67637218111196, "bge_top3": null, "bge_max": null, "title": "Famotidine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Famotidine: Pediatric drug information\")  GERD: Oral:  Treatment of GERD (short-term):  Infants 1 to <3 months: 0.5 mg/kg/dose once daily for up to 8 weeks; if not effe…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 38.284575833218, "bm25_max": 38.284575833218, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 38.16425177988217, "bm25_max": 38.16425177988217, "bge_top3": 0.7172311544418335, "bge_max": 0.7172311544418335, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Acute otitis media (off-label use): Oral: 30 to 40 mg/kg/day in 3 divided doses for 5 to 10 days. Use with or without concomitant third-generation cephalosporin for failure of initial antibiotic therapy; use with a third…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 37.396134206465, "bm25_max": 37.396134206465, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefprozil: Pediatric drug information\")  Acute bacterial exacerbation of chronic bronchitis: Children >12 years and Adolescents: Refer to adult dosing.  Otitis media: O…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": 37.11973868198135, "bm25_max": 37.11973868198135, "bge_top3": null, "bge_max": null, "title": "Cephalexin: Drug information", "rep_snippet": "Impetigo: Children: Oral: 25 to 50 mg/kg/day in 3 to 4 divided doses; continue for 7 days, depending upon clinical response (IDSA [Stevens 2014])  Otitis media: Children: 75 to 100 mg/kg/day in 4 divided doses  Pharyngit…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 36.80615035663459, "bm25_max": 36.80615035663459, "bge_top3": 0.7102512121200562, "bge_max": 0.7102512121200562, "title": "Clarithromycin: Drug information", "rep_snippet": "Primary prophylaxis: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily  Secondary prophylaxis: 7.5 mg/kg/dose (maximum: 500 mg/dose) twice daily, plus ethambutol, with or without rifabutin  Treatment: 7.5-15 mg/kg/dose (…"}, {"doc_id": "hydroxychloroquine-drug-information", "bm25_top3": 36.67608988382888, "bm25_max": 36.67608988382888, "bge_top3": null, "bge_max": null, "title": "Hydroxychloroquine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxychloroquine: Pediatric drug information\")  Note: Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phospha…"}, {"doc_id": "prochlorperazine-drug-information", "bm25_top3": 35.0859135798722, "bm25_max": 35.0859135798722, "bge_top3": null, "bge_max": null, "title": "Prochlorperazine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prochlorperazine: Pediatric drug information\")  Note: Injection solution mesylate formulation is a Canadian product (not available in US).  Use is contraindicated in ch…"}, {"doc_id": "ciprofloxacin-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7172529995441437, "bge_max": 0.7331247925758362, "title": "Ciprofloxacin and dexamethasone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and dexamethasone: Pediatric drug information\")  Acute otitis externa: Infants ≥6 months of age, Children, and Adolescents: Otic: Refer to adult dosing.…"}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7216891050338745, "bge_max": 0.7216891050338745, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic rhinitis, chronic spontaneous urticaria: Oral:  Children ≥2 to <12 years:  10 kg to 25 kg: 2.5 mg once daily (maximum: 2.5 mg/day).  >25 kg: 5 mg once daily (maximum: 5 mg/day).  Children ≥12…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7195804119110107, "bge_max": 0.7195804119110107, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "acetic-acid-otic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.717839241027832, "bge_max": 0.717839241027832, "title": "Acetic acid (otic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Acetic acid (otic): Pediatric drug information\")  Otitis externa: Children ≥3 years and Adolescents: Otic: Insert saturated wick; keep moist 24 hours by adding 3 to 5 d…"}, {"doc_id": "ciprofloxacin-and-hydrocortisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7153730988502502, "bge_max": 0.7153730988502502, "title": "Ciprofloxacin and hydrocortisone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and hydrocortisone: Pediatric drug information\")  Acute otitis externa: Children ≥1 year and Adolescents: Otic: Refer to adult dosing."}, {"doc_id": "azathioprine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.715011477470398, "bge_max": 0.715011477470398, "title": "Azathioprine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Azathioprine: Pediatric drug information\")  Uveitis (off- label use): Oral: 1 to 3.2 mg/kg/day either alone or in conjunction with corticosteroids and/or immunosuppress…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7148929238319397, "bge_max": 0.7148929238319397, "title": "Oxacillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oxacillin: Pediatric drug information\")  Note: May contain a significant amount of sodium; consult product specific labeling for amount.  General dosing, susceptible in…"}, {"doc_id": "ciprofloxacin-and-fluocinolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7146470546722412, "bge_max": 0.7146470546722412, "title": "Ciprofloxacin and fluocinolone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin and fluocinolone: Pediatric drug information\")  Acute otitis media in patients with tympanostomy tubes: Infants ≥6 months, Children, and Adolescents: Inst…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7144217491149902, "bge_max": 0.7144217491149902, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Weight-based dosing: Infants, Children, and Adolescents: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (APS, 2008; Sullivan, 2011); do not exceed 5 doses in 24 hours; maximum daily dose: 75 mg/kg/day not to exceed 4 g…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7119258642196655, "bge_max": 0.7119258642196655, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Minoxidil (systemic): Pediatric drug information\")  Hypertension:  Children <12 years: Oral: Initial: 0.2 mg/kg once daily; maximum daily initial dose: 5 mg daily; titr…"}, {"doc_id": "simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.708690881729126, "bge_max": 0.708690881729126, "title": "Simethicone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Simethicone: Pediatric drug information\")  Gas retention: Oral:  Infants and Children <2 years or <11 kg: 20 mg 4 times daily after meals and at bedtime, as needed (max…"}, {"doc_id": "potassium-p-aminobenzoate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.70778489112854, "bge_max": 0.70778489112854, "title": "Potassium p-aminobenzoate: Drug information", "rep_snippet": "Dosing: Pediatric  Oral: 1 g/10 pounds of weight/day; administer in divided doses"}, {"doc_id": "cycloserine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7062433958053589, "bge_max": 0.7062433958053589, "title": "Cycloserine: Drug information", "rep_snippet": "Children and Adolescents <15 years of age weighing >40 kg or Adolescents ≥15 years of age: Oral: 10 to 15 mg/kg/day divided every 12 to 24 hours; usual dose 250 to 500 mg; maximum daily dose: 1,000 mg/day. Note: Patients…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7056893706321716, "bge_max": 0.7056893706321716, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ampicillin: Pediatric drug information\")  Usual dosage range: Infants, Children, and Adolescents:  Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/da…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7055062651634216, "bge_max": 0.7055062651634216, "title": "Amlodipine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amlodipine: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: 2.5 to 5 mg once daily"}, {"doc_id": "probenecid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7045459151268005, "bge_max": 0.7045459151268005, "title": "Probenecid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Probenecid: Pediatric drug information\")  Note: Contraindicated in children <2 years of age.  Prolong penicillin serum levels: Children ≥2 years and Adolescents: Oral:…"}, {"doc_id": "nabumetone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7045454978942871, "bge_max": 0.7045454978942871, "title": "Nabumetone: Drug information", "rep_snippet": "Dosing: Adult  Arthritis: Oral: Initial: 1,000 mg as a single dose; adjust dose based on patient response up to 2,000 mg/day in 1 to 2 divided doses; doses >2,000 mg/day have not been studied.  Note: Patients <50 kg are…"}, {"doc_id": "hydroxyzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7045270204544067, "bge_max": 0.7045270204544067, "title": "Hydroxyzine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydroxyzine: Pediatric drug information\")  Antiemetic: IM: 1.1 mg/kg/dose  Anxiety: Oral:  Children <6 years: 50 mg/day in divided doses  Children ≥6 years and Adolesce…"}, {"doc_id": "propiverine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7040406465530396, "bge_max": 0.7040406465530396, "title": "Propiverine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Overactive bladder: Children and Adolescents: Oral: Immediate release: 0.8 mg/kg/day in 2 divided doses or alternatively the following body weight adjusted dosing may be used:  12 to 16 kg: 5 mg two ti…"}, {"doc_id": "bezafibrate-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.703936755657196, "bge_max": 0.703936755657196, "title": "Bezafibrate (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Dyslipidemia: Children and Adolescents: Oral: 10 to 20 mg/kg/day (maximum: 400 mg daily). Note: Limited experience available; use caution. Based on child’s weight, dosing may not be possible as the man…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7034016847610474, "bge_max": 0.7034016847610474, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7032995820045471, "bge_max": 0.7032995820045471, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Infants and Children: 2 mg/kg/dose or 15 mg/m2/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015)  Adolescents (mild to moderate disease): Refer to…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7032026052474976, "bge_max": 0.7032026052474976, "title": "Amiloride: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Amiloride: Pediatric drug information\")  Hypertension (off-label use): Children and Adolescents 1 to 17 years: Oral: 0.4 to 0.625 mg/kg/day (maximum: 20 mg daily) (NHBP…"}, {"doc_id": "demeclocycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7027498483657837, "bge_max": 0.7027498483657837, "title": "Demeclocycline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Demeclocycline: Pediatric drug information\")  Susceptible infections: Oral: Children >8 years and Adolescents: 7 to 13 mg/kg/day (maximum: 600 mg/day) divided every 6-1…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7025207877159119, "bge_max": 0.7025207877159119, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7025021314620972, "bge_max": 0.7025021314620972, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Dosing: Pediatric  Partial-onset seizures (epilepsy) (monotherapy or adjunctive therapy): Children ≥4 years of age and Adolescents: Oral:  11 to 21 kg: Initial: 200 mg once daily; increase in weekly increments of no more…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7022931575775146, "bge_max": 0.7022931575775146, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral: Children ≥12 years and Adolescents: Liquid: Acid Gone (aluminum hydroxide 31.7 mg/magnesium carbonate 119.3 mg per 5 mL): 15 to 30 mL 4 times daily (maximum: 120 mL per 24 hours)"}, {"doc_id": "aliskiren-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7012284398078918, "bge_max": 0.7012284398078918, "title": "Aliskiren: Drug information", "rep_snippet": "Dosing: Pediatric  Hypertension: Children ≥6 years of age and Adolescents: Oral: Initial:  <20 kg: Not recommended.  20 kg to 50 kg: 75 mg once daily (maximum: 150 mg/day). Note: Prior to initiation, correct hypovolemia…"}]}
{"qid": "Q2", "query": "12 kg child with fever — calculate acetaminophen dose (mg/kg) and volume using 160 mg/5 mL liquid.", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 48.5059716739389, "bm25_max": 49.18789982473047, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-doxylamine-drug-information", "bm25_top3": 49.13747195840201, "bm25_max": 49.13747195840201, "bge_top3": 0.7193396091461182, "bge_max": 0.7193396091461182, "title": "Acetaminophen (paracetamol), dextromethorphan, and doxylamine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 47.87258634552802, "bm25_max": 47.87258634552802, "bge_top3": null, "bge_max": null, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Chronic drinker: 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a 10% solution]  Dosage adjustment for hemodialysis: Maintenance dose:  Nondrinker: 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a 10% solution]…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 40.878972401349245, "bm25_max": 47.490888037387606, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "Multifocal motor neuropathy (MMN) (Gammagard Liquid): IV: 500 to 2400 mg/kg/month based upon response  Primary humoral immunodeficiency disorders:  IV infusion dosing:  Bivigam, Gammaplex: IV: 300 to 800 mg/kg every 3 to…"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": 42.371668863817085, "bm25_max": 47.18286018757145, "bge_top3": 0.6818616986274719, "bge_max": 0.6818616986274719, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Dosing: Adult  Note: Adult doses ≥60 mg codeine fail to give commensurate relief of pain but merely prolong analgesia and are associated with an appreciably increased incidence of side effects.  Pain management: Oral:  S…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 45.35556709551397, "bm25_max": 45.35556709551397, "bge_top3": 0.7164345979690552, "bge_max": 0.7164345979690552, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Pricing: US  Capsules (Tylenol Oral)  325 mg (20): $3.60  Chewable (Acetaminophen Oral)  80 mg (30): $1.37  Chewable (Mapap Childrens Oral)  160 mg (24): $2.10  Gel (ElixSure Fever/Pain Oral)  160 mg/5 mL (120 mL): $4.86…"}, {"doc_id": "diphenoxylate-and-atropine-drug-information", "bm25_top3": 45.35072552268413, "bm25_max": 45.35072552268413, "bge_top3": null, "bge_max": null, "title": "Diphenoxylate and atropine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diphenoxylate and atropine: Pediatric drug information\")  Diarrhea, adjunct therapy: Note: Clinical improvement of acute diarrhea is usually observed within 48 hours. I…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 39.22917081343478, "bm25_max": 40.88815424099107, "bge_top3": 0.720103124777476, "bge_max": 0.7531003952026367, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Delsym Cgh/Cld Nighttime Child Oral)  12.5-5-325 mg/10 mL (180 mL): $10.13  Liquid (Delsym Cough/Cold Night Time Oral)  12.5-5-325 mg/10 mL (180 mL): $10.13  Liquid (Dimetapp MultiSymptom Cold/Flu Or…"}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 37.96894859901075, "bm25_max": 39.73988212963118, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Opioid-induced constipation with advanced illness: There are no dosage adjustments provided in the manufacturer's labeling. For the injection, consider following the subcutaneous dosing recomm…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 36.30606386091326, "bm25_max": 38.6308986003464, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 38.58065266501292, "bm25_max": 38.58065266501292, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 38.14093519858856, "bm25_max": 38.14093519858856, "bge_top3": 0.6724355816841125, "bge_max": 0.6724355816841125, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 37.034341697145436, "bm25_max": 37.970630105722414, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Hematopoietic radiation injury syndrome (acute): Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after s…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 37.40176971156834, "bm25_max": 37.40176971156834, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 37.30258527589348, "bm25_max": 37.30258527589348, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 36.34691963993576, "bm25_max": 36.34691963993576, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 36.24619436919664, "bm25_max": 36.24619436919664, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 35.78790942900175, "bm25_max": 35.78790942900175, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Oral: 200 mg twice daily (IDSA [Galgiani 2016]); limited data (case reports) also report using higher doses (range: 250 mg to 400 mg twice daily) during the treatment course based on clinical response to therapy (Cortez…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 35.76472046030638, "bm25_max": 35.76472046030638, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "zidovudine-drug-information", "bm25_top3": 35.66876317605045, "bm25_max": 35.66876317605045, "bge_top3": null, "bge_max": null, "title": "Zidovudine: Drug information", "rep_snippet": "Infants (born at or near term with PMA ≥35 weeks) weighing ≥4 kg, Children, and Adolescents: Note: The 3-times-daily dosing is FDA approved but rarely used in practice; twice-daily dosing is recommended in the current pe…"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": 35.61039777109791, "bm25_max": 35.61039777109791, "bge_top3": null, "bge_max": null, "title": "Dinutuximab: Drug information", "rep_snippet": "Antiemetics: Dinutuximab is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Antihistamine: Administer an antihistamine (eg, diphenhydramine 0.5 to 1 mg/kg/dose; m…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 35.435676064562756, "bm25_max": 35.435676064562756, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 35.01469144484515, "bm25_max": 35.01469144484515, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "plerixafor-drug-information", "bm25_top3": 34.98491763764449, "bm25_max": 34.98491763764449, "bge_top3": null, "bge_max": null, "title": "Plerixafor: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Creatinine clearance estimate based on Cockcroft-Gault formula:  CrCl >50 mL/minute: No dosage adjustment necessary.  CrCl ≤50 mL/minute:  Patients ≤83 kg: 13 mg fixed dose or 0.16 mg/kg o…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 29.962416739352264, "bm25_max": 34.35411821942135, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  See tables.  Induction Dosing of Foscarnet in Patients With Abnormal Renal Function  CrCl (mL/min/kg)  HSV  HSV  CMV  CMV  Equivalent to 40 mg/kg every 12 hours  Equivalent to 40 mg/kg e…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 34.32891877619746, "bm25_max": 34.32891877619746, "bge_top3": 0.6725093722343445, "bge_max": 0.6725093722343445, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "stavudine-drug-information", "bm25_top3": 34.27314044008882, "bm25_max": 34.27314044008882, "bge_top3": null, "bge_max": null, "title": "Stavudine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl >50 mL/minute:  <60 kg: 30 mg every 12 hours  ≥60 kg: 40 mg every 12 hours  CrCl 26-50 mL/minute:  <60 kg: 15 mg every 12 hours  ≥60 kg: 20 mg every 12 hours  CrCl 10-25 mL/minute…"}, {"doc_id": "guaifenesin-drug-information", "bm25_top3": 34.02855357447627, "bm25_max": 34.02855357447627, "bge_top3": null, "bge_max": null, "title": "Guaifenesin: Drug information", "rep_snippet": "Pricing: US  Liquid (Buckleys Chest Congestion Oral)  100 mg/5 mL (118 mL): $4.79  Liquid (Diabetic Tussin Oral)  100 mg/5 mL (118 mL): $4.20  Liquid (GuaiFENesin Oral)  100 mg/5 mL (10 mL): $0.64  Liquid (Mucinex Chest…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": 33.93160236456119, "bm25_max": 33.93160236456119, "bge_top3": null, "bge_max": null, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diazepam: Pediatric drug information\")  Conscious sedation for procedures:  Oral:  Children: 0.2 to 0.3 mg/kg (maximum dose: 10 mg) 45 to 60 minutes prior to procedure…"}, {"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 33.92066327608286, "bm25_max": 33.92066327608286, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Infants and Small Children Dose Estimates of Digoxin Immune Fab (in mg) From Steady-State Serum Digoxin Concentration  Patient Weight  (kg)  Serum Digoxin Concentration (ng/mL)  1  2  4  8  12  16  20  1Dilution of recon…"}, {"doc_id": "tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 33.827766550944034, "bm25_max": 33.827766550944034, "bge_top3": null, "bge_max": null, "title": "Tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Tenofovir disoproxil fumarate: Pediatric drug information\")  Hepatitis B infection: Oral: Children ≥12 years (and ≥35 kg) and Adolescents: Refer to adult dosing.  HIV-1…"}, {"doc_id": "rilonacept-drug-information", "bm25_top3": 33.1450678475137, "bm25_max": 33.1450678475137, "bge_top3": null, "bge_max": null, "title": "Rilonacept: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Rilonacept: Pediatric drug information\")  Cryopyrin-associated periodic syndromes: SubQ:  Children ≥12 years and Adolescents <18 years:  Initial: 4.4 mg/kg (maximum loa…"}, {"doc_id": "dextromethorphan-drug-information", "bm25_top3": 32.78336864207702, "bm25_max": 32.78336864207702, "bge_top3": null, "bge_max": null, "title": "Dextromethorphan: Drug information", "rep_snippet": "Pricing: US  Capsules (Robitussin Lingering CoughGels Oral)  15 mg (20): $5.16  Gel (ElixSure Cough Oral)  7.5 mg/5 mL (120 mL): $4.86  Liquid (Buckleys Cough Oral)  12.5 mg/5 mL (118 mL): $4.79  Liquid (Little Colds Cou…"}, {"doc_id": "guaifenesin-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": 30.744179931860856, "bm25_max": 30.744179931860856, "bge_top3": null, "bge_max": null, "title": "Guaifenesin, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Pricing: US  Liquid (Biotuss Pediatric Oral)  2.5-5-50 mg/mL (60 mL): $4.78  Liquid (Broncotron PED Drops Oral)  2.5-5-100 mg/mL (60 mL): $14.38  Liquid (Broncotron PED Oral)  10-15-350 mg/5 mL (118 mL): $14.38  Liquid (…"}, {"doc_id": "benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 24.980808902684387, "bm25_max": 24.980808902684387, "bge_top3": null, "bge_max": null, "title": "Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Administration  Administer with or without food, approximately 12 hours apart.  To make slurry using 12.5 or 100 mg tablets:  Place prescribed dose in a cup and add the specified volume of water (also refer to manufactur…"}, {"doc_id": "chlorpheniramine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7093873620033264, "bge_max": 0.7185602188110352, "title": "Chlorpheniramine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to <12 years: One tablet (chlorpheniramine 2 mg/acetaminophen 325 mg) every 4 to 6 hours (maximum: 5 tablets in 24 hours [chlorpheniramine 10 mg/acetaminophen 1…"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7136437892913818, "bge_max": 0.7177468538284302, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cold and flu symptoms: Oral:  Children 6 to 11 years: Vicks DayQuil Cold & Flu Multi-Symptom Liquid: Acetaminophen 325 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 15 mL: 15 mL every 4 hours (maxim…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7133552432060242, "bge_max": 0.7133552432060242, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Allergies/co…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7066612839698792, "bge_max": 0.7066612839698792, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6986371278762817, "bge_max": 0.6986371278762817, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Allergies/common cold/hay fever: Oral: Note: OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6930147409439087, "bge_max": 0.6930147409439087, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "zinc-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6920966506004333, "bge_max": 0.6920966506004333, "title": "Zinc gluconate: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Children ≥12 years and Adolescents ≤17 years of age: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours a…"}, {"doc_id": "chlophedianol-and-dexbrompheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6896446347236633, "bge_max": 0.6896446347236633, "title": "Chlophedianol and dexbrompheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and cold symptoms:  Children 6 to <12 years: Oral: Chlophedianol 12.5 mg/dexbrompheniramine 1 mg (5 mL) every 6 hours (Maximum: Chlophedianol 50 mg/dexbrompheniramine 4 mg (20 mL) per 24 hours.…"}, {"doc_id": "dextromethorphan-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6872108578681946, "bge_max": 0.6872108578681946, "title": "Dextromethorphan and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines; consult specific product labeling.  Cough, cold symptoms: Oral:  Children 6 to 11 years: Dextromethorphan 15 mg and chlorpheniramine 2 mg every 6 hours as needed (maximum: 60…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6862158179283142, "bge_max": 0.6862158179283142, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "clofedanol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6857703328132629, "bge_max": 0.6857703328132629, "title": "Clofedanol (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Cough: Oral:  Children 2 to <6 years: 12.5 mg 3 to 4 times daily as needed  Children 6 to <12 years: 12.5 to 25 mg 3 to 4 times daily as needed  Children ≥12 years and Adolescents: Refer to adult dosin…"}, {"doc_id": "metyrapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6856673955917358, "bge_max": 0.6856673955917358, "title": "Metyrapone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metyrapone: Pediatric drug information\")  ACTH function testing: Oral:  Single-dose/overnight test: 30 mg/kg (maximum: 3 g) at midnight  Multiple-dose test: 15 mg/kg (m…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6839320659637451, "bge_max": 0.6839320659637451, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "simethicone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6834059953689575, "bge_max": 0.6834059953689575, "title": "Simethicone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Simethicone: Pediatric drug information\")  Gas retention: Oral:  Infants and Children <2 years or <11 kg: 20 mg 4 times daily after meals and at bedtime, as needed (max…"}, {"doc_id": "atenolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6830733418464661, "bge_max": 0.6830733418464661, "title": "Atenolol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Atenolol: Pediatric drug information\")  Hypertension: Oral: Children and Adolescents: Initial: 0.5 to 1 mg/kg/dose either once daily or divided in doses twice daily; ti…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6789289911588033, "bge_max": 0.6825935244560242, "title": "Aminophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Aminophylline: Pediatric drug information\")  Note: All dosages expressed as aminophylline; use ideal body weight (theophylline distributes poorly into body fat) to calc…"}, {"doc_id": "promethazine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6808271408081055, "bge_max": 0.6808271408081055, "title": "Promethazine and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms: Oral: Children:  2 to <6 years: 1.25 to 2.5 mL every 4 to 6 hours; maximum: 10 mL in 24 hours  6 to <12 years: 2.5 to 5 mL every 4 to 6 hours; maximum: 20 mL in 24…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6801514625549316, "bge_max": 0.6801514625549316, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Infants and Children: 2 mg/kg/dose or 15 mg/m2/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015)  Adolescents (mild to moderate disease): Refer to…"}, {"doc_id": "xenon-xe-133-gas-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6789803504943848, "bge_max": 0.6789803504943848, "title": "Xenon Xe-133 gas: Drug information", "rep_snippet": "Dosing: Adult  Cerebral blood flow: Inhalation (based on 70 kg patient): 10 to 30 mCi (370 to 1,110 MBq) in 3 L of air  Pulmonary function, including imaging: Inhalation (based on 70 kg patient): 2 to 30 mCi (74 to 1,110…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6785825490951538, "bge_max": 0.6785825490951538, "title": "Oseltamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Oseltamivir: Pediatric drug information\")  Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]): Oral:  Prophylaxis:  I…"}, {"doc_id": "dexbrompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6774046421051025, "bge_max": 0.6774046421051025, "title": "Dexbrompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold/upper respiratory allergies: Oral:  Children 6 to <12 years:  Dexbrompheniramine 1 mg/phenylephrine 5 mg: One tablet or 5 mL every 4 hours (maximum: 6 tablets or 30 mL [dexbrompheniramine 6…"}, {"doc_id": "chlorpheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6771124005317688, "bge_max": 0.6771124005317688, "title": "Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Note: All dosing is presented in terms of chlorpheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide.  Cough and upper respiratory symptoms: Oral: Dosing may vary by pro…"}, {"doc_id": "gemtuzumab-ozogamicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6769245862960815, "bge_max": 0.6769245862960815, "title": "Gemtuzumab ozogamicin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Gemtuzumab ozogamicin: Pediatric drug information\")  Note: Premedicate with acetaminophen 15 mg/kg (maximum: 650 mg) orally and diphenhydramine 1 mg/kg (maximum: 50 mg)…"}, {"doc_id": "pentazocine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6765677332878113, "bge_max": 0.6765677332878113, "title": "Pentazocine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Adult  Note: Maximum daily intake of acetaminophen from all sources should not exceed 4 g.  Analgesic: Oral: One caplet (pentazocine 25 mg/acetaminophen 650 mg) every 4 hours as needed (maximum: 6 caplets/day)"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.676378607749939, "bge_max": 0.676378607749939, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dexamethasone (systemic): Pediatric drug information\")  Anti-inflammatory/immunosuppressive/endocrine disorders: Infants, Children, and Adolescents: Oral, IM, IV: Initi…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6752926707267761, "bge_max": 0.6752926707267761, "title": "Aluminum hydroxide and magnesium carbonate: Drug information", "rep_snippet": "Dosing: Pediatric  Antacid: Oral: Children ≥12 years and Adolescents: Liquid: Acid Gone (aluminum hydroxide 31.7 mg/magnesium carbonate 119.3 mg per 5 mL): 15 to 30 mL 4 times daily (maximum: 120 mL per 24 hours)"}, {"doc_id": "phenylephrine-pyrilamine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6751633882522583, "bge_max": 0.6751633882522583, "title": "Phenylephrine, pyrilamine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Relief of cough, congestion: Oral: Note: All dosing is presented in terms of phenylephrine hydrochloride, pyrilamine maleate, and dextromethorphan hydrobromide.  Children 6-11 years: Liquid:  Phenyleph…"}, {"doc_id": "hydrocodone-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6751073002815247, "bge_max": 0.6751073002815247, "title": "Hydrocodone and acetaminophen (paracetamol): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Hydrocodone and acetaminophen (paracetamol): Pediatric drug information\")  Analgesic, opioid-naive: Oral: Note: Doses based on hydrocodone; titrate to appropriate analg…"}, {"doc_id": "dexchlorpheniramine-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6746985912322998, "bge_max": 0.6746985912322998, "title": "Dexchlorpheniramine, dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms: Oral:  Children 2 to <6 years of age: Dexchlorpheniramine 1 mg/dextromethorphan 10 mg/phenylephrine 5 mg per 5 mL: 2.5 mL every 4 hours (maximum: 15 mL/24 hours)…"}, {"doc_id": "dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6745030879974365, "bge_max": 0.6745030879974365, "title": "Dextromethorphan and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  General dosing guidelines. Also refer to specific product labeling.  Cough/decongestant: Oral: Liquid (dextromethorphan 5 mg and phenylephrine 2.5 mg per 5 mL):  Children 4 to 5 years: 5 mL every 4 hou…"}, {"doc_id": "betamethasone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6742389798164368, "bge_max": 0.6742389798164368, "title": "Betamethasone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Betamethasone (systemic): Pediatric drug information\")  Note: Dosages expressed as combined amount of betamethasone sodium phosphate and betamethasone acetate; 1 mg is…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6741374731063843, "bge_max": 0.6741374731063843, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6740500926971436, "bge_max": 0.6740500926971436, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Promethazine and phenylephrine: Pediatric drug information\")  Upper respiratory symptoms: Oral:  Children 2 to <6 years: 1.25 to 2.5 mL (promethazine 1.56 to 3.12 mg/ph…"}, {"doc_id": "formoterol-and-mometasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6736090779304504, "bge_max": 0.6736090779304504, "title": "Formoterol and mometasone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Formoterol and mometasone: Pediatric drug information\")  Asthma: Children ≥12 years and Adolescents: Metered-dose inhaler: Inhalation: Refer to adult dosing."}, {"doc_id": "reslizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6734667420387268, "bge_max": 0.6734667420387268, "title": "Reslizumab: Drug information", "rep_snippet": "Dosing: Adult  Asthma: IV: 3 mg/kg once every 4 weeks."}, {"doc_id": "cefepime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6731590032577515, "bge_max": 0.6731590032577515, "title": "Cefepime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefepime: Pediatric drug information\")  General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents: IM, IV:  Mild to moderate infec…"}, {"doc_id": "brompheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6722278594970703, "bge_max": 0.6722278594970703, "title": "Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms associated with allergy or common cold: Oral:  Children 2 to <6 years: Brompheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg per 5 mL: 2.5 mL ever…"}, {"doc_id": "acetaminophen-paracetamol-isometheptene-and-dichloralphenazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6721577048301697, "bge_max": 0.6721577048301697, "title": "Acetaminophen (paracetamol), isometheptene, and dichloralphenazone: Drug information", "rep_snippet": "• Dosage limit: Limit acetaminophen dose from all sources (prescription, OTC) ≤4 g/day (adults)."}]}
{"qid": "Q3", "query": "12 kg child with fever — calculate ibuprofen dose (mg/kg) and volume using 100 mg/5 mL suspension.", "candidates": [{"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 55.31420120437729, "bm25_max": 56.046586243920174, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 49.801392886099435, "bm25_max": 49.801392886099435, "bge_top3": null, "bge_max": null, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Chronic drinker: 154 mg/kg/hour [equivalent to 1.96 mL/kg/hour using a 10% solution]  Dosage adjustment for hemodialysis: Maintenance dose:  Nondrinker: 169 mg/kg/hour [equivalent to 2.13 mL/kg/hour using a 10% solution]…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 48.0125480553118, "bm25_max": 48.0125480553118, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Children ≥8 years and Adolescents: 2.2 mg/kg/dose (maximum: 100 mg per dose) twice daily for 14 days (CDC 2013).  Chronic: ID consult recommended for treatment of chronic Q fever (CDC 2013)  Rocky Mountain spotted fever:…"}, {"doc_id": "equine-serum-heptavalent-botulism-antitoxin-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": 44.72962433483626, "bm25_max": 44.72962433483626, "bge_top3": null, "bge_max": null, "title": "Equine serum heptavalent botulism antitoxin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Equine serum heptavalent botulism antitoxin (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 40.03873088749355, "bm25_max": 43.87646746514484, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Weight-directed dosing: Body weight 10 to <15 kg: Darunavir 35 mg/kg (maximum dose 800 mg/dose) once daily plus ritonavir 7 mg/kg (maximum dose: 100 mg/dose) once daily  Fixed dosing: Oral solution (darunavir: 100 mg/mL)…"}, {"doc_id": "acetylcysteine-drug-information", "bm25_top3": 42.69158462898796, "bm25_max": 42.69158462898796, "bge_top3": null, "bge_max": null, "title": "Acetylcysteine: Drug information", "rep_snippet": "Oral: (Effervescent tablets [Cetylev]; solution for oral administration): Note: Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetyl…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": 41.87245795344354, "bm25_max": 41.87245795344354, "bge_top3": null, "bge_max": null, "title": "Raltegravir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Raltegravir: Pediatric drug information\")  HIV-1 infection, treatment: Oral:  Note: Raltegravir film-coated tablets and chewable tablets or oral suspension are not bioe…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 38.800330602391384, "bm25_max": 41.68227668330606, "bge_top3": 0.717179924249649, "bge_max": 0.7380877733230591, "title": "Ibuprofen: Drug information", "rep_snippet": "Pricing: US  Capsules (Advil Migraine Oral)  200 mg (40): $6.97  Capsules (Advil Oral)  200 mg (2): $0.27  Capsules (Ibuprofen Oral)  200 mg (80): $6.32  Chewable (Advil Junior Strength Oral)  100 mg (24): $4.32  Kit (Ib…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": 39.941691356385334, "bm25_max": 39.941691356385334, "bge_top3": null, "bge_max": null, "title": "Cefixime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefixime: Pediatric drug information\")  Note: Suprax 400 mg tablets have been discontinued in the US for more than 1 year.  Susceptible infections: Oral: Note: Otitis m…"}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 37.96894859901075, "bm25_max": 39.73988212963118, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Opioid-induced constipation with advanced illness: There are no dosage adjustments provided in the manufacturer's labeling. For the injection, consider following the subcutaneous dosing recomm…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 37.228030841089414, "bm25_max": 38.93924108417391, "bge_top3": 0.6576796770095825, "bge_max": 0.6576796770095825, "title": "Voriconazole: Drug information", "rep_snippet": "Oral: 200 mg twice daily (IDSA [Galgiani 2016]); limited data (case reports) also report using higher doses (range: 250 mg to 400 mg twice daily) during the treatment course based on clinical response to therapy (Cortez…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 38.58065266501292, "bm25_max": 38.58065266501292, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 50 mL/minute/1.73 m2: 1 mg/kg/dose every 12 hours  GFR 10 to 29 mL/minute/1.73 m2: 0.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 0.5 mg/kg…"}, {"doc_id": "pegfilgrastim-drug-information", "bm25_top3": 37.034341697145436, "bm25_max": 37.970630105722414, "bge_top3": null, "bge_max": null, "title": "Pegfilgrastim: Drug information", "rep_snippet": "Hematopoietic radiation injury syndrome (acute): Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after s…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 37.40176971156834, "bm25_max": 37.40176971156834, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Alternate recommendations:  Children and Adolescents (Veltri 2004): Oral, IV: Note: Renally adjusted dose recommendations are based on doses of 3 to 5 mg/kg/dose every 12 hours.  CrCl 10 to 50 mL/minute/1.73 m2: 3 to 5 m…"}, {"doc_id": "ganciclovir-systemic-drug-information", "bm25_top3": 37.022740465826885, "bm25_max": 37.30258527589348, "bge_top3": null, "bge_max": null, "title": "Ganciclovir (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.  IV (Induction):  CrCl ≥7…"}, {"doc_id": "dinutuximab-drug-information", "bm25_top3": 37.03212325023614, "bm25_max": 37.03212325023614, "bge_top3": null, "bge_max": null, "title": "Dinutuximab: Drug information", "rep_snippet": "Antiemetics: Dinutuximab is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Antihistamine: Administer an antihistamine (eg, diphenhydramine 0.5 to 1 mg/kg/dose; m…"}, {"doc_id": "capreomycin-drug-information", "bm25_top3": 36.59065696840857, "bm25_max": 36.59065696840857, "bge_top3": null, "bge_max": null, "title": "Capreomycin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer's labeling (maximum: 1 g/dose):  CrCl 110 mL/minute: 13.9 mg/kg every 24 hours  CrCl 100 mL/minute: 12.7 mg/kg every 24 hours  CrCl 80 mL/minute: 10.4 mg/kg every 24 hours…"}, {"doc_id": "ustekinumab-drug-information", "bm25_top3": 36.43490085028138, "bm25_max": 36.43490085028138, "bge_top3": null, "bge_max": null, "title": "Ustekinumab: Drug information", "rep_snippet": "Dosing: Adult  Crohn disease:  Induction: IV:  ≤55 kg: 260 mg as single dose  >55 kg to 85 kg: 390 mg as single dose  >85 kg: 520 mg as single dose  Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 week…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 36.34691963993576, "bm25_max": 36.34691963993576, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Oral:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose by 50%.  End-stage renal disease…"}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 36.25745401887964, "bm25_max": 36.25745401887964, "bge_top3": null, "bge_max": null, "title": "Deferasirox: Drug information", "rep_snippet": "Dosing: Adult  Note: Calculate dose to the nearest whole tablet size or nearest whole granules packet.  Chronic iron overload due to transfusions: Oral: Note: Treatment should only be initiated with evidence of chronic i…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 36.24619436919664, "bm25_max": 36.24619436919664, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "GFR 10 to 29 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 12 hours  GFR <10 mL/minute/1.73 m2: 25 to 37.5 mg/kg/dose every 24 hours  Hemodialysis: 25 to 37.5 mg/kg/dose every 24 hours  Peritoneal dialysis: 25 to 37.5 m…"}, {"doc_id": "cytomegalovirus-immune-globulin-drug-information", "bm25_top3": 35.96074374144409, "bm25_max": 35.96074374144409, "bge_top3": null, "bge_max": null, "title": "Cytomegalovirus immune globulin: Drug information", "rep_snippet": "Dosing: Adult  Prophylaxis of CMV disease in kidney transplant: IV:  Initial dose (within 72 hours of transplant): 150 mg/kg/dose  2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose  12- and 16 weeks after transpla…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 35.76472046030638, "bm25_max": 35.76472046030638, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Tuberculosis:  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly  End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 t…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 35.435676064562756, "bm25_max": 35.435676064562756, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "foscarnet-drug-information", "bm25_top3": 29.962416739352264, "bm25_max": 34.35411821942135, "bge_top3": null, "bge_max": null, "title": "Foscarnet: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  See tables.  Induction Dosing of Foscarnet in Patients With Abnormal Renal Function  CrCl (mL/min/kg)  HSV  HSV  CMV  CMV  Equivalent to 40 mg/kg every 12 hours  Equivalent to 40 mg/kg e…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 34.32891877619746, "bm25_max": 34.32891877619746, "bge_top3": 0.6709879636764526, "bge_max": 0.6709879636764526, "title": "Theophylline: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Theophylline: Pediatric drug information\")  Note: Individualize dose based on steady-state serum concentrations; use ideal body weight (theophylline distributes poorly…"}, {"doc_id": "diazepam-drug-information", "bm25_top3": 33.93160236456119, "bm25_max": 33.93160236456119, "bge_top3": null, "bge_max": null, "title": "Diazepam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Diazepam: Pediatric drug information\")  Conscious sedation for procedures:  Oral:  Children: 0.2 to 0.3 mg/kg (maximum dose: 10 mg) 45 to 60 minutes prior to procedure…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 33.7817297624051, "bm25_max": 33.7817297624051, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "1-day regimen: 30 mg/kg as a single dose (maximum dose: 1,500 mg)  3-day regimen: 10 mg/kg once daily for 3 days (maximum: 500 mg daily)  5-day regimen: 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day o…"}, {"doc_id": "dolasetron-drug-information", "bm25_top3": 33.628419298812844, "bm25_max": 33.628419298812844, "bge_top3": null, "bge_max": null, "title": "Dolasetron: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dolasetron: Pediatric drug information\")  Note: Anzemet injection has been discontinued in the US for more than 1 year.  Prevention of chemotherapy-associated nausea an…"}, {"doc_id": "methohexital-drug-information", "bm25_top3": 33.5478645346281, "bm25_max": 33.5478645346281, "bge_top3": null, "bge_max": null, "title": "Methohexital: Drug information", "rep_snippet": "Preoperative, anesthesia induction, or preprocedural: Children and Adolescents: ﻿Rectal: Usual: 25 mg/kg/dose; range: 20 to 35 mg/kg/dose; maximum dose: 500 mg/dose; give as 10% (100 mg/mL) aqueous solution 5 to15 minute…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 33.52314121209525, "bm25_max": 33.52314121209525, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Switching from cysteamine hydrochloride or phosphocysteamine solutions to cysteamine bitartrate: Initiate immediate release cysteamine bitartrate at an equimolar dose to the cysteamine hydrochloride or phosphocysteamine.…"}, {"doc_id": "benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 25.11392841754156, "bm25_max": 25.11392841754156, "bge_top3": null, "bge_max": null, "title": "Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Administration  Administer with or without food, approximately 12 hours apart.  To make slurry using 12.5 or 100 mg tablets:  Place prescribed dose in a cup and add the specified volume of water (also refer to manufactur…"}, {"doc_id": "pseudoephedrine-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6865298946698507, "bge_max": 0.708297848701477, "title": "Pseudoephedrine and ibuprofen: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pseudoephedrine and ibuprofen: Pediatric drug information\")  Cold, sinus, and flu symptoms: Children ≥12 years and Adolescents Refer to adult dosing."}, {"doc_id": "ibuprofen-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7024641036987305, "bge_max": 0.7024641036987305, "title": "Ibuprofen and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Common cold/flu: Oral: Ibuprofen 200 mg/phenylephrine 10 mg every 4 hours (maximum: ibuprofen 1,200 mg/phenylephrine 60 mg per 24 hours)"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6868820190429688, "bge_max": 0.6868820190429688, "title": "Buprenorphine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Buprenorphine: Pediatric drug information\")  Acute pain (moderate to severe):  Immediate-release injection:  Children 2 to 12 years: IM, slow IV: 2 to 6 mcg/kg every 4…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6801875233650208, "bge_max": 0.6801875233650208, "title": "Peramivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Peramivir: Pediatric drug information\")  Influenza: IV: Note: Administer within 2 days of onset of symptoms of influenza.  Children: 2 to 12 years: 12 mg/kg as a single…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6795682311058044, "bge_max": 0.6795682311058044, "title": "Cefotaxime: Drug information", "rep_snippet": "Typhoid fever: Infants and Children ≤12 years: IM, IV: 150 to 200 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily); fluoroquinolone resistant: 80 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily)"}, {"doc_id": "valproate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6764487028121948, "bge_max": 0.6764487028121948, "title": "Valproate: Drug information", "rep_snippet": "Status epilepticus (off-label use): Infants, Children, and Adolescents: IV: 20 to 40 mg/kg administered at rate of 1.5 to 3 mg/kg/minute; if necessary, may give an additional dose of 20 mg/kg 10 minutes after the loading…"}, {"doc_id": "ibuprofen-phenylephrine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6703217327594757, "bge_max": 0.6720107793807983, "title": "Ibuprofen, phenylephrine, and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Common cold/upper respiratory allergies: Oral: One tablet (ibuprofen 200 mg/phenylephrine 10 mg/chlorpheniramine 4 mg) every 4 hours. Maximum: 6 tablets (ibuprofen 1,200 mg/phenylephrine 60 mg/chlorphenira…"}, {"doc_id": "dapsone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6703466773033142, "bge_max": 0.6703466773033142, "title": "Dapsone (systemic): Drug information", "rep_snippet": "Infants and Children: 2 mg/kg/dose or 15 mg/m2/dose once daily (maximum daily dose: 25 mg/day), in combination with pyrimethamine and leucovorin (HHS [OI pediatric] 2015)  Adolescents (mild to moderate disease): Refer to…"}, {"doc_id": "azathioprine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6699643135070801, "bge_max": 0.6699643135070801, "title": "Azathioprine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Azathioprine: Pediatric drug information\")  Uveitis (off- label use): Oral: 1 to 3.2 mg/kg/day either alone or in conjunction with corticosteroids and/or immunosuppress…"}, {"doc_id": "brompheniramine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6696020364761353, "bge_max": 0.6696020364761353, "title": "Brompheniramine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Brompheniramine and pseudoephedrine: Pediatric drug information\")  Note: These are general dosage guidelines; also refer to product specific dosing.  Upper respiratory…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6665728092193604, "bge_max": 0.6665728092193604, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Flu/cold symptoms: Oral: General dosing guidelines; refer to specific product labeling:  Children 6 to 11 years: Liquid: Acetaminophen 325 mg/diphenhydramine 12.5 mg/phenylephrine 5 mg every 4 hours as…"}, {"doc_id": "guaifenesin-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6662037968635559, "bge_max": 0.6662037968635559, "title": "Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory tract symptoms: Oral:  Note: Dosing may vary by product. Consult specific product labeling.  Drops (dextromethorphan 2.5 mg/guaifenesin 25 mg/pseudoephedrine 7.5 mg per mL):…"}, {"doc_id": "ephedrine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6660078167915344, "bge_max": 0.6660078167915344, "title": "Ephedrine (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ephedrine (systemic): Pediatric drug information\")  Hypotension, anesthesia induced: Infants, Children, and Adolescents ≤15 years (off-label dose): IV: 0.1 to 0.3 mg/kg…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.664187490940094, "bge_max": 0.664187490940094, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Promethazine and phenylephrine: Pediatric drug information\")  Upper respiratory symptoms: Oral:  Children 2 to <6 years: 1.25 to 2.5 mL (promethazine 1.56 to 3.12 mg/ph…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6637474298477173, "bge_max": 0.6637474298477173, "title": "Ondansetron: Drug information", "rep_snippet": "Infants ≥1 month and Children ≤12 years: IV:  ≤40 kg: 0.1 mg/kg as a single dose over 2 to 5 minutes  >40 kg: 4 mg as a single dose over 2 to 5 minutes  Adolescents >12 years: IV, IM: Refer to adult dosing."}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636627912521362, "bge_max": 0.6636627912521362, "title": "Aminophylline: Drug information", "rep_snippet": "Infants 6 to 52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79  Children 1 to <9 years: 1.01 mg/kg/hour  Children 9 to <12 years: 0.89 mg/kg/hour  Adolescents 12 to <16 years (cigarette or mar…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6633042097091675, "bge_max": 0.6633042097091675, "title": "Benazepril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Benazepril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: Initial: 0.2 mg/kg once daily (maximum initial dose: 10 mg/day) as mono…"}, {"doc_id": "nalbuphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6628661155700684, "bge_max": 0.6628661155700684, "title": "Nalbuphine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nalbuphine: Pediatric drug information\")  Pain, moderate to severe (off-label use): Children ≥1 year and Adolescents: IM, IV, SubQ: 0.1 to 0.2 mg/kg every 3 to 4 hours…"}, {"doc_id": "busulfan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6626889705657959, "bge_max": 0.6626889705657959, "title": "Busulfan: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Intravenous:  Busulfex: 6 mg/mL (10 mL)  Generic: 6 mg/mL (10 mL)  Solution…"}, {"doc_id": "potassium-p-aminobenzoate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6626431941986084, "bge_max": 0.6626431941986084, "title": "Potassium p-aminobenzoate: Drug information", "rep_snippet": "Dosing: Pediatric  Oral: 1 g/10 pounds of weight/day; administer in divided doses"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6614239811897278, "bge_max": 0.6614239811897278, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)  >15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maxim…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6613205671310425, "bge_max": 0.6613205671310425, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = discontinued product  Tablet, oral:  Ibudone:  5/200: Hydrocodone bitartrate 5…"}, {"doc_id": "xenon-xe-133-gas-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6613113880157471, "bge_max": 0.6613113880157471, "title": "Xenon Xe-133 gas: Drug information", "rep_snippet": "Dosing: Adult  Cerebral blood flow: Inhalation (based on 70 kg patient): 10 to 30 mCi (370 to 1,110 MBq) in 3 L of air  Pulmonary function, including imaging: Inhalation (based on 70 kg patient): 2 to 30 mCi (74 to 1,110…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6610738635063171, "bge_max": 0.6610738635063171, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "promethazine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6610735058784485, "bge_max": 0.6610735058784485, "title": "Promethazine and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms: Oral: Children:  2 to <6 years: 1.25 to 2.5 mL every 4 to 6 hours; maximum: 10 mL in 24 hours  6 to <12 years: 2.5 to 5 mL every 4 to 6 hours; maximum: 20 mL in 24…"}, {"doc_id": "lincomycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6592170000076294, "bge_max": 0.6592170000076294, "title": "Lincomycin: Drug information", "rep_snippet": "Dosing: Pediatric  Bacterial infection (serious): Note: Administration frequency may be increased if needed due to severity of infection: Infants >1 month, Children, and Adolescents:  IM: 10 mg/kg every 12 to 24 hours  I…"}, {"doc_id": "methyldopa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6590251922607422, "bge_max": 0.6590251922607422, "title": "Methyldopa: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Methyldopa: Pediatric drug information\")  Hypertension:  Oral: Initial: 10 mg/kg/day in 2 to 4 divided doses; increase or decrease daily dose every 2 days based on resp…"}, {"doc_id": "phenylephrine-pyrilamine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6586565971374512, "bge_max": 0.6586565971374512, "title": "Phenylephrine, pyrilamine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Relief of cough, congestion: Oral: Note: All dosing is presented in terms of phenylephrine hydrochloride, pyrilamine maleate, and dextromethorphan hydrobromide.  Children 6-11 years: Liquid:  Phenyleph…"}, {"doc_id": "thonzylamine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6585298180580139, "bge_max": 0.6585298180580139, "title": "Thonzylamine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Note: Contains phenylephrine 10 mg and thonzylamine 50 mg per 15 mL.  Symptoms of common cold or upper respiratory allergies:  Children 6 to <12 years: Oral: 7.5 mL every 4-6 hours; maximum 6 doses (45…"}, {"doc_id": "brompheniramine-pseudoephedrine-and-dextromethorphan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6577101945877075, "bge_max": 0.6577101945877075, "title": "Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information", "rep_snippet": "Dosing: Pediatric  Cough and upper respiratory symptoms associated with allergy or common cold: Oral:  Children 2 to <6 years: Brompheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg per 5 mL: 2.5 mL ever…"}, {"doc_id": "triprolidine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6576118469238281, "bge_max": 0.6576118469238281, "title": "Triprolidine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Triprolidine and pseudoephedrine: Pediatric drug information\")  Cold, allergy symptoms: Oral:  Liquid (triprolidine 0.938 mg and pseudoephedrine 10 mg per 1 mL):  Child…"}, {"doc_id": "brompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.657120943069458, "bge_max": 0.657120943069458, "title": "Brompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Upper respiratory tract conditions: Oral: Note: These are general dosage guidelines; also refer to product specific dosing. All dosing is presented in terms of brompheniramine maleate and phenylephrine…"}, {"doc_id": "ferric-carboxymaltose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6568490266799927, "bge_max": 0.6568490266799927, "title": "Ferric carboxymaltose: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Intravenous:  Injectafer: 750 mg/15 mL (15 mL)"}, {"doc_id": "fosinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566123962402344, "bge_max": 0.6566123962402344, "title": "Fosinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fosinopril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents >50 kg: Oral: Initial: 5 to 10 mg once daily (maximum: 40 mg once daily)"}, {"doc_id": "botulism-immune-globulin-intravenous-human-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6565619111061096, "bge_max": 0.6565619111061096, "title": "Botulism immune globulin (intravenous human): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Botulism immune globulin (intravenous human): Pediatric drug information\")  Infant botulism: Infants <1 year: IV: 50 mg/kg as a single dose as soon as diagnosis of infa…"}, {"doc_id": "dexbrompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562705039978027, "bge_max": 0.6562705039978027, "title": "Dexbrompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold/upper respiratory allergies: Oral:  Children 6 to <12 years:  Dexbrompheniramine 1 mg/phenylephrine 5 mg: One tablet or 5 mL every 4 hours (maximum: 6 tablets or 30 mL [dexbrompheniramine 6…"}, {"doc_id": "sufentanil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6561512351036072, "bge_max": 0.6561512351036072, "title": "Sufentanil: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Sufentanil: Pediatric drug information\")  Surgical anesthesia (cardiovascular surgery): IV: Children <12 years: Induction: 10 to 25 mcg/kg with 100% O2; maintenance: up…"}, {"doc_id": "interferon-alfa-n3-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6560001373291016, "bge_max": 0.6560001373291016, "title": "Interferon alfa-n3: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, Injection:  Alferon N: 5,000,000 units/mL (1 mL)"}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.655982255935669, "bge_max": 0.655982255935669, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Dosing: Pediatric  Allergic rhinitis, chronic spontaneous urticaria: Oral:  Children ≥2 to <12 years:  10 kg to 25 kg: 2.5 mg once daily (maximum: 2.5 mg/day).  >25 kg: 5 mg once daily (maximum: 5 mg/day).  Children ≥12…"}, {"doc_id": "trimeprazine-alimemazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558908224105835, "bge_max": 0.6558908224105835, "title": "Trimeprazine (alimemazine): Drug information", "rep_snippet": "Dosing: Pediatric  Cough, pruritus: Note: Initiate at low dosage and titrate as needed.  Children 2 to 12 years: Oral: Initial: 2.5 mg to 5 mg once daily at bedtime; if necessary, administer additional dosage of 2.5 mg t…"}, {"doc_id": "zinc-gluconate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6549422740936279, "bge_max": 0.6549422740936279, "title": "Zinc gluconate: Drug information", "rep_snippet": "Dosing: Pediatric  Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Children ≥12 years and Adolescents ≤17 years of age: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours a…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6536239385604858, "bge_max": 0.6536239385604858, "title": "Naproxen: Drug information", "rep_snippet": "OTC labeling: Pain, fever: 200 mg every 8 to 12 hours; if needed, may take 400 mg for the initial dose; maximum: 400 mg in any 8- to 12-hour period or 600 mg/24 hours"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6535473465919495, "bge_max": 0.6535473465919495, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}]}
{"qid": "Q4", "query": "Nonvalvular AF: 82 y, 58 kg, SCr 1.6 mg/dL — choose the apixaban dose (consider dose-reduction criteria).", "candidates": [{"doc_id": "apixaban-drug-information", "bm25_top3": 42.83625535032258, "bm25_max": 47.495711972745795, "bge_top3": 0.717582901318868, "bge_max": 0.7323477268218994, "title": "Apixaban: Drug information", "rep_snippet": "Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral): Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.  Conv…"}, {"doc_id": "tranexamic-acid-drug-information", "bm25_top3": 37.23904643368142, "bm25_max": 37.23904643368142, "bge_top3": null, "bge_max": null, "title": "Tranexamic acid: Drug information", "rep_snippet": "Dosing: Renal Impairment  IV formulation:  Tooth extraction in patients with hemophilia:  Serum creatinine 1.36 to 2.83 mg/dL: Maintenance dose of 10 mg/kg/dose twice daily  Serum creatinine 2.83 to 5.66 mg/dL: Maintenan…"}, {"doc_id": "edetate-calcium-disodium-calcium-edta-drug-information", "bm25_top3": 37.13341047778227, "bm25_max": 37.13341047778227, "bge_top3": null, "bge_max": null, "title": "Edetate calcium disodium (calcium EDTA): Drug information", "rep_snippet": "Lead nephropathy: An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine; Note: Repeat regimen monthly until lead levels are reduced to an acceptable level: IM, IV:…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 36.724793174918425, "bm25_max": 36.724793174918425, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  Deterioration of renal function during IV therapy: Stop treatment.  Clasteon [DSC]:  Serum creatinine (Scr) >5 mg/dL: Use is contraindicated.  Scr ≥2.5 to 5 mg/dL: There are no specific dosage a…"}, {"doc_id": "ribavirin-systemic-drug-information", "bm25_top3": 30.49556335628705, "bm25_max": 33.29865307021538, "bge_top3": null, "bge_max": null, "title": "Ribavirin (systemic): Drug information", "rep_snippet": "Children and Adolescents: Oral capsules, solution: Decrease ribavirin by 200 mg daily (regardless of the patient’s initial dose); decrease peginterferon alfa-2b dose by 50%; monitor and evaluate weekly. If hemoglobin <8.…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": 32.29716322191388, "bm25_max": 32.29716322191388, "bge_top3": null, "bge_max": null, "title": "Amiloride: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling: Use of amiloride in patients with diabetes mellitus, SCr >1.5 mg/dL, or BUN >30 mg/dL should be done with caution and careful monitoring; use is contraindicated in patie…"}, {"doc_id": "sodium-glycerophosphate-drug-information", "bm25_top3": 29.104979134259974, "bm25_max": 30.714486200890793, "bge_top3": null, "bge_max": null, "title": "Sodium glycerophosphate: Drug information", "rep_snippet": "Low dose, serum phosphorus level 2.3-3 mg/dL (0.74-0.96 mmol/L): 0.16-0.32 mmol/kg over 4-6 hours  Intermediate dose, serum phosphorus level 1.6-2.2 mg/dL (0.51-0.71 mmol/L): 0.32-0.64 mmol/kg over 4-6 hours  High dose,…"}, {"doc_id": "fluoride-drug-information", "bm25_top3": 30.653637730779135, "bm25_max": 30.653637730779135, "bge_top3": null, "bge_max": null, "title": "Fluoride: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluoride: Pediatric drug information\")  Oral: Children 6 months to 16 years: Fluor-A-Day, Fluorabon, Fluoritab drops, Flura-drops, Lozi-flur:  The recommended daily dos…"}, {"doc_id": "fibrinogen-concentrate-from-human-plasma-drug-information", "bm25_top3": 30.47535608364265, "bm25_max": 30.47535608364265, "bge_top3": null, "bge_max": null, "title": "Fibrinogen, concentrate from human plasma: Drug information", "rep_snippet": "Dosing: Adult  Congenital fibrinogen deficiency: IV: Note: Maintain a target fibrinogen level of 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.  When baseline fibrinogen level is known:  Fibryga: Dose (mg…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": 29.20940768866098, "bm25_max": 29.988370622890226, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):  Hemoglobin:  HCV genotype 1 (treatment-naive):  Hemoglobin <10 g/dL: Continue cu…"}, {"doc_id": "succinylcholine-suxamethonium-drug-information", "bm25_top3": 27.696319366837653, "bm25_max": 29.644935803036784, "bge_top3": null, "bge_max": null, "title": "Succinylcholine (suxamethonium): Drug information", "rep_snippet": "Dosing: Adult  Neuromuscular blockade: Dose to effect; doses will vary due to interpatient variability. Use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic…"}, {"doc_id": "ramucirumab-drug-information", "bm25_top3": 29.24765492822903, "bm25_max": 29.24765492822903, "bge_top3": null, "bge_max": null, "title": "Ramucirumab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Infusion-related reaction:  Grade 1 or 2: Reduce infusion rate by 50%  Grade 3 or 4: Permanently discontinue  Hypertension:  Severe hypertension: Interrupt infusion until controlled with…"}, {"doc_id": "daunorubicin-drug-information", "bm25_top3": 27.077659950436257, "bm25_max": 29.191331561897766, "bge_top3": null, "bge_max": null, "title": "Daunorubicin: Drug information", "rep_snippet": "Dosing: Renal Impairment  The manufacturer's labeling recommends the following adjustment: Scr >3 mg/dL: Administer 50% of normal dose  The following adjustments have also been recommended (Aronoff, 2007):  Adults: No do…"}, {"doc_id": "acetaminophen-paracetamol-drug-information", "bm25_top3": 29.151346807568547, "bm25_max": 29.151346807568547, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol): Drug information", "rep_snippet": "Weight-based dosing: Infants, Children, and Adolescents: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (APS, 2008; Sullivan, 2011); do not exceed 5 doses in 24 hours; maximum daily dose: 75 mg/kg/day not to exceed 4 g…"}, {"doc_id": "mannitol-oral-inhalation-drug-information", "bm25_top3": 29.045670746062566, "bm25_max": 29.045670746062566, "bge_top3": null, "bge_max": null, "title": "Mannitol (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Assessment of bronchial hyper-responsiveness: Inhalation: Administer in a stepwise fashion (measuring FEV1 in duplicate after each administration) until the patient has a positive response or 635 mg of man…"}, {"doc_id": "arsenic-trioxide-drug-information", "bm25_top3": 28.915964878896983, "bm25_max": 28.915964878896983, "bge_top3": null, "bge_max": null, "title": "Arsenic trioxide: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Dosage reduction levels (for hematologic and nonhematologic toxicities; tretinoin may also require dose reduction):  Initial dosage: 0.15 mg/kg once daily  First dose reduction level: 0.1…"}, {"doc_id": "hydroxyurea-hydroxycarbamide-drug-information", "bm25_top3": 28.763876078584083, "bm25_max": 28.763876078584083, "bge_top3": null, "bge_max": null, "title": "Hydroxyurea (hydroxycarbamide): Drug information", "rep_snippet": "Droxia: Initial: 15 mg/kg/day as a single daily dose. Monitor blood counts every 2 weeks; if blood counts are in an acceptable range, may increase by 5 mg/kg/day every 12 weeks until the maximum tolerated dose of 35 mg/k…"}, {"doc_id": "epoetin-alfa-drug-information", "bm25_top3": 28.67434670391337, "bm25_max": 28.67434670391337, "bge_top3": null, "bge_max": null, "title": "Epoetin alfa: Drug information", "rep_snippet": "Anemia due to zidovudine in HIV-infected patients: Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Hemoglobin levels should not exceed 12 g/dL.…"}, {"doc_id": "guanfacine-drug-information", "bm25_top3": 28.459353023155572, "bm25_max": 28.459353023155572, "bge_top3": null, "bge_max": null, "title": "Guanfacine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Guanfacine: Pediatric drug information\")  ADHD: Extended release: Children ≥6 years and Adolescents ≤17 years: Oral: Initial: 1 mg once daily; may adjust by increments…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 28.373551522526487, "bm25_max": 28.373551522526487, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Critically-ill adult patients receiving concurrent enteral/parenteral nutrition (Brown, 2006; Clark, 1995): Note: Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing pa…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2b-drug-information", "bm25_top3": 28.28462311707777, "bm25_max": 28.28462311707777, "bge_top3": null, "bge_max": null, "title": "Pegylated interferon (peginterferon) alfa-2b: Drug information", "rep_snippet": "Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for depression below  Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction with…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 27.400211037292397, "bm25_max": 27.400211037292397, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Infants and Children 6 months to 11 years: See table; use of weight to select dose is preferred; doses may be repeated every 6 to 8 hours (maximum: 4 doses/day)  Children ≥12 years and Adolescents: Refer to adult dosing.…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": 26.688758309297206, "bm25_max": 27.117981888397342, "bge_top3": null, "bge_max": null, "title": "Potassium phosphate: Drug information", "rep_snippet": "Note: The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic. Do not exceed the maximum dose of 0.24 mmol/kg/…"}, {"doc_id": "ado-trastuzumab-emtansine-drug-information", "bm25_top3": 26.953849884748863, "bm25_max": 26.953849884748863, "bge_top3": null, "bge_max": null, "title": "Ado-trastuzumab emtansine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: After a dose reduction is implemented, do not re-escalate dose.  Infusion-related reaction: Slow infusion rate or interrupt infusion. Permanently discontinue if life-threatening inf…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": 26.844537248524368, "bm25_max": 26.844537248524368, "bge_top3": null, "bge_max": null, "title": "Sorafenib: Drug information", "rep_snippet": "Third occurrence: Permanently discontinue.  Following improvement of grade 2 or 3 dermatologic toxicity to grade 0 or 1 after at least 28 days of a reduced dose, the sorafenib dose may be increased 1 dose level from the…"}, {"doc_id": "bezafibrate-united-states-not-available-drug-information", "bm25_top3": 26.811114176482434, "bm25_max": 26.811114176482434, "bge_top3": null, "bge_max": null, "title": "Bezafibrate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl ≥60 mL/minute: No dosage adjustment required  CrCl <60 mL/minute or Scr >1.5 mg/dL [>135 micromol/L]: Use is contraindicated  Dialysis: Use is contraindicated."}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 26.68075228506476, "bm25_max": 26.68075228506476, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Pantoprazole: Pediatric drug information\")  Erosive esophagitis associated with GERD:  Oral:  Children 1 to 5 years: Limited data available: 0.3, 0.6, or 1.2 mg/kg/day…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 26.601483830704943, "bm25_max": 26.601483830704943, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Furosemide: Pediatric drug information\")  Note: Oral dose equivalency (approximate) for patients with normal renal function (Brater 1983; Cody 1994; Vargo 1995): Furose…"}, {"doc_id": "amsacrine-united-states-not-available-drug-information", "bm25_top3": 26.580505007252228, "bm25_max": 26.580505007252228, "bge_top3": null, "bge_max": null, "title": "Amsacrine (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  BUN >20 mg/dL and/or serum creatinine >1.2 mg/dL: Dosage reduction is recommended; however there are no specific adjustments provided in the manufacturer’s labeling. The following adjustments ha…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 26.380426031730973, "bm25_max": 26.380426031730973, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "14 to <18.5 kg: 250 mg every 6 hours  18.5 to <23 kg: 300 mg every 6 hours  23 to <32 kg: 350 mg every 6 hours  32 to <41 kg: 400 mg every 6 hours  41 to ≤50 kg: 450 mg every 6 hours  >50 kg: 500 mg every 6 hours  Altern…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 20.79225901514837, "bm25_max": 25.27146112124734, "bge_top3": null, "bge_max": null, "title": "Rivaroxaban: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Clinical trials evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (weight range of patients enrolled in clinical trials: 33 to 209 kg)…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": 25.1013286643958, "bm25_max": 25.1013286643958, "bge_top3": null, "bge_max": null, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)  IV:  If the usual recommended dose is 10 mg/kg/dose every 8 hours:  CrCl >50 mL/minute/1.73 m2: No dosage adjustment necessary…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": 24.281252817290536, "bm25_max": 24.281252817290536, "bge_top3": null, "bge_max": null, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Initial: 8 to 10 mg/kg once daily (not to exceed 600 mg/day in the first week)  Maintenance: The target maintenance dose should be achieved over 2 to 3 weeks with dose increases of 8 to 10 mg/kg/day increments at weekly…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 23.838331029446657, "bm25_max": 23.838331029446657, "bge_top3": null, "bge_max": null, "title": "Fluconazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluconazole: Pediatric drug information\")  The daily dose of fluconazole is the same for oral and IV administration  Usual dosage range: Oral, IV: Loading dose: 6 to 12…"}, {"doc_id": "instant-glucose-and-intravenous-dextrose-drug-information", "bm25_top3": 14.152163025370536, "bm25_max": 14.209343186506327, "bge_top3": null, "bge_max": null, "title": "Instant glucose and intravenous dextrose: Drug information", "rep_snippet": "Following 50 g dose: If levels ≥130 mg/dL at 1 hour postdose, proceed to 100 g oral glucose tolerance test (Note: Cutoffs of ≥135 or ≥140 mg/dL have also been recommended; increased sensitivity and decreased specificity…"}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 11.232780356489378, "bm25_max": 11.232780356489378, "bge_top3": null, "bge_max": null, "title": "Cabozantinib: Drug information", "rep_snippet": "Pricing: US  Kit (Cometriq (100 mg Daily Dose) Oral)  1 X 80 & 1 X 20 mg (56): $17,746.61  Kit (Cometriq (140 mg Daily Dose) Oral)  1 X 80 & 3 X 20 mg (112): $17,746.61  Kit (Cometriq (60 mg Daily Dose) Oral)  20 mg (84)…"}, {"doc_id": "agalsidase-alfa-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6941511631011963, "bge_max": 0.6941511631011963, "title": "Agalsidase alfa: Drug information", "rep_snippet": "Dosing: Adult  Note: Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.  Fabry disease: IV: 0.2 mg/kg every 2 weeks"}, {"doc_id": "arginine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6794831454753876, "bge_max": 0.6885726451873779, "title": "Arginine: Drug information", "rep_snippet": "Unconfirmed/pending diagnosis: IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012); if ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day  BSA-dir…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6763085921605428, "bge_max": 0.6879256367683411, "title": "Edoxaban: Drug information", "rep_snippet": "• Nonvalvular atrial fibrillation: [US Boxed Warning]: Do not administer to nonvalvular atrial fibrillation (NVAF) patients with CrCl >95 mL/minute (calculated using the Cockcroft-Gault formula). In clinical trials, thes…"}, {"doc_id": "deflazacort-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.683749794960022, "bge_max": 0.683749794960022, "title": "Deflazacort: Drug information", "rep_snippet": "Dosing: Adult  Duchenne muscular dystrophy: Oral: Usual dose: 0.9 mg/kg once daily. Note: Round up to nearest possible dose when using tablets; round up to nearest tenth of a mL when using suspension.  Concomitant modera…"}, {"doc_id": "ethambutol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6833438873291016, "bge_max": 0.6833438873291016, "title": "Ethambutol: Drug information", "rep_snippet": "Nodular/bronchiectatic disease: 25 mg/kg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and rifampin; continue treatment until patient is culture negative on t…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761741936206818, "bge_max": 0.6830530762672424, "title": "Rosuvastatin: Drug information", "rep_snippet": "Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) and:  Age ≤75 years: High-intensity therapy:…"}, {"doc_id": "raxibacumab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6811689734458923, "bge_max": 0.6811689734458923, "title": "Raxibacumab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Drug information", "rep_snippet": "Dosing: Adult  Anthrax, prophylaxis or treatment: IV: 40 mg/kg as a single dose  Note: Administer diphenhydramine 25-50 mg (may administer oral or IV depending on the proximity to start of raxibacumab infusion) ≤1 hour p…"}, {"doc_id": "riluzole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6803048253059387, "bge_max": 0.6803048253059387, "title": "Riluzole: Drug information", "rep_snippet": "Dosing: Adult  Amyotrophic lateral sclerosis (ALS): Oral: 50 mg twice daily."}, {"doc_id": "pravastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6787061095237732, "bge_max": 0.6787061095237732, "title": "Pravastatin: Drug information", "rep_snippet": "Age 40 to 75 years and an estimated 10-year ASCVD risk ≥7.5%: Moderate to high intensity therapy: 40 to 80 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)  Secondary preve…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6770985722541809, "bge_max": 0.6770985722541809, "title": "Pitavastatin: Drug information", "rep_snippet": "Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) and:  Age ≤75 years: High intensity therapy…"}, {"doc_id": "gadopentetate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6757261753082275, "bge_max": 0.6757261753082275, "title": "Gadopentetate dimeglumine: Drug information", "rep_snippet": "Dosing: Adult  Body, CNS, head, and neck imaging: IV: 0.1 mmol/kg (0.2 mL/kg)  Note: Dosing for patients >130 kg (286 pounds) has not been studied."}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.675540030002594, "bge_max": 0.675540030002594, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Patients weighing <40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose:…"}, {"doc_id": "entecavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.675507128238678, "bge_max": 0.675507128238678, "title": "Entecavir: Drug information", "rep_snippet": ">30 kg: 1 mg once daily (oral solution or tablet)"}, {"doc_id": "obiltoxaximab-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6749510169029236, "bge_max": 0.6749510169029236, "title": "Obiltoxaximab (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department) : Drug information", "rep_snippet": "Dosing: Adult  Anthrax, inhalational (treatment and prophylaxis): IV: Note: Premedicate with diphenhydramine prior to infusion.  <40 kg: 24 mg/kg/dose as a single dose  >40 kg: 16 mg/kg/dose as a single dose"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6745052337646484, "bge_max": 0.6745052337646484, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial therapy and patients not controlled on valsartan 80 mg or nebivolol ≤10 mg: Nebivolol 5 mg/valsartan 80 mg once daily. Note: May be substituted for individual components in pati…"}, {"doc_id": "levetiracetam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6744433641433716, "bge_max": 0.6744433641433716, "title": "Levetiracetam: Drug information", "rep_snippet": "Children ≥6 years and weighing 20 kg to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg/dose to the maximum recommended dose of 750 mg twice daily.  Children ≥6 years (weighing >40 kg) and Adolescent…"}, {"doc_id": "edaravone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6740918755531311, "bge_max": 0.6740918755531311, "title": "Edaravone: Drug information", "rep_snippet": "Dosing: Adult  Amyotrophic lateral sclerosis  (ALS): IV:  Initial cycle: 60 mg once daily for 14 days, followed by a 14-day drug-free period.  Subsequent cycles: 60 mg once daily for 10 days within a 14-day period, follo…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6739649176597595, "bge_max": 0.6739649176597595, "title": "Gadodiamide: Drug information", "rep_snippet": "Dosing: Adult  Note: Dosing for patients >130 kg (286 pounds) has not been studied.  Body imaging: IV:  Kidney: 0.05 mmol/kg (0.1 mL/kg)  Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.1 mmol/kg (0.2 mL/…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.673707902431488, "bge_max": 0.673707902431488, "title": "Amiodarone: Drug information", "rep_snippet": "Dosing: Adult  Note: Lower loading and maintenance doses are preferable in women and all patients with low body weight.  Ventricular arrhythmias:  Prevention of recurrent life-threatening ventricular arrhythmias (eg, VF…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6715765297412872, "bge_max": 0.6732276678085327, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Alternate fixed dosing for patients weighing ≥15 kg who are able to swallow tablets: Dosing approximates lopinavir 230 mg/m2/dose:  BSA ≥0.6 to <0.9 m2: Lopinavir 200 mg twice daily  BSA ≥0.9 to <1.4 m2: Lopinavir 300 mg…"}, {"doc_id": "agalsidase-beta-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6731827855110168, "bge_max": 0.6731827855110168, "title": "Agalsidase beta: Drug information", "rep_snippet": "Dosing: Adult  Fabry disease: IV: 1 mg/kg every 2 weeks"}, {"doc_id": "vigabatrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6727849841117859, "bge_max": 0.6727849841117859, "title": "Vigabatrin: Drug information", "rep_snippet": "Children and Adolescents 10 to <17 years and 25 to 60 kg: Initial: 250 mg twice daily; increase daily dose by 500 mg increments at weekly intervals based on response and tolerability. Recommended dose: 1,000 mg twice dai…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6724650263786316, "bge_max": 0.6724650263786316, "title": "Simvastatin: Drug information", "rep_snippet": "Age 40 to 75 years and an estimated 10-year ASCVD risk ≥7.5%: Moderate to high intensity therapy: 20 to 40 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)  Secondary preve…"}, {"doc_id": "nadolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6705260276794434, "bge_max": 0.6705260276794434, "title": "Nadolol: Drug information", "rep_snippet": "Secondary prophylaxis: Initial: 40 mg once daily; adjust to maximal tolerated dose"}, {"doc_id": "afatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6705107688903809, "bge_max": 0.6705107688903809, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Adult  Non-small cell lung cancer (NSCLC), metastatic, with nonresistant EGFR mutations: Oral: 40 mg once daily until disease progression or unacceptable toxicity  NSCLC, metastatic squamous (previously treated):…"}, {"doc_id": "dimethyl-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6701893210411072, "bge_max": 0.6701893210411072, "title": "Dimethyl fumarate: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis (relapsing): Oral: Initial: 120 mg twice daily; after 7 days, increase to the maintenance dose: 240 mg twice daily"}, {"doc_id": "darunavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6700394153594971, "bge_max": 0.6700394153594971, "title": "Darunavir: Drug information", "rep_snippet": "≥40 kg: Darunavir 800 mg (tablet or combination of tablets) plus ritonavir 100 mg once daily  Treatment-experienced patients with at least one darunavir resistance-associated mutation: Children ≥3 years of age weighing ≥…"}, {"doc_id": "gadobenate-dimeglumine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6698366403579712, "bge_max": 0.6698366403579712, "title": "Gadobenate dimeglumine: Drug information", "rep_snippet": "Dosing: Adult  CNS lesions (MRI): IV: 0.1 mmol/kg (0.2 mL/kg); may begin imaging immediately after administration  Renal or aorto-ilio-femoral vasculature imaging (MRA): IV: 0.1 mmol/kg (0.2 mL/kg); may begin imaging imm…"}, {"doc_id": "teriflunomide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6692699193954468, "bge_max": 0.6692699193954468, "title": "Teriflunomide: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis: Adults: Oral: 7 mg or 14 mg once daily"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688148975372314, "bge_max": 0.6688148975372314, "title": "Fluvastatin: Drug information", "rep_snippet": "Immediate release: 40 mg twice daily.  Extended release: 80 mg once daily.  Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk ≥7.5%: High-intensity therapy necessary; use alternate statin ther…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.668418824672699, "bge_max": 0.668418824672699, "title": "Verapamil: Drug information", "rep_snippet": "Calan SR, Isoptin SR (Canadian product): Initial: 180 mg once daily in the morning; in patients with increased response to verapamil (eg, small stature): 120 mg once daily; if inadequate response to 180 mg once daily, ma…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6680369973182678, "bge_max": 0.6680369973182678, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing; adjust for renal impairment.  Breast cancer: Patients >60 years: IV: CMF regimen: 30 mg/m2 days 1 and 8 every 4 weeks (in combination with cyclophosphamide and fluorouracil) for…"}, {"doc_id": "alpha-1-proteinase-inhibitor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6679924726486206, "bge_max": 0.6679924726486206, "title": "Alpha-1 proteinase inhibitor: Drug information", "rep_snippet": "Dosing: Adult  Note: The vial strength (mg) of some products (ie, Prolastin-C, Zemaira) varies by manufacturer lot; consult individual vial labels for exact amount prior to preparation for administration.  Alpha1-antitry…"}, {"doc_id": "bevacizumab-including-biosimilars-of-bevacizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6679758429527283, "bge_max": 0.6679758429527283, "title": "Bevacizumab (including biosimilars of bevacizumab): Drug information", "rep_snippet": "Dosing: Adult  Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.  Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6669391989707947, "bge_max": 0.6669391989707947, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Patients previously taking a moderate to high dose ACE inhibitor (ie, >10 mg/day of enalapril or equivalent) or ARB (ie, >160 mg/day of valsartan or equivalent): Initial: Sacubitril 49 mg/valsartan 51 mg twice daily. Dou…"}, {"doc_id": "tezacaftor-and-ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6664406657218933, "bge_max": 0.6664406657218933, "title": "Tezacaftor and ivacaftor: Drug information", "rep_snippet": "Dosing: Hepatic Impairment (Adult)  Mild impairment (Child-Pugh class A): No dosage adjustment necessary.  Moderate impairment (Child-Pugh class B): Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning. The eveni…"}, {"doc_id": "dexrazoxane-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6664218306541443, "bge_max": 0.6664218306541443, "title": "Dexrazoxane: Drug information", "rep_snippet": "Dosing: Adult  Prevention of doxorubicin cardiomyopathy: IV: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m2:doxorubicin 50 mg/m2). Note: Cardiac monitoring should continue during dexrazoxane therapy; doxo…"}, {"doc_id": "norepinephrine-noradrenaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6660460233688354, "bge_max": 0.6660460233688354, "title": "Norepinephrine (noradrenaline): Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is stated in terms of norepinephrine base.  Hypotension/shock: Continuous IV infusion:  Initial: 8 to 12 mcg/minute; titrate to desired response. Usual maintenance range: 2 to 4 mcg/minute; dosa…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6659428477287292, "bge_max": 0.6659428477287292, "title": "Atorvastatin: Drug information", "rep_snippet": "Age 40 to 75 years and an estimated 10-year ASCVD risk ≥7.5%: Moderate- to high-intensity therapy: 10 to 80 mg once daily  Secondary prevention:  Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or per…"}]}
{"qid": "Q5", "query": "Acute DVT treatment in normal renal function — what is the enoxaparin dosing regimen?", "candidates": [{"doc_id": "enoxaparin-drug-information", "bm25_top3": 33.262467856573664, "bm25_max": 35.4490273951492, "bge_top3": 0.6109714309374491, "bge_max": 0.6331202983856201, "title": "Enoxaparin: Drug information", "rep_snippet": "Prevention of recurrent venous thromboembolism in pregnancy (off-label use): 40 mg once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates 2012).  DVT treatment (acute) and pulmonary embolism…"}, {"doc_id": "pregabalin-drug-information", "bm25_top3": 23.465835135951338, "bm25_max": 25.307250280603853, "bge_top3": null, "bge_max": null, "title": "Pregabalin: Drug information", "rep_snippet": "Extended release: Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (CrCl ≥60 mL/minu…"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": 22.26199562346196, "bm25_max": 22.26199562346196, "bge_top3": null, "bge_max": null, "title": "Celecoxib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; however, since <1% of the drug is excreted in the urine, dosage adjustment is not necessary…"}, {"doc_id": "toremifene-drug-information", "bm25_top3": 21.74812145051329, "bm25_max": 21.74812145051329, "bge_top3": null, "bge_max": null, "title": "Toremifene: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments listed in the manufacturer’s labeling. However, pharmacokinetics in patients with renal impairment are similar to those in patients with normal renal function and…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 21.596971427595854, "bm25_max": 21.596971427595854, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  No dosage adjustment necessary if renal function is normal; however, in patients with hepatic impairment and concomitant severe renal impairment, a dosage reduction or prolonged dosing interva…"}, {"doc_id": "magnesium-chloride-drug-information", "bm25_top3": 21.029692819649814, "bm25_max": 21.029692819649814, "bge_top3": null, "bge_max": null, "title": "Magnesium chloride: Drug information", "rep_snippet": "Dosing: Adult  Note: Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum levels may be transiently normal for a few hours after a dose is given; therefore, aim fo…"}, {"doc_id": "fondaparinux-drug-information", "bm25_top3": 12.809434413438268, "bm25_max": 20.87536181761231, "bge_top3": 0.574896514415741, "bge_max": 0.574896514415741, "title": "Fondaparinux: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl >50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling. Total clearance is reduced ~25% compared to patients with normal renal function.  CrCl 30 to 50 mL/mi…"}, {"doc_id": "aflibercept-ziv-aflibercept-systemic-drug-information", "bm25_top3": 20.838813694278528, "bm25_max": 20.838813694278528, "bge_top3": null, "bge_max": null, "title": "Aflibercept (ziv-aflibercept) (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, need for adjustment is not likely because exposure in patients with mild, moderate, and severe impairment was si…"}, {"doc_id": "protamine-sulfate-drug-information", "bm25_top3": 20.82182066000208, "bm25_max": 20.82182066000208, "bge_top3": 0.551591545343399, "bge_max": 0.5521195530891418, "title": "Protamine sulfate: Drug information", "rep_snippet": "Dalteparin, nadroparin, and tinzaparin: 1 mg protamine for every 100 anti-Xa units of LMWH administered in the past 3 to 5 half-lives; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If life…"}, {"doc_id": "bezlotoxumab-drug-information", "bm25_top3": 20.527290696373925, "bm25_max": 20.527290696373925, "bge_top3": null, "bge_max": null, "title": "Bezlotoxumab: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling, although in a pharmacokinetic study, no clinically meaningful differences in exposure between patients with renal impairm…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": 20.156558997385442, "bm25_max": 20.156558997385442, "bge_top3": null, "bge_max": null, "title": "Indomethacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral/rectal: There are no dosage adjustments provided in the manufacturer's labeling; not recommended in patients with advanced renal disease.  Injection: If anuria or marked oliguria (urinary o…"}, {"doc_id": "potassium-phosphate-and-sodium-phosphate-drug-information", "bm25_top3": 20.141770167959052, "bm25_max": 20.141770167959052, "bge_top3": null, "bge_max": null, "title": "Potassium phosphate and sodium phosphate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustment provided in the manufacturer’s labeling. Use with caution. Contraindicated in patients with severe impairment (<30% of normal function)."}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 19.810844115123338, "bm25_max": 19.810844115123338, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Use with caution in patients with GFR <10 mL/minute (AUC increased by 35% compared to patients with normal renal function); however, no dosage adjustment is provided in the manufacturer's labeli…"}, {"doc_id": "neostigmine-drug-information", "bm25_top3": 19.66819110533865, "bm25_max": 19.66819110533865, "bge_top3": null, "bge_max": null, "title": "Neostigmine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in manufacturer's labeling. The manufacturer recommends close monitoring in patients with impaired renal function.  The following adjustments have been r…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 19.573427616182517, "bm25_max": 19.573427616182517, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; avoid use in advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for N…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 19.50570853913478, "bm25_max": 19.50570853913478, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment  Deterioration of renal function during IV therapy: Stop treatment.  Clasteon [DSC]:  Serum creatinine (Scr) >5 mg/dL: Use is contraindicated.  Scr ≥2.5 to 5 mg/dL: There are no specific dosage a…"}, {"doc_id": "alfentanil-drug-information", "bm25_top3": 19.473971966795908, "bm25_max": 19.473971966795908, "bge_top3": null, "bge_max": null, "title": "Alfentanil: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; use with caution. The pharmacokinetics of alfentanil were evaluated in adult patients with chronic renal failure and comp…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": 19.421915168496426, "bm25_max": 19.421915168496426, "bge_top3": null, "bge_max": null, "title": "Potassium phosphate: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.  Oral: Contraindicated in patients with severe impairment (<30% of normal function) or with hyperphosph…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": 19.386541463759976, "bm25_max": 19.386541463759976, "bge_top3": null, "bge_max": null, "title": "Melphalan: Drug information", "rep_snippet": "Dosing: Renal Impairment  The manufacturer's labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:  Oral: Moderate to severe renal impairment: Consider…"}, {"doc_id": "entecavir-drug-information", "bm25_top3": 19.206682306460454, "bm25_max": 19.206682306460454, "bge_top3": null, "bge_max": null, "title": "Entecavir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Daily-dosage regimen preferred:  CrCl ≥50 mL/minute: No dosage adjustment necessary.  CrCl 30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hour…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 19.13785612124717, "bm25_max": 19.13785612124717, "bge_top3": 0.5567486882209778, "bge_max": 0.5567486882209778, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Psoriasis (severe):  Abnormal renal function prior to treatment: Use is contraindicated.  Abnormal renal function during treatment:  Serum creatinine levels ≥25% above pretreatment levels: Take…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 19.126846561843106, "bm25_max": 19.126846561843106, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in manufacturer’s labeling. Efficacy of hydrochlorothiazide is limited in patients with CrCl <30 mL/minute; use is contraindicated in patients with anuri…"}, {"doc_id": "medroxyprogesterone-acetate-drug-information", "bm25_top3": 18.793053182820085, "bm25_max": 18.793053182820085, "bge_top3": null, "bge_max": null, "title": "Medroxyprogesterone acetate: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Medroxyprogesterone is extensively metabolized in the liver and elimination is significantly reduced in patients with advanced hepatic disease. Most products are contraindicated in patients wi…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 18.41910064710702, "bm25_max": 18.41910064710702, "bge_top3": 0.5760117769241333, "bge_max": 0.5760117769241333, "title": "Vancomycin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Note: Initial IV dosing in nonobese patients should be based on actual body weight; subsequent dosing should generally be adjusted based on serum trough vancomycin concentrations and re…"}, {"doc_id": "bivalirudin-drug-information", "bm25_top3": 17.483814038129303, "bm25_max": 17.483814038129303, "bge_top3": null, "bge_max": null, "title": "Bivalirudin: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. No dosage adjustment is needed in elderly patients with normal renal function. Puncture site hemorrhage and catheterization site hemorrhage were seen in more patients ≥65 years o…"}, {"doc_id": "immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information", "bm25_top3": 13.765276501146197, "bm25_max": 13.765276501146197, "bge_top3": null, "bge_max": null, "title": "Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary ed…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 10.97343614863252, "bm25_max": 10.97343614863252, "bge_top3": 0.564117431640625, "bge_max": 0.564117431640625, "title": "Warfarin: Drug information", "rep_snippet": "• Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 10.734712521048646, "bm25_max": 10.734712521048646, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "• Renal impairment: Evaluate renal function prior to and during therapy, particularly if used in patients with any degree of preexisting renal impairment or in any condition that may result in a decline in renal function…"}, {"doc_id": "cidofovir-drug-information", "bm25_top3": 10.101261252854496, "bm25_max": 10.101261252854496, "bge_top3": null, "bge_max": null, "title": "Cidofovir: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Nephrotoxicity:  Renal impairment is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as 1 or 2 doses of…"}, {"doc_id": "cytomegalovirus-immune-globulin-drug-information", "bm25_top3": 9.703181502938612, "bm25_max": 9.703181502938612, "bge_top3": null, "bge_max": null, "title": "Cytomegalovirus immune globulin: Drug information", "rep_snippet": "• Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characteriz…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 9.489725641030475, "bm25_max": 9.489725641030475, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "• Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported with sitagliptin. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pan…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 9.486401729126616, "bm25_max": 9.486401729126616, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Nephropathy (tablet):  There have been rare but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. So…"}, {"doc_id": "botulism-immune-globulin-intravenous-human-drug-information", "bm25_top3": 9.466796985613062, "bm25_max": 9.466796985613062, "bge_top3": null, "bge_max": null, "title": "Botulism immune globulin (intravenous human): Drug information", "rep_snippet": "• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with IGIV use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxe…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 9.393439645396754, "bm25_max": 9.393439645396754, "bge_top3": null, "bge_max": null, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": 9.393439645396754, "bm25_max": 9.393439645396754, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 9.233153318242703, "bm25_max": 9.233153318242703, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the rena…"}, {"doc_id": "zoledronic-acid-drug-information", "bm25_top3": 8.87185878452279, "bm25_max": 8.87185878452279, "bge_top3": null, "bge_max": null, "title": "Zoledronic acid: Drug information", "rep_snippet": "• Renal impairment: Use with caution in mild to moderate renal impairment. Single and multiple infusions in patients with both normal and impaired renal function have been associated with renal deterioration, resulting i…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 7.393668983612599, "bm25_max": 7.393668983612599, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "glucarpidase-drug-information", "bm25_top3": 7.344944261542576, "bm25_max": 7.344944261542576, "bge_top3": null, "bge_max": null, "title": "Glucarpidase: Drug information", "rep_snippet": "Use  Methotrexate toxicity: Treatment of toxic methotrexate plasma concentrations (>1 micromole/L) in patients with delayed clearance due to renal impairment.  Limitations of use: Due to the risk of subtherapeutic methot…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 7.128965212073208, "bm25_max": 7.128965212073208, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "Pharmacodynamics/Kinetics: Additional Considerations  Renal function impairment: Formoterol systemic exposure (AUC0-12) in subjects with moderate renal impairment (CrCl 45 mL/minute) is expected to be approximately 45% h…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": 5.348368923886582, "bm25_max": 5.348368923886582, "bge_top3": null, "bge_max": null, "title": "Cobicistat: Drug information", "rep_snippet": "Renal: Nephrolithiasis (<2%), renal disease (<2%), decreased creatinine clearance (no effect on renal glomerular function in patients with normal renal function), increased serum creatinine, renal insufficiency"}, {"doc_id": "nadroparin-united-states-not-available-drug-information", "bm25_top3": 5.073718568080253, "bm25_max": 5.073718568080253, "bge_top3": 0.5829083025455475, "bge_max": 0.5946575403213501, "title": "Nadroparin (United States: Not available): Drug information", "rep_snippet": "Use  Fraxiparine:  Acute coronary syndromes: Treatment of unstable angina and non-ST-elevation myocardial infarction (NSTEMI) myocardial infarction (ie, non-Q wave MI)  Anticoagulation during hemodialysis: Prevention of…"}, {"doc_id": "acyclovir-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5827678442001343, "bge_max": 0.5827678442001343, "title": "Acyclovir (systemic): Drug information", "rep_snippet": "Peritoneal dialysis (PD): 2.5 to 5 mg/kg/dose every 24 hours; no supplemental dose needed (Aronoff 2007). Note: Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.  Continuous re…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5826100707054138, "bge_max": 0.5826100707054138, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5691937804222107, "bge_max": 0.5816107988357544, "title": "Rivaroxaban: Drug information", "rep_snippet": "Postoperative DVT thromboprophylaxis: Oral: Note: Initiate therapy after hemostasis has been established, 6 to 10 hours postoperatively.  Knee replacement: 10 mg once daily; recommended total duration of therapy: 12 days…"}, {"doc_id": "tinzaparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5769103169441223, "bge_max": 0.5769103169441223, "title": "Tinzaparin: Drug information", "rep_snippet": "Dosing: Adult  Note: 1 mg of tinzaparin equals 70 to 120 units of anti-Xa activity  DVT and/or PE treatment: SubQ: 175 anti-Xa units/kg once daily; maximum dose: 18,000 anti-Xa units/day. Note: In patients with VTE and w…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5758571028709412, "bge_max": 0.5758571028709412, "title": "Dalteparin: Drug information", "rep_snippet": "DVT (with or without PE; noncancer-related) treatment (off-label use): SubQ: 200 units/kg once daily (AHA [Jaff 2011]; Feissinger 1996; Wells 2005). Note: In patients with VTE and without cancer, oral anticoagulants are…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5703617930412292, "bge_max": 0.5703617930412292, "title": "Fluconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5673536658287048, "bge_max": 0.5673536658287048, "title": "Apixaban: Drug information", "rep_snippet": "Use  Deep vein thrombosis: Treatment of deep vein thrombosis; to reduce the risk of recurrent deep vein thrombosis following initial therapy  Note: The American College of Chest Physicians (ACCP) guidelines for VTE sugge…"}, {"doc_id": "oxaprozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5642333030700684, "bge_max": 0.5642333030700684, "title": "Oxaprozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  In general, NSAIDs are not recommended for use in patients with advanced renal disease but the manufacturer of oxaprozin does provide some guidelines for adjustment in renal dysfunction.  Severe…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5589075684547424, "bge_max": 0.5633203387260437, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "mitoxantrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5631033778190613, "bge_max": 0.5631033778190613, "title": "Mitoxantrone: Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "idarubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5630563497543335, "bge_max": 0.5630563497543335, "title": "Idarubicin: Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "epirubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5628319978713989, "bge_max": 0.5628319978713989, "title": "Epirubicin: Drug information", "rep_snippet": "Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate e…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.562157928943634, "bge_max": 0.562157928943634, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring o…"}, {"doc_id": "daunorubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5620827674865723, "bge_max": 0.5620827674865723, "title": "Daunorubicin: Drug information", "rep_snippet": "Dexrazoxane: Adults: 1000 mg/m2 (maximum dose: 2000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m2 (maximum dose: 1000 mg) IV over 1 to 2 hours day 3;…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5607113242149353, "bge_max": 0.5612095594406128, "title": "Edoxaban: Drug information", "rep_snippet": "Long-term (first 3 months): 3 months is the minimum duration for most patients without cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016)  Extended therapy (after first 3 mont…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5591104030609131, "bge_max": 0.5591104030609131, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, sign…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5590262413024902, "bge_max": 0.5590262413024902, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Normal renal function dosing of 750 or 1,000 mg daily (treatment of tuberculosis only) (CDC 2003): CrCl <30 mL/minute: Administer 750 or 1,000 mg 3 times per week (in hemodialysis patients administer after dialysis on di…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5581686496734619, "bge_max": 0.5581686496734619, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5567837357521057, "bge_max": 0.5567837357521057, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5566411018371582, "bge_max": 0.5566411018371582, "title": "Voriconazole: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5548595190048218, "bge_max": 0.5556745529174805, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range:  Oral: 250 to 500 mg every 6 hours  IM, IV: 1 to 2 g every 4 to 6 hours or 50 to 250 mg/kg/day in divided doses (maximum: 12 g/day)  Endocarditis, treatment (off-label dose; AHA [Baddou…"}, {"doc_id": "colistin-colistimethate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.555402398109436, "bge_max": 0.555402398109436, "title": "Colistin (colistimethate): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "meropenem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5546284317970276, "bge_max": 0.5546284317970276, "title": "Meropenem: Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Kuti 2005; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close mon…"}, {"doc_id": "aztreonam-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5544430613517761, "bge_max": 0.5544430613517761, "title": "Aztreonam (systemic): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring o…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5539857745170593, "bge_max": 0.5539857745170593, "title": "Digoxin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Oral, IV:  Loading dose: There are no dosage adjustments provided in the manufacturer’s labeling, however, 50% to 70% of a digoxin dose is excreted unchanged in the urine. The following…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5535215735435486, "bge_max": 0.5535215735435486, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Note: Estimation of renal function for the purpose of drug dosing should be done using the Modification of Diet in Renal Disease (MDRD) formula. Dosage recommendations are expressed as g…"}, {"doc_id": "recombinant-human-growth-hormone-somatropin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5534780621528625, "bge_max": 0.5534780621528625, "title": "Recombinant human growth hormone (somatropin): Drug information", "rep_snippet": "Note: Therapy should be discontinued when patient has reached satisfactory height, when epiphyses have fused, or when the patient ceases to respond. Some guidelines recommend discontinuing therapy when growth velocity is…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5534287691116333, "bge_max": 0.5534287691116333, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5502134561538696, "bge_max": 0.5502134561538696, "title": "Simvastatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to moderate impairment: No dosage adjustment necessary; simvastatin does not undergo significant renal excretion.  Severe impairment: Initial: 5 mg once daily with close monitoring."}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5495292544364929, "bge_max": 0.5495292544364929, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "• Renal impairment: Assess renal function prior to initiation and periodically during treatment. Do not initiate therapy in patients with eGFR <60 mL/minute/1.73 m2 and discontinue use if eGFR falls persistently below 60…"}]}
{"qid": "Q6", "query": "Type 2 diabetes, eGFR 28 — is metformin contraindicated or adjusted; what’s the recommendation?", "candidates": [{"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 27.9330622123691, "bm25_max": 34.778487046295396, "bge_top3": 0.6453151305516561, "bge_max": 0.6554314494132996, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 27.631429093997028, "bm25_max": 33.24206738888916, "bge_top3": 0.641931802034378, "bge_max": 0.6471245884895325, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral: Initial doses should be based on current daily dose of alogliptin and metformin; Range: Alogliptin 12.5 mg/metformin 500 to 1000 mg twice daily. Maximum: Alogliptin 12.5 mg…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 27.385774918846916, "bm25_max": 30.964164440900046, "bge_top3": 0.6598709225654602, "bge_max": 0.665117621421814, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 25.994757005006996, "bm25_max": 30.96328729909626, "bge_top3": 0.6526504556337992, "bge_max": 0.657699465751648, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 23.910027359277333, "bm25_max": 26.483867111153277, "bge_top3": 0.651329775651296, "bge_max": 0.6632375717163086, "title": "Metformin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) when hyperglycemia cannot be managed with diet and exercise alone.  Note: If not contraindicated and if tolerated, metf…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 24.537360526705115, "bm25_max": 26.329609912996467, "bge_top3": 0.6475590070088705, "bge_max": 0.6544746160507202, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 23.904435084881, "bm25_max": 25.194852599633865, "bge_top3": 0.6349797546863556, "bge_max": 0.6366363167762756, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metfo…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 23.995568292205476, "bm25_max": 24.916174800263757, "bge_top3": 0.6340417265892029, "bge_max": 0.6460044384002686, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Management of adults with type 2 diabetes mellitus as an adjunct to diet and exercise when treatment with both saxagliptin and metformin is appropriate."}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 23.82789783100148, "bm25_max": 24.567492904787386, "bge_top3": 0.6352666020393372, "bge_max": 0.6471245884895325, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "• Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 23.31799136802744, "bm25_max": 24.440466799108766, "bge_top3": 0.640813151995341, "bge_max": 0.6509408950805664, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when treatment with both sitagliptin and metformin is appropriate"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 23.404857649662482, "bm25_max": 24.440466799108766, "bge_top3": 0.6481696764628092, "bge_max": 0.656676709651947, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate."}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 23.410906063043228, "bm25_max": 24.346078336978167, "bge_top3": 0.6448043386141459, "bge_max": 0.6480286717414856, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate. Note: Empagliflozin is…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 22.362086048954346, "bm25_max": 22.475733789108286, "bge_top3": 0.6420749723911285, "bge_max": 0.6471245884895325, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "• Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m2; or with a history of hepatic disease, alcoholism…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 21.19228756575489, "bm25_max": 21.19228756575489, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "insulin-nph-drug-information", "bm25_top3": 20.61161117291105, "bm25_max": 20.61161117291105, "bge_top3": null, "bge_max": null, "title": "Insulin NPH: Drug information", "rep_snippet": "General considerations for insulin use in type 2 diabetes:  Timing of  initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recomme…"}, {"doc_id": "insulin-regular-drug-information", "bm25_top3": 20.475125511750555, "bm25_max": 20.475125511750555, "bge_top3": null, "bge_max": null, "title": "Insulin regular: Drug information", "rep_snippet": "General considerations for insulin use in type 2 diabetes (off-label):  Timing of  initiation: Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents…"}, {"doc_id": "insulin-glargine-drug-information", "bm25_top3": 19.716651751792686, "bm25_max": 19.716651751792686, "bge_top3": null, "bge_max": null, "title": "Insulin glargine: Drug information", "rep_snippet": "Surgical patients: On the morning of surgery or procedure, give 60% to 80% of the usual dose of long-acting analogs (eg, detemir, glargine, or degludec) (ADA 2017d)  General considerations for insulin use in type 2 diabe…"}, {"doc_id": "insulin-degludec-and-insulin-aspart-drug-information", "bm25_top3": 19.40919825229515, "bm25_max": 19.40919825229515, "bge_top3": null, "bge_max": null, "title": "Insulin degludec and insulin aspart: Drug information", "rep_snippet": "Missed dose: Administer next dose with the next main meal of the day then resume normal dosing schedule; do not administer an extra dose to make up for the missed dose.  General considerations for insulin use in type 2 d…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 14.9367385466279, "bm25_max": 14.9367385466279, "bge_top3": 0.6465510129928589, "bge_max": 0.6465510129928589, "title": "Empagliflozin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control; risk reduction of cardiovascular mortality in adults with type 2 diabetes mellitus and…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 12.34396822140797, "bm25_max": 12.34396822140797, "bge_top3": 0.6231862306594849, "bge_max": 0.6231862306594849, "title": "Canagliflozin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise to improve glycemic control  Guideline recommendation: In patients with established a…"}, {"doc_id": "liraglutide-drug-information", "bm25_top3": 11.170948599709021, "bm25_max": 11.170948599709021, "bge_top3": null, "bge_max": null, "title": "Liraglutide: Drug information", "rep_snippet": "Use  Chronic weight management (Saxenda): As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 kg/m2 or greater (ob…"}, {"doc_id": "inhaled-insulin-drug-information", "bm25_top3": 6.752243544863198, "bm25_max": 6.752243544863198, "bge_top3": null, "bge_max": null, "title": "Inhaled insulin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 1 or type 2: Treatment of diabetes mellitus (type 1 or type 2) to improve glycemic control  Guideline recommendations: Inhaled insulin is generally not used in patients with type 2 diabetes b…"}, {"doc_id": "pramlintide-drug-information", "bm25_top3": 5.254427439911396, "bm25_max": 5.254427439911396, "bge_top3": null, "bge_max": null, "title": "Pramlintide: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 1 and type 2: Adjunct treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin ther…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6357681353886923, "bge_max": 0.6477711200714111, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Dosing: Adult  Diabetes mellitus, type 2: Oral:  Patients with inadequate glycemic control on diet and exercise alone: Initial: Glyburide 1.25 mg/metformin 250 mg once daily with a meal; patients with HbA1c >9% or fastin…"}]}
{"qid": "Q7", "query": "Uncomplicated cystitis, eGFR 25 — is nitrofurantoin appropriate?", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 28.122712324236833, "bm25_max": 33.5773193514878, "bge_top3": 0.6379707852999369, "bge_max": 0.7166274785995483, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Use  Cystitis, acute uncomplicated:  Nitrofurantoin monohydrate/macrocrystals (Macrobid): Treatment of acute uncomplicated cystitis caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus in pat…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 8.561080145395225, "bm25_max": 11.773933321304476, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Use: Off-Label  Cystitis, acute uncomplicated"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 11.31976385779329, "bm25_max": 11.31976385779329, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Use  Chronic bronchitis, acute bacterial exacerbation: Treatment of acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (non-beta-lactamase-producing strains only…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": 8.480491983431595, "bm25_max": 10.623643761176915, "bge_top3": 0.5674441456794739, "bge_max": 0.5758674144744873, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Cystitis, acute uncomplicated: Note: Use for uncomplicated urinary tract infections is discouraged due to significant E. coli resistance and safety issues; reserve for clinical situations where other appropriate treatmen…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 7.817892906569796, "bm25_max": 7.817892906569796, "bge_top3": 0.5604504346847534, "bge_max": 0.5604504346847534, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Use  Treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections (uncomplicated), urethral and cervical gonorrhea (acute, uncomplicated), urethritis and cervic…"}, {"doc_id": "fosfomycin-drug-information", "bm25_top3": 7.659282697595874, "bm25_max": 7.659282697595874, "bge_top3": 0.5907268524169922, "bge_max": 0.5907268524169922, "title": "Fosfomycin: Drug information", "rep_snippet": "Use  Uncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.  Limitations of use: No…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": 7.482758481626355, "bm25_max": 7.482758481626355, "bge_top3": null, "bge_max": null, "title": "Cefaclor: Drug information", "rep_snippet": "Skin and skin structure infections, uncomplicated: Treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible) or S. pyogenes (capsules and oral suspension only).…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": 7.141079809896908, "bm25_max": 7.141079809896908, "bge_top3": null, "bge_max": null, "title": "Trimethoprim: Drug information", "rep_snippet": "Use  Cystitis, acute uncomplicated, treatment (tablets, oral solution): Treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of Escherichia coli, Proteus mirabilis, Klebsiell…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 6.921909498741327, "bm25_max": 6.921909498741327, "bge_top3": null, "bge_max": null, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 6.411896240042369, "bm25_max": 6.411896240042369, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Urinary tract infection (off-label dose):  Cystitis, acute uncomplicated (empiric use [avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months] or targeted therapy [if the isolate is…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": 6.0333962539240815, "bm25_max": 6.0333962539240815, "bge_top3": null, "bge_max": null, "title": "Sulfanilamide: Drug information", "rep_snippet": "• Appropriate use: Topical antifungal agents or oral fluconazole are generally considered to be the preferred treatment for uncomplicated vulvovaginal candidiasis (Pappas, 2009; Reef, 1993; Sobel, 2007). Sulfanilamide is…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 5.913156272002103, "bm25_max": 5.913156272002103, "bge_top3": 0.5737186074256897, "bge_max": 0.5737186074256897, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": 5.809247619666815, "bm25_max": 5.809247619666815, "bge_top3": 0.5630711317062378, "bge_max": 0.5630711317062378, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "• G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.  • Pediatric: Safety and efficacy have not been established in children; other quinolones ha…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 4.359337635677836, "bm25_max": 4.957687118470339, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 4.830986087747629, "bm25_max": 4.830986087747629, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 4.621207846861255, "bm25_max": 4.621207846861255, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": 4.5973162875825295, "bm25_max": 4.5973162875825295, "bge_top3": null, "bge_max": null, "title": "Mirabegron: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl 30 to 89 mL/minute or eGFR 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  CrCl 15 to 29 mL/minute or eGFR 15 to 29 mL/minute/1.73 m2: Do not exceed 25 mg once daily.  CrCl <15…"}, {"doc_id": "osimertinib-drug-information", "bm25_top3": 4.475830642416302, "bm25_max": 4.475830642416302, "bge_top3": null, "bge_max": null, "title": "Osimertinib: Drug information", "rep_snippet": "Mechanism of Action  Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which binds to select mutant forms of EGFR, including T790M, L858R, and exon 19 deletion at lower conc…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 4.446074441152092, "bm25_max": 4.446074441152092, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "• Elderly: Avoid use of spironolactone doses >25 mg/day in elderly patients with heart failure or with reduced renal function (eg, CrCl <30 mL/minute or eGFR ≤30 mL/minute/1.73 m2 [Yancy 2013 ]).  Other warnings/precauti…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 4.445773470665159, "bm25_max": 4.445773470665159, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 4.445773470665159, "bm25_max": 4.445773470665159, "bge_top3": null, "bge_max": null, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 4.408249990998868, "bm25_max": 4.408249990998868, "bge_top3": 0.5622124075889587, "bge_max": 0.5622124075889587, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "gefitinib-drug-information", "bm25_top3": 4.267093911250696, "bm25_max": 4.275429031570182, "bge_top3": 0.5498169660568237, "bge_max": 0.5498169660568237, "title": "Gefitinib: Drug information", "rep_snippet": "• Appropriate use: Establish EGFR mutation status prior to treatment. Do not use in patients with EGFR mutation-negative tumors. Studies have demonstrated a subset of patients who are more likely to respond to gefitinib…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 4.250774793273749, "bm25_max": 4.250774793273749, "bge_top3": null, "bge_max": null, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 4.211742382733087, "bm25_max": 4.211742382733087, "bge_top3": 0.5511757135391235, "bge_max": 0.5511757135391235, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 4.211742382733087, "bm25_max": 4.211742382733087, "bge_top3": null, "bge_max": null, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 4.154429277386644, "bm25_max": 4.154429277386644, "bge_top3": 0.5506412982940674, "bge_max": 0.5506412982940674, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 4.138490616810765, "bm25_max": 4.138490616810765, "bge_top3": null, "bge_max": null, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "cyclophosphamide-drug-information", "bm25_top3": 4.036343198648238, "bm25_max": 4.036343198648238, "bge_top3": null, "bge_max": null, "title": "Cyclophosphamide: Drug information", "rep_snippet": "• Urinary/renal toxicity: Cyclophosphamide is associated with the development of hemorrhagic cystitis, pyelitis, ureteritis, and hematuria. Hemorrhagic cystitis may rarely be severe or fatal. Bladder fibrosis may also oc…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 3.9389551721610783, "bm25_max": 3.9389551721610783, "bge_top3": 0.5592911839485168, "bge_max": 0.563234806060791, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 3.8305412629935347, "bm25_max": 3.8305412629935347, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "dimethyl-sulfoxide-drug-information", "bm25_top3": 3.6968898167939592, "bm25_max": 3.6968898167939592, "bge_top3": null, "bge_max": null, "title": "Dimethyl sulfoxide: Drug information", "rep_snippet": "Use  Interstitial cystitis: Symptomatic relief of interstitial cystitis.  Limitation of use: There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial urinary tract infections."}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 3.6566581335054575, "bm25_max": 3.6566581335054575, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 3.6181694878225805, "bm25_max": 3.6181694878225805, "bge_top3": 0.5631973743438721, "bge_max": 0.5631973743438721, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 3.5669309981964528, "bm25_max": 3.5669309981964528, "bge_top3": 0.5574594736099243, "bge_max": 0.5574594736099243, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5666817724704742, "bge_max": 0.5731469392776489, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Dosing: Adult  Nephropathic cystinosis: Oral: Note: Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.  Immediate release (Cystagon):  Initial: Initiate therapy with 1/6 to 1/4 of maint…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5667788088321686, "bge_max": 0.5721847414970398, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "cefixime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5674163103103638, "bge_max": 0.5674163103103638, "title": "Cefixime: Drug information", "rep_snippet": "Use  Treatment of uncomplicated urinary tract infections (due to Escherichia coli and Proteus mirabilis), otitis media (due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), pharyngitis and t…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.566089391708374, "bge_max": 0.566089391708374, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Pulmonary disease (severe nodular/bronchiectatic or cavitary disease) in non-HIV-infected patients (off-label use): 250 to 300 mg once daily in combination with a rifamycin plus ethambutol; continue treatment until patie…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.56505286693573, "bge_max": 0.56505286693573, "title": "Pralatrexate: Drug information", "rep_snippet": "500 to 1,000/mm3 with fever or ANC <500/mm3 (recurrent or for 2-week duration): Omit dose and give filgrastim or sargramostim support; decrease to 20 mg/m2 (10 mg/m2 in patients with eGFR 15 to <30 mL/minute/1.73 m2) wit…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5593045949935913, "bge_max": 0.564824104309082, "title": "Erlotinib: Drug information", "rep_snippet": "Use  Non-small cell lung cancer, metastatic: Treatment of metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations a…"}, {"doc_id": "tofacitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5575811266899109, "bge_max": 0.5617350339889526, "title": "Tofacitinib: Drug information", "rep_snippet": "Use  Psoriatic arthritis: Treatment of active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).  Rheumatoid arthriti…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5555976033210754, "bge_max": 0.560509443283081, "title": "Apixaban: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Deep vein thrombosis (DVT), pulmonary embolism (PE), reduction in the risk of recurrent DVT and PE  : No dosage adjustment is recommended by the manufacturer for any degree of renal imp…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5602328181266785, "bge_max": 0.5602328181266785, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Use  Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: Reduction of the risk of NSAID-associated gastric ulcers in patients at risk of developing gastric ulcers who require an NSAID for the relief of signs an…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5555495023727417, "bge_max": 0.5597615838050842, "title": "Glipizide and metformin: Drug information", "rep_snippet": "• Renal impairment: The metabolism and excretion of glipizide may be slowed in patients with renal impairment. Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and p…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5593509674072266, "bge_max": 0.5593509674072266, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "• Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using eGFR; the risk of metformin accumulation and lactic acidosis i…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5586252212524414, "bge_max": 0.5586252212524414, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral:  Mild or moderate impairment: No dosage adjustment necessary.  Significant impairment or advanced renal disease: Use is not recommended.  Injection:  Mild impairment: There are no dosage a…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5571222305297852, "bge_max": 0.5571222305297852, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5545586347579956, "bge_max": 0.5545586347579956, "title": "Ibuprofen: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; avoid use in advanced renal disease.  KDIGO 2012 guidelines provide the following recommendations for N…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5544179677963257, "bge_max": 0.5544179677963257, "title": "Ceftriaxone: Drug information", "rep_snippet": "Cervicitis, proctitis, urethritis (off-label  ), pharyngitis (off-label)  :  Dual-therapy regimen (preferred): IM: 250 mg in a single dose plus oral azithromycin (CDC [Workowski 2015])  Treatment  failure:  Note: Reinfec…"}, {"doc_id": "levofloxacin-united-states-not-available-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5529530048370361, "bge_max": 0.5529530048370361, "title": "Levofloxacin (United States: Not available) (oral inhalation): Drug information", "rep_snippet": "Use  Note: Not approved in the US.  Cystic fibrosis: Management of cystic fibrosis in patients 18 years and older with chronic pulmonary Pseudomonas aeruginosa infections.  Limitations of use: Safety and efficacy not dem…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5528836250305176, "bge_max": 0.5528836250305176, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5526461601257324, "bge_max": 0.5526461601257324, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2: There are no specific dosage adjustments provided in the manufacturer’s labeling for the combination product; insulin requirements may be red…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5525456070899963, "bge_max": 0.5525456070899963, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}, {"doc_id": "metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.551871657371521, "bge_max": 0.551871657371521, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been r…"}, {"doc_id": "epirubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509953498840332, "bge_max": 0.5509953498840332, "title": "Epirubicin: Drug information", "rep_snippet": "ECF regimen: 50 mg/m2 on day 1 every 21 days for 3 preoperative and 3 postoperative cycles in combination with cisplatin and fluorouracil (Cunningham 2006)  Gastric cancer (off-label use): IV:  ECF, ECX, EOF, and EOX reg…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509636402130127, "bge_max": 0.5509636402130127, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Mild, moderate, or severe impairment: No dosage adjustment necessary.  Compensated cirrhosis: Consider risks and benefits before initiating therapy in patients with compensated cirrhosis who h…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5509289503097534, "bge_max": 0.5509289503097534, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling; however the following adjustments have been recommended (Aronoff 2007): Cetirizine:  Adults:  GFR >50 mL/min…"}]}
{"qid": "Q8", "query": "Warfarin co-administration with TMP-SMX — interaction severity and management action.", "candidates": [{"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": 33.96147651911753, "bm25_max": 34.799997686756726, "bge_top3": null, "bge_max": null, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\")  Note: Weight-based dosing recommendations are based on the trimethoprim (TMP) component. E…"}, {"doc_id": "fluorescein-and-benoxinate-drug-information", "bm25_top3": 23.474265358164715, "bm25_max": 23.474265358164715, "bge_top3": null, "bge_max": null, "title": "Fluorescein and benoxinate: Drug information", "rep_snippet": "Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anes…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": 23.257570241203197, "bm25_max": 23.257570241203197, "bge_top3": null, "bge_max": null, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents. If concomitant the…"}, {"doc_id": "calcium-carbonate-and-simethicone-drug-information", "bm25_top3": 22.54380458818582, "bm25_max": 22.54380458818582, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate and simethicone: Drug information", "rep_snippet": "Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart…"}, {"doc_id": "calcium-and-vitamin-d-drug-information", "bm25_top3": 22.54380458818582, "bm25_max": 22.54380458818582, "bge_top3": null, "bge_max": null, "title": "Calcium and vitamin D: Drug information", "rep_snippet": "Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 22.43495907880274, "bm25_max": 22.43495907880274, "bge_top3": 0.5692875981330872, "bge_max": 0.5692875981330872, "title": "Warfarin: Drug information", "rep_snippet": "Food Interactions  Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and dec…"}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 22.27829730153786, "bm25_max": 22.27829730153786, "bge_top3": null, "bge_max": null, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Separating administer of oral phosphate supplements from antacid admin…"}, {"doc_id": "aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information", "bm25_top3": 22.24514910504511, "bm25_max": 22.24514910504511, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information", "rep_snippet": "Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate. Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in…"}, {"doc_id": "aluminum-hydroxide-and-magnesium-hydroxide-drug-information", "bm25_top3": 22.24514910504511, "bm25_max": 22.24514910504511, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide and magnesium hydroxide: Drug information", "rep_snippet": "Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate. Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in…"}, {"doc_id": "magnesium-hydroxide-and-mineral-oil-emulsion-drug-information", "bm25_top3": 22.172604263607006, "bm25_max": 22.215478729670465, "bge_top3": null, "bge_max": null, "title": "Magnesium hydroxide and mineral oil emulsion: Drug information", "rep_snippet": "Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an i…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 20.60113056696881, "bm25_max": 20.60113056696881, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Severe, acute phase: Infants ≥3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours for ≥10 days with or without TMP/SMX (maximum dose: 2,000 mg/dose) (Lipsitz 2012). Note: Depending on infection severity,…"}, {"doc_id": "bupivacaine-drug-information", "bm25_top3": 12.474265358164715, "bm25_max": 12.474265358164715, "bge_top3": null, "bge_max": null, "title": "Bupivacaine: Drug information", "rep_snippet": "Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anes…"}, {"doc_id": "colestipol-drug-information", "bm25_top3": 11.863994794377682, "bm25_max": 12.40164912122131, "bge_top3": null, "bge_max": null, "title": "Colestipol: Drug information", "rep_snippet": "Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant adm…"}, {"doc_id": "colesevelam-drug-information", "bm25_top3": 12.40164912122131, "bm25_max": 12.40164912122131, "bge_top3": null, "bge_max": null, "title": "Colesevelam: Drug information", "rep_snippet": "Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant adm…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 12.117914754436843, "bm25_max": 12.40164912122131, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant adm…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 12.223232962865374, "bm25_max": 12.223232962865374, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "Antacids: May decrease the serum concentration of Dabigatran Etexilate. Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other si…"}, {"doc_id": "calcium-carbonate-drug-information", "bm25_top3": 11.543804588185822, "bm25_max": 11.543804588185822, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate: Drug information", "rep_snippet": "Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 11.37136375549193, "bm25_max": 11.53552372415458, "bge_top3": null, "bge_max": null, "title": "Rivaroxaban: Drug information", "rep_snippet": "Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "aluminum-hydroxide-drug-information", "bm25_top3": 11.527641792349375, "bm25_max": 11.527641792349375, "bge_top3": null, "bge_max": null, "title": "Aluminum hydroxide: Drug information", "rep_snippet": "Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a…"}, {"doc_id": "mineral-oil-drug-information", "bm25_top3": 11.516855266712753, "bm25_max": 11.516855266712753, "bge_top3": null, "bge_max": null, "title": "Mineral oil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Multivitamins/Fluoride (with ADE): Mineral Oil may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Management: Avo…"}, {"doc_id": "sucroferric-oxyhydroxide-drug-information", "bm25_top3": 11.247324592137442, "bm25_max": 11.247324592137442, "bge_top3": 0.6020411849021912, "bge_max": 0.6020411849021912, "title": "Sucroferric oxyhydroxide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Levothyroxine: Sucroferric Oxyhydroxide may decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral…"}, {"doc_id": "magnesium-carbonate-drug-information", "bm25_top3": 11.215478729670464, "bm25_max": 11.215478729670464, "bge_top3": null, "bge_max": null, "title": "Magnesium carbonate: Drug information", "rep_snippet": "Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an i…"}, {"doc_id": "magnesium-hydroxide-drug-information", "bm25_top3": 11.215478729670464, "bm25_max": 11.215478729670464, "bge_top3": null, "bge_max": null, "title": "Magnesium hydroxide: Drug information", "rep_snippet": "Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an i…"}, {"doc_id": "citric-acid-bladder-mixture-drug-information", "bm25_top3": 11.215478729670464, "bm25_max": 11.215478729670464, "bge_top3": null, "bge_max": null, "title": "Citric acid bladder mixture: Drug information", "rep_snippet": "Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an i…"}, {"doc_id": "chloroprocaine-drug-information", "bm25_top3": 11.19070795670993, "bm25_max": 11.19070795670993, "bge_top3": null, "bge_max": null, "title": "Chloroprocaine: Drug information", "rep_snippet": "Sulfonamide Antibiotics: Chloroprocaine may diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 11.134884280323806, "bm25_max": 11.134884280323806, "bge_top3": null, "bge_max": null, "title": "Edoxaban: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Edoxaban. Spec…"}, {"doc_id": "apixaban-drug-information", "bm25_top3": 11.081309445441258, "bm25_max": 11.081309445441258, "bge_top3": null, "bge_max": null, "title": "Apixaban: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Apixaban. Spec…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": 10.880357194472285, "bm25_max": 10.880357194472285, "bge_top3": null, "bge_max": null, "title": "Levothyroxine: Drug information", "rep_snippet": "Sucralfate: May decrease the serum concentration of Levothyroxine. Risk C: Monitor therapy  Sucroferric Oxyhydroxide: May decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral levot…"}, {"doc_id": "atovaquone-drug-information", "bm25_top3": 7.217630457035336, "bm25_max": 7.217630457035336, "bge_top3": null, "bge_max": null, "title": "Atovaquone: Drug information", "rep_snippet": "Use  Pneumocystis jirovecii pneumonia (PCP), prophylaxis: Prevention of PCP in adults and adolescents 13 years and older who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMZ)  Pneumocystis jirovecii pneumonia (PC…"}, {"doc_id": "capecitabine-drug-information", "bm25_top3": 5.9539399402514, "bm25_max": 5.9539399402514, "bge_top3": 0.6301567554473877, "bge_max": 0.6301567554473877, "title": "Capecitabine: Drug information", "rep_snippet": "ALERT: US Boxed Warning  Warfarin interaction:  Frequently monitor the anticoagulant response (international normalized ratio [INR] or prothrombin time [PT]) of patients receiving concomitant capecitabine and oral coumar…"}, {"doc_id": "liposomal-irinotecan-drug-information", "bm25_top3": 5.660059428724132, "bm25_max": 5.660059428724132, "bge_top3": null, "bge_max": null, "title": "Liposomal irinotecan: Drug information", "rep_snippet": "Administration  Irinotecan (liposomal) is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017).  IV: Administer by IV infusion over 90 minutes. Premedicat…"}, {"doc_id": "miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": 5.630203207455063, "bm25_max": 5.630203207455063, "bge_top3": null, "bge_max": null, "title": "Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "Mechanism of Action  Exact mechanism unknown; likely interaction with phospholipids and steroids in parasitic cell membranes, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death."}, {"doc_id": "ibalizumab-uiyk-drug-information", "bm25_top3": 5.472696204479915, "bm25_max": 5.472696204479915, "bge_top3": null, "bge_max": null, "title": "Ibalizumab-uiyk: Drug information", "rep_snippet": "Mechanism of Action  Ibalizumab-uiyk, a recombinant humanized monoclonal antibody, is a post-attachment inhibitor. It blocks HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4+ cell receptors leading to a co…"}, {"doc_id": "ofatumumab-drug-information", "bm25_top3": 5.366415769861774, "bm25_max": 5.366415769861774, "bge_top3": null, "bge_max": null, "title": "Ofatumumab: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Infusion reaction: Interrupt infusion for infusion reaction (any severity). If the reaction resolves or remains at ≤ grade 2, resume with the following modifications (based on the grade o…"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6427596807479858, "bge_max": 0.6427596807479858, "title": "Tigecycline: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Tigecycline may increase the serum concentration of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "fluorouracil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363415718078613, "bge_max": 0.6363415718078613, "title": "Fluorouracil (systemic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "methyl-salicylate-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161578893661499, "bge_max": 0.6161578893661499, "title": "Methyl salicylate and menthol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Salicylates (Topical) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "trolamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161578893661499, "bge_max": 0.6161578893661499, "title": "Trolamine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Warfarin: Salicylates (Topical) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy"}, {"doc_id": "palifermin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.600359320640564, "bge_max": 0.600359320640564, "title": "Palifermin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antineoplastic Agents: Palifermin may enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5972737669944763, "bge_max": 0.5972737669944763, "title": "Aprepitant: Drug information", "rep_snippet": "Monitoring Parameters  In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; monitor for signs/symptoms of hypersensitivity reaction."}, {"doc_id": "tolbutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5948333740234375, "bge_max": 0.5948333740234375, "title": "Tolbutamide: Drug information", "rep_snippet": "Food Interactions  Possible disulfiram-like reaction with concurrent ethanol use. Management: Monitor patients."}, {"doc_id": "tolazamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5948333740234375, "bge_max": 0.5948333740234375, "title": "Tolazamide: Drug information", "rep_snippet": "Food Interactions  Possible disulfiram-like reaction with concurrent ethanol use. Management: Monitor patients."}, {"doc_id": "vemurafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5925150513648987, "bge_max": 0.5925150513648987, "title": "Vemurafenib: Drug information", "rep_snippet": "Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Warfarin: Vemurafenib may increase the serum concentration of Warfarin. Risk C: Monitor therapy  Xipam…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5804788172245026, "bge_max": 0.5902712345123291, "title": "Sorafenib: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ephedrine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5877234935760498, "bge_max": 0.5877234935760498, "title": "Ephedrine (systemic): Drug information", "rep_snippet": "• Tolerance: Tachyphylaxis and tolerance may develop with repeated, prolonged, or excessive administration; temporary cessation of therapy restores its effectiveness."}, {"doc_id": "prothrombin-complex-concentrate-3-factor-unactivated-from-human-plasma-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5875176191329956, "bge_max": 0.5875176191329956, "title": "Prothrombin complex concentrate, 3-factor, unactivated, from human plasma: Drug information", "rep_snippet": "Monitoring Parameters  Levels of factor IX; PT, PTT; INR (when used for warfarin reversal); signs and symptoms of hypersensitivity reactions, DIC, thrombosis, especially in patients with liver disease, surgical patients,…"}, {"doc_id": "ferumoxytol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5862506628036499, "bge_max": 0.5862506628036499, "title": "Ferumoxytol: Drug information", "rep_snippet": "Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult d…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.58384770154953, "bge_max": 0.58384770154953, "title": "Phenelzine: Drug information", "rep_snippet": "Foods high in tyramine or dopamine content; foods and/or supplements containing tyrosine, phenylalanine, tryptophan, or caffeine  Documentation of allergenic cross-reactivity for monoamine oxidase inhibitors is limited.…"}, {"doc_id": "fosaprepitant-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5771744847297668, "bge_max": 0.5835133790969849, "title": "Fosaprepitant: Drug information", "rep_snippet": "Warfarin: Fosaprepitant may decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect. Risk C: Monitor therapy"}, {"doc_id": "carboplatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5809606313705444, "bge_max": 0.5809606313705444, "title": "Carboplatin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "chlorpropamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5796955823898315, "bge_max": 0.5796955823898315, "title": "Chlorpropamide: Drug information", "rep_snippet": "Food Interactions  Possible disulfiram-like reaction may occur with concurrent ethanol use. Management: Monitor patients."}, {"doc_id": "dalfampridine-fampridine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5796767473220825, "bge_max": 0.5796767473220825, "title": "Dalfampridine (fampridine): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cimetidine: May increase the serum concentration of Dalfampridine. Management: Recommendations differ significantly between international…"}, {"doc_id": "erythromycin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5784381031990051, "bge_max": 0.5784381031990051, "title": "Erythromycin (ophthalmic): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Vitamin K Antagonists (eg, warfarin): Erythromycin (Ophthalmic) may increase the serum concentration of Vitamin K Antagonists. Risk C: Mo…"}, {"doc_id": "tamoxifen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5783360600471497, "bge_max": 0.5783360600471497, "title": "Tamoxifen: Drug information", "rep_snippet": "Contraindications  Known hypersensitivity to tamoxifen or any component of the formulation; concurrent warfarin therapy or history of deep vein thrombosis or pulmonary embolism (when tamoxifen is used for breast cancer r…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5742001831531525, "bge_max": 0.5775352716445923, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5774487257003784, "bge_max": 0.5774487257003784, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "• Diabetes mellitus: Use with caution in patients with diabetes mellitus; management of diabetes may be more difficult in patients taking rifampin.  • Hepatic impairment: Use with caution and close monitoring in patients…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.57733553647995, "bge_max": 0.57733553647995, "title": "Dextroamphetamine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "regorafenib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5772532224655151, "bge_max": 0.5772532224655151, "title": "Regorafenib: Drug information", "rep_snippet": "Warfarin: May enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.576915979385376, "bge_max": 0.576915979385376, "title": "Erlotinib: Drug information", "rep_snippet": "Teriflunomide: May decrease the serum concentration of Erlotinib. Management: Avoid the concomitant use of erlotinib and teriflunomide if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg…"}, {"doc_id": "minoxidil-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5762314796447754, "bge_max": 0.5762314796447754, "title": "Minoxidil (topical): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased.…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5760400891304016, "bge_max": 0.5760400891304016, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Risk X: Avoid combination  Antimalarial Age…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5738353729248047, "bge_max": 0.5738353729248047, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Tablets, oral solution: Coadministration with fusidic acid, salmeterol, vardenafil, astemizole (not available in Canada), terfenadine (not available in Canada), venetoclax (during dose initiation and the ramp-up phase)…"}, {"doc_id": "sulfanilamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5738198161125183, "bge_max": 0.5738198161125183, "title": "Sulfanilamide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C:…"}, {"doc_id": "dapsone-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5737018585205078, "bge_max": 0.5737018585205078, "title": "Dapsone (topical): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be incr…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5735141634941101, "bge_max": 0.5735141634941101, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detaile…"}, {"doc_id": "telotristat-ethyl-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5734450221061707, "bge_max": 0.5734450221061707, "title": "Telotristat ethyl: Drug information", "rep_snippet": "Food Interactions  Administration with food results in higher exposure to telotristat ethyl and telotristat."}, {"doc_id": "phenylephrine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.572974681854248, "bge_max": 0.572974681854248, "title": "Phenylephrine (ophthalmic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5729037523269653, "bge_max": 0.5729037523269653, "title": "Methamphetamine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "aminophylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5726067423820496, "bge_max": 0.5726067423820496, "title": "Aminophylline: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "sulfacetamide-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5725704431533813, "bge_max": 0.5725704431533813, "title": "Sulfacetamide (topical): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Autoimmune effects: Fatalities associated with severe reactions, including drug-induced systemic lupus erythematosus, have occurred with sulfonamides (regardl…"}, {"doc_id": "sulfur-and-sulfacetamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5723791122436523, "bge_max": 0.5723791122436523, "title": "Sulfur and sulfacetamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Autoimmune diseases: Fatalities associated with severe reactions, including drug-induced systemic lupus erythematosus, have occurred with sulfonamides (regard…"}, {"doc_id": "nitrofurantoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5716159343719482, "bge_max": 0.5716159343719482, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Food Interactions  Nitrofurantoin serum concentrations may be increased if taken with food. Management: Administer with meals."}, {"doc_id": "telmisartan-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5712918639183044, "bge_max": 0.5712918639183044, "title": "Telmisartan and amlodipine: Drug information", "rep_snippet": "Food Interactions  Rate and extent of telmisartan absorption (in combination with amlodipine) is decreased by 60% and 24%, respectively, when administered with a high-fat meal. Management: May administer without regard t…"}, {"doc_id": "interferon-beta-1b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5699989199638367, "bge_max": 0.5699989199638367, "title": "Interferon beta-1b: Drug information", "rep_snippet": "• Neuropsychiatric disorders: Interferons have been associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms.…"}, {"doc_id": "adalimumab-including-biosimilars-of-adalimumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5697906017303467, "bge_max": 0.5697906017303467, "title": "Adalimumab (including biosimilars of adalimumab): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5697519183158875, "bge_max": 0.5697519183158875, "title": "Caspofungin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentratio…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5690579414367676, "bge_max": 0.5690579414367676, "title": "Clarithromycin: Drug information", "rep_snippet": "Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult d…"}, {"doc_id": "tesamorelin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5690369009971619, "bge_max": 0.5690369009971619, "title": "Tesamorelin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cortisone: Tesamorelin may decrease serum concentrations of the active metabolite(s) of Cortisone. Risk D: Consider therapy modification…"}]}
{"qid": "Q9", "query": "Atorvastatin with clarithromycin — risks and what to do (hold/switch/monitor).", "candidates": [{"doc_id": "amlodipine-and-atorvastatin-drug-information", "bm25_top3": 22.894796184705722, "bm25_max": 25.80172440991593, "bge_top3": 0.6756041049957275, "bge_max": 0.6904507875442505, "title": "Amlodipine and atorvastatin: Drug information", "rep_snippet": "Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered,…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 20.980960954691696, "bm25_max": 23.15362866036985, "bge_top3": 0.6736097733179728, "bge_max": 0.7071571350097656, "title": "Atorvastatin: Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, monitor patient…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 19.244665407020705, "bm25_max": 20.80033675584194, "bge_top3": 0.683368444442749, "bge_max": 0.683368444442749, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, mo…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 18.107965881821166, "bm25_max": 20.80033675584194, "bge_top3": 0.6638619899749756, "bge_max": 0.683368444442749, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "AtorvaSTATin: Clarithromycin may increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin. If this combination is used, mo…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 18.08216130798544, "bm25_max": 20.30524653652157, "bge_top3": 0.6576269567012787, "bge_max": 0.6642784476280212, "title": "Clarithromycin: Drug information", "rep_snippet": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination  Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: A…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": 19.24792033974466, "bm25_max": 19.24792033974466, "bge_top3": null, "bge_max": null, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: COPD: Do not use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta2-agonist to treat acute symptoms. Do not initiate in patients…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": 16.64245931889733, "bm25_max": 16.64245931889733, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "• Lactose: Some products may contain lactose; allergic reactions possible in patients with severe milk protein allergy. Use with caution in patients with severe hypersensitivity to milk proteins.  Other warnings:  • Appr…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": 16.033576469675914, "bm25_max": 16.033576469675914, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "pramoxine-and-hydrocortisone-drug-information", "bm25_top3": 15.823797800356687, "bm25_max": 15.823797800356687, "bge_top3": null, "bge_max": null, "title": "Pramoxine and hydrocortisone: Drug information", "rep_snippet": "Rectal: Proctofoam HC: Shake vigorously for 5 to 10 seconds prior to use. Do not remove cap during use. Hold container upright to fill applicator. Gently insert applicator tip into anus. Only use applicator provided by m…"}, {"doc_id": "chlorpromazine-drug-information", "bm25_top3": 7.949489869839258, "bm25_max": 7.949489869839258, "bge_top3": null, "bge_max": null, "title": "Chlorpromazine: Drug information", "rep_snippet": "Breast-Feeding Considerations  Chlorpromazine and its metabolites have been detected in breast milk; concentrations in the milk do not correlate with those in the mother and may be higher than what is in the maternal pla…"}, {"doc_id": "lenalidomide-drug-information", "bm25_top3": 6.800189323830912, "bm25_max": 7.300756066629162, "bge_top3": null, "bge_max": null, "title": "Lenalidomide: Drug information", "rep_snippet": "Combination therapy with dexamethasone:  Platelets <30,000/mm3: Hold treatment, check CBC weekly  When platelets return to ≥30,000/mm3: Resume at next lower dose; do not dose below 2.5 mg daily  Additional occurrence of…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": 7.203212402200091, "bm25_max": 7.203212402200091, "bge_top3": null, "bge_max": null, "title": "Ivacaftor: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  ALT or AST >5 times ULN: Hold ivacaftor; may resume if elevated transaminases resolved and after assessing benefits vs risks of continued treatment."}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 7.102079742831357, "bm25_max": 7.102079742831357, "bge_top3": 0.6480162143707275, "bge_max": 0.6480162143707275, "title": "Dabigatran: Drug information", "rep_snippet": "Aspirin: May enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Cana…"}, {"doc_id": "rivaroxaban-drug-information", "bm25_top3": 6.964371971723416, "bm25_max": 6.964371971723416, "bge_top3": 0.6643695831298828, "bge_max": 0.6805128455162048, "title": "Rivaroxaban: Drug information", "rep_snippet": "Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocou…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 6.953398278553934, "bm25_max": 6.953398278553934, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Atazanavir: May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir. Management: Voriconazole…"}, {"doc_id": "erwinia-asparaginase-drug-information", "bm25_top3": 6.932989091590176, "bm25_max": 6.932989091590176, "bge_top3": null, "bge_max": null, "title": "Erwinia asparaginase: Drug information", "rep_snippet": "Hyperglycemia: Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior d…"}, {"doc_id": "e-coli-asparaginase-united-states-not-available-drug-information", "bm25_top3": 6.884900759862472, "bm25_max": 6.884900759862472, "bge_top3": null, "bge_max": null, "title": "E. coli asparaginase (United States: Not available): Drug information", "rep_snippet": "Hyperglycemia: Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior d…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": 6.096296613631706, "bm25_max": 6.096296613631706, "bge_top3": 0.6499640345573425, "bge_max": 0.6536163091659546, "title": "Pravastatin: Drug information", "rep_snippet": "Moderate-intensity therapy (30% to 50% reduction of LDL-C generally): 40 to 80 mg once daily  High-intensity therapy (≥50% reduction of LDL-C generally): Use alternate statin therapy (eg, atorvastatin or rosuvastatin)  D…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 5.939850037478566, "bm25_max": 5.939850037478566, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. Risk X: Avoid combination  Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. Risk X: A…"}, {"doc_id": "aluminum-chloride-hexahydrate-drug-information", "bm25_top3": 5.599733738559195, "bm25_max": 5.599733738559195, "bge_top3": null, "bge_max": null, "title": "Aluminum chloride hexahydrate: Drug information", "rep_snippet": "Administration  Topical:  Antiperspirant: Apply to dry skin. Area may be covered with plastic wrap held in place with snug-fitting T-shirt. Do not hold in place with tape.  Hemostatic solution (Lumicain): Apply solution…"}, {"doc_id": "influenza-virus-vaccine-inactivated-drug-information", "bm25_top3": 5.394990300290889, "bm25_max": 5.394990300290889, "bge_top3": null, "bge_max": null, "title": "Influenza virus vaccine (inactivated): Drug information", "rep_snippet": "Administration  Fluzone Intradermal Quadrivalent: For intradermal administration, preferably into the skin over the deltoid muscle only. Gently shake gently prior to use. Hold system using the thumb and middle finger (do…"}, {"doc_id": "letermovir-drug-information", "bm25_top3": 5.154260963463038, "bm25_max": 5.154260963463038, "bge_top3": null, "bge_max": null, "title": "Letermovir: Drug information", "rep_snippet": "ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be requi…"}, {"doc_id": "cysteamine-systemic-drug-information", "bm25_top3": 4.95217771327439, "bm25_max": 4.95217771327439, "bge_top3": null, "bge_max": null, "title": "Cysteamine (systemic): Drug information", "rep_snippet": "Switching from cysteamine hydrochloride or phosphocysteamine solutions to cysteamine bitartrate: Monitor WBC cystine concentrations 2 weeks after the switch, then every 3 months thereafter.  Patients switching to the del…"}, {"doc_id": "elbasvir-and-grazoprevir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6825908422470093, "bge_max": 0.6825908422470093, "title": "Elbasvir and grazoprevir: Drug information", "rep_snippet": "AtorvaSTATin: Elbasvir may increase the serum concentration of AtorvaSTATin. Management: Limit the dose of atorvastatin to a maximum of 20 mg/day when used together with elbasvir and grazoprevir. Monitor closely for evid…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6614099740982056, "bge_max": 0.6614099740982056, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "Telithromycin: May increase the serum concentration of Simvastatin. Risk X: Avoid combination  Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Risk C: Monitor therapy  Ticagrelor: May i…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6594874858856201, "bge_max": 0.6594874858856201, "title": "Fluvastatin: Drug information", "rep_snippet": "Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Risk C: Monitor therapy  Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorva…"}, {"doc_id": "drospirenone-and-estradiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6561271548271179, "bge_max": 0.6561271548271179, "title": "Drospirenone and estradiol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the po…"}, {"doc_id": "ethinyl-estradiol-and-drospirenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6561271548271179, "bge_max": 0.6561271548271179, "title": "Ethinyl estradiol and drospirenone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the po…"}, {"doc_id": "ethinyl-estradiol-drospirenone-and-levomefolate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6561271548271179, "bge_max": 0.6561271548271179, "title": "Ethinyl estradiol, drospirenone, and levomefolate: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acitretin: May diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. Management: Given the po…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6555907130241394, "bge_max": 0.6555907130241394, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy  Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteract…"}, {"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521318554878235, "bge_max": 0.6521318554878235, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Telithromycin: May increase the serum concentration of Lovastatin. Risk X: Avoid combination  Ticagrelor: May increase the serum concentration of Lovastatin. Management: Avoid using doses of lovastatin greater than 40 mg…"}, {"doc_id": "armodafinil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6516149044036865, "bge_max": 0.6516149044036865, "title": "Armodafinil: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Risk X: Avoid combination  Alcohol (Ethyl): May diminish the therap…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512482762336731, "bge_max": 0.6512482762336731, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Alfentanil: Erythromycin (Systemic) may increase the serum concentration of Alfentanil. Management: For patients who are actively receiving erythromycin, caution should be used in administering alfentanil; monitor for in…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6508983373641968, "bge_max": 0.6508983373641968, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy  ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. M…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6506079435348511, "bge_max": 0.6506079435348511, "title": "Simvastatin: Drug information", "rep_snippet": "Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Risk C: Monitor therapy  Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins)…"}, {"doc_id": "diltiazem-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6505254507064819, "bge_max": 0.6505254507064819, "title": "Diltiazem: Drug information", "rep_snippet": "AtorvaSTATin: May increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of AtorvaSTATin. Management: Consider using lower atorvastatin doses when used together with diltiazem. Risk…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6502043008804321, "bge_max": 0.6502043008804321, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Risk C: Monitor therapy  Bezafibrate: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and c…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6485370993614197, "bge_max": 0.6485370993614197, "title": "Pitavastatin: Drug information", "rep_snippet": "DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping HMG-Co…"}, {"doc_id": "amlodipine-olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6455999612808228, "bge_max": 0.6455999612808228, "title": "Amlodipine, olmesartan, and hydrochlorothiazide: Drug information", "rep_snippet": "Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy  Macrolide A…"}, {"doc_id": "tolvaptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6453440189361572, "bge_max": 0.6453440189361572, "title": "Tolvaptan: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Angiotensin II Receptor Blockers: Tolvaptan may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Risk C: Monitor ther…"}, {"doc_id": "orphenadrine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6432423889636993, "bge_max": 0.6437009572982788, "title": "Orphenadrine, aspirin, and caffeine: Drug information", "rep_snippet": "Ammonium Chloride: May increase the serum concentration of Salicylates. Risk C: Monitor therapy  Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme I…"}, {"doc_id": "aliskiren-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6425275206565857, "bge_max": 0.6425275206565857, "title": "Aliskiren and amlodipine: Drug information", "rep_snippet": "Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy  Macrolide A…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6425275206565857, "bge_max": 0.6425275206565857, "title": "Amlodipine: Drug information", "rep_snippet": "Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy  Macrolide A…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6425275206565857, "bge_max": 0.6425275206565857, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy  Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy  Macrolide A…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6424596905708313, "bge_max": 0.6424596905708313, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in pa…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6424596905708313, "bge_max": 0.6424596905708313, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. Management: Consider alternative antibiotics. Reduce clarithromycin dose by 50% in pa…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6422993540763855, "bge_max": 0.6422993540763855, "title": "Salmeterol: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  AtoMOXetine:…"}]}
{"qid": "Q10", "query": "Linezolid in a patient on sertraline — is concomitant use safe; required washout/monitoring?", "candidates": [{"doc_id": "sertraline-drug-information", "bm25_top3": 22.829369902774097, "bm25_max": 23.883469519852447, "bge_top3": 0.6231085956096649, "bge_max": 0.6286717653274536, "title": "Sertraline: Drug information", "rep_snippet": "Contraindications  Use of MAOIs including linezolid or methylene blue (concurrently or within 14 days of stopping an MAOI or sertraline); concurrent use with pimozide; hypersensitivity (eg, anaphylaxis, angioedema) to se…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 20.451581249008854, "bm25_max": 20.763995712743924, "bge_top3": 0.6659455299377441, "bge_max": 0.6880666017532349, "title": "Linezolid: Drug information", "rep_snippet": "• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs, agents which reduce linezolid's metabolism,…"}, {"doc_id": "dasatinib-drug-information", "bm25_top3": 14.303850168268994, "bm25_max": 14.303850168268994, "bge_top3": null, "bge_max": null, "title": "Dasatinib: Drug information", "rep_snippet": "Dosage adjustment for concomitant strong CYP3A4 inhibitors: Avoid concomitant administration with strong CYP3A4 inhibitors and grapefruit juice; if concomitant administration with a strong CYP3A4 inhibitor cannot be avoi…"}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 13.920442973951605, "bm25_max": 13.920442973951605, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "If therapy cannot be interrupted and concurrent use with a strong CYP3A4 inhibitor cannot be avoided, consider reducing the nilotinib dose to 300 mg once daily in patients with resistant or intolerant Ph+ CML (chronic or…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 12.920776385367141, "bm25_max": 12.920776385367141, "bge_top3": null, "bge_max": null, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Canadian labeling does not provide further recommendations regarding use of linezolid and methylene blue in patients receiving moclobemide. The US Food and Drug Administration (FDA) recommends that when urgent treatment…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": 12.719294231630762, "bm25_max": 12.719294231630762, "bge_top3": null, "bge_max": null, "title": "Isocarboxazid: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving isocarboxazid and potential benefits outweigh potential risks, discontinue isocarboxazid promptly and administer linezoli…"}, {"doc_id": "vilazodone-drug-information", "bm25_top3": 12.47435358448795, "bm25_max": 12.47435358448795, "bge_top3": null, "bge_max": null, "title": "Vilazodone: Drug information", "rep_snippet": "Do not initiate vilazodone in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.  If urgent treatment with linezolid or IV methylene blue is required in a patient a…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": 12.153881349079555, "bm25_max": 12.153881349079555, "bge_top3": null, "bge_max": null, "title": "Phenelzine: Drug information", "rep_snippet": "If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving phenelzine and potential benefits outweigh potential risks, discontinue phenelzine promptly and administer linezolid or I…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 11.848624781767583, "bm25_max": 11.848624781767583, "bge_top3": 0.6193435192108154, "bge_max": 0.6193435192108154, "title": "Fluoxetine: Drug information", "rep_snippet": "Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (linezolid or IV methylene blue):  Do not initiate fluox…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 9.850947927811744, "bm25_max": 11.734871498683102, "bge_top3": null, "bge_max": null, "title": "Amoxapine: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing amoxapine and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):  Do not in…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": 11.734871498683102, "bm25_max": 11.734871498683102, "bge_top3": null, "bge_max": null, "title": "Maprotiline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing maprotiline and initiation of an MAO inhibitor intended to treat psychiatric disorders.  Use with other MAO inhibitors (such as linezolid or IV methylene blue):  Do not initi…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": 10.83057648403311, "bm25_max": 10.83057648403311, "bge_top3": null, "bge_max": null, "title": "Levomilnacipran: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of levomilnacipran.  Allow 7 days to elapse between discontinuing levomilnacipran and initiation of an…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 10.730970842286556, "bm25_max": 10.730970842286556, "bge_top3": null, "bge_max": null, "title": "Protriptyline: Drug information", "rep_snippet": "Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of protriptyline.  Allow 14 days to elapse between discontinuing protriptyline and initiation of an MA…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": 10.298621202556081, "bm25_max": 10.298621202556081, "bge_top3": null, "bge_max": null, "title": "Milnacipran: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow ≥14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of milnacipran.  Allo…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 10.287026667985224, "bm25_max": 10.287026667985224, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "Monitoring Parameters  Monitor patients for adequate food consumption (to ensure absorption and efficacy); ECG monitoring is advised if concomitant use of other agents that prolong the QT interval is medically required"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 9.175089496189166, "bm25_max": 10.252116942665435, "bge_top3": null, "bge_max": null, "title": "Trimipramine: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of trimipramine.  Allo…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": 9.57411314896493, "bm25_max": 10.252116942665435, "bge_top3": null, "bge_max": null, "title": "Citalopram: Drug information", "rep_snippet": "Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of citalopram.  Allow…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 9.846482334367114, "bm25_max": 9.846482334367114, "bge_top3": null, "bge_max": null, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "MAO inhibitor recommendations:  Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and i…"}, {"doc_id": "lorazepam-drug-information", "bm25_top3": 9.82012524953911, "bm25_max": 9.82012524953911, "bge_top3": null, "bge_max": null, "title": "Lorazepam: Drug information", "rep_snippet": "• Concomitant use with opioids: [US Boxed Warning]: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": 9.759366158402315, "bm25_max": 9.759366158402315, "bge_top3": null, "bge_max": null, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "MAO inhibitor recommendations:  Switching to or from an MAO inhibitor intended to treat psychiatric disorders:  Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and i…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 9.545287126623212, "bm25_max": 9.545287126623212, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Phenytoin: Disulfiram may increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible. Phenytoin dose adjustment will likely be necessary when starting and/o…"}, {"doc_id": "buprenorphine-and-naloxone-drug-information", "bm25_top3": 8.95633239932909, "bm25_max": 8.95633239932909, "bge_top3": null, "bge_max": null, "title": "Buprenorphine and naloxone: Drug information", "rep_snippet": "• Benzodiazepines and other CNS depressants: Concomitant use of benzodiazepines or other CNS depressants, including alcohol and opioids, may result in profound sedation, respiratory depression, coma, and death. Prohibiti…"}, {"doc_id": "atracurium-drug-information", "bm25_top3": 8.924986335041748, "bm25_max": 8.924986335041748, "bge_top3": null, "bge_max": null, "title": "Atracurium: Drug information", "rep_snippet": "Medication Safety Issues  High alert medication:  The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when…"}, {"doc_id": "pancuronium-drug-information", "bm25_top3": 8.924986335041748, "bm25_max": 8.924986335041748, "bge_top3": null, "bge_max": null, "title": "Pancuronium: Drug information", "rep_snippet": "Medication Safety Issues  High alert medication:  The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": 8.907939923657532, "bm25_max": 8.907939923657532, "bge_top3": null, "bge_max": null, "title": "Buprenorphine: Drug information", "rep_snippet": "• Benzodiazepines and other CNS depressants: [US Boxed Warning]: Buccal film, extended-release and immediate-release injection, transdermal patch: Concomitant use of benzodiazepines or other CNS depressants, including al…"}, {"doc_id": "tolvaptan-drug-information", "bm25_top3": 8.867326393321175, "bm25_max": 8.867326393321175, "bge_top3": null, "bge_max": null, "title": "Tolvaptan: Drug information", "rep_snippet": "Prescribing and Access Restrictions  Jinarc [Canadian product]: Only physicians experienced in the diagnosis and treatment of polycystic kidney disease should prescribe Jinarc. Prior to initiating therapy, a patient-pres…"}, {"doc_id": "aliskiren-drug-information", "bm25_top3": 8.861236162947396, "bm25_max": 8.861236162947396, "bge_top3": null, "bge_max": null, "title": "Aliskiren: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hyperkalemia: May occur; risk increased in patients with renal impairment or diabetes, or concomitant use with ACE inhibitors, ARBs, NSAIDs, potassium-sparing…"}, {"doc_id": "aliskiren-and-amlodipine-drug-information", "bm25_top3": 8.757691844274673, "bm25_max": 8.757691844274673, "bge_top3": null, "bge_max": null, "title": "Aliskiren and amlodipine: Drug information", "rep_snippet": "• Hypersensitivity: Anaphylaxis and angioedema have been reported. Since the effect of aliskiren on bradykinin levels is unknown, the risk of kinin-mediated etiologies of angioedema occurring is also unknown. Use with ca…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 8.688258993439161, "bm25_max": 8.688258993439161, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Coumadin may be confused with Cardura, Compazine, Kemadrin  Jantoven may be confused with Janumet, Januvia  High alert medication:  The Institute for Safe Medicat…"}, {"doc_id": "tamoxifen-drug-information", "bm25_top3": 8.614925275044317, "bm25_max": 8.614925275044317, "bge_top3": null, "bge_max": null, "title": "Tamoxifen: Drug information", "rep_snippet": "• Selective serotonin reuptake inhibitors (SSRI): Concomitant use with select SSRIs may result in decreased tamoxifen efficacy. Strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine) and moderate CYP2D6 inhibitors (eg, se…"}, {"doc_id": "iodixanol-drug-information", "bm25_top3": 8.595628461626209, "bm25_max": 8.595628461626209, "bge_top3": null, "bge_max": null, "title": "Iodixanol: Drug information", "rep_snippet": "Medication Safety Issues  High alert medication:  This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significan…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": 8.360451278262904, "bm25_max": 8.412565858095453, "bge_top3": null, "bge_max": null, "title": "Clozapine: Drug information", "rep_snippet": "Dosage adjustment with concomitant therapy:  Strong CYP1A2 inhibitors (eg, fluvoxamine, ciprofloxacin):  Initiating clozapine with concomitant medication or adding a concomitant medication while taking clozapine: Use one…"}, {"doc_id": "octreotide-drug-information", "bm25_top3": 8.337820597856464, "bm25_max": 8.337820597856464, "bge_top3": null, "bge_max": null, "title": "Octreotide: Drug information", "rep_snippet": "• Pancreatitis: May alter absorption of dietary fats; monitor for pancreatitis.  Disease-related concerns:  • Cardiovascular disease: Use with caution in patients with heart failure or concomitant medications that alter…"}, {"doc_id": "sodium-oxybate-gamma-hydroxybutyrate-drug-information", "bm25_top3": 8.326774558876528, "bm25_max": 8.326774558876528, "bge_top3": null, "bge_max": null, "title": "Sodium oxybate (gamma hydroxybutyrate): Drug information", "rep_snippet": "Prescribing and Access Restrictions  In Canada, access to sodium oxybate is restricted under the Xyrem Success Program. The program is intended to educate prescribers, pharmacists, and patients on the safe use, storage,…"}, {"doc_id": "prucalopride-united-states-not-available-drug-information", "bm25_top3": 8.287509933091123, "bm25_max": 8.287509933091123, "bge_top3": null, "bge_max": null, "title": "Prucalopride (United States: Not available): Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with a history of arrhythmias, ischemic cardiovascular disease, pre-excitation syndromes (eg, Wolff-Parkinson-White syndrome), or A-V nodal rhythm disorders. Slight…"}, {"doc_id": "flibanserin-drug-information", "bm25_top3": 8.27872594183271, "bm25_max": 8.27872594183271, "bge_top3": null, "bge_max": null, "title": "Flibanserin: Drug information", "rep_snippet": "• Hepatic impairment: [US Boxed Warning]: Use in patients with hepatic impairment results in increased flibanserin concentrations and a subsequent increased risk of severe hypotension and syncope; use in this patient pop…"}, {"doc_id": "methadone-drug-information", "bm25_top3": 8.269321242700794, "bm25_max": 8.269321242700794, "bge_top3": null, "bge_max": null, "title": "Methadone: Drug information", "rep_snippet": "Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, is a risk factor for respiratory depression and death. Reserve concomitant prescribing of methadone and benzodiazepines or othe…"}, {"doc_id": "rocuronium-drug-information", "bm25_top3": 8.258111140164264, "bm25_max": 8.258111140164264, "bge_top3": null, "bge_max": null, "title": "Rocuronium: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Zemuron may be confused with Remeron  High alert medication:  The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs…"}, {"doc_id": "cisatracurium-drug-information", "bm25_top3": 8.258111140164264, "bm25_max": 8.258111140164264, "bge_top3": null, "bge_max": null, "title": "Cisatracurium: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Nimbex may be confused with NovoLOG  High alert medication:  The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs w…"}, {"doc_id": "natalizumab-drug-information", "bm25_top3": 8.202429764305297, "bm25_max": 8.202429764305297, "bge_top3": null, "bge_max": null, "title": "Natalizumab: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis: IV: 300 mg infused over 1 hour every 4 weeks.  Crohn disease: IV: 300 mg infused over 1 hour every 4 weeks; discontinue if therapeutic benefit is not observed within initial 12 weeks of…"}, {"doc_id": "lapatinib-drug-information", "bm25_top3": 8.095635560985674, "bm25_max": 8.095635560985674, "bge_top3": null, "bge_max": null, "title": "Lapatinib: Drug information", "rep_snippet": "CYP3A4 inhibitors: Avoid the use of concomitant strong CYP3A4 inhibitors. If concomitant use cannot be avoided, consider reducing lapatinib to 500 mg once daily with careful monitoring. When a strong CYP3A4 inhibitor is…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 8.07211226754792, "bm25_max": 8.07211226754792, "bge_top3": null, "bge_max": null, "title": "Vancomycin: Drug information", "rep_snippet": "Oral/rectal therapy: Serum sample monitoring is not typically required; consider monitoring serum trough concentrations, especially with renal insufficiency, severe colitis, rectal vancomycin administration (SHEA/IDSA [C…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": 8.022017365817131, "bm25_max": 8.022017365817131, "bge_top3": null, "bge_max": null, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Adult  Note: Entresto contains sacubitril (24 mg, 49 mg, or 97 mg) and valsartan (26 mg, 51 mg, or 103 mg). Use caution when prescribing since dosing in clinical trials was based on the total amount of both compo…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": 7.967024356940385, "bm25_max": 7.967024356940385, "bge_top3": null, "bge_max": null, "title": "Clomipramine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490251421928406, "bge_max": 0.6490251421928406, "title": "Ergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergoloid-mesylates-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490251421928406, "bge_max": 0.6490251421928406, "title": "Ergoloid mesylates: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490251421928406, "bge_max": 0.6490251421928406, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "ergotamine-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6455990672111511, "bge_max": 0.6455990672111511, "title": "Ergotamine and caffeine: Drug information", "rep_snippet": "Letermovir: May increase the serum concentration of Ergot Derivatives. Risk X: Avoid combination  Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic ag…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438490152359009, "bge_max": 0.6438490152359009, "title": "Bromocriptine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "methamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6374533176422119, "bge_max": 0.6374533176422119, "title": "Methamphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6354935765266418, "bge_max": 0.6354935765266418, "title": "Lithium: Drug information", "rep_snippet": "Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. Risk C: Monitor therapy  Eplerenone: May increase the serum concentration of Lithiu…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6305179595947266, "bge_max": 0.6305179595947266, "title": "Vortioxetine: Drug information", "rep_snippet": "Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result…"}, {"doc_id": "lorcaserin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6278945207595825, "bge_max": 0.6278945207595825, "title": "Lorcaserin: Drug information", "rep_snippet": "Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. Risk C: Monitor therapy  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin s…"}, {"doc_id": "dextroamphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.624968409538269, "bge_max": 0.624968409538269, "title": "Dextroamphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.624968409538269, "bge_max": 0.624968409538269, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "dextroamphetamine-and-amphetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.624968409538269, "bge_max": 0.624968409538269, "title": "Dextroamphetamine and amphetamine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "amphetamine-sulfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.624968409538269, "bge_max": 0.624968409538269, "title": "Amphetamine sulfate: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6247690916061401, "bge_max": 0.6247690916061401, "title": "Duloxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Metaxalone: May enhance the serotonergic effect of Serot…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6236695647239685, "bge_max": 0.6236695647239685, "title": "Salmeterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6222195029258728, "bge_max": 0.6222195029258728, "title": "Paroxetine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Risk X: Avoid combination  Lithium: May enhance the serotonergic effect of Selective Ser…"}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220574378967285, "bge_max": 0.6220574378967285, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6209918856620789, "bge_max": 0.6209918856620789, "title": "Eletriptan: Drug information", "rep_snippet": "Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline.…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6184467077255249, "bge_max": 0.6184467077255249, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "promethazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6184467077255249, "bge_max": 0.6184467077255249, "title": "Promethazine: Drug information", "rep_snippet": "Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 week…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171134114265442, "bge_max": 0.6171134114265442, "title": "Naratriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6171134114265442, "bge_max": 0.6171134114265442, "title": "Frovatriptan: Drug information", "rep_snippet": "Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Risk C: Monitor therapy  Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. S…"}, {"doc_id": "acetaminophen-paracetamol-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6170679330825806, "bge_max": 0.6170679330825806, "title": "Acetaminophen (paracetamol), aspirin, and caffeine: Drug information", "rep_snippet": "Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin. Ris…"}, {"doc_id": "cabergoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169846653938293, "bge_max": 0.6169846653938293, "title": "Cabergoline: Drug information", "rep_snippet": "Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Risk X: Avoid combination  Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Manage…"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6162778735160828, "bge_max": 0.6162778735160828, "title": "Olodaterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6162778735160828, "bge_max": 0.6162778735160828, "title": "Formoterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "ergonovine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6161246299743652, "bge_max": 0.6161246299743652, "title": "Ergonovine (United States: Not available): Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "acetaminophen-paracetamol-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6159780621528625, "bge_max": 0.6159780621528625, "title": "Acetaminophen (paracetamol) and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "acetaminophen-guaifenesin-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6159780621528625, "bge_max": 0.6159780621528625, "title": "Acetaminophen, guaifenesin, and phenylephrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "methylergonovine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.615465521812439, "bge_max": 0.615465521812439, "title": "Methylergonovine: Drug information", "rep_snippet": "Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk…"}, {"doc_id": "doxapram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6152533292770386, "bge_max": 0.6152533292770386, "title": "Doxapram: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149429678916931, "bge_max": 0.6149429678916931, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "tiotropium-and-olodaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149429678916931, "bge_max": 0.6149429678916931, "title": "Tiotropium and olodaterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-indacaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149429678916931, "bge_max": 0.6149429678916931, "title": "Glycopyrrolate (glycopyrronium) and indacaterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "umeclidinium-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149429678916931, "bge_max": 0.6149429678916931, "title": "Umeclidinium and vilanterol: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "aclidinium-and-formoterol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6149429678916931, "bge_max": 0.6149429678916931, "title": "Aclidinium and formoterol (United States: Not available): Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "tetracaine-and-oxymetazoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6144866347312927, "bge_max": 0.6144866347312927, "title": "Tetracaine and oxymetazoline: Drug information", "rep_snippet": "Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.…"}, {"doc_id": "acetaminophen-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6137424111366272, "bge_max": 0.6137424111366272, "title": "Acetaminophen and pseudoephedrine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6107771396636963, "bge_max": 0.6107771396636963, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.  • Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; ma…"}, {"doc_id": "orphenadrine-aspirin-and-caffeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6107769012451172, "bge_max": 0.6107769012451172, "title": "Orphenadrine, aspirin, and caffeine: Drug information", "rep_snippet": "Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific…"}, {"doc_id": "butalbital-compound-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6104897260665894, "bge_max": 0.6104897260665894, "title": "Butalbital compound: Drug information", "rep_snippet": "LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate,…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6104897260665894, "bge_max": 0.6104897260665894, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine. Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate,…"}]}
{"qid": "Q11", "query": "Digoxin starting amiodarone — interaction mechanism and dose adjustment/monitoring.", "candidates": [{"doc_id": "lovastatin-and-niacin-drug-information", "bm25_top3": 28.90570942716316, "bm25_max": 28.90570942716316, "bge_top3": 0.650347888469696, "bge_max": 0.650347888469696, "title": "Lovastatin and niacin: Drug information", "rep_snippet": "Dosage adjustment with concomitant medications:  Amiodarone: Maximum lovastatin dose: 40 mg/day  Danazol, diltiazem, dronedarone, or verapamil: Initial lovastatin dose: 10 mg once daily (dosage unavailable with combinati…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": 28.84925430517844, "bm25_max": 28.84925430517844, "bge_top3": 0.668999433517456, "bge_max": 0.668999433517456, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Dosage adjustment with concomitant medications: Oral: Note: Patients currently tolerating and requiring a dose of simvastatin 80 mg who require initiation of an interacting drug with a dose cap for simvastatin should be…"}, {"doc_id": "digoxin-immune-fab-drug-information", "bm25_top3": 26.133834793565928, "bm25_max": 28.479443274028306, "bge_top3": null, "bge_max": null, "title": "Digoxin immune Fab: Drug information", "rep_snippet": "Approximate Dose of Digoxin Immune Fab (in vials) for Reversal of a Single Large Digoxin Overdose  Number of Digoxin Tablets or Capsules Ingested1  Dose of Digoxin Immune Fab  (# of Vials)  1250 mcg tablets with 80% bioa…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": 27.0842114362662, "bm25_max": 28.12462450089306, "bge_top3": 0.6619827747344971, "bge_max": 0.6642287969589233, "title": "Digoxin: Drug information", "rep_snippet": "Loading dose: There are no dosage adjustments provided in the manufacturer’s labeling; however, 50% to 70% of a digoxin dose is excreted unchanged in the urine.  Maintenance dose: Dosage reductions and close monitoring r…"}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 25.28903675645661, "bm25_max": 27.100270394506495, "bge_top3": null, "bge_max": null, "title": "Amiodarone: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Dosage adjustment is probably necessary in substantial hepatic impairment. No specific guidelines available. If hepatic enzymes exceed 3 times normal or double in a patient with an elevated ba…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": 22.94292813296468, "bm25_max": 22.94292813296468, "bge_top3": null, "bge_max": null, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Amiodarone: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone.…"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 22.27904750700836, "bm25_max": 22.27904750700836, "bge_top3": 0.6624314785003662, "bge_max": 0.6624314785003662, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Dabigatran dose reductions may be needed. Specific recommendations…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 21.76336708605128, "bm25_max": 21.76336708605128, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 21.730310567954536, "bm25_max": 21.730310567954536, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Digoxin: MiFEPRIStone may increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereaft…"}, {"doc_id": "erlotinib-drug-information", "bm25_top3": 19.066224696495336, "bm25_max": 19.066224696495336, "bge_top3": null, "bge_max": null, "title": "Erlotinib: Drug information", "rep_snippet": "CYP3A4 inducers: Avoid concurrent use if possible; if concomitant administration with CYP3A4 inducers cannot be avoided, increase erlotinib dose in 50 mg increments at 2-week intervals to a maximum of 450 mg; reduce erlo…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 18.61928512087785, "bm25_max": 18.61928512087785, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  The manufacturer's labeling recommends considering a reduced dose (starting at the low end of the dosing range) with close monitoring for toxicity dose in patients with baseline hepatic impair…"}, {"doc_id": "vinorelbine-drug-information", "bm25_top3": 17.157988850815197, "bm25_max": 17.157988850815197, "bge_top3": null, "bge_max": null, "title": "Vinorelbine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.  Dosage adjustment in hema…"}, {"doc_id": "sildenafil-drug-information", "bm25_top3": 16.323322840972736, "bm25_max": 16.434970830503627, "bge_top3": null, "bge_max": null, "title": "Sildenafil: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Revatio: No dosage adjustment necessary.  Viagra: Starting dose of 25 mg should be considered."}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 15.364521391465283, "bm25_max": 16.29384644664444, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) has occurred in patients receiving amiodarone and a sofosbuvir-containing regimen. A fatal cardiac arrest was reported in a patient taking ami…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 15.2622836784331, "bm25_max": 16.089371020580074, "bge_top3": 0.6644331812858582, "bge_max": 0.6644331812858582, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) has occurred in patients receiving amiodarone and sofosbuvir in combination with daclatasvir or simeprevir. A fatal cardiac arrest was reporte…"}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": 15.254031258250656, "bm25_max": 16.04478936890516, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) and fatal cardiac arrest has occurred in patients receiving amiodarone and ledipasvir/sofosbuvir. Bradycardia generally occurred within hours…"}, {"doc_id": "lidocaine-and-prilocaine-drug-information", "bm25_top3": 14.252398879408867, "bm25_max": 14.252398879408867, "bge_top3": null, "bge_max": null, "title": "Lidocaine and prilocaine: Drug information", "rep_snippet": "Monitoring Parameters  Serum methemoglobin before, during, and after use in neonates and infants up to 3 months of age. Consider ECG monitoring in patients treated with Class III antiarrhythmic drugs (eg, amiodarone)."}, {"doc_id": "dronedarone-drug-information", "bm25_top3": 13.059573348983886, "bm25_max": 13.059573348983886, "bge_top3": 0.6674602031707764, "bge_max": 0.6674602031707764, "title": "Dronedarone: Drug information", "rep_snippet": "Digoxin: May enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin. Management: Avoid con…"}, {"doc_id": "telaprevir-united-states-not-available-drug-information", "bm25_top3": 12.719503967099598, "bm25_max": 12.719503967099598, "bge_top3": null, "bge_max": null, "title": "Telaprevir (United States: Not available): Drug information", "rep_snippet": "Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort. Management: Administer one third of the recommended deflazacort dose when used together with a strong…"}, {"doc_id": "ivabradine-drug-information", "bm25_top3": 11.242066451524728, "bm25_max": 11.242066451524728, "bge_top3": 0.6527121663093567, "bge_max": 0.6527121663093567, "title": "Ivabradine: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate (prior to initiation, prior to increasing dose, or after decreasing dose); monitor heart rate more closely if receiving other negative chronotropes (eg, amiodarone, beta-blockers, digoxi…"}, {"doc_id": "cimetidine-drug-information", "bm25_top3": 10.376865566630617, "bm25_max": 10.376865566630617, "bge_top3": null, "bge_max": null, "title": "Cimetidine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib. Management: To minimize the poten…"}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": 9.228316528062152, "bm25_max": 9.228316528062152, "bge_top3": null, "bge_max": null, "title": "Daclatasvir: Drug information", "rep_snippet": "• Bradycardia: When used in combination with sofosbuvir and amiodarone, symptomatic bradycardia (eg, near-fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, con…"}, {"doc_id": "simeprevir-drug-information", "bm25_top3": 6.561248827371907, "bm25_max": 6.561248827371907, "bge_top3": null, "bge_max": null, "title": "Simeprevir: Drug information", "rep_snippet": "• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) has occurred in patients receiving amiodarone and sofosbuvir in combination with another direct acting antiviral, including simeprevir. Fatal…"}, {"doc_id": "bretylium-united-states-not-available-drug-information", "bm25_top3": 6.1960279204069355, "bm25_max": 6.1960279204069355, "bge_top3": null, "bge_max": null, "title": "Bretylium (United States: Not available): Drug information", "rep_snippet": "• Cardiac glycosides: Avoid concomitant use with cardiac glycosides (eg, digoxin). May consider use in digitalized patients with serious arrhythmias that are unrelated to digoxin toxicity and resistant to other therapy.…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": 4.136276808130034, "bm25_max": 5.183178471355536, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir: Drug information", "rep_snippet": "• Amiodarone: Symptomatic bradycardia (some requiring pacemaker intervention) has occurred in patients receiving amiodarone and a sofosbuvir-containing regimen. Fatal cardiac arrest occurred in a patient taking amiodaron…"}, {"doc_id": "niacin-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6715825796127319, "bge_max": 0.6715825796127319, "title": "Niacin and simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alcohol (…"}, {"doc_id": "regadenoson-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6710542440414429, "bge_max": 0.6710542440414429, "title": "Regadenoson: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.668999433517456, "bge_max": 0.668999433517456, "title": "Simvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "emicizumab-kxwh-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Emicizumab-kxwh: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Amiloride: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "calcifediol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Calcifediol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "oritavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Oritavancin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "elvitegravir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Elvitegravir: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "cabergoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Cabergoline: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "riociguat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Riociguat: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Cefazolin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "clofarabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Clofarabine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "copanlisib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Copanlisib: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "miglitol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Miglitol: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Gadofosveset: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "niraparib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Niraparib: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "romidepsin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Romidepsin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Cefotaxime: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Caspofungin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "brentuximab-vedotin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Brentuximab vedotin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "anagrelide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Anagrelide: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "clemastine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636025905609131, "bge_max": 0.6636025905609131, "title": "Clemastine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "toremifene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6623151898384094, "bge_max": 0.6623151898384094, "title": "Toremifene: Drug information", "rep_snippet": "• Drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more det…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6622343063354492, "bge_max": 0.6622343063354492, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "difenoxin-and-atropine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562910079956055, "bge_max": 0.6562910079956055, "title": "Difenoxin and atropine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "amlodipine-and-atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.654238224029541, "bge_max": 0.654238224029541, "title": "Amlodipine and atorvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Alfuzosin…"}, {"doc_id": "eluxadoline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6540380120277405, "bge_max": 0.6540380120277405, "title": "Eluxadoline: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6516684293746948, "bge_max": 0.6516684293746948, "title": "Lovastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Amiodaron…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6508424282073975, "bge_max": 0.6508424282073975, "title": "Atorvastatin: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy  Aliskiren…"}, {"doc_id": "macitentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6495083570480347, "bge_max": 0.6495083570480347, "title": "Macitentan: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "isotretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6495083570480347, "bge_max": 0.6495083570480347, "title": "Isotretinoin: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "adenosine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6494772434234619, "bge_max": 0.6494772434234619, "title": "Adenosine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Caffeine and Caffeine Containing Products: May diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of…"}, {"doc_id": "bedaquiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6489841938018799, "bge_max": 0.6489841938018799, "title": "Bedaquiline: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "trazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6489841938018799, "bge_max": 0.6489841938018799, "title": "Trazodone: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6489841938018799, "bge_max": 0.6489841938018799, "title": "Vortioxetine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6489841938018799, "bge_max": 0.6489841938018799, "title": "Clomipramine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}]}
{"qid": "Q12", "query": "Influenza treatment: eGFR 45 — what is the oseltamivir dose (renal adjustment)?", "candidates": [{"doc_id": "oseltamivir-drug-information", "bm25_top3": 31.58324729436453, "bm25_max": 34.91951704258693, "bge_top3": 0.6471617420514425, "bge_max": 0.6609984636306763, "title": "Oseltamivir: Drug information", "rep_snippet": "Note: Data suggest that increased doses (>150 mg daily) in critically ill patients is not necessary since blood concentrations of oseltamivir were comparable or higher compared to ambulatory patients given similar dosing…"}, {"doc_id": "canagliflozin-and-metformin-drug-information", "bm25_top3": 31.254339925920636, "bm25_max": 31.254339925920636, "bge_top3": 0.65504390001297, "bge_max": 0.65504390001297, "title": "Canagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Limit the dose of canagliflozin/metformin to canagliflozin 100 mg/day. If patient is receiving conc…"}, {"doc_id": "canagliflozin-drug-information", "bm25_top3": 19.999855517058165, "bm25_max": 30.75228230613517, "bge_top3": 0.6528951525688171, "bge_max": 0.6528951525688171, "title": "Canagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 45 to <60 mL/minute/1.73 m2: Maximum dose: 100 mg once daily. If patient receiving concurrent UDP-glucuronosyl transferase (UGT)…"}, {"doc_id": "empagliflozin-and-metformin-drug-information", "bm25_top3": 20.751641220580282, "bm25_max": 29.97304526500787, "bge_top3": 0.6136554479598999, "bge_max": 0.6136554479598999, "title": "Empagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR <45 mL/minute/1.73 m2: Use is contraindicated by the manufacturer; refer also to indiv…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": 22.391423240967853, "bm25_max": 29.89661968270482, "bge_top3": 0.6453949213027954, "bge_max": 0.6453949213027954, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, t…"}, {"doc_id": "saxagliptin-and-metformin-drug-information", "bm25_top3": 18.07746916457505, "bm25_max": 29.07408885065482, "bge_top3": 0.624796986579895, "bge_max": 0.624796986579895, "title": "Saxagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "sitagliptin-and-metformin-drug-information", "bm25_top3": 18.276855417954543, "bm25_max": 28.604669849054, "bge_top3": 0.6545780897140503, "bge_max": 0.6545780897140503, "title": "Sitagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": 19.914056027829545, "bm25_max": 27.391293016393867, "bge_top3": 0.634480357170105, "bge_max": 0.634480357170105, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "linagliptin-and-metformin-drug-information", "bm25_top3": 27.391293016393867, "bm25_max": 27.391293016393867, "bge_top3": 0.6368728280067444, "bge_max": 0.6368728280067444, "title": "Linagliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during ther…"}, {"doc_id": "repaglinide-and-metformin-drug-information", "bm25_top3": 17.15400018423287, "bm25_max": 27.046176469222363, "bge_top3": 0.6496634483337402, "bge_max": 0.6496634483337402, "title": "Repaglinide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to 45 mL/minute/1.73 m2:  Preexisting impairment: Use of repaglinide/metformin is not recommended for initiation of therapy. R…"}, {"doc_id": "dapagliflozin-and-saxagliptin-drug-information", "bm25_top3": 19.82578152925455, "bm25_max": 26.58150854177827, "bge_top3": 0.6354413032531738, "bge_max": 0.6354413032531738, "title": "Dapagliflozin and saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 45 to <60 mL/minute/1.73 m2: Do not initiate therapy if eGFR <60 mL/minute/1.73 m2; discontinue therapy if eGFR falls persistentl…"}, {"doc_id": "rosiglitazone-and-metformin-drug-information", "bm25_top3": 26.48615896079652, "bm25_max": 26.48615896079652, "bge_top3": 0.6366047859191895, "bge_max": 0.6366047859191895, "title": "Rosiglitazone and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 45 mL/minute/1.73 m2: Use is not recommended for initiation of therapy; if eGFR falls to <45 mL/minute/1.73 m2 during thera…"}, {"doc_id": "metformin-drug-information", "bm25_top3": 16.92570338147899, "bm25_max": 26.265749533201937, "bge_top3": 0.6377072334289551, "bge_max": 0.6377072334289551, "title": "Metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >45 mL/minute/1.73 m2: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been r…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": 16.509198275977475, "bm25_max": 25.15392686666117, "bge_top3": 0.6289616823196411, "bge_max": 0.6289616823196411, "title": "Empagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <45 mL/minute/1.73 m2: The manufacturer recommends to not initiate therapy, or in patients already taking empagliflozin, d…"}, {"doc_id": "glipizide-and-metformin-drug-information", "bm25_top3": 13.847353028401306, "bm25_max": 24.348926980495403, "bge_top3": 0.638582706451416, "bge_max": 0.638582706451416, "title": "Glipizide and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥45 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  eGFR 30 to <45 mL/minute/1.73 m2:  Preexisting impairment: Use of glipizide/metformi…"}, {"doc_id": "sitagliptin-drug-information", "bm25_top3": 24.1018739456898, "bm25_max": 24.1018739456898, "bge_top3": 0.6448297500610352, "bge_max": 0.6448297500610352, "title": "Sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR ≥30 to <45 mL/minute/1.73 m2: 50 mg once daily  eGFR <30 mL/minute/1.73 m2: 25 mg once daily  ESRD requiring hemodialysis or per…"}, {"doc_id": "saxagliptin-drug-information", "bm25_top3": 18.193276692608404, "bm25_max": 23.90355297614014, "bge_top3": 0.6355857253074646, "bge_max": 0.6355857253074646, "title": "Saxagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥45 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <45 mL/minute/1.73 m2: 2.5 mg once daily.  ESRD requiring hemodialysis: 2.5 mg once daily; administer postdialysis  Peritoneal d…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": 23.343091058413687, "bm25_max": 23.343091058413687, "bge_top3": null, "bge_max": null, "title": "Lesinurad: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting renal impairment:  Estimated CrCl ≥60 mL/minute: No dosage adjustment necessary.  Estimated CrCl 45 to <60 mL/minute: No dosage adjustment is necessary; monitor more frequently.  Est…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": 23.148265180691844, "bm25_max": 23.148265180691844, "bge_top3": 0.6462786197662354, "bge_max": 0.6462786197662354, "title": "Afatinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The manufacturer recommends using the Modification of Diet in Renal Disease (MDRD) formula to estimate the glomerular filtration rate (eGFR).  Preexisting impairment:  eGFR >30 mL/minute/1…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": 21.694512551090437, "bm25_max": 21.694512551090437, "bge_top3": 0.640014111995697, "bge_max": 0.640014111995697, "title": "Delafloxacin: Drug information", "rep_snippet": "Dosing: Renal Impairment  Oral, IV:  Estimated glomerular filtration rate (eGFR) 30 to 89 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to 29 mL/minute/1.73 m2:  Oral: No dosage adjustment necessary.  IV: 2…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": 21.432875176733337, "bm25_max": 21.432875176733337, "bge_top3": null, "bge_max": null, "title": "Fenofibrate: Drug information", "rep_snippet": "Dialysis: Use is contraindicated.  TriCor:  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to 59 mL/minute/1.73 m2: Initiate at 48 mg once daily  eGFR <30 mL/minute/1.73 m2: Use is contraindicated.…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 21.296789325733982, "bm25_max": 21.296789325733982, "bge_top3": null, "bge_max": null, "title": "Spironolactone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer's labeling:  Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.  Suspension:  Edema, hypertension: There…"}, {"doc_id": "alogliptin-and-metformin-drug-information", "bm25_top3": 20.959773492958377, "bm25_max": 20.959773492958377, "bge_top3": 0.6137083768844604, "bge_max": 0.6137083768844604, "title": "Alogliptin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR >60 mL/minute/1.73 m2: No dosage adjustment necessary. Monitor renal function at least annually.  eGFR 30 to 60 mL/minute/1.73 m2: Use is not recommended.  eGFR <30 mL/minute/1.73 m2: Use i…"}, {"doc_id": "dapagliflozin-and-metformin-drug-information", "bm25_top3": 20.453459863945003, "bm25_max": 20.453459863945003, "bge_top3": null, "bge_max": null, "title": "Dapagliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <60 mL/minute/1.73 m2: Use is contraindicated.  Hemodialysis: Use is contraindicated."}, {"doc_id": "cabozantinib-drug-information", "bm25_top3": 20.34984484625143, "bm25_max": 20.34984484625143, "bge_top3": 0.6287049651145935, "bge_max": 0.6287049651145935, "title": "Cabozantinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR…"}, {"doc_id": "dapagliflozin-drug-information", "bm25_top3": 19.540552680934457, "bm25_max": 19.540552680934457, "bge_top3": 0.6196713447570801, "bge_max": 0.6196713447570801, "title": "Dapagliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Use is not recommended for initiation of therapy or when eGFR is persistently between 30 and <60 mL…"}, {"doc_id": "ertugliflozin-and-sitagliptin-drug-information", "bm25_top3": 19.481513033146868, "bm25_max": 19.481513033146868, "bge_top3": 0.6201421022415161, "bge_max": 0.6201421022415161, "title": "Ertugliflozin and sitagliptin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is pe…"}, {"doc_id": "ertugliflozin-drug-information", "bm25_top3": 19.481513033146868, "bm25_max": 19.481513033146868, "bge_top3": 0.6182045340538025, "bge_max": 0.6182045340538025, "title": "Ertugliflozin: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when eGFR is p…"}, {"doc_id": "ertugliflozin-and-metformin-drug-information", "bm25_top3": 19.404702428355332, "bm25_max": 19.404702428355332, "bge_top3": 0.6209088563919067, "bge_max": 0.6209088563919067, "title": "Ertugliflozin and metformin: Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 30 to <60 mL/minute/1.73 m2: Not recommended for initiation of therapy in preexisting impairment or continued use when e…"}, {"doc_id": "glyburide-and-metformin-drug-information", "bm25_top3": 7.452455800237477, "bm25_max": 7.452455800237477, "bge_top3": null, "bge_max": null, "title": "Glyburide and metformin: Drug information", "rep_snippet": "Monitoring Parameters  Signs and symptoms of hypoglycemia, blood glucose, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treat…"}, {"doc_id": "ezetimibe-and-simvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6562329530715942, "bge_max": 0.6562329530715942, "title": "Ezetimibe and simvastatin: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR <60 mL/minute/1.73 m2: Ezetimibe 10 mg and simvastatin 20 mg once daily in the evening (higher doses should be used with caution)."}, {"doc_id": "amantadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.634670078754425, "bge_max": 0.634670078754425, "title": "Amantadine: Drug information", "rep_snippet": "Dosing: Adult  Note: Osmolex ER tablets: FDA approved February 2018; anticipated availability is currently unknown. Dosing for Osmolex ER differs from Gocovri extended release capsules; monograph edits for Osmolex ER are…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6327729225158691, "bge_max": 0.6327729225158691, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute/1.73 m2: Initial: Sacubitril 24 mg/valsartan 26 mg twice daily"}, {"doc_id": "albiglutide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.629186749458313, "bge_max": 0.629186749458313, "title": "Albiglutide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 to 89 mL/minute/1.73 m2: No dosage adjustment necessary; use caution when initiating or escalating doses.  eGFR <15 mL/minute/1.73 m2: There are no dosage adjustments provided in the ma…"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6277217864990234, "bge_max": 0.6277217864990234, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been recommended (Aronoff, 2007):  Adults:  GFR >50 mL/minute: No dosage adjustme…"}, {"doc_id": "pentazocine-and-naloxone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6260969638824463, "bge_max": 0.6260969638824463, "title": "Pentazocine and naloxone: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. The following recommendations have been used by some clinicians based on pentazocine component (Aronoff…"}, {"doc_id": "pentazocine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6256042718887329, "bge_max": 0.6256042718887329, "title": "Pentazocine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution. The following recommendations have been used by some clinicians (Aronoff, 2007):  GFR ≥50 mL/minute: No…"}, {"doc_id": "zanamivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6243336796760559, "bge_max": 0.6243336796760559, "title": "Zanamivir: Drug information", "rep_snippet": "Dosing: Adult  Influenza: Oral inhalation:  Manufacturer's labeling:  Prophylaxis, household setting: Two inhalations (10 mg) once daily for 10 days. Begin within 36 hours following onset of signs or symptoms of index ca…"}, {"doc_id": "pralatrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6240911483764648, "bge_max": 0.6240911483764648, "title": "Pralatrexate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Peripheral T-cell lymphoma (PTCL), relapsed or refractory:  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR 15 to <30 mL/minute/1.73 m2:…"}, {"doc_id": "tetracycline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6236368417739868, "bge_max": 0.6236368417739868, "title": "Tetracycline: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  Manufacturer’s labeling: There are no specific dosage adjustments provided in the manufacturer’s labeling; decrease dose and/or extend dosing interval.  Alternative dosing (Aronoff 2007…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6220585107803345, "bge_max": 0.6220585107803345, "title": "Posaconazole: Drug information", "rep_snippet": "Dosing: Renal Impairment  Delayed-release tablets and oral suspension:  eGFR 20 to 80 mL/minute/1.73 m2: No dosage adjustment necessary.  eGFR <20 mL/minute/1.73 m2: No dosage adjustment necessary; however, monitor for b…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6202511787414551, "bge_max": 0.6202511787414551, "title": "Apalutamide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Note: Renal function estimated by the modification of diet in renal disease (MDRD) equation.  eGFR 30 to 89 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer’s labe…"}, {"doc_id": "lisdexamfetamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.619152307510376, "bge_max": 0.619152307510376, "title": "Lisdexamfetamine: Drug information", "rep_snippet": "Dosing: Renal Impairment  GFR ≥30 mL/minute/1.73 m2: There are no dosage adjustments provided in the manufacturer's labeling.  GFR 15 to <30 mL/minute/1.73 m2: Maximum dose: 50 mg/day.  GFR <15 mL/minute/1.73 m2: Maximum…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.617530345916748, "bge_max": 0.617530345916748, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "The following adjustments have been recommended (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours:  GFR >50 mL/minute/1.73 m2: No dosage adjustment necessary.…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6173250675201416, "bge_max": 0.6173250675201416, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  GFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary.  GFR 30 to 59 mL/minute/1.73 m2: There are no specific dosage recommendations provided in the manufacturer's labeling; use lowe…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6169066429138184, "bge_max": 0.6169066429138184, "title": "Sofosbuvir: Drug information", "rep_snippet": "Dosing: Renal Impairment  Estimated glomerular filtration rate (eGFR) ≥30 mL/minute: No dosage adjustment necessary.  eGFR <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not b…"}, {"doc_id": "nateglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6168578863143921, "bge_max": 0.6168578863143921, "title": "Nateglinide: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild to moderate impairment: No dosage adjustment necessary.  Severe impairment: Initiate conservatively at 60 mg 3 times daily with meals if eGFR <30 mL/minute/1.73 m2 (ADA 2018d). Use with cau…"}, {"doc_id": "hydralazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6142888069152832, "bge_max": 0.6142888069152832, "title": "Hydralazine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):  Children and Adolescents: Note: Renally adjuste…"}, {"doc_id": "auranofin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6139023303985596, "bge_max": 0.6139023303985596, "title": "Auranofin: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustments provided in the manufacturer’s labeling. The following guidelines have been used by some clinicians (Aronoff 2007):  GFR 51 to 80 mL/minute: Administer 50% of dos…"}, {"doc_id": "insulin-glargine-and-lixisenatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6137311458587646, "bge_max": 0.6137311458587646, "title": "Insulin glargine and lixisenatide: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥15 mL/minute/1.73 m2 to <90 mL/minute/1.73 m2: There are no specific dosage adjustments provided in the manufacturer’s labeling for the combination product; insulin requirements may be red…"}, {"doc_id": "cetirizine-and-pseudoephedrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6123298406600952, "bge_max": 0.6123298406600952, "title": "Cetirizine and pseudoephedrine: Drug information", "rep_snippet": "Dosing: Renal Impairment  US labeling: There are no dosage adjustments provided in the manufacturer’s labeling; however the following adjustments have been recommended (Aronoff 2007): Cetirizine:  Adults:  GFR >50 mL/min…"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6105687618255615, "bge_max": 0.6105687618255615, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Dosing: Renal Impairment  eGFR ≥30 mL/minute per 1.73 m2: No dosage adjustment necessary.  eGFR <30 mL/minute per 1.73 m2: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); u…"}, {"doc_id": "fexofenadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6105217933654785, "bge_max": 0.6105217933654785, "title": "Fexofenadine: Drug information", "rep_snippet": "Dosing: Renal Impairment  There are no dosage adjustment provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):  Adults:  GFR >50 mL/minute: No dosage adjustment…"}]}
{"qid": "Q13", "query": "Adult hypertension — starting dose and max dose for lisinopril; any renal adjustment or contraindication?", "candidates": [{"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 28.70989352976647, "bm25_max": 41.17646613642935, "bge_top3": 0.7104954123497009, "bge_max": 0.7104954123497009, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "vinorelbine-drug-information", "bm25_top3": 33.45375317328171, "bm25_max": 33.45375317328171, "bge_top3": null, "bge_max": null, "title": "Vinorelbine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.  Dosage adjustment in hema…"}, {"doc_id": "sildenafil-drug-information", "bm25_top3": 27.59759420529397, "bm25_max": 33.24201440988355, "bge_top3": null, "bge_max": null, "title": "Sildenafil: Drug information", "rep_snippet": "Dosing: Renal Impairment  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute:  Revatio: No dosage adjustment necessary.  Viagra: Starting dose of 25 mg should be considered."}, {"doc_id": "loratadine-drug-information", "bm25_top3": 31.547502129542888, "bm25_max": 31.547502129542888, "bge_top3": null, "bge_max": null, "title": "Loratadine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling; however, the following recommendations have been recommended (Aronoff, 2007):  Adults:  CrCl 10-50 mL/minute: Recommended dose every 24…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 25.644282355007697, "bm25_max": 25.644282355007697, "bge_top3": null, "bge_max": null, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "betrixaban-drug-information", "bm25_top3": 25.562165550762387, "bm25_max": 25.562165550762387, "bge_top3": null, "bge_max": null, "title": "Betrixaban: Drug information", "rep_snippet": "Dosing: Adult  VTE (prophylaxis): Oral: 160 mg as a single dose on day 1, followed by 80 mg once daily for 35 to 42 days  Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and…"}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 25.168426582981954, "bm25_max": 25.168426582981954, "bge_top3": null, "bge_max": null, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "• Renal impairment: Cumulative effects of hydrochlorothiazide may develop, including azotemia, in patients with impaired renal function. Avoid hydrochlorothiazide in severe renal disease (ineffective). Spironolactone may…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 25.03800941316804, "bm25_max": 25.03800941316804, "bge_top3": null, "bge_max": null, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with oth…"}, {"doc_id": "riociguat-drug-information", "bm25_top3": 24.785007961706825, "bm25_max": 24.785007961706825, "bge_top3": null, "bge_max": null, "title": "Riociguat: Drug information", "rep_snippet": "Dosing: Adult  Chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension: Oral: Initial: 1 mg 3 times daily; may initiate dose at 0.5 mg 3 times daily in patients who may not tolerate the hypotensive…"}, {"doc_id": "ambrisentan-drug-information", "bm25_top3": 23.61769300502373, "bm25_max": 23.61769300502373, "bge_top3": null, "bge_max": null, "title": "Ambrisentan: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary arterial hypertension: Oral: Initial: 5 mg once daily, with or without tadalafil; at 4-week intervals, as tolerated and necessary, may increase either the dose of ambrisentan (maximum dose: 10 mg…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 22.51200951817201, "bm25_max": 22.51200951817201, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong…"}, {"doc_id": "axitinib-drug-information", "bm25_top3": 22.113367850287467, "bm25_max": 22.113367850287467, "bge_top3": null, "bge_max": null, "title": "Axitinib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Adverse events: May require temporary interruption, dose decreases (reduce dose from 5 mg twice daily to 3 mg twice daily; further reduce to 2 mg twice daily) or discontinuation  Cardiac…"}, {"doc_id": "epoprostenol-drug-information", "bm25_top3": 21.66987352791068, "bm25_max": 21.66987352791068, "bge_top3": 0.6564860343933105, "bge_max": 0.6564860343933105, "title": "Epoprostenol: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary arterial hypertension (PAH): IV: Initial: 2 ng/kg/minute; a lower initial dose may be used if patient is intolerant of starting dose. Increase dose in increments of 1 to 2 ng/kg/minute at interva…"}, {"doc_id": "eprosartan-drug-information", "bm25_top3": 21.405178612678863, "bm25_max": 21.405178612678863, "bge_top3": null, "bge_max": null, "title": "Eprosartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Dosage must be individualized. Can administer once or twice daily with total daily doses of 400 to 800 mg. Usual starting dose is 600 mg once daily as monotherapy in patients who are eu…"}, {"doc_id": "irbesartan-drug-information", "bm25_top3": 21.23102128061666, "bm25_max": 21.23102128061666, "bge_top3": null, "bge_max": null, "title": "Irbesartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: 150 mg once daily; patients may be titrated to 300 mg once daily; usual dosage range (ASH/ISH [Weber, 2014]): 150 to 300 mg daily; target dose (JNC 8 [James, 2013]): 300 mg once daily.…"}, {"doc_id": "tadalafil-drug-information", "bm25_top3": 21.108777819219693, "bm25_max": 21.108777819219693, "bge_top3": null, "bge_max": null, "title": "Tadalafil: Drug information", "rep_snippet": "Dosing: Geriatric  Refer to adult dosing. No dose adjustment for patients >65 years of age in the absence of renal or hepatic impairment."}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 20.87226001286966, "bm25_max": 20.87226001286966, "bge_top3": null, "bge_max": null, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Initial: No dosage adjustment necessary. Use with caution and titrate dose per seizure control and tolerability; metabolites primarily undergo renal elimination."}, {"doc_id": "sonidegib-drug-information", "bm25_top3": 20.828982458106168, "bm25_max": 20.828982458106168, "bge_top3": null, "bge_max": null, "title": "Sonidegib: Drug information", "rep_snippet": "Dosing: Adult  Note: Verify pregnancy status of females of reproductive potential prior to therapy initiation. Measure serum creatine kinase (CK) levels and renal function tests in all patients prior to starting treatmen…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": 20.787145479222822, "bm25_max": 20.787145479222822, "bge_top3": null, "bge_max": null, "title": "Sorafenib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Manufacturer’s labeling: No dosage adjustment is necessary for mild, moderate, or severe impairment (not dependent on dialysis); has not been studied in dialysis patients.  A pharmacokinetic stu…"}, {"doc_id": "methoxy-polyethylene-glycol-epoetin-beta-drug-information", "bm25_top3": 20.468445471515384, "bm25_max": 20.468445471515384, "bge_top3": null, "bge_max": null, "title": "Methoxy polyethylene glycol-epoetin beta: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Serious allergic/anaphylactic reactions: Discontinue immediately (and permanently).  Hypertension (difficult to control): Reduce dose or withhold treatment (use is contraindicated in unco…"}, {"doc_id": "rucaparib-drug-information", "bm25_top3": 20.227508680896744, "bm25_max": 20.227508680896744, "bge_top3": null, "bge_max": null, "title": "Rucaparib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Consider therapy interruption or dose reduction if adverse events occur.  Recommended rucaparib dose reductions:  Starting dose: 600 mg twice daily  1st dose reduction: 500 mg twice daily…"}, {"doc_id": "brigatinib-drug-information", "bm25_top3": 19.93158573644445, "bm25_max": 19.93158573644445, "bge_top3": null, "bge_max": null, "title": "Brigatinib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Note: Once the dose is reduced for toxicity, do not subsequently escalate the dose.  Recommended brigatinib dosage adjustment levels:  If the dose received was 90 mg once daily:  First do…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": 19.802759621543963, "bm25_max": 19.802759621543963, "bge_top3": null, "bge_max": null, "title": "Nimodipine: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment provided in manufacturer’s labeling. However, nimodipine undergoes minimal renal elimination and dose adjustment may not be necessary. Not removed by hemo- or peritoneal dia…"}, {"doc_id": "bosutinib-drug-information", "bm25_top3": 19.7705261133318, "bm25_max": 19.7705261133318, "bge_top3": null, "bge_max": null, "title": "Bosutinib: Drug information", "rep_snippet": "Dosing: Renal Impairment  Preexisting impairment:  Ph+ CML, newly diagnosed chronic phase:  CrCl >50 to 80 mL/minute: There are no dosage adjustments provided in manufacturer's labeling, however, based on the pharmacokin…"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 19.653139223517854, "bm25_max": 19.653139223517854, "bge_top3": 0.6547952890396118, "bge_max": 0.6547952890396118, "title": "Flucytosine: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: The manufacturer recommends dose reduction for elevated BUN or serum creatinine (or other signs of renal impairment); however, no specific dosage adjustments are provided. The following…"}, {"doc_id": "ribociclib-drug-information", "bm25_top3": 19.613126902260166, "bm25_max": 19.613126902260166, "bge_top3": null, "bge_max": null, "title": "Ribociclib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Recommended ribociclib dosage adjustment levels:  Starting dose: 600 mg/day.  First dose reduction: Reduce to 400 mg/day.  Second dose reduction: Reduce to 200 mg/day.  If further dose re…"}, {"doc_id": "caspofungin-drug-information", "bm25_top3": 19.612608149535344, "bm25_max": 19.612608149535344, "bge_top3": null, "bge_max": null, "title": "Caspofungin: Drug information", "rep_snippet": "Dosing: Renal Impairment  No dosage adjustment necessary.  End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis…"}, {"doc_id": "abemaciclib-drug-information", "bm25_top3": 19.58510381553372, "bm25_max": 19.58510381553372, "bge_top3": null, "bge_max": null, "title": "Abemaciclib: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  Recommended abemaciclib dosage adjustments for adverse reactions:  Starting dose 200 mg twice a day (monotherapy):  First dose reduction: Reduce abemaciclib dose to 150 mg twice daily.  S…"}, {"doc_id": "propiverine-united-states-not-available-drug-information", "bm25_top3": 19.536341517446072, "bm25_max": 19.536341517446072, "bge_top3": null, "bge_max": null, "title": "Propiverine (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Mild to moderate impairment: No dosage adjustment necessary.  Severe impairment: Maximum dose: 30 mg/day"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 19.514414967443045, "bm25_max": 19.514414967443045, "bge_top3": null, "bge_max": null, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  CrCl >40 mL/minute: No dosage adjustment necessary.  CrCl ≤40 mL/minute (or patients on hemodialysis/CAPD): 160 mg once daily (administer dose following hemodialysis)."}, {"doc_id": "oprelvekin-united-states-not-available-drug-information", "bm25_top3": 18.490821230856586, "bm25_max": 18.490821230856586, "bge_top3": null, "bge_max": null, "title": "Oprelvekin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  For dosage adjustment purposes, renal function may be estimated using the Cockcroft-Gault formula.  CrCl ≥30 mL/minute: No dosage adjustment necessary.  CrCl <30 mL/minute: Reduce dose t…"}, {"doc_id": "ketorolac-nasal-drug-information", "bm25_top3": 18.004595699926863, "bm25_max": 18.004595699926863, "bge_top3": null, "bge_max": null, "title": "Ketorolac (nasal): Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with hepatic impairment or a history of liver disease. Closely monitor patients with any abnormal LFT.  • Hypertension: Use with caution; may cause new-onset hypertensio…"}, {"doc_id": "piroxicam-drug-information", "bm25_top3": 17.1308561340733, "bm25_max": 17.1308561340733, "bge_top3": null, "bge_max": null, "title": "Piroxicam: Drug information", "rep_snippet": "• Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Monitor blood pressure closely with initiation and during piroxicam therapy.  • Renal impairment: NSAID use may co…"}, {"doc_id": "rasagiline-drug-information", "bm25_top3": 16.28157536292202, "bm25_max": 16.28157536292202, "bge_top3": null, "bge_max": null, "title": "Rasagiline: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • CNS effects: May cause new or worsening mental status and behavioral changes, which may be severe, including paranoid ideation, delusions, hallucinations, con…"}, {"doc_id": "salsalate-drug-information", "bm25_top3": 14.932405590311134, "bm25_max": 14.932405590311134, "bge_top3": null, "bge_max": null, "title": "Salsalate: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT.  • Hypertension: Use with caution; may cause new-onset hypertension or worsening of exis…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 14.51732486801997, "bm25_max": 14.51732486801997, "bge_top3": 0.684651255607605, "bge_max": 0.6991320848464966, "title": "Spironolactone: Drug information", "rep_snippet": "• Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, ≥ lisinopril 10 mg daily in adults) (ACCF/AHA [Yancy 2013]). Use with…"}, {"doc_id": "tiaprofenic-acid-united-states-not-available-drug-information", "bm25_top3": 14.327784608621851, "bm25_max": 14.327784608621851, "bge_top3": null, "bge_max": null, "title": "Tiaprofenic acid (United States: Not available): Drug information", "rep_snippet": "• Asthma: Do not administer to patients with asthma; severe bronchospasm may occur.  • Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal liver fu…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 14.110267182410741, "bm25_max": 14.110267182410741, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with oth…"}, {"doc_id": "tolmetin-drug-information", "bm25_top3": 13.258584200065805, "bm25_max": 13.258584200065805, "bge_top3": null, "bge_max": null, "title": "Tolmetin: Drug information", "rep_snippet": "• Coronary artery bypass graft surgery: [US Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased…"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": 13.081291674245275, "bm25_max": 13.081291674245275, "bge_top3": null, "bge_max": null, "title": "Celecoxib: Drug information", "rep_snippet": "• Renal impairment: NSAID use may compromise existing renal function. Dose-dependent decreases in prostaglandin synthesis may result from NSAID use, causing a reduction in renal blood flow which may cause renal decompens…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": 11.164711708905326, "bm25_max": 11.164711708905326, "bge_top3": null, "bge_max": null, "title": "Indinavir: Drug information", "rep_snippet": "Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy  SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin. Manage…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": 10.525626718288535, "bm25_max": 10.525626718288535, "bge_top3": null, "bge_max": null, "title": "Sirolimus: Drug information", "rep_snippet": "Isavuconazonium Sulfate: May increase the serum concentration of Sirolimus. Risk C: Monitor therapy  Itraconazole: May increase the serum concentration of Sirolimus. Management: Sirolimus dose adjustments will likely be…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": 9.96013055672558, "bm25_max": 9.96013055672558, "bge_top3": null, "bge_max": null, "title": "Nelfinavir: Drug information", "rep_snippet": "Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Risk X: Avoid combination  Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": 9.96013055672558, "bm25_max": 9.96013055672558, "bge_top3": null, "bge_max": null, "title": "Atazanavir: Drug information", "rep_snippet": "Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Risk X: Avoid combination  Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": 9.96013055672558, "bm25_max": 9.96013055672558, "bge_top3": null, "bge_max": null, "title": "Ritonavir: Drug information", "rep_snippet": "Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Risk X: Avoid combination  Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C…"}, {"doc_id": "fosamprenavir-drug-information", "bm25_top3": 8.754672847971797, "bm25_max": 8.754672847971797, "bge_top3": null, "bge_max": null, "title": "Fosamprenavir: Drug information", "rep_snippet": "Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with oth…"}, {"doc_id": "lisinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7076875865459442, "bge_max": 0.7078323364257812, "title": "Lisinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Lisinopril: Pediatric drug information\")  Hypertension: Note: Compounded and commercially available oral solutions available in multiple concentrations; precautions sho…"}, {"doc_id": "fosinopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6810944080352783, "bge_max": 0.6810944080352783, "title": "Fosinopril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fosinopril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents >50 kg: Oral: Initial: 5 to 10 mg once daily (maximum: 40 mg once daily)"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6808800101280212, "bge_max": 0.6808800101280212, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Perindopril 3.5 mg/amlodipine 2.5 mg once daily; adjust dose to response in 7- to 14-day intervals; maximum dose: perindopril 14 mg/amlodipine 10 mg per day"}, {"doc_id": "enalapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6783062219619751, "bge_max": 0.6783062219619751, "title": "Enalapril: Drug information", "rep_snippet": "Dosing: Adult  Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe HF, decreased renal function, or in those receiving diuretics.  Asymptomatic left ventricular dysfunction: Oral: Initial: 2.…"}, {"doc_id": "aliskiren-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6729744076728821, "bge_max": 0.6729744076728821, "title": "Aliskiren and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage must be individualized. Prior to initiation, correct hypovolemia and/or closely monitor volume status in patients on concurrent diuretics during treatment initiation.  Init…"}, {"doc_id": "reserpine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6704761981964111, "bge_max": 0.6704761981964111, "title": "Reserpine (United States: not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Reserpine tablets are no longer available in the US.  Hypertension:  Manufacturer's labeling: Initial: 0.5 mg/day for 1-2 weeks; maintenance: 0.1-0.25 mg/day  Note: Clinically, the need for a “loadin…"}, {"doc_id": "fosinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6703640222549438, "bge_max": 0.6703640222549438, "title": "Fosinopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Fosinopril 10 to 80 mg/hydrochlorothiazide 12.5 to 50 mg per day; titrate dosage based on clinical response  Note: Dose is individualized. A patient whose blood pressure is not adequate…"}, {"doc_id": "captopril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6697022914886475, "bge_max": 0.6697022914886475, "title": "Captopril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is individualized; may be substituted for previously titrated dosages of the individual components; alternatively, may initiate as follows: Oral:  Hypertension: Initial: Captopril 25 mg/hydrochl…"}, {"doc_id": "perindopril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6670441627502441, "bge_max": 0.6670441627502441, "title": "Perindopril: Drug information", "rep_snippet": "Dosing: Adult  Heart failure (off-label use): Oral: Initial: 2 mg once daily with gradual dose titration to a target dose of 8 to 16 mg once daily (ACCF/AHA [Yancy 2013]).  Hypertension: Oral: Initial: 4 mg once daily; m…"}, {"doc_id": "bisoprolol-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.665942370891571, "bge_max": 0.665942370891571, "title": "Bisoprolol and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg once daily; dose may be titrated at ≥2-week intervals. Maximum dose: Bisoprolol 20 mg/hydrochlorothiazide 12.5 mg once daily.  Add…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6638922691345215, "bge_max": 0.6638922691345215, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 50 mg once daily; may increase to 50 mg twice daily if response is not adequate; may take up to 4 weeks for full therapeutic response. Doses >100 mg/day are not recommended due…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618525385856628, "bge_max": 0.6618525385856628, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage must be individualized.  Arcosyl products: Initial: Perindopril arginine 2.5 mg/indapamide 0.625 mg once daily; may adjust dose based on blood pressure response to perindop…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6616566181182861, "bge_max": 0.6616566181182861, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults: Note: Renally adjusted dose recommendations are based on the amoxicillin 250 mg/clavulanate 125 mg and amoxicillin 500 mg/clavulanate 125 mg tablets.  CrCl ≥30 mL/minute: No dosage adjus…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6614496111869812, "bge_max": 0.6614496111869812, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage is individualized. Initial: Amlodipine 5 mg/olmesartan 20 mg once daily; dose may be increased after 1 to 2 weeks of therapy. Maximum dose: Amlodipine 10 mg/olmesartan 40 m…"}, {"doc_id": "amlodipine-and-benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6613112688064575, "bge_max": 0.6613112688064575, "title": "Amlodipine and benazepril: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monot…"}, {"doc_id": "ramipril-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6607676148414612, "bge_max": 0.6611721515655518, "title": "Ramipril and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "bosentan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6605077981948853, "bge_max": 0.6605077981948853, "title": "Bosentan: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary artery hypertension: Oral:  <40 kg: Initial and maintenance: 62.5 mg twice daily  ≥40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily. Doses >125…"}, {"doc_id": "losartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6594974994659424, "bge_max": 0.6594974994659424, "title": "Losartan and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dose must be individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequat…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.659403920173645, "bge_max": 0.659403920173645, "title": "Amiloride: Drug information", "rep_snippet": "Dosing: Adult  Hypertension, heart failure (to limit potassium loss): Oral: Initial: 5 mg once daily; may increase to 10 mg daily if necessary; doses >10 mg daily are usually not necessary; however, if patient is persist…"}, {"doc_id": "moexipril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6593389511108398, "bge_max": 0.6593389511108398, "title": "Moexipril: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 7.5 mg once daily (in patients not receiving a diuretic) or 3.75 mg once daily (when combined with a diuretic); adjust dose to blood pressure response; maintenance dose: 7.5 to…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6583099961280823, "bge_max": 0.6583099961280823, "title": "Trandolapril: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral:  Patients not receiving a diuretic: Initial: 1 mg once daily (2 mg daily in black patients). Adjust dosage at intervals of ≥1 week according to blood pressure response; usual dosage (AS…"}, {"doc_id": "moexipril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6581358313560486, "bge_max": 0.6581358313560486, "title": "Moexipril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy. Dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately or in patients not controlled with monotherapy…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6570370197296143, "bge_max": 0.6570370197296143, "title": "Pravastatin: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more; dos…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6569623947143555, "bge_max": 0.6569623947143555, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Enalapril 10 mg/hydrochlorothiazide 25 mg once daily; may increase dose based on patient response after 2 to 3 weeks (maximum: enalapril 20 mg/hydrochlorothiazide 50 mg per day…"}, {"doc_id": "losartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6568892002105713, "bge_max": 0.6568892002105713, "title": "Losartan: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 50 mg once daily; adjust dose to blood pressure response; can be administered once or twice daily with total daily doses ranging from 25 to 100 mg; (maximum: 100 mg/day); usual…"}, {"doc_id": "amlodipine-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566740274429321, "bge_max": 0.6566740274429321, "title": "Amlodipine and valsartan: Drug information", "rep_snippet": "Dosing: Adult  Note: Dose must be individualized.  Hypertension: Oral:  Initial therapy: Amlodipine 5 mg/valsartan 160 mg once daily; dose may be titrated after 1 to 2 weeks. Maximum dose: amlodipine 10 mg/valsartan 320…"}, {"doc_id": "maraviroc-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6560335159301758, "bge_max": 0.6560335159301758, "title": "Maraviroc: Drug information", "rep_snippet": "Dosing: Renal Impairment  Adults:  CrCl ≥30 mL/minute: No dosage adjustment necessary  CrCl <30 mL/minute:  Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer) or concomitant potent CYP3A inducer…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6559668779373169, "bge_max": 0.6559668779373169, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 5 mg once daily, increase dose gradually in single or divided doses every 3 days or more (or every 6 hours with careful monitoring if rapid management required) (maximum: 100 m…"}, {"doc_id": "fenofibrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6557496786117554, "bge_max": 0.6557496786117554, "title": "Fenofibrate: Drug information", "rep_snippet": "Dosing: Geriatric  Oral: Initial: Adjust dosage based on renal function; additional product-specific recommendations for initial dose:  Lipidil EZ [Canadian product]: 48 mg once daily  Lofibra (micronized): 67 mg once da…"}, {"doc_id": "aliskiren-amlodipine-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6546943187713623, "bge_max": 0.6546943187713623, "title": "Aliskiren, amlodipine, and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Not for initial therapy. Dose is individualized. Prior to initiation, correct hypovolemia and/or closely monitor volume status during treatment initiation.  Add-on/switch therapy:…"}, {"doc_id": "quinapril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6546791195869446, "bge_max": 0.6546791195869446, "title": "Quinapril: Drug information", "rep_snippet": "Dosing: Adult  Heart failure: Oral: Initial: 5 mg twice daily; titrate at weekly intervals to effective dose, usually 10 to 20 mg twice daily. Target dose (ACCF/AHA [Yancy, 2013]): 20 mg twice daily.  Hypertension: Oral:…"}, {"doc_id": "metolazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6543943285942078, "bge_max": 0.6543943285942078, "title": "Metolazone: Drug information", "rep_snippet": "Dosing: Adult  Edema (renal disease): Oral: Initial: 5-20 mg once daily.  Edema (heart failure) (off-label dose): Oral: Initial: 2.5 mg once daily; maximum daily dose: 20 mg (ACCF/AHA [Yancy, 2013]); Note: Dosing frequen…"}, {"doc_id": "pegylated-interferon-peginterferon-alfa-2a-and-ribavirin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6543388962745667, "bge_max": 0.6543388962745667, "title": "Pegylated interferon (peginterferon) alfa-2a and ribavirin (United States: Not available): Drug information", "rep_snippet": "Dosing: Renal Impairment (Adult)  Peginterferon alfa-2a: SubQ:  CrCl >20 mL/minute: No dosage adjustment necessary. Monitor closely as dose reduction may be warranted with onset of adverse events.  End-stage renal diseas…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6536473035812378, "bge_max": 0.6536473035812378, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy; dose is individualized; may be substituted for individual components in patients currently maintained on both agents separately.  Hypertension: Oral: Trandolapril 1 to 4 mg/v…"}, {"doc_id": "benazepril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6530209183692932, "bge_max": 0.6530209183692932, "title": "Benazepril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Note: Not for initial therapy; dose should be individualized.  Hypertension: Oral:  Add-on therapy:  Patients not adequately controlled on benazepril or hydrochlorothiazide monotherapy: Initial: Benazepril…"}, {"doc_id": "nadolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6525765657424927, "bge_max": 0.6525765657424927, "title": "Nadolol: Drug information", "rep_snippet": "Dosing: Adult  Angina: Oral: Initial: 40 mg once daily, increase dosage gradually by 40 to 80 mg increments at 3- to 7-day intervals until optimum clinical response is obtained usual dose: 40 to 80 mg daily; maximum dose…"}, {"doc_id": "bupropion-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6521204113960266, "bge_max": 0.6521204113960266, "title": "Bupropion and naltrexone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Mild impairment: There are no dosage adjustment provided in the manufacturer’s labeling (has not been studied); use with caution.  Moderate or severe impairment: Maximum dose: One tablet (naltre…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517090797424316, "bge_max": 0.6517090797424316, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Not for initial therapy. Correct volume and/or salt depletion before initiating therapy.  Replacement therapy: Combination product may be substituted for individually titrated age…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.651567280292511, "bge_max": 0.651567280292511, "title": "Benazepril: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Benazepril: Pediatric drug information\")  Hypertension: Children ≥6 years and Adolescents: Oral: Initial: 0.2 mg/kg once daily (maximum initial dose: 10 mg/day) as mono…"}, {"doc_id": "bisoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6498376131057739, "bge_max": 0.6498376131057739, "title": "Bisoprolol: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: 2.5 to 5 mg once daily; may be increased to 10 mg and then up to 20 mg once daily, if necessary; usual dose range (ASH/ISH [Weber 2014]): 5 to 10 mg once daily  Atrial fibrilla…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6496524810791016, "bge_max": 0.6496524810791016, "title": "Ramipril: Drug information", "rep_snippet": "Dosing: Adult  Note: Consider discontinuation or dose reduction of concomitant diuretic when initiating ramipril. If diuretic cannot be discontinued or dose reduced, consider reduced initial ramipril dose. Monitor blood…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.649509608745575, "bge_max": 0.649509608745575, "title": "Paroxetine: Drug information", "rep_snippet": "Dosing: Hepatic Impairment  Adults: In hepatic dysfunction, plasma concentration is 2 times that seen in normal function.  Brisdelle: No dosage adjustment necessary.  Paxil, Paxil CR, Pexeva:  Mild-to-moderate impairment…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6492488980293274, "bge_max": 0.6492488980293274, "title": "Verapamil: Drug information", "rep_snippet": "Dosing: Geriatric  Hypertension: Oral: Note: When switching from immediate-release to extended-release formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion.…"}]}
{"qid": "Q14", "query": "Community-acquired pneumonia outpatient — standard adult dose for azithromycin (Z-Pak schedule specifics).", "candidates": [{"doc_id": "ceftriaxone-drug-information", "bm25_top3": 36.15616840500101, "bm25_max": 37.963265352531366, "bge_top3": 0.6969519257545471, "bge_max": 0.6969519257545471, "title": "Ceftriaxone: Drug information", "rep_snippet": "Treatment failure following initial therapy of an alternative dual therapy regimen (cefixime and azithromycin): IM: 250 mg in a single dose plus azithromycin 2 g orally as a single dose (CDC [Workowski 2015])  Treatment…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 32.908656773169334, "bm25_max": 36.95623281530659, "bge_top3": 0.6738855044047037, "bge_max": 0.7137506604194641, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "≥45.5 kg: Refer to adult dosing.  Chlamydia trachomatis  infection: Oral:  Cervicitis, urethritis (off-label): Children ≥45 kg: 1 g as a single dose (CDC [Workowski 2015])  Conjunctivitis (off-label use; alternative agen…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 27.026084061310947, "bm25_max": 35.60560821346851, "bge_top3": 0.6862821578979492, "bge_max": 0.6904536485671997, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (hospitalized patient): As a component of empiric therapy or pathogen-specific therapy for community-acquired methicillin-resistant S. aureus: 15 to 20 mg/kg/dose (usual maximum: 2 g/do…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 23.804180919778776, "bm25_max": 31.48038450995856, "bge_top3": 0.6928010880947113, "bge_max": 0.7127747535705566, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": 30.441522628866718, "bm25_max": 30.441522628866718, "bge_top3": 0.6274679899215698, "bge_max": 0.6274679899215698, "title": "Cefotaxime: Drug information", "rep_snippet": "Lyme disease (as an alternative to ceftriaxone): Cardiac or CNS manifestations: Infants and Children: IV: 150 to 200 mg/kg/day in divided doses every 6 to 8 hours for 14 to 28 days; maximum daily dose: 6 g daily (Halperi…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 30.04598253163264, "bm25_max": 30.04598253163264, "bge_top3": 0.6662387549877167, "bge_max": 0.696653425693512, "title": "Doxycycline: Drug information", "rep_snippet": "Pneumonia, community-acquired (CAP): Children >7 years: Oral: Note: A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.  Presumed atypical, mild atypical (M. pneumoniae, C. pneumo…"}, {"doc_id": "ceftaroline-drug-information", "bm25_top3": 20.57132324194169, "bm25_max": 28.82255239356592, "bge_top3": 0.6624341011047363, "bge_max": 0.6624341011047363, "title": "Ceftaroline: Drug information", "rep_snippet": "Dosing: Adult  Pneumonia, community-acquired: IV: 600 mg every 12 hours for 5 to 7 days  Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days"}, {"doc_id": "tigecycline-drug-information", "bm25_top3": 23.72334564420998, "bm25_max": 28.62106814122663, "bge_top3": 0.6581015288829803, "bge_max": 0.6590188145637512, "title": "Tigecycline: Drug information", "rep_snippet": "Dosing: Adult  Pneumonia, community-acquired: IV: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 7 to 14 days  Intra-abdominal infections, complicated (cIAI): IV: Initial: 100 mg as a single…"}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 18.539464000977578, "bm25_max": 28.4713280875379, "bge_top3": 0.6605826020240784, "bge_max": 0.6605826020240784, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Factive is no longer available in the United States.  Susceptible infections: Oral: 320 mg once daily  Acute exacerbations of chronic bronchitis: Oral: 320 mg once daily for 5 days  Community-acquire…"}, {"doc_id": "cefditoren-drug-information", "bm25_top3": 18.416629770884718, "bm25_max": 26.82157396038991, "bge_top3": 0.6613391637802124, "bge_max": 0.6613391637802124, "title": "Cefditoren: Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial exacerbation of chronic bronchitis: Oral: 400 mg twice daily for 10 days  Community-acquired pneumonia: Oral: 400 mg twice daily for 14 days  Pharyngitis, tonsillitis, uncomplicated skin an…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 18.30732724227331, "bm25_max": 26.005716069328454, "bge_top3": 0.7034872770309448, "bge_max": 0.7034872770309448, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (systemic): Pediatric drug information\")  Community-acquired pneumonia (CAP) due to atypical pathogens (M. pneumoniae, Chlamydophila [also known as Chlamyd…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": 25.097086587942545, "bm25_max": 25.097086587942545, "bge_top3": 0.6655821800231934, "bge_max": 0.6655821800231934, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Use  Intra-abdominal infections: Treatment of appendicitis complicated by rupture or abscess and peritonitis caused by beta-lactamase-producing strains of Escherichia coli, Bacteroides fragilis, Bacteroides ovatus, Bacte…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 16.323250198824518, "bm25_max": 24.848058572890057, "bge_top3": 0.6304490566253662, "bge_max": 0.6304490566253662, "title": "Cefpodoxime: Drug information", "rep_snippet": "Dosing: Adult  Bronchitis (chronic), bacterial exacerbation: Oral: 200 mg every 12 hours for 10 days  Cystitis, acute uncomplicated (alternative agent): Oral: 100 mg twice daily for 5 to 7 days (Hooton 2018)  Pharyngitis…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 16.885405914413305, "bm25_max": 24.199495906144033, "bge_top3": 0.6474501192569733, "bge_max": 0.6709856986999512, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Pneumonia, community-acquired; Group A Streptococcus, mild infection or step-down therapy (off-label use): Infants ≥3 months, Children, and Adolescents: Oral: 50 to 75 mg/kg/day in 3 to 4 divided doses (Bradley 2011); ma…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": 18.005118580620035, "bm25_max": 23.546805803788548, "bge_top3": 0.6761830151081085, "bge_max": 0.6838598251342773, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Intra-abdominal infection, complicated, community-acquired (in combination with metronidazole) (off-label use) (Solomkin, [IDSA] 2010): IV: 750 mg once daily for 4 to 7 days (provided source controlled). Note: Avoid usin…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 23.466941221932046, "bm25_max": 23.466941221932046, "bge_top3": 0.6716997623443604, "bge_max": 0.6716997623443604, "title": "Ampicillin: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia (children); Endocarditis, prophylaxis; Endocarditis, treatment (HACEK organisms) (adults); Osteomyelitis, native vertebral; Prophylaxis in patients with prosthetic joint impla…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 22.62779431420415, "bm25_max": 22.62779431420415, "bge_top3": null, "bge_max": null, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Cervicitis/urethritis: Oral:  Nongonococcal (due to Chlamydia trachomatis): 300 mg every 12 hours for 7 days  Gonococcal (acute, uncomplicated): 400 mg as a single dose; Note: As of April 2007, the CDC no…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": 18.53770723595775, "bm25_max": 22.50099630385916, "bge_top3": null, "bge_max": null, "title": "Ertapenem: Drug information", "rep_snippet": "Dosing: Adult  Note: IV therapy may be administered for up to 14 days; IM for up to 7 days  Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis): IM, IV: 1 g once daily; durati…"}, {"doc_id": "zanamivir-drug-information", "bm25_top3": 20.979291225762346, "bm25_max": 20.979291225762346, "bge_top3": 0.6257567405700684, "bge_max": 0.6257567405700684, "title": "Zanamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Zanamivir: Pediatric drug information\")  Influenza: Oral inhalation:  Manufacturer's labeling:  Prophylaxis, household setting: Children ≥5 years (US labeling) or ≥7 ye…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 20.740108488254933, "bm25_max": 20.740108488254933, "bge_top3": null, "bge_max": null, "title": "Cefazolin: Drug information", "rep_snippet": "Use: Off-Label  Catheter-related bloodstream infections (adults); Community-acquired pneumonia (children); Endocarditis, prophylaxis; Prophylaxis in patients with prosthetic joint implants undergoing dental procedures wh…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": 16.03736967097723, "bm25_max": 16.03736967097723, "bge_top3": 0.6319434642791748, "bge_max": 0.6319434642791748, "title": "Oseltamivir: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia (children)"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 14.707108183994219, "bm25_max": 16.033173466758875, "bge_top3": 0.6667228937149048, "bge_max": 0.6667228937149048, "title": "Clarithromycin: Drug information", "rep_snippet": "Pharyngitis/tonsillitis: Treatment of pharyngitis/tonsillitis due to susceptible Streptococcus pyogenes (alternative agent).  Pneumonia, community-acquired: Treatment of community-acquired pneumonia due to susceptible My…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": 14.714147687597738, "bm25_max": 14.714147687597738, "bge_top3": null, "bge_max": null, "title": "Cephalexin: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia (children); Endocarditis, prophylaxis; Prosthetic joint infection"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": 13.926615048305663, "bm25_max": 13.926615048305663, "bge_top3": null, "bge_max": null, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Use: Off-Label  Acute bacterial rhinosinusitis; Bite wounds (animal/human); Endocarditis, treatment (adults); Endocarditis, treatment (pediatric); Intra-abdominal infections; Intravascular catheter-associated bloodstream…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 13.823879013900026, "bm25_max": 13.823879013900026, "bge_top3": 0.6249330043792725, "bge_max": 0.6249330043792725, "title": "Linezolid: Drug information", "rep_snippet": "Use  Enterococcal infections (vancomycin-resistant): Treatment of vancomycin-resistant (VRE) Enterococcus faecium infections, including cases with concurrent bacteremia. Note: Not a preferred agent in resistant E. faecal…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": 12.830788803247927, "bm25_max": 12.830788803247927, "bge_top3": null, "bge_max": null, "title": "Oxacillin: Drug information", "rep_snippet": "Use: Off-Label  Catheter-related bloodstream infections; Community-acquired pneumonia (children); Skin and soft tissue necrotizing infections; Surgical site infections"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": 12.80836939962289, "bm25_max": 12.80836939962289, "bge_top3": 0.678806722164154, "bge_max": 0.678806722164154, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Acne vulgaris; Bartonella spp. infections (treatment); Bartonella spp. infections (treatment) in HIV-infected patients (adolescents and adults); Chancroid; Community-acquired pneumonia (children); Gastrop…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 12.500316132034413, "bm25_max": 12.500316132034413, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Community-acquired pneumonia: Treatment of community-acquired pneumonia in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), H. parainfluenzae (including beta-lactamase-producin…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": 12.072584210853673, "bm25_max": 12.072584210853673, "bge_top3": null, "bge_max": null, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia (children); Cutibacterium acnes infection of deep-brain stimulation hardware; Group B streptococcus, maternal dose (neonatal prophylaxis); Leptospirosis; Lyme neuroborreliosis…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 11.578105673606089, "bm25_max": 11.578105673606089, "bge_top3": null, "bge_max": null, "title": "Cefprozil: Drug information", "rep_snippet": "Use: Off-Label  Community-acquired pneumonia treatment in children 3 months to younger than 12 years caused by S. pneumoniae; Urinary tract infections in children (empiric)"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 10.920480993314932, "bm25_max": 10.920480993314932, "bge_top3": null, "bge_max": null, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "Respiratory: Acute respiratory distress (3%), pneumothorax (1%)  <1%, postmarketing, and/or case reports: Colitis (microscopic), dermatitis, diaphoresis, dysgeusia, gastric polyp (benign), hepatotoxicity (idiosyncratic;…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 9.525480655790162, "bm25_max": 9.525480655790162, "bge_top3": 0.6446633338928223, "bge_max": 0.6481638550758362, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Use  Pneumonia, community-acquired: Extended-release tablets only: Treatment of patients with community-acquired pneumonia (CAP) caused by confirmed or suspected beta-lactamase-producing pathogens (ie, Haemophilus influe…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6801601648330688, "bge_max": 0.6801601648330688, "title": "Amoxicillin: Drug information", "rep_snippet": "Pneumonia, community-acquired (CAP) (Bradley [IDSA 2011]): Infants ≥3 months, Children, and Adolescents: Note: In pediatric patients 5 to 15 years of age, a macrolide antibiotic may be a more reasonable first choice as M…"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438238620758057, "bge_max": 0.6438238620758057, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Community-acquired pneumonia: IM, IV: Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours  Severe infections (eg, gynecologic, intra-abdominal, nosocomial pneumonia,…"}, {"doc_id": "amikacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6364690065383911, "bge_max": 0.6364690065383911, "title": "Amikacin: Drug information", "rep_snippet": "Reference Range  Traditional dosing:  Therapeutic levels:  Peak:  Life-threatening infections: 25 to 40 mcg/mL  Serious infections: 20 to 25 mcg/mL  Urinary tract infections: 15 to 20 mcg/mL  Trough: <8 mcg/mL  The Ameri…"}, {"doc_id": "carglumic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6328892111778259, "bge_max": 0.6328892111778259, "title": "Carglumic acid: Drug information", "rep_snippet": "Dosing: Adult  Acute hyperammonemia: Oral: 100 to 250 mg/kg/day given in 2 or 4 divided doses (rounded to the nearest 100 mg); titrate to age-appropriate plasma ammonia levels. Concomitant adjunctive ammonia-lowering the…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6310598850250244, "bge_max": 0.6310598850250244, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Osteomyelitis due to MRSA (off-label use): IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for a minimum of 4 to 6 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])  Pharyngitis, group A streptococci (IDSA recommendations…"}, {"doc_id": "penicillin-g-benzathine-long-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6302858591079712, "bge_max": 0.6302858591079712, "title": "Penicillin G benzathine (long-acting intramuscular): Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: IM: 1.2 to 2.4 million units as a single dose  Upper respiratory infection, group A streptococci: IM: 1.2 million units as a single dose  Secondary prevention of glomerulonephritis: 1.2…"}, {"doc_id": "amantadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6272124648094177, "bge_max": 0.6272124648094177, "title": "Amantadine: Drug information", "rep_snippet": "Dosing: Geriatric  Drug-induced extrapyramidal symptoms/Parkinson disease: Refer to adult dosing; some patients tolerate the immediate-release formulations better when administered in 2 divided daily doses (to avoid adve…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6264486312866211, "bge_max": 0.6264486312866211, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Pneumococcal pneumonia (uncomplicated, moderately severe): IM: 600,000 to 1,000,000 units daily.  Staphylococcal infections (moderately severe to severe): IM: 600,000 to 1,000,000 units daily  Streptococcal infections (G…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6258220076560974, "bge_max": 0.6258220076560974, "title": "Telavancin: Drug information", "rep_snippet": "Dosing: Adult  Complicated skin and skin structure infection: IV: 10 mg/kg every 24 hours for 1 to 2 weeks  Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP): IV: 10 mg/kg every 24 hours for 1 t…"}, {"doc_id": "erythromycin-and-benzoyl-peroxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6255067586898804, "bge_max": 0.6255067586898804, "title": "Erythromycin and benzoyl peroxide: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Gel, topical:  Aktipak: Erythromycin 3% and benzoyl pero…"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6251779198646545, "bge_max": 0.6251779198646545, "title": "Zafirlukast: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral: 20 mg twice daily  Chronic urticaria (off-label use): Oral: 20 mg twice daily (Bagenstose, 2004)"}, {"doc_id": "prednisone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6250443458557129, "bge_max": 0.6250443458557129, "title": "Prednisone: Drug information", "rep_snippet": "Dosing: Adult  General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Oral: Initial: 5 to 60 mg daily:  Note: Dose depends upon condition being treated and response of patient. Consider alternate day th…"}, {"doc_id": "ciprofloxacin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6246120929718018, "bge_max": 0.6246120929718018, "title": "Ciprofloxacin (systemic): Drug information", "rep_snippet": "Pneumonia, community-acquired, as a component of empiric therapy for P. aeruginosa coverage (hospitalized patient) (off-label use) (File 2017a; IDSA/ATS [Mandell 2007]): Note: For empiric therapy, must be used in combina…"}, {"doc_id": "rifampin-rifampicin-and-isoniazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.624478280544281, "bge_max": 0.624478280544281, "title": "Rifampin (rifampicin) and isoniazid: Drug information", "rep_snippet": "Dosing: Adult  Tuberculosis: Oral: Rifampin 600 mg/isoniazid 300 mg once daily. Note: Concomitant antituberculosis medications should be administered according to current guideline recommendations (Nahid 2016)"}, {"doc_id": "pentamidine-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6241640448570251, "bge_max": 0.6241640448570251, "title": "Pentamidine (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Pneumocystis jirovecii pneumonia (PCP), prevention: Primary or secondary prophylaxis (alternative to preferred therapy): Inhalation: 300 mg once every 4 weeks via Respirgard II nebulizer (HHS [OI adult 201…"}, {"doc_id": "zileuton-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6226592659950256, "bge_max": 0.6226592659950256, "title": "Zileuton: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Zileuton: Pediatric drug information\")  Asthma: Oral: Children ≥12 years and Adolescents: Refer to adult dosing."}]}
{"qid": "Q15", "query": "Dental prophylaxis for endocarditis — amoxicillin adult dose; alternatives for penicillin allergy.", "candidates": [{"doc_id": "ampicillin-drug-information", "bm25_top3": 35.687469577832104, "bm25_max": 36.57111830160642, "bge_top3": 0.6878771185874939, "bge_max": 0.6940130591392517, "title": "Ampicillin: Drug information", "rep_snippet": "Dental, oral, or respiratory tract procedures: IM, IV: 2 g within 30 to 60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. IM injections should be avoided in patient…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 30.4760946998365, "bm25_max": 35.141826026977384, "bge_top3": 0.679914265871048, "bge_max": 0.6872673630714417, "title": "Amoxicillin: Drug information", "rep_snippet": "Peritonitis, prophylaxis (for patients receiving peritoneal dialysis who require dental procedures) (off-label use): Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes before dental procedur…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 30.672958398894284, "bm25_max": 34.75248319984489, "bge_top3": 0.7135281562805176, "bge_max": 0.7135281562805176, "title": "Cefazolin: Drug information", "rep_snippet": "Endocarditis, prophylaxis (off-label use): Dental and upper respiratory procedures: Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 1,000 mg (AHA [Wilson 2007]). Note…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 34.49815218288036, "bm25_max": 34.49815218288036, "bge_top3": 0.6751047372817993, "bge_max": 0.6752184629440308, "title": "Vancomycin: Drug information", "rep_snippet": "S. pneumoniae, moderate to severe infection (MICs to penicillin ≥4.0 mcg/mL) (alternative to ceftriaxone in beta-lactam allergic patients): 40 to 60 mg/kg/day divided every 6 to 8 hours  Health care–associated pneumonia…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": 34.42840378916715, "bm25_max": 34.42840378916715, "bge_top3": null, "bge_max": null, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Cutibacterium acnes: 20 million units/day as a continuous infusion every 24 hours or in divided doses every 4 hours for 4 to 6 weeks (Osmon 2013)  Rat bite fever (including Haverhill fever): IV:  Uncomplicated infection:…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 30.112164005087454, "bm25_max": 33.660173977079765, "bge_top3": 0.6954385240872701, "bge_max": 0.7589514255523682, "title": "Ceftriaxone: Drug information", "rep_snippet": "Endocarditis, treatment (off-label use) (AHA [Baddour 2015]):  Enterococcus, native or prosthetic valve (penicillin-susceptible/gentamicin-susceptible or penicillin-susceptible/aminoglycoside resistant): IV: 2 g every 12…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 32.65317534650236, "bm25_max": 32.65317534650236, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Manufacturer’s labeling states for IM administration only, however, IV administration (off-label route) has been described (Morris 1994; Peloquin 1992; Tanoira 2014).  Usual dosage range: IM: 15 to 3…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 24.480746487675113, "bm25_max": 30.49838220080297, "bge_top3": null, "bge_max": null, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "High dose: Amoxicillin 90 mg/kg/day in divided doses 2 times daily (using the 600 mg per 5 mL suspension). Note: A wider dosing range of 80 to 100 mg/kg/day divided every 8 hours has also been used (Bradley 2002).  Sinus…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 23.06530292998802, "bm25_max": 23.06530292998802, "bge_top3": 0.6527427434921265, "bge_max": 0.6527427434921265, "title": "Clarithromycin: Drug information", "rep_snippet": "Hybrid regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, a standard-dose PPI twice da…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 22.488164414580133, "bm25_max": 22.488164414580133, "bge_top3": null, "bge_max": null, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial rhinosinusitis: Oral, IV: 400 mg every 24 hours for 10 days (manufacturer’s labeling) or 5 to 7 days (Chow 2012). Note: Recommended in patients with beta-lactam allergy; may also be used if…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 22.46144435151647, "bm25_max": 22.46144435151647, "bge_top3": 0.6506605744361877, "bge_max": 0.6506605744361877, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Sequential regimen: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": 21.897686559982624, "bm25_max": 21.897686559982624, "bge_top3": 0.6768837571144104, "bge_max": 0.6768837571144104, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Use  Anthrax, prophylaxis: To reduce the incidence of the disease following exposure to aerosolized Bacillus anthracis.  Anthrax, treatment: Treatment of anthrax, including post-exposure inhalational disease due to aeros…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": 14.38245875117225, "bm25_max": 21.227204645971906, "bge_top3": 0.6444878578186035, "bge_max": 0.6444878578186035, "title": "Daptomycin: Drug information", "rep_snippet": "Dosing: Adult  Diabetic foot infections without osteomyelitis (off-label use): IV: 4 mg/kg once daily (Lipsky 2005)  Endocarditis, treatment: IV:  S. aureus (right-sided, native valve): Note: Clinical trial demonstrating…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": 14.891338612147532, "bm25_max": 20.885329534565148, "bge_top3": null, "bge_max": null, "title": "Cephalexin: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Oral: 250 to 1,000 mg every 6 hours or 500 mg every 12 hours (maximum: 4 g/day)  Indication-specific dosing:  Cellulitis (nonpurulent)/erysipelas, mild (alternative agent): Oral: 500 mg…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 20.547347253673312, "bm25_max": 20.547347253673312, "bge_top3": null, "bge_max": null, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Use  Fusospirochetosis (Vincent gingivitis and pharyngitis): Treatment of fusospirochetosis (Vincent gingivitis and pharyngitis), in conjunction with dental care for infections involving gum tissue.  Pneumococcal infecti…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 20.16241179639365, "bm25_max": 20.16241179639365, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Linezolid: Pediatric drug information\")  Usual dosage: Oral, IV:  Children ≤11 years: 10 mg/kg (maximum: 600 mg/dose) every 8 hours  Children ≥12 years and Adolescents:…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 19.611446180399863, "bm25_max": 19.611446180399863, "bge_top3": 0.6692539155483246, "bge_max": 0.6786102652549744, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Prophylaxis against infective endocarditis (off-label use): Oral: 15 mg/kg 30 to 60 minutes before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasi…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 17.71210196039253, "bm25_max": 19.554382707402798, "bge_top3": 0.6766064763069153, "bge_max": 0.6766064763069153, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Osteomyelitis due to MRSA (off-label use): IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for a minimum of 4 to 6 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])  Pharyngitis, group A streptococci (IDSA recommendations…"}, {"doc_id": "zanamivir-drug-information", "bm25_top3": 18.995539579302307, "bm25_max": 18.995539579302307, "bge_top3": null, "bge_max": null, "title": "Zanamivir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Zanamivir: Pediatric drug information\")  Influenza: Oral inhalation:  Manufacturer's labeling:  Prophylaxis, household setting: Children ≥5 years (US labeling) or ≥7 ye…"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 17.199687299200516, "bm25_max": 17.199687299200516, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Pneumonia, community acquired: Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Rhinosinusitis, acute maxillary:  Infants ≥…"}, {"doc_id": "mepivacaine-and-levonordefrin-drug-information", "bm25_top3": 16.892649838912078, "bm25_max": 16.892649838912078, "bge_top3": null, "bge_max": null, "title": "Mepivacaine and levonordefrin: Drug information", "rep_snippet": "Use  Dental anesthesia: Production of local anesthesia for dental procedures by infiltration or nerve block in adult and pediatric patients"}, {"doc_id": "penicilloyl-polylysine-drug-information", "bm25_top3": 9.882209546931875, "bm25_max": 10.4826784649417, "bge_top3": null, "bge_max": null, "title": "Penicilloyl-polylysine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Allergic reactions: Rare systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should…"}, {"doc_id": "pneumococcal-polysaccharide-vaccine-23-valent-drug-information", "bm25_top3": 10.438842600984213, "bm25_max": 10.438842600984213, "bge_top3": null, "bge_max": null, "title": "Pneumococcal polysaccharide vaccine (23-valent): Drug information", "rep_snippet": "• Antibiotic prophylaxis: This vaccine does not replace the need for penicillin (or other antibiotic) prophylaxis against pneumococcal infection. In persons who require penicillin (or other antibiotic) prophylaxis agains…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 9.735947265559737, "bm25_max": 10.088271659414374, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Brucellosis; Endocarditis, treatment (viridans group streptococcus [VGS] and S. bovis [native or prosthetic valve]) (adults); Gonococcal infection, uncomplicated (patients with severe cephalosporin allerg…"}, {"doc_id": "cefadroxil-drug-information", "bm25_top3": 9.413549197198478, "bm25_max": 9.413549197198478, "bge_top3": 0.6531457901000977, "bge_max": 0.6531457901000977, "title": "Cefadroxil: Drug information", "rep_snippet": "Other warnings/precautions:  • Appropriate use: Only IM penicillin has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oroph…"}, {"doc_id": "neomycin-and-polymyxin-b-drug-information", "bm25_top3": 9.099085681690074, "bm25_max": 9.099085681690074, "bge_top3": null, "bge_max": null, "title": "Neomycin and polymyxin B: Drug information", "rep_snippet": "Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Bacampicillin; Clox…"}, {"doc_id": "neomycin-polymyxin-b-and-gramicidin-drug-information", "bm25_top3": 9.099085681690074, "bm25_max": 9.099085681690074, "bge_top3": null, "bge_max": null, "title": "Neomycin, polymyxin B, and gramicidin: Drug information", "rep_snippet": "Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Bacampicillin; Clox…"}, {"doc_id": "oral-mucosal-barrier-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6796154379844666, "bge_max": 0.6796154379844666, "title": "Oral mucosal barrier gel: Drug information", "rep_snippet": "Dosing: Adult  Mucosal protection: Oral:  Episil: Apply 1 to 3 pumps to the oral cavity 2 to 3 times daily, or as needed; maximum duration for continuous use: 30 days  Gelclair: Rinse, gargle, and spit 15 mL (1 single-us…"}, {"doc_id": "cetylpyridinium-and-benzocaine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6759703755378723, "bge_max": 0.6759703755378723, "title": "Cetylpyridinium and benzocaine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Antiseptic/anesthetic: Oral: Dissolve in mouth as needed for sore throat  Antiseptic/anesthetic (dental use): Oral: Dissolve in mouth as needed for pain"}, {"doc_id": "aspirin-and-extended-release-dipyridamole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6704520583152771, "bge_max": 0.6704520583152771, "title": "Aspirin and extended-release dipyridamole: Drug information", "rep_snippet": "Dosing: Adult  Stroke prevention: Oral: One capsule (dipyridamole extended release 200 mg/aspirin 25 mg) twice daily  Alternative regimen for patients with intolerable headache: Oral: One capsule (dipyridamole extended r…"}, {"doc_id": "metoprolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6689633131027222, "bge_max": 0.6689633131027222, "title": "Metoprolol: Drug information", "rep_snippet": "Use  Angina (oral formulations): Long term treatment of angina pectoris.  Heart failure (extended-release oral formulation): Treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive…"}, {"doc_id": "triclosan-and-fluoride-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6594883501529694, "bge_max": 0.6675423383712769, "title": "Triclosan and fluoride (dental): Drug information", "rep_snippet": "Dosing: Adult  Prevention of dental caries and gingivitis: Oral: Brush teeth thoroughly after each meal or at least twice daily"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6605383157730103, "bge_max": 0.6605383157730103, "title": "Clopidogrel: Drug information", "rep_snippet": "Secondary prevention of cardioembolic stroke (patient not candidate for oral anticoagulation): The combination of clopidogrel and aspirin is recommended (ACCP [Guyatt 2012])  Secondary prevention of cardiovascular diseas…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6592792868614197, "bge_max": 0.6592792868614197, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: Oral: One tablet (naproxen 375 mg/esomeprazole 20 mg or naproxen 500 mg/esomeprazole 20 mg) twice daily  Note: If a total daily dose of esomepr…"}, {"doc_id": "chlorhexidine-gluconate-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517243385314941, "bge_max": 0.6591858267784119, "title": "Chlorhexidine gluconate (oral): Drug information", "rep_snippet": "Use  Oral rinse: Antibacterial dental rinse for gingivitis treatment  Periodontal chip: Adjunctive therapy to reduce pocket depth in patients with periodontitis"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6588785648345947, "bge_max": 0.6588785648345947, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Dosing: Adult  Secondary prevention of cardiovascular and cerebrovascular events: Oral: One tablet (aspirin 81 mg/omeprazole 40 mg or aspirin 325 mg/omeprazole 40 mg) once daily. Note: Generally 81 mg of aspirin has been…"}, {"doc_id": "doxycycline-hyclate-periodontal-extended-release-liquid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6571367383003235, "bge_max": 0.6571367383003235, "title": "Doxycycline hyclate periodontal extended-release liquid: Drug information", "rep_snippet": "Use  Periodontitis: Treatment of chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing."}, {"doc_id": "prilocaine-with-epinephrine-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.656338095664978, "bge_max": 0.656338095664978, "title": "Prilocaine with epinephrine (dental): Drug information", "rep_snippet": "Dosing: Pediatric  Dental anesthesia:  Children <10 years: Doses >40 mg (1 mL) of prilocaine hydrochloride as a 4% solution with epinephrine 1:200,000 are rarely needed for procedures involving a single tooth, in a maxil…"}, {"doc_id": "liposomal-amphotericin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558945178985596, "bge_max": 0.6558945178985596, "title": "Liposomal amphotericin B: Drug information", "rep_snippet": "Note: Premedication: For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory…"}, {"doc_id": "empagliflozin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6557568907737732, "bge_max": 0.6557568907737732, "title": "Empagliflozin: Drug information", "rep_snippet": "Use  Diabetes mellitus, type 2: Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control; risk reduction of cardiovascular mortality in adults with type 2 diabetes mellitus and…"}, {"doc_id": "isosorbide-dinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6535216569900513, "bge_max": 0.6535216569900513, "title": "Isosorbide dinitrate: Drug information", "rep_snippet": "Use  Angina pectoris, prevention: Prevention of angina pectoris due to coronary artery disease.  Note: Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode."}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6522213220596313, "bge_max": 0.6522213220596313, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Note: Dosage must be individualized.  Arcosyl products: Initial: Perindopril arginine 2.5 mg/indapamide 0.625 mg once daily; may adjust dose based on blood pressure response to perindop…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6522164344787598, "bge_max": 0.6522164344787598, "title": "Rosuvastatin: Drug information", "rep_snippet": "Secondary prevention: Adjunctive therapy to diet to slow the progression of atherosclerosis in adults as part of a treatment strategy to lower total cholesterol and LDL-C to target levels.  Guideline recommendations: Pri…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6518303155899048, "bge_max": 0.6518303155899048, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "Dosing: Adult  Hypertension: Oral: Initial: Perindopril 3.5 mg/amlodipine 2.5 mg once daily; adjust dose to response in 7- to 14-day intervals; maximum dose: perindopril 14 mg/amlodipine 10 mg per day"}, {"doc_id": "secukinumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6511699557304382, "bge_max": 0.6511699557304382, "title": "Secukinumab: Drug information", "rep_snippet": "Use  Ankylosing spondylitis: Treatment of active ankylosing spondylitis in adults.  Plaque psoriasis: Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.  P…"}, {"doc_id": "tenoxicam-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6495890617370605, "bge_max": 0.6495890617370605, "title": "Tenoxicam (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, and/or extra-articular inflammation: Oral: 10 to 20 mg once daily (higher doses associated with increased risk of adverse effects and usually d…"}, {"doc_id": "empagliflozin-and-linagliptin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6461034417152405, "bge_max": 0.6481674313545227, "title": "Empagliflozin and linagliptin: Drug information", "rep_snippet": "Dosing: Adult  Note: If present, correct volume depletion prior to initiation.  Diabetes mellitus, type 2: Oral: Initial: Empagliflozin 10 mg/linagliptin 5 mg once daily; may increase to empagliflozin 25 mg/linagliptin 5…"}, {"doc_id": "quinupristin-and-dalfopristin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.646329253911972, "bge_max": 0.6476655602455139, "title": "Quinupristin and dalfopristin: Drug information", "rep_snippet": "Use: Off-Label  Bacteremia (methicillin-resistant Staphylococcus aureus); Infective endocarditis (methicillin resistant Staphylococcus aureus), treatment (adults); Infective endocarditis (multidrug resistant Enterococcus…"}, {"doc_id": "hyoscyamine-atropine-scopolamine-and-phenobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6476132273674011, "bge_max": 0.6476132273674011, "title": "Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer, irritable bowel syndrome, and acute enterocolitis, adjunct treatment: Oral:  Immediate release: 1 to 2 tablets or 5 to 10 mL of elixir 3 to 4 times/day  Extended release: One tablet every 1…"}, {"doc_id": "sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6462007761001587, "bge_max": 0.6462007761001587, "title": "Sodium bicarbonate: Drug information", "rep_snippet": "Use  Management of metabolic acidosis; gastric hyperacidity; alkalinization of the urine; treatment of hyperkalemia; management of overdose of certain drugs, including tricyclic antidepressants and aspirin  Neutralizing…"}, {"doc_id": "sucralfate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6460385322570801, "bge_max": 0.6460385322570801, "title": "Sucralfate: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral:  Active duodenal ulcer: Suspension, tablet: Initial: 1 g 4 times daily for 4 to 8 weeks  Maintenance therapy: Tablet: 1 g twice daily"}, {"doc_id": "phenylephrine-and-pyrilamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6449735164642334, "bge_max": 0.6449735164642334, "title": "Phenylephrine and pyrilamine: Drug information", "rep_snippet": "Dosing: Adult  Treatment of allergic rhinitis: Oral:  Suspension: Phenylephrine 5 mg and pyrilamine 16 mg per 5 mL: 5 to 10 mL every 6 hours (maximum: 40 mL/24 hours)  Tablet: Phenylephrine 10 mg and pyrilamine 25 mg: On…"}, {"doc_id": "dipyridamole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6440560221672058, "bge_max": 0.6440560221672058, "title": "Dipyridamole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Dipyridamole: Pediatric drug information\")  Adjunctive therapy for prophylaxis of thromboembolism with cardiac valve replacement: Oral: Children ≥12 years: Refer to adu…"}]}
{"qid": "Q16", "query": "Migraine acute treatment — max daily dose and triptan contraindications in sumatriptan monograph.", "candidates": [{"doc_id": "sumatriptan-and-naproxen-drug-information", "bm25_top3": 29.400255195176392, "bm25_max": 34.33464531543579, "bge_top3": 0.686550517876943, "bge_max": 0.7080636620521545, "title": "Sumatriptan and naproxen: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Sumatriptan and naproxen: Pediatric drug information\")  Note: Use care when prescribing; there are 2 different Treximet tablet strengths available.  Migraine headache:…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 20.553561405482483, "bm25_max": 23.438746417191034, "bge_top3": 0.6697538495063782, "bge_max": 0.6931991577148438, "title": "Sumatriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine or cluster headache prophylaxis, or for the treatment of hemiplegic or basilar…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 11.832948970447346, "bm25_max": 18.643237152071325, "bge_top3": 0.6317346096038818, "bge_max": 0.6317346096038818, "title": "Naproxen: Drug information", "rep_snippet": "Naproxen extended-release tablets: Initial: 1,000 to 1,500 mg once daily followed by 1,000 mg once daily until attack subsides  Pain (mild to moderate), dysmenorrhea, acute tendonitis, bursitis: Oral: Initial: 500 mg, fo…"}, {"doc_id": "zolmitriptan-drug-information", "bm25_top3": 12.613079788205509, "bm25_max": 17.826163291768427, "bge_top3": 0.658297061920166, "bge_max": 0.6621706485748291, "title": "Zolmitriptan: Drug information", "rep_snippet": "Dosing: Adult  Migraine:  Initial dose: Note: Administer at the onset of migraine headache.  Nasal inhalation: 2.5 mg (maximum single dose: 5 mg)  Oral:  Tablet: 1.25 to 2.5 mg (maximum single dose: 5 mg)  Orally disinte…"}, {"doc_id": "mometasone-nasal-drug-information", "bm25_top3": 15.365432711328001, "bm25_max": 17.57048244695062, "bge_top3": null, "bge_max": null, "title": "Mometasone (nasal): Drug information", "rep_snippet": "Rhinosinusitis, adjunctive treatment (acute) (off-label use): Intranasal: Intranasal corticosteroids such as mometasone are recommended by IDSA and AAO-HNS guidelines but no specific dosing recommendations are made. Alte…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 17.280845009729116, "bm25_max": 17.280845009729116, "bge_top3": null, "bge_max": null, "title": "Amitriptyline: Drug information", "rep_snippet": "Irritable bowel syndrome (off-label use): Oral: Initial: 10 to 25 mg daily at bedtime; may increase dose based on response and tolerability up to 75 mg (Rajagopalan 1998; Vahedi 2008).  Migraine prophylaxis (off-label us…"}, {"doc_id": "dihydroergotamine-drug-information", "bm25_top3": 11.222007303399955, "bm25_max": 16.29196142011601, "bge_top3": 0.6515987515449524, "bge_max": 0.6515987515449524, "title": "Dihydroergotamine: Drug information", "rep_snippet": "Dosing: Adult  Migraine, cluster headache:  IM, SubQ: 1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week  IV: 1 mg at first sign of headache; repeat hourly up to a maximu…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": 16.200508108832885, "bm25_max": 16.200508108832885, "bge_top3": null, "bge_max": null, "title": "Desipramine: Drug information", "rep_snippet": "Dosing: Adult  Bulimia nervosa (off-label use): Oral: Initial: 25 mg/day for 3 days, then increase in 25 to 50 mg increments every 3 to 5 days based on response and tolerability up to 300 mg/day. Average doses in clinica…"}, {"doc_id": "celecoxib-drug-information", "bm25_top3": 16.058030743832845, "bm25_max": 16.058030743832845, "bge_top3": null, "bge_max": null, "title": "Celecoxib: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.  Acute pain or primary dysmenorrhea: Oral: Initial dose: 400 mg, followed by an ad…"}, {"doc_id": "thioguanine-drug-information", "bm25_top3": 15.871723634864832, "bm25_max": 15.871723634864832, "bge_top3": null, "bge_max": null, "title": "Thioguanine: Drug information", "rep_snippet": "Dosing: Adult  Acute myeloid leukemia (AML): Oral: 2 mg/kg once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with care…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 15.826458254815256, "bm25_max": 15.826458254815256, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Adult  Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dos…"}, {"doc_id": "almotriptan-drug-information", "bm25_top3": 10.513660489353454, "bm25_max": 14.21309190782626, "bge_top3": 0.67445836464564, "bge_max": 0.6796096563339233, "title": "Almotriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic migraine, or basilar migraine. If a patient does not…"}, {"doc_id": "pyrimethamine-drug-information", "bm25_top3": 13.946585989049122, "bm25_max": 13.946585989049122, "bge_top3": null, "bge_max": null, "title": "Pyrimethamine: Drug information", "rep_snippet": "Treatment of congenital toxoplasmosis: Infants and Children: Loading dose: 2 mg/kg/day once daily for 2 days, then 1 mg/kg/day once daily for 2 to 6 months, followed by 1 mg/kg administered 3 times weekly, in combination…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 13.583716512027681, "bm25_max": 13.583716512027681, "bge_top3": null, "bge_max": null, "title": "Cefdinir: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefdinir: Pediatric drug information\")  Infants ≥6 months and Children:  Acute bacterial otitis media, pharyngitis/tonsillitis: Oral: 7 mg/kg/dose twice daily for 5 to…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 8.179358854260657, "bm25_max": 13.507957430453228, "bge_top3": 0.6546336809794108, "bge_max": 0.6723880767822266, "title": "Naratriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for the acute treatment of migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic, or basilar migraine. If a patient does not respond to t…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 13.202117007033413, "bm25_max": 13.202117007033413, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Use: Off-Label  Pericarditis; Acute migraine headache; Ankylosing spondylitis; Cystic fibrosis; Gout; Juvenile idiopathic arthritis; Migraine prophylaxis"}, {"doc_id": "eletriptan-drug-information", "bm25_top3": 8.877607656249547, "bm25_max": 12.544604064148391, "bge_top3": 0.6719015836715698, "bge_max": 0.6952590942382812, "title": "Eletriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. If a patient does not respond to the fi…"}, {"doc_id": "frovatriptan-drug-information", "bm25_top3": 8.80491259664201, "bm25_max": 12.399213944933319, "bge_top3": 0.6469690601030985, "bge_max": 0.6673974990844727, "title": "Frovatriptan: Drug information", "rep_snippet": "• Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic or basilar migraine. If a patient does not respond to…"}, {"doc_id": "diclofenac-systemic-drug-information", "bm25_top3": 5.76698320302898, "bm25_max": 8.700347753443808, "bge_top3": null, "bge_max": null, "title": "Diclofenac (systemic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "inosine-pranobex-united-states-not-available-drug-information", "bm25_top3": 7.938254662220665, "bm25_max": 7.938254662220665, "bge_top3": null, "bge_max": null, "title": "Inosine pranobex (United States: Not available): Drug information", "rep_snippet": "Contraindications  There are no contraindications listed in the manufacturer’s product monograph."}, {"doc_id": "rizatriptan-drug-information", "bm25_top3": 7.114572992552255, "bm25_max": 7.70482468093512, "bge_top3": 0.6701988379160563, "bge_max": 0.6821204423904419, "title": "Rizatriptan: Drug information", "rep_snippet": "• Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which…"}, {"doc_id": "bromocriptine-drug-information", "bm25_top3": 7.10971073592145, "bm25_max": 7.10971073592145, "bge_top3": null, "bge_max": null, "title": "Bromocriptine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to bromocriptine, ergot alkaloids, or any component of the formulation  Additional product-specific contraindications:  Cycloset: Syncopal migraine; breast-feeding  Parlodel: Uncontrol…"}, {"doc_id": "flunarizine-united-states-not-available-drug-information", "bm25_top3": 4.134344727609996, "bm25_max": 4.134344727609996, "bge_top3": 0.6517237722873688, "bge_max": 0.6596727967262268, "title": "Flunarizine (United States: Not available): Drug information", "rep_snippet": "Use  Note: Not approved in the US  Migraine: Prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded satisfactorily to other treatments, and/or do not tolerate…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": 2.885419565052965, "bm25_max": 2.885419565052965, "bge_top3": null, "bge_max": null, "title": "Metoclopramide: Drug information", "rep_snippet": "Use: Off-Label  Gastric bezoars; Gastroparesis (regardless of etiology); Hiccups; Migraine (acute); Prevention of chemotherapy-associated nausea and vomiting (pediatrics); Prevention of radiation therapy-induced nausea a…"}, {"doc_id": "pizotifen-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6601064801216125, "bge_max": 0.666685938835144, "title": "Pizotifen (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Migraine prophylaxis: Oral: Initial: 0.5 mg at bedtime; may increase dose gradually to 1.5 mg daily administered as single dose at bedtime or in 3 divided doses; average maintenance dose: 1.5 mg daily; usu…"}, {"doc_id": "butalbital-acetaminophen-paracetamol-caffeine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438474059104919, "bge_max": 0.6438474059104919, "title": "Butalbital, acetaminophen (paracetamol), caffeine, and codeine: Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "pentazocine-and-acetaminophen-paracetamol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438474059104919, "bge_max": 0.6438474059104919, "title": "Pentazocine and acetaminophen (paracetamol): Drug information", "rep_snippet": "Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen."}, {"doc_id": "neostigmine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6398988366127014, "bge_max": 0.6398988366127014, "title": "Neostigmine: Drug information", "rep_snippet": "Dosing: Adult  Note: Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.  Myasthenia gravis: Diagnosis: Canadian labeling: Note: Pretreatment with atropine is recommended, and atropine…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6349342167377472, "bge_max": 0.6386148929595947, "title": "Maprotiline: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to maprotiline or any component of the formulation; seizure disorder; use of MAO inhibitors (concurrently or within 14 days of discontinuing either maprotiline or the MAO inhibitor); u…"}, {"doc_id": "edrophonium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6360479593276978, "bge_max": 0.6360479593276978, "title": "Edrophonium: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cholinergic crisis: Overdosage can cause cholinergic crisis, which may be fatal. Atropine should always be readily available as an antagonist and for treatmen…"}, {"doc_id": "corticotropin-injection-gel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6352771520614624, "bge_max": 0.6352771520614624, "title": "Corticotropin injection gel: Drug information", "rep_snippet": "Dosing: Adult  Note: Sudden withdrawal may lead to adrenal insufficiency or recurrent symptoms; tapering the dose prior to discontinuation may be necessary following prolonged administration.  Acute exacerbation of multi…"}, {"doc_id": "epirubicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6350327730178833, "bge_max": 0.6350327730178833, "title": "Epirubicin: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to epirubicin, other anthracyclines, anthracenediones, or any component of the formulation; cardiomyopathy and/or heart failure, recent myocardial infarction, severe arrhythmias; previ…"}, {"doc_id": "rifampin-rifampicin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6348495483398438, "bge_max": 0.6348495483398438, "title": "Rifampin (rifampicin): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Rifampin (rifampicin): Pediatric drug information\")  Tuberculosis, active (drug-susceptible) (excludes meningitis): Oral, IV: Use as part of a multidrug regimen:  Manuf…"}, {"doc_id": "isosorbide-mononitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6322247385978699, "bge_max": 0.6322247385978699, "title": "Isosorbide mononitrate: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to isosorbide mononitrate, other nitrates or nitrites, or any component of the formulation; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or varden…"}, {"doc_id": "liposomal-morphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6285805106163025, "bge_max": 0.6285805106163025, "title": "Liposomal morphine: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to morphine, morphine salts or any component of the formulation; respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected paralytic ileus;…"}, {"doc_id": "infliximab-including-biosimilars-of-infliximab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6279547214508057, "bge_max": 0.6279547214508057, "title": "Infliximab (including biosimilars of infliximab): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to infliximab, murine proteins, or any component of the formulation; doses >5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)  Canadian labeling: Additional…"}]}
{"qid": "Q17", "query": "Bacterial vaginosis — standard regimen and alcohol warning relevance in metronidazole (oral vs gel).", "candidates": [{"doc_id": "metronidazole-topical-drug-information", "bm25_top3": 34.20345092298005, "bm25_max": 39.94585981576261, "bge_top3": 0.6844808260599772, "bge_max": 0.6928771138191223, "title": "Metronidazole (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation following oral administration. The amoun…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 28.21510348439685, "bm25_max": 30.02246681317926, "bge_top3": 0.6353253920873007, "bge_max": 0.6579135656356812, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommen…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 19.887175667478534, "bm25_max": 29.307937616394874, "bge_top3": 0.6354401707649231, "bge_max": 0.6354401707649231, "title": "Tinidazole: Drug information", "rep_snippet": "Dosing: Adult  Amebiasis, intestinal: Oral: 2 g once daily for 3 days  Amebiasis, liver abscess: Oral: 2 g once daily for 3 to 5 days  Bacterial vaginosis: Oral: 2 g once daily for 2 days or 1 g once daily for 5 days  Ba…"}, {"doc_id": "clindamycin-topical-drug-information", "bm25_top3": 24.501178715780593, "bm25_max": 24.501178715780593, "bge_top3": 0.6223822832107544, "bge_max": 0.6223822832107544, "title": "Clindamycin (topical): Drug information", "rep_snippet": "Use  Acne vulgaris: Treatment of acne vulgaris (topical gel, topical lotion, topical solution)  Bacterial vaginosis: Treatment of bacterial vaginosis (vaginal cream, vaginal suppository)"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 24.081472964811105, "bm25_max": 24.081472964811105, "bge_top3": null, "bge_max": null, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Methadone: May enhance the QTc-prolonging effect of Lopinavir. Lopinavir may decrease the serum concentration of Methadone. More specifically, the combination of Lopinavir and Ritonavir may decrease Methadone serum conce…"}, {"doc_id": "metronidazole-and-nystatin-united-states-not-available-drug-information", "bm25_top3": 22.42578508975106, "bm25_max": 22.82317787055961, "bge_top3": 0.6675395568211874, "bge_max": 0.6933938264846802, "title": "Metronidazole and nystatin (United States: Not available): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. M…"}, {"doc_id": "bismuth-subcitrate-metronidazole-and-tetracycline-drug-information", "bm25_top3": 22.55569061366349, "bm25_max": 22.730424347596802, "bge_top3": 0.602663516998291, "bge_max": 0.602663516998291, "title": "Bismuth subcitrate, metronidazole, and tetracycline: Drug information", "rep_snippet": "Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum. Risk D: Consider therapy modification  Lithium: MetroNI…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": 21.65626581748878, "bm25_max": 21.65626581748878, "bge_top3": null, "bge_max": null, "title": "Amoxicillin: Drug information", "rep_snippet": "Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue…"}, {"doc_id": "ethanol-topical-and-injection-drug-information", "bm25_top3": 21.42928037107666, "bm25_max": 21.42928037107666, "bge_top3": 0.6333115696907043, "bge_max": 0.6333115696907043, "title": "Ethanol (topical and injection): Drug information", "rep_snippet": "Methylphenidate: Alcohol (Ethyl) may enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate. Risk X: Avoid combination  MetroNIDAZOLE (Systemic): May…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 20.453962093522314, "bm25_max": 20.453962093522314, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Lopinavir: May enhance the adverse/toxic effect of Disulfiram. Specifically, the combination of lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-alcohol reaction if combined. Risk X: A…"}, {"doc_id": "secnidazole-drug-information", "bm25_top3": 19.97809454420686, "bm25_max": 20.06218027015836, "bge_top3": 0.6332279145717621, "bge_max": 0.6566920280456543, "title": "Secnidazole: Drug information", "rep_snippet": "Dosing: Adult  Bacterial vaginosis: Oral: 2 g single dose"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 16.289420241008635, "bm25_max": 18.952303665207126, "bge_top3": null, "bge_max": null, "title": "Clarithromycin: Drug information", "rep_snippet": "Clarithromycin triple therapy: 500 mg twice daily, in combination with a standard-dose or double-dose proton pump inhibitor, and either amoxicillin 1 g twice daily or metronidazole 500 mg three times daily; continue regi…"}, {"doc_id": "tetracycline-drug-information", "bm25_top3": 14.46445393634459, "bm25_max": 14.46445393634459, "bge_top3": null, "bge_max": null, "title": "Tetracycline: Drug information", "rep_snippet": "Dosing: Adult  Usual dosage range: Oral: 250 to 500 mg every 6 to 12 hours  Acne: Oral: Initial dose: 1 g daily in divided doses; reduce gradually to 125 to 500 mg/day once improvement is noted (alternate day or intermit…"}, {"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": 13.864857120070862, "bm25_max": 13.864857120070862, "bge_top3": null, "bge_max": null, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Diabetic foot infections, moderate to severe (off-label use): Oral, IV: Note: Initial treatment should begin with an IV regimen for severe infections; moderate infections may initially be treated with IV or oral regimen…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 13.40269488061822, "bm25_max": 13.40269488061822, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "Bismuth quadruple regimen: 40 mg twice daily in combination with tetracycline 500 mg 4 times per day, metronidazole 250 mg 4 times per day or 500 mg 3 or 4 times per day, and either bismuth subcitrate 120 to 300 mg 4 tim…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 12.118395278696143, "bm25_max": 12.852557987579214, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 12.50941527989275, "bm25_max": 12.852557987579214, "bge_top3": null, "bge_max": null, "title": "Esomeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times daily; continue regimen for 14 days. Not…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 11.986123323579573, "bm25_max": 12.631562158968158, "bge_top3": null, "bge_max": null, "title": "Rabeprazole: Drug information", "rep_snippet": "Clarithromycin triple regimen: 20 to 40 mg twice daily in combination with clarithromycin 500 mg twice daily and either amoxicillin 1 g twice daily or metronidazole 500 mg 3 times per day; continue regimen for 14 days. N…"}, {"doc_id": "dronabinol-drug-information", "bm25_top3": 12.44692864049576, "bm25_max": 12.44692864049576, "bge_top3": null, "bge_max": null, "title": "Dronabinol: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to dronabinol, sesame oil (capsules), alcohol (oral solution) or any component of the formulation; receiving, or have recently received, disulfiram- or metronidazole-containing product…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 12.339879587456949, "bm25_max": 12.339879587456949, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "Bismuth quadruple regimen: 30 mg twice daily in combination with tetracycline 500 mg 4 times daily, metronidazole 250 mg 4 times daily or 500 mg 3 or 4 times daily, and either bismuth subcitrate 120 to 300 mg 4 times dai…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-drug-information", "bm25_top3": 11.938632819737673, "bm25_max": 11.938632819737673, "bge_top3": null, "bge_max": null, "title": "Polyethylene glycol electrolyte solution: Drug information", "rep_snippet": "Adverse Reactions  >10%:  Central nervous system: Sleep disorder (35%; evening prep vs oral sodium phosphate solution [90 mL]), rigors (34%; evening prep vs oral sodium phosphate solution [90 mL]), malaise (18% to 27%; M…"}, {"doc_id": "hyaluronate-derivatives-drug-information", "bm25_top3": 10.869815637838784, "bm25_max": 10.869815637838784, "bge_top3": null, "bge_max": null, "title": "Hyaluronate derivatives: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, topical [sodium hyaluronate]:  Bionect: 0.2% (25…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 10.798557730181175, "bm25_max": 10.798557730181175, "bge_top3": null, "bge_max": null, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Use: Off-Label  Acute bacterial rhinosinusitis; Acute otitis media (children); Anthrax; Babesiosis; Bacterial vaginosis; Bite wounds (animal); Community-acquired pneumonia (children); Diabetic foot infections; Group A st…"}, {"doc_id": "terconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6148175001144409, "bge_max": 0.6148175001144409, "title": "Terconazole: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, Vaginal:  Terazol 7: 0.4% (45 g) [contains cetyl…"}, {"doc_id": "estradiol-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6099833846092224, "bge_max": 0.6099833846092224, "title": "Estradiol (systemic): Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Alora may be confused with Aldara  Elestrin may be confused with alosetron  Geriatric Patients: High-Risk Medication:  Beers Criteria: Estrogens (oral or topical…"}, {"doc_id": "lidocaine-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6084387302398682, "bge_max": 0.6084387302398682, "title": "Lidocaine and menthol: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External:  AvaDERM: Lidocaine 4% and menthol 1% (…"}, {"doc_id": "metolazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6068106889724731, "bge_max": 0.6068106889724731, "title": "Metolazone: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  MetOLazone may be confused with metaxalone, methadone, methazolAMIDE, methIMAzole, methotrexate, metoclopramide, metoprolol, minoxidil  Zaroxolyn may be confused…"}, {"doc_id": "cefotaxime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6046196818351746, "bge_max": 0.6046196818351746, "title": "Cefotaxime: Drug information", "rep_snippet": "Complicated community-acquired intra-abdominal infection of mild-to-moderate severity, including hepatic abscess (in combination with metronidazole): IV: 1 to 2 g every 6 to 8 hours for 4 to 7 days (provided source contr…"}, {"doc_id": "sulfacetamide-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6045522689819336, "bge_max": 0.6045522689819336, "title": "Sulfacetamide (topical): Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External, as sodium:  Ovace Plus: 10% (57 g) [con…"}, {"doc_id": "butoconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6039999127388, "bge_max": 0.6039999127388, "title": "Butoconazole: Drug information", "rep_snippet": "Warnings/Precautions  Dosage form specific issues:  • Vaginal cream: Contains mineral oil that may weaken latex or rubber (condoms or diaphragms); use of these products within 72 hours of treatment is not recommended.  O…"}, {"doc_id": "dalteparin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6037200093269348, "bge_max": 0.6037200093269348, "title": "Dalteparin: Drug information", "rep_snippet": "Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulation is recommended."}, {"doc_id": "itraconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.603706955909729, "bge_max": 0.603706955909729, "title": "Itraconazole: Drug information", "rep_snippet": "• Oral capsules/tablets: Absorption of itraconazole capsules is reduced when gastric acidity is reduced (eg, achlorhydria, acid suppressive therapy) administer capsules or tablets with an acidic beverage (eg, non-diet co…"}, {"doc_id": "oxybutynin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6036427021026611, "bge_max": 0.6036427021026611, "title": "Oxybutynin: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Gel, Transdermal:  Gelnique: 3% (92 g [DSC]) [contains p…"}, {"doc_id": "ciclopirox-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6021571159362793, "bge_max": 0.6021571159362793, "title": "Ciclopirox: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Cream, External, as olamine [strength expressed as base]…"}, {"doc_id": "benzyl-alcohol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5992147326469421, "bge_max": 0.5992147326469421, "title": "Benzyl alcohol: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Contact dermatitis: Allergic or irritant dermatitis may occur.  • Eye irritation: Avoid eye exposure. If eye is exposed, flush immediately with water.  Specia…"}, {"doc_id": "mebendazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5989594459533691, "bge_max": 0.5989594459533691, "title": "Mebendazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Mebendazole: Pediatric drug information\")  Intestinal nematode infection (hookworm, pinworm, roundworm, whipworm): Children ≥2 years and Adolescents: Oral: Refer to adu…"}, {"doc_id": "benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5974811315536499, "bge_max": 0.5974811315536499, "title": "Benznidazole (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "conjugated-equine-estrogens-topical-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.5959029793739319, "bge_max": 0.5959029793739319, "title": "Conjugated equine estrogens (topical): Drug information", "rep_snippet": "• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the…"}, {"doc_id": "progesterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.595362663269043, "bge_max": 0.595362663269043, "title": "Progesterone: Drug information", "rep_snippet": "Dosing: Adult  Females:  Amenorrhea: IM: 5 to 10 mg/day for 6 to 8 consecutive days.  Amenorrhea, secondary:  Intravaginal gel: 45 mg (4% gel) every other day for up to a total of 6 doses; if response is inadequate, may…"}]}
{"qid": "Q18", "query": "Acute gout flare — dose and renal cautions for colchicine (loading/maintenance; avoid in strong CYP3A4/P-gp inhibitors).", "candidates": [{"doc_id": "colchicine-drug-information", "bm25_top3": 49.94285778434549, "bm25_max": 59.08813572656843, "bge_top3": 0.7932816545168558, "bge_max": 0.8016144037246704, "title": "Colchicine: Drug information", "rep_snippet": "Patients <70 kg or unable to tolerate higher dosing regimen: 0.5 mg twice daily given on post-operative day 3, followed by 0.5 mg once daily for 1 month (Imazio 2010a).  Regimens without loading dose:  Patients ≥70 kg: 0…"}, {"doc_id": "colchicine-and-probenecid-drug-information", "bm25_top3": 49.24751100502992, "bm25_max": 49.24751100502992, "bge_top3": 0.7270425260066986, "bge_max": 0.7361370921134949, "title": "Colchicine and probenecid: Drug information", "rep_snippet": "Contraindications  Hypersensitivity to colchicine, probenecid, or any component of the formulation; children <2 years of age; small- or large-dose aspirin therapy; blood dyscrasias; uric acid kidney stones; initiation du…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 40.05765367094541, "bm25_max": 41.472663231482386, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "Breast cancer, neuroendocrine tumors, RCC, renal angiomyolipoma:  CYP3A4/P-gp inducers: Strong inducers: Avoid coadministration with strong CYP3A4/P-gp inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin, ri…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 39.417167855743514, "bm25_max": 39.417167855743514, "bge_top3": 0.678782045841217, "bge_max": 0.678782045841217, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "lopinavir-and-ritonavir-drug-information", "bm25_top3": 39.38720024600917, "bm25_max": 39.38720024600917, "bge_top3": 0.6811789274215698, "bge_max": 0.6811789274215698, "title": "Lopinavir and ritonavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 34.59103620002199, "bm25_max": 37.74660837411403, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "lumacaftor-and-ivacaftor-drug-information", "bm25_top3": 35.51627120805941, "bm25_max": 35.51627120805941, "bge_top3": null, "bge_max": null, "title": "Lumacaftor and ivacaftor: Drug information", "rep_snippet": "Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerni…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 35.358155730572115, "bm25_max": 35.358155730572115, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "darunavir-and-cobicistat-drug-information", "bm25_top3": 34.681756381698804, "bm25_max": 34.681756381698804, "bge_top3": null, "bge_max": null, "title": "Darunavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "atazanavir-and-cobicistat-drug-information", "bm25_top3": 34.681756381698804, "bm25_max": 34.681756381698804, "bge_top3": null, "bge_max": null, "title": "Atazanavir and cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": 34.658669619657104, "bm25_max": 34.658669619657104, "bge_top3": null, "bge_max": null, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or les…"}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": 34.64830330225605, "bm25_max": 34.64830330225605, "bge_top3": null, "bge_max": null, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 34.565374567195775, "bm25_max": 34.565374567195775, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "mifepristone-and-misoprostol-united-states-not-available-drug-information", "bm25_top3": 33.36163798242944, "bm25_max": 33.36163798242944, "bge_top3": null, "bge_max": null, "title": "Mifepristone and misoprostol (United States: Not available): Drug information", "rep_snippet": "Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. Management: If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-disoproxil-fumarate-stribild-drug-information", "bm25_top3": 33.0681162708906, "bm25_max": 33.0681162708906, "bge_top3": 0.6845574378967285, "bge_max": 0.6845574378967285, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (Stribild): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-genvoya-drug-information", "bm25_top3": 33.0681162708906, "bm25_max": 33.0681162708906, "bge_top3": 0.6845574378967285, "bge_max": 0.6845574378967285, "title": "Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "tezacaftor-and-ivacaftor-drug-information", "bm25_top3": 32.126935683742715, "bm25_max": 32.126935683742715, "bge_top3": null, "bge_max": null, "title": "Tezacaftor and ivacaftor: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "glecaprevir-and-pibrentasvir-drug-information", "bm25_top3": 32.01906240896113, "bm25_max": 32.01906240896113, "bge_top3": null, "bge_max": null, "title": "Glecaprevir and pibrentasvir: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Glecaprevir and Pibrentasvir. Risk C: Monitor therapy  Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distri…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 31.965213559166777, "bm25_max": 31.965213559166777, "bge_top3": 0.6763032674789429, "bge_max": 0.6763032674789429, "title": "Voriconazole: Drug information", "rep_snippet": "Cobicistat: Voriconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Voriconazole. Management: Careful consideration of the risk/benefit ratio for voriconazole u…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 28.829358710096443, "bm25_max": 28.829358710096443, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. Risk X: Avoid combination  Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Managemen…"}, {"doc_id": "clarithromycin-drug-information", "bm25_top3": 28.417167855743514, "bm25_max": 28.417167855743514, "bge_top3": 0.678782045841217, "bge_max": 0.678782045841217, "title": "Clarithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ketoconazole-systemic-drug-information", "bm25_top3": 28.387200246009172, "bm25_max": 28.387200246009172, "bge_top3": 0.6811789274215698, "bge_max": 0.6811789274215698, "title": "Ketoconazole (systemic): Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "ritonavir-drug-information", "bm25_top3": 27.023408459558723, "bm25_max": 27.023408459558723, "bge_top3": null, "bge_max": null, "title": "Ritonavir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "eliglustat-drug-information", "bm25_top3": 25.015805475829815, "bm25_max": 25.015805475829815, "bge_top3": 0.6920241713523865, "bge_max": 0.6920241713523865, "title": "Eliglustat: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "atazanavir-drug-information", "bm25_top3": 23.681756381698804, "bm25_max": 23.681756381698804, "bge_top3": null, "bge_max": null, "title": "Atazanavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 23.681756381698804, "bm25_max": 23.681756381698804, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": 23.584876156802537, "bm25_max": 23.584876156802537, "bge_top3": null, "bge_max": null, "title": "Posaconazole: Drug information", "rep_snippet": "CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. Risk C: Monitor therapy  Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. Risk X: Avoid…"}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": 23.440716349535506, "bm25_max": 23.440716349535506, "bge_top3": null, "bge_max": null, "title": "Daclatasvir: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 23.30051011267507, "bm25_max": 23.30051011267507, "bge_top3": 0.6752930283546448, "bge_max": 0.6752930283546448, "title": "Ranolazine: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "rolapitant-drug-information", "bm25_top3": 22.963187729603582, "bm25_max": 22.963187729603582, "bge_top3": null, "bge_max": null, "title": "Rolapitant: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "dronedarone-drug-information", "bm25_top3": 22.851917098578078, "bm25_max": 22.851917098578078, "bge_top3": null, "bge_max": null, "title": "Dronedarone: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "saquinavir-drug-information", "bm25_top3": 22.828307826923307, "bm25_max": 22.828307826923307, "bge_top3": null, "bge_max": null, "title": "Saquinavir: Drug information", "rep_snippet": "Cobicistat: May increase the serum concentration of Saquinavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available. Risk X: Avoid combination  Cobimetinib:…"}, {"doc_id": "neratinib-drug-information", "bm25_top3": 22.795658515192187, "bm25_max": 22.795658515192187, "bge_top3": null, "bge_max": null, "title": "Neratinib: Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "nelfinavir-drug-information", "bm25_top3": 22.0681162708906, "bm25_max": 22.0681162708906, "bge_top3": 0.6845574378967285, "bge_max": 0.6845574378967285, "title": "Nelfinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "indinavir-drug-information", "bm25_top3": 22.0681162708906, "bm25_max": 22.0681162708906, "bge_top3": 0.6845574378967285, "bge_max": 0.6845574378967285, "title": "Indinavir: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "cobicistat-drug-information", "bm25_top3": 22.0681162708906, "bm25_max": 22.0681162708906, "bge_top3": 0.6845574378967285, "bge_max": 0.6845574378967285, "title": "Cobicistat: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP…"}, {"doc_id": "nefazodone-drug-information", "bm25_top3": 21.831025234812103, "bm25_max": 21.831025234812103, "bge_top3": null, "bge_max": null, "title": "Nefazodone: Drug information", "rep_snippet": "Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors…"}, {"doc_id": "darunavir-drug-information", "bm25_top3": 21.737994113723836, "bm25_max": 21.737994113723836, "bge_top3": null, "bge_max": null, "title": "Darunavir: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk C: Monitor therapy  Co…"}, {"doc_id": "verapamil-drug-information", "bm25_top3": 21.585924988096146, "bm25_max": 21.585924988096146, "bge_top3": null, "bge_max": null, "title": "Verapamil: Drug information", "rep_snippet": "Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchic…"}, {"doc_id": "quinidine-drug-information", "bm25_top3": 21.141135639808464, "bm25_max": 21.141135639808464, "bge_top3": null, "bge_max": null, "title": "Quinidine: Drug information", "rep_snippet": "Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk D: Consider therapy modi…"}, {"doc_id": "ivacaftor-drug-information", "bm25_top3": 21.126935683742715, "bm25_max": 21.126935683742715, "bge_top3": null, "bge_max": null, "title": "Ivacaftor: Drug information", "rep_snippet": "Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotam…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 20.969712619641463, "bm25_max": 20.969712619641463, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Clarithromycin: May increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Clarithromycin. Risk C: Monitor therapy  CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": 20.6273227050496, "bm25_max": 20.6273227050496, "bge_top3": null, "bge_max": null, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated…"}, {"doc_id": "pegloticase-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7324864466985067, "bge_max": 0.762338399887085, "title": "Pegloticase: Drug information", "rep_snippet": "Dosing: Adult  Note: Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prop…"}, {"doc_id": "allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7216184437274933, "bge_max": 0.7600142955780029, "title": "Allopurinol: Drug information", "rep_snippet": "• Acute gout attacks: Even when normal or subnormal serum uric acid levels have been attained, an increase in acute gout attacks has been reported during the early stages of allopurinol administration. When allopurinol i…"}, {"doc_id": "febuxostat-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.707398513952891, "bge_max": 0.7513590455055237, "title": "Febuxostat: Drug information", "rep_snippet": "• Appropriate use: Administer concurrently with an NSAID or colchicine (up to 6 months) to prevent gout flare, which may occur upon initiation of therapy. Do not use to treat asymptomatic or secondary hyperuricemia."}, {"doc_id": "probenecid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7080722451210022, "bge_max": 0.7080722451210022, "title": "Probenecid: Drug information", "rep_snippet": "Use  Treatment of hyperuricemia associated with gout or gouty arthritis; prolongation and elevation of beta-lactam plasma levels  Guideline recommendations:  Gout: Uricosurics, such as probenecid, are recommended alone o…"}, {"doc_id": "lesinurad-and-allopurinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.693479597568512, "bge_max": 0.7018256783485413, "title": "Lesinurad and allopurinol: Drug information", "rep_snippet": "Dosing: Adult  Note: Use of this combination product is not recommended in patients taking allopurinol <300 mg/day (or <200 mg/day in patients with estimated CrCl <60 mL/min). Gout flare prophylaxis is recommended in pat…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7017747759819031, "bge_max": 0.7017747759819031, "title": "Methenamine: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Gout: Avoid use in patients with gout; may precipitate urate crystals in urine.  • Hepatic impairment: Use with caution in patients with hepatic impairment; reversible i…"}, {"doc_id": "polyethylene-glycol-electrolyte-solution-and-sulfate-solution-kit-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6935611367225647, "bge_max": 0.6935611367225647, "title": "Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Drug information", "rep_snippet": "• Renal impairment: Use caution in patients with renal impairment; adequate hydration is particularly important in these patients or in patients receiving concomitant medications that may affect renal function (eg, diure…"}, {"doc_id": "rifampin-rifampicin-isoniazid-and-pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.691146969795227, "bge_max": 0.691146969795227, "title": "Rifampin (rifampicin), isoniazid, and pyrazinamide: Drug information", "rep_snippet": "• Alcoholism: Use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).  • Diabetes: Use with caution in patients with diabetes mellitus; management of diabet…"}, {"doc_id": "inosine-pranobex-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6906993389129639, "bge_max": 0.6906993389129639, "title": "Inosine pranobex (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Uric acid: Inosine undergoes rapid metabolism to uric acid. Use with caution in patients with a history of gout, urolithiasis, nephrolithiasis, or renal impai…"}, {"doc_id": "lesinurad-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6868411302566528, "bge_max": 0.6868411302566528, "title": "Lesinurad: Drug information", "rep_snippet": "Dosing: Adult  Hyperuricemia associated with gout: Oral: 200 mg once daily (in combination with a xanthine oxidase inhibitor, including allopurinol or febuxostat); maximum dose: 200 mg once daily. Note: If treatment with…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6862086653709412, "bge_max": 0.6862086653709412, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "benazepril-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6862086653709412, "bge_max": 0.6862086653709412, "title": "Benazepril and hydrochlorothiazide: Drug information", "rep_snippet": "• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997…"}, {"doc_id": "losartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6858267188072205, "bge_max": 0.6858267188072205, "title": "Losartan and hydrochlorothiazide: Drug information", "rep_snippet": "• Aortic/mitral stenosis: Use losartan with caution in patients with significant aortic/mitral stenosis.  • Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a chan…"}, {"doc_id": "tolterodine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6857088804244995, "bge_max": 0.6857088804244995, "title": "Tolterodine: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required.  Concurrent drug therapy issues:  • CYP3A4 inhibitors: Dosage adjustment is recommended in patients receiving CYP3A4…"}, {"doc_id": "clonidine-and-chlorthalidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6819685697555542, "bge_max": 0.6819685697555542, "title": "Clonidine and chlorthalidone: Drug information", "rep_snippet": "Disease-related concerns:  • Cardiovascular disease: Use clonidine with caution in patients with severe coronary insufficiency, including recent MI and conduction disturbances, such as sinus node dysfunction.  • Cerebrov…"}, {"doc_id": "afatinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.679877758026123, "bge_max": 0.679877758026123, "title": "Afatinib: Drug information", "rep_snippet": "• Hepatic impairment: Use in severe hepatic impairment (Child-Pugh class C) has not been studied; closely monitor patients with severe impairment, may require dosage adjustments if not tolerated.  • Renal impairment: Dos…"}, {"doc_id": "aliskiren-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6785619258880615, "bge_max": 0.6785619258880615, "title": "Aliskiren and hydrochlorothiazide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hyperkalemia may occur with renin inhibitors; risk increased in patients with renal impairment or diabetes, or concomitant use with…"}, {"doc_id": "hydrochlorothiazide-and-triamterene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6783043146133423, "bge_max": 0.6783043146133423, "title": "Hydrochlorothiazide and triamterene: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia may occur with hydrochlorothiazide.  • Gout: In certain patients with a histo…"}, {"doc_id": "azilsartan-and-chlorthalidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6774098873138428, "bge_max": 0.6774098873138428, "title": "Azilsartan and chlorthalidone: Drug information", "rep_snippet": "Disease-related concerns:  • Aortic/mitral stenosis: Use azilsartan with caution in patients with significant aortic/mitral stenosis.  • Diabetes: Use chlorthalidone with caution in patients with prediabetes or diabetes…"}, {"doc_id": "ergotamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6760342717170715, "bge_max": 0.6760342717170715, "title": "Ergotamine: Drug information", "rep_snippet": "• Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.  Concurrent drug therapy issues:  • CYP3A4 inhibitors: [US Boxed Warning]: Ergot alka…"}]}
{"qid": "Q19", "query": "Post-MI dual antiplatelet — maintenance dosing and duration in clopidogrel monograph; CYP2C19 issue.", "candidates": [{"doc_id": "clopidogrel-drug-information", "bm25_top3": 36.260668318716085, "bm25_max": 39.423335759743374, "bge_top3": 0.6836652954419454, "bge_max": 0.6905928254127502, "title": "Clopidogrel: Drug information", "rep_snippet": "Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Durati…"}, {"doc_id": "aspirin-drug-information", "bm25_top3": 27.714065154906177, "bm25_max": 36.14592207849677, "bge_top3": null, "bge_max": null, "title": "Aspirin: Drug information", "rep_snippet": "STEMI: Aspirin is recommended in combination with either clopidogrel, prasugrel, or ticagrelor given as early as possible or at time of PCI. In addition to dual antiplatelet therapy, parenteral anticoagulant therapy is i…"}, {"doc_id": "prasugrel-drug-information", "bm25_top3": 23.2985403337502, "bm25_max": 26.644891466949954, "bge_top3": 0.6309124231338501, "bge_max": 0.6309124231338501, "title": "Prasugrel: Drug information", "rep_snippet": "Duration of prasugrel (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis, MI, and death. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (…"}, {"doc_id": "vorapaxar-drug-information", "bm25_top3": 24.605018983643202, "bm25_max": 24.605018983643202, "bge_top3": null, "bge_max": null, "title": "Vorapaxar: Drug information", "rep_snippet": "Dosing: Adult  History of myocardial infarction (MI) or established peripheral arterial disease (PAD): Oral: 2.08 mg once daily in combination with aspirin and/or clopidogrel. Note: Vorapaxar 2.08 mg is equivalent to vor…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 22.993463890373278, "bm25_max": 22.993463890373278, "bge_top3": 0.6620769500732422, "bge_max": 0.6860911846160889, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 20.59477451277207, "bm25_max": 20.59477451277207, "bge_top3": 0.6476283967494965, "bge_max": 0.6580164432525635, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "ticagrelor-drug-information", "bm25_top3": 17.610226206957424, "bm25_max": 19.32864706517978, "bge_top3": 0.6315639019012451, "bge_max": 0.6315639019012451, "title": "Ticagrelor: Drug information", "rep_snippet": "Duration of ticagrelor (in combination with aspirin) after stent placement: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Duration of Dua…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": 17.452031916012743, "bm25_max": 17.452031916012743, "bge_top3": null, "bge_max": null, "title": "Ramipril: Drug information", "rep_snippet": "Reduction in risk of MI, stroke, and death from cardiovascular causes: Oral: Initial: 2.5 mg once daily for 1 week, then 5 mg once daily for the next 3 weeks, then increase as tolerated to maintenance dose of 10 mg once…"}, {"doc_id": "ticlopidine-united-states-not-available-drug-information", "bm25_top3": 17.279909461005513, "bm25_max": 17.279909461005513, "bge_top3": 0.6327371597290039, "bge_max": 0.6327371597290039, "title": "Ticlopidine (United States: Not available): Drug information", "rep_snippet": "• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medi…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 17.199262748840255, "bm25_max": 17.199262748840255, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "oxycodone-and-aspirin-drug-information", "bm25_top3": 17.125372806144362, "bm25_max": 17.125372806144362, "bge_top3": null, "bge_max": null, "title": "Oxycodone and aspirin: Drug information", "rep_snippet": "• Surgery: Aspirin should be avoided (if possible) in surgical patients for 1 to 2 weeks prior to surgery, to reduce the risk of excessive bleeding (except in patients with cardiac stents that have not completed their fu…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 17.091306546994055, "bm25_max": 17.091306546994055, "bge_top3": 0.6653468012809753, "bge_max": 0.6653468012809753, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "valganciclovir-drug-information", "bm25_top3": 17.031636600393046, "bm25_max": 17.031636600393046, "bge_top3": null, "bge_max": null, "title": "Valganciclovir: Drug information", "rep_snippet": "Dosing: Adult  Cytomegalovirus (CMV) retinitis, treatment (AIDS-related): Oral:  Manufacturer's labeling:  Induction: 900 mg twice daily for 21 days  Maintenance: Following induction treatment, or for patients with inact…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 16.44785807726328, "bm25_max": 16.44785807726328, "bge_top3": null, "bge_max": null, "title": "Eplerenone: Drug information", "rep_snippet": "Dosing: Renal Impairment  Hypertension:  CrCl ≥50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.  CrCl <50 mL/minute or serum creatinine >2 mg/dL (males) or >1.8 mg/dL (females): Use…"}, {"doc_id": "butalbital-compound-and-codeine-drug-information", "bm25_top3": 16.435378858629065, "bm25_max": 16.435378858629065, "bge_top3": null, "bge_max": null, "title": "Butalbital compound and codeine: Drug information", "rep_snippet": "Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients sho…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 9.84686569930171, "bm25_max": 9.84686569930171, "bge_top3": 0.677229642868042, "bge_max": 0.677229642868042, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 9.671464729895746, "bm25_max": 9.671464729895746, "bge_top3": 0.6556582450866699, "bge_max": 0.6556582450866699, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 9.186949688643988, "bm25_max": 9.186949688643988, "bge_top3": 0.6416113972663879, "bge_max": 0.6547634601593018, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 9.184843371036802, "bm25_max": 9.184843371036802, "bge_top3": 0.6321042776107788, "bge_max": 0.6365253925323486, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 8.182858646774847, "bm25_max": 8.182858646774847, "bge_top3": 0.6396313905715942, "bge_max": 0.6396313905715942, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 7.7479531814027816, "bm25_max": 7.7479531814027816, "bge_top3": 0.6352899074554443, "bge_max": 0.6352899074554443, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 7.497335329906843, "bm25_max": 7.497335329906843, "bge_top3": 0.6592010259628296, "bge_max": 0.6592010259628296, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "cangrelor-drug-information", "bm25_top3": 7.490395877605131, "bm25_max": 7.490395877605131, "bge_top3": 0.6364427208900452, "bge_max": 0.6364427208900452, "title": "Cangrelor: Drug information", "rep_snippet": "Clopidogrel: Cangrelor may diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopido…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 6.722536552326986, "bm25_max": 6.722536552326986, "bge_top3": 0.6465668678283691, "bge_max": 0.6465668678283691, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 6.26900297860416, "bm25_max": 6.26900297860416, "bge_top3": 0.630190372467041, "bge_max": 0.630190372467041, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 6.199262748840255, "bm25_max": 6.199262748840255, "bge_top3": null, "bge_max": null, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 5.886844547344488, "bm25_max": 5.886844547344488, "bge_top3": 0.659523069858551, "bge_max": 0.659523069858551, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 5.5317563578187965, "bm25_max": 5.5317563578187965, "bge_top3": 0.6746076345443726, "bge_max": 0.6746076345443726, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "warfarin-drug-information", "bm25_top3": 3.1725713416990153, "bm25_max": 4.494340059901884, "bge_top3": null, "bge_max": null, "title": "Warfarin: Drug information", "rep_snippet": "2If coronary stent not placed, maintain anticoagulation (in combination with low-dose aspirin) for 3 months followed by discontinuation of warfarin and use of dual antiplatelet therapy (eg, aspirin and clopidogrel) for u…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": 3.9298014113297626, "bm25_max": 3.9298014113297626, "bge_top3": null, "bge_max": null, "title": "Trandolapril: Drug information", "rep_snippet": "Use  Hypertension: Management of hypertension.  Post-myocardial infarction (MI) heart failure or left-ventricular dysfunction: Treatment of post-MI heart failure (HF) in patients who are symptomatic from HF within the fi…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.652888834476471, "bge_max": 0.652888834476471, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Pioglitazone. Risk C: Monitor therapy  Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to c…"}, {"doc_id": "erythromycin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6429983377456665, "bge_max": 0.6429983377456665, "title": "Erythromycin (systemic): Drug information", "rep_snippet": "Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical). Risk X: Avoid combination  Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopido…"}, {"doc_id": "romiplostim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6407805681228638, "bge_max": 0.6407805681228638, "title": "Romiplostim: Drug information", "rep_snippet": "• Discontinuation: Upon discontinuation of therapy, rebound thrombocytopenia and risk of bleeding may develop. Severity may be greater than pretreatment level. Monitor CBCs and platelet counts weekly for at least 2 weeks…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6375450789928436, "bge_max": 0.6378498077392578, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6343686878681183, "bge_max": 0.6372403502464294, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "pioglitazone-and-metformin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6354779601097107, "bge_max": 0.6354779601097107, "title": "Pioglitazone and metformin: Drug information", "rep_snippet": "Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (inclu…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6342530846595764, "bge_max": 0.6342530846595764, "title": "Cilostazol: Drug information", "rep_snippet": "CYP2C19 Inhibitors: May increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D: Consider th…"}, {"doc_id": "luliconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6338043212890625, "bge_max": 0.6338043212890625, "title": "Luliconazole: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 5…"}, {"doc_id": "paclitaxel-conventional-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6286337077617645, "bge_max": 0.6303050518035889, "title": "Paclitaxel (conventional): Drug information", "rep_snippet": "Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy  Clopidogrel: May increase the serum concentration of PACLitaxel (Conventional). Risk C: Monitor ther…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6299952268600464, "bge_max": 0.6299952268600464, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6276544332504272, "bge_max": 0.6276544332504272, "title": "Paroxetine: Drug information", "rep_snippet": "Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a nar…"}, {"doc_id": "pyrimethamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6271970272064209, "bge_max": 0.6271970272064209, "title": "Pyrimethamine: Drug information", "rep_snippet": "Monitoring Parameters  CBC, including platelet counts twice weekly with high-dose therapy (eg, when used for toxoplasmosis treatment; frequency not defined for lower doses); hepatic and renal function"}]}
{"qid": "Q20", "query": "UTI in pregnancy — safety status and preferred use of nitrofurantoin by trimester.", "candidates": [{"doc_id": "nitrofurantoin-drug-information", "bm25_top3": 32.230188438866996, "bm25_max": 36.70252454075508, "bge_top3": 0.6823782920837402, "bge_max": 0.7251555919647217, "title": "Nitrofurantoin: Drug information", "rep_snippet": "Pregnancy Implications  Adverse effects have not been observed in animal reproduction studies. Nitrofurantoin crosses the placenta (Perry 1967) and maternal serum concentrations may be lower in pregnancy (Philipson 1979)…"}, {"doc_id": "insulin-aspart-protamine-and-insulin-aspart-drug-information", "bm25_top3": 28.809571501847444, "bm25_max": 28.809571501847444, "bge_top3": 0.64322429895401, "bge_max": 0.64322429895401, "title": "Insulin aspart protamine and insulin aspart: Drug information", "rep_snippet": "Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Insulin requirements tend to fall during the fir…"}, {"doc_id": "aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information", "bm25_top3": 27.581003466170777, "bm25_max": 27.581003466170777, "bge_top3": null, "bge_max": null, "title": "Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information", "rep_snippet": "Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). The ACOG recommends that therapy during pregnancy be ind…"}, {"doc_id": "oxymetazoline-nasal-drug-information", "bm25_top3": 25.629340050646494, "bm25_max": 25.629340050646494, "bge_top3": 0.6372343897819519, "bge_max": 0.6372343897819519, "title": "Oxymetazoline (nasal): Drug information", "rep_snippet": "Pregnancy Implications  Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes…"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 24.558291098841213, "bm25_max": 24.558291098841213, "bge_top3": 0.6592599153518677, "bge_max": 0.6592599153518677, "title": "Tinidazole: Drug information", "rep_snippet": "Pregnancy Implications  The manufacturer contraindicates use of tinidazole during the first trimester of pregnancy. Adverse events have been observed in some animal reproduction studies. Tinidazole crosses the human plac…"}, {"doc_id": "phenylephrine-systemic-drug-information", "bm25_top3": 23.044677208784755, "bm25_max": 23.044677208784755, "bge_top3": 0.6432796716690063, "bge_max": 0.6432796716690063, "title": "Phenylephrine (systemic): Drug information", "rep_snippet": "Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 22.211702061496833, "bm25_max": 22.211702061496833, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimeste…"}, {"doc_id": "triamcinolone-systemic-drug-information", "bm25_top3": 21.684463181309063, "bm25_max": 21.684463181309063, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies.  Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts o…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 21.684463181309063, "bm25_max": 21.684463181309063, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta (Anderson 1981). Some studies have shown an association between first…"}, {"doc_id": "hydrocortisone-systemic-drug-information", "bm25_top3": 19.360724855390842, "bm25_max": 21.310360927016255, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or…"}, {"doc_id": "pseudoephedrine-drug-information", "bm25_top3": 21.180375054124887, "bm25_max": 21.180375054124887, "bge_top3": null, "bge_max": null, "title": "Pseudoephedrine: Drug information", "rep_snippet": "Pregnancy Implications  Use of pseudoephedrine during the first trimester may be associated with a possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine's vasoconstric…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 21.03081464197436, "bm25_max": 21.03081464197436, "bge_top3": null, "bge_max": null, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Prednisolone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant females with PAI should be monitored at least once each trimester (Bornstein 2016). Prednisolone may b…"}, {"doc_id": "zopiclone-united-states-not-available-drug-information", "bm25_top3": 20.865296794882738, "bm25_max": 20.865296794882738, "bge_top3": null, "bge_max": null, "title": "Zopiclone (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  There is insufficient data on safety in pregnancy; however, benzodiazepines may cause congenital malformations during the 1st trimester and neonatal CNS depression during the last few weeks of pre…"}, {"doc_id": "edoxaban-drug-information", "bm25_top3": 20.432440140897857, "bm25_max": 20.432440140897857, "bge_top3": null, "bge_max": null, "title": "Edoxaban: Drug information", "rep_snippet": "Pregnancy Implications  Ten pregnancies were reported in a study using edoxaban for the treatment of DVT or PE. Estimated exposure occurred during the first trimester with duration of exposure ~6 weeks; outcomes included…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 18.6449776187854, "bm25_max": 20.34553860827488, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommen…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": 19.771715955732027, "bm25_max": 19.771715955732027, "bge_top3": null, "bge_max": null, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Pregnancy Implications  Penicillin crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Due to pregnancy-induced physiologic changes, some pharmacoki…"}, {"doc_id": "dimenhydrinate-drug-information", "bm25_top3": 19.598003627280217, "bm25_max": 19.598003627280217, "bge_top3": null, "bge_max": null, "title": "Dimenhydrinate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Dimenhydrinate crosses the placenta. The risk of fetal abnormalities was not increased following maternal use of dimenhydrinat…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 19.10901783846889, "bm25_max": 19.10901783846889, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Ceftazidime crosses the placenta and reaches the cord serum and amniotic fluid. An increase in most types of birth defects was…"}, {"doc_id": "naratriptan-drug-information", "bm25_top3": 18.922641878801592, "bm25_max": 18.922641878801592, "bge_top3": null, "bge_max": null, "title": "Naratriptan: Drug information", "rep_snippet": "Pregnancy Implications  Pregnancy outcome information for naratriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 57 infants/fetuses exposed to narat…"}, {"doc_id": "hydrocortisone-topical-drug-information", "bm25_top3": 18.565320883792143, "bm25_max": 18.77421930450427, "bge_top3": null, "bge_max": null, "title": "Hydrocortisone (topical): Drug information", "rep_snippet": "The treatment of psoriasis in pregnancy is initiated with conservative treatment as in nonpregnant females. When a topical steroid is needed, low to moderate potency corticosteroids are preferred initially. High potency…"}, {"doc_id": "terconazole-drug-information", "bm25_top3": 18.493680532266403, "bm25_max": 18.493680532266403, "bge_top3": null, "bge_max": null, "title": "Terconazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Although the manufacturer recommends that use should be avoided during the first trimester of pregnancy (due to systemic abso…"}, {"doc_id": "mometasone-topical-drug-information", "bm25_top3": 18.41503298878095, "bm25_max": 18.41503298878095, "bge_top3": null, "bge_max": null, "title": "Mometasone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies.  Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further in…"}, {"doc_id": "thiothixene-drug-information", "bm25_top3": 18.407057988850937, "bm25_max": 18.407057988850937, "bge_top3": null, "bge_max": null, "title": "Thiothixene: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS])…"}, {"doc_id": "triamcinolone-topical-drug-information", "bm25_top3": 18.356422463080015, "bm25_max": 18.356422463080015, "bge_top3": null, "bge_max": null, "title": "Triamcinolone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be furthe…"}, {"doc_id": "alclometasone-drug-information", "bm25_top3": 18.12612795395345, "bm25_max": 18.12612795395345, "bge_top3": null, "bge_max": null, "title": "Alclometasone: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids following topical application in animal reproduction studies.  Systemic bioavailability of topical corticosteroids is variable (integrity of…"}, {"doc_id": "fluocinonide-drug-information", "bm25_top3": 18.011132856108954, "bm25_max": 18.011132856108954, "bge_top3": null, "bge_max": null, "title": "Fluocinonide: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic derm…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 17.740940095709487, "bm25_max": 17.740940095709487, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Pregnancy Implications  Endogenous thyroid hormones minimally cross the placenta. Desiccated thyroid has not been found to adversely affect the fetus following maternal use during pregnancy.  Uncontrolled maternal hypoth…"}, {"doc_id": "phenylephrine-nasal-drug-information", "bm25_top3": 17.572477240335274, "bm25_max": 17.572477240335274, "bge_top3": null, "bge_max": null, "title": "Phenylephrine (nasal): Drug information", "rep_snippet": "Pregnancy Implications  When administered intravenously, phenylephrine crosses the placenta. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Short-term use (<3 days) of intranas…"}, {"doc_id": "sumatriptan-drug-information", "bm25_top3": 17.246554349656495, "bm25_max": 17.246554349656495, "bge_top3": null, "bge_max": null, "title": "Sumatriptan: Drug information", "rep_snippet": "An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not o…"}, {"doc_id": "inhaled-insulin-drug-information", "bm25_top3": 17.146647265104495, "bm25_max": 17.146647265104495, "bge_top3": null, "bge_max": null, "title": "Inhaled insulin: Drug information", "rep_snippet": "Pregnancy Implications  In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007)…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 17.129630026900514, "bm25_max": 17.129630026900514, "bge_top3": null, "bge_max": null, "title": "Fluconazole: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Following exposure during the first trimester, malformations have been noted in humans when fluconazole was used in higher do…"}, {"doc_id": "diflucortolone-united-states-not-available-drug-information", "bm25_top3": 17.084427709449905, "bm25_max": 17.084427709449905, "bge_top3": null, "bge_max": null, "title": "Diflucortolone (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids (including diflucortolone) in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 16.954229607791838, "bm25_max": 16.954229607791838, "bge_top3": 0.654606819152832, "bge_max": 0.654606819152832, "title": "Mercaptopurine: Drug information", "rep_snippet": "Pregnancy Implications  May cause fetal harm if administered during pregnancy. Case reports of fetal loss have been noted with mercaptopurine administration during the first trimester; adverse effects have also been note…"}, {"doc_id": "dexamethasone-systemic-drug-information", "bm25_top3": 16.80457841843271, "bm25_max": 16.80457841843271, "bge_top3": null, "bge_max": null, "title": "Dexamethasone (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Dexamethasone crosses the placenta (Brownfoot 2013); and is partially metabolized by placental enzymes to an…"}, {"doc_id": "hydroxyprogesterone-caproate-drug-information", "bm25_top3": 16.630522785465537, "bm25_max": 16.630522785465537, "bge_top3": null, "bge_max": null, "title": "Hydroxyprogesterone caproate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events observed in some animal reproduction studies. Adverse events were not observed in human studies following second or third trimester exposure; use not studied during first trimester.…"}, {"doc_id": "betamethasone-topical-drug-information", "bm25_top3": 16.426122579022504, "bm25_max": 16.426122579022504, "bge_top3": null, "bge_max": null, "title": "Betamethasone (topical): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic derm…"}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 8.44325868390446, "bm25_max": 8.44325868390446, "bge_top3": null, "bge_max": null, "title": "Gabapentin: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC], Zarontin"}, {"doc_id": "flucytosine-drug-information", "bm25_top3": 7.4596790747490545, "bm25_max": 7.4596790747490545, "bge_top3": null, "bge_max": null, "title": "Flucytosine: Drug information", "rep_snippet": "Use  Candida/Cryptococcus infections: Adjunctive treatment of systemic fungal infections (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of Candida or Cryptococcus"}, {"doc_id": "oxytocin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.651254415512085, "bge_max": 0.664905309677124, "title": "Oxytocin: Drug information", "rep_snippet": "• Appropriate use: Abortion: For the adjunctive management of abortion in the first trimester, curettage is generally considered primary therapy. Oxytocin infusion in second trimester abortion will often be effective; ho…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6646115779876709, "bge_max": 0.6646115779876709, "title": "Lithium: Drug information", "rep_snippet": "For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean 2009). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentr…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.658391535282135, "bge_max": 0.658391535282135, "title": "Trimethoprim: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid (Reid 1975). Adverse events may be ass…"}, {"doc_id": "all-trans-retinoic-acid-systemic-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6508567631244659, "bge_max": 0.6536151766777039, "title": "All-trans retinoic acid (systemic tretinoin): Drug information", "rep_snippet": "Pregnancy (Category D): There is a high risk that a severely deformed infant will result if tretinoin is administered during pregnancy. If, nonetheless, it is determined that tretinoin represents the best available treat…"}, {"doc_id": "carboprost-tromethamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6523063778877258, "bge_max": 0.6523063778877258, "title": "Carboprost tromethamine: Drug information", "rep_snippet": "Use  Termination of pregnancy: For aborting pregnancy between week 13 and 20 of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester a…"}, {"doc_id": "fluocinolone-hydroquinone-and-tretinoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6517961025238037, "bge_max": 0.6517961025238037, "title": "Fluocinolone, hydroquinone, and tretinoin: Drug information", "rep_snippet": "Pregnancy Implications  There are no adequate and well-controlled studies in pregnant women. Tretinoin appears to have a low risk of teratogenicity when used topically since it is rapidly metabolized by the skin; however…"}, {"doc_id": "polycarbophil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512752771377563, "bge_max": 0.6512752771377563, "title": "Polycarbophil: Drug information", "rep_snippet": "Pregnancy Implications  When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003)."}, {"doc_id": "methylcellulose-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6512752771377563, "bge_max": 0.6512752771377563, "title": "Methylcellulose: Drug information", "rep_snippet": "Pregnancy Implications  When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003)."}, {"doc_id": "nilotinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.650884747505188, "bge_max": 0.650884747505188, "title": "Nilotinib: Drug information", "rep_snippet": "Pregnancy Implications  Based on data from animal reproduction studies and the mechanism of action, nilotinib may cause fetal harm if administered during pregnancy. Verify pregnancy status in females of reproductive pote…"}, {"doc_id": "cetirizine-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6499922275543213, "bge_max": 0.6499922275543213, "title": "Cetirizine (systemic): Drug information", "rep_snippet": "Pregnancy Implications  Maternal use of cetirizine has not been associated with an increased risk of major malformations. Cetirizine may be used for the treatment of rhinitis and urticaria during pregnancy (NAEPP 2005; W…"}, {"doc_id": "calcium-and-vitamin-d-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6497814655303955, "bge_max": 0.6497814655303955, "title": "Calcium and vitamin D: Drug information", "rep_snippet": "Pregnancy Implications  Available evidence suggests safe use during pregnancy."}, {"doc_id": "nitroglycerin-glyceryl-trinitrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6470136642456055, "bge_max": 0.6470136642456055, "title": "Nitroglycerin (glyceryl trinitrate): Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted with all products; adverse events were not observed in animal reproduction studies conducted using the ointment. Nitroglycerin crosses the place…"}, {"doc_id": "gonadorelin-acetate-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6453389525413513, "bge_max": 0.6453389525413513, "title": "Gonadorelin acetate (United States: Not available): Drug information", "rep_snippet": "Pregnancy Implications  The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first tr…"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6445093154907227, "bge_max": 0.6445093154907227, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Pregnancy Implications  Information related to the use of intranasal triamcinolone in pregnant women is limited (Bérard 2016). Intranasal corticosteroids, including triamcinolone, may be acceptable for the treatment of r…"}, {"doc_id": "erythromycin-and-sulfisoxazole-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.644335925579071, "bge_max": 0.644335925579071, "title": "Erythromycin and sulfisoxazole (United States: Not available): Drug information", "rep_snippet": "Individually, erythromycin and sulfonamides may be used to treat infections in pregnant women when clinically appropriate for confirmed infections caused by susceptible organisms. Use of sulfonamides during the first tri…"}, {"doc_id": "uridine-triacetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6442497372627258, "bge_max": 0.6442497372627258, "title": "Uridine triacetate: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies. Information related to the use of uridine triacetate for the treatment of hereditary orotic aciduria and fluoropyrimidine overdose/…"}, {"doc_id": "misoprostol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6438164114952087, "bge_max": 0.6438164114952087, "title": "Misoprostol: Drug information", "rep_snippet": "Use  NSAID-induced gastric ulcers, prevention: To reduce the risk of NSAID-induced gastric ulcers in patients at high risk of complications  Termination of intrauterine pregnancy: Medical termination of intrauterine preg…"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6417936682701111, "bge_max": 0.6417936682701111, "title": "Nivolumab: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in animal reproduction studies. Nivolumab may be expected to cross the placenta; effects to the fetus may be greater in the second and third trimesters. Based on its m…"}, {"doc_id": "indomethacin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6416510343551636, "bge_max": 0.6416510343551636, "title": "Indomethacin: Drug information", "rep_snippet": "The clearance of indomethacin may be increased during pregnancy (Rytting 2014). NSAIDs have been used in the management of preterm labor. When choosing a specific agent, the benefits of the available tocolytic agents sho…"}, {"doc_id": "zidovudine-and-lamivudine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6414602994918823, "bge_max": 0.6414602994918823, "title": "Zidovudine and lamivudine: Drug information", "rep_snippet": "Pregnancy Implications  The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with zidovudine as an alternative NRTI backbone for initial therapy in antiretroviral-naive pregnant…"}, {"doc_id": "nicardipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6412783861160278, "bge_max": 0.6412783861160278, "title": "Nicardipine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Nicardipine has been used for the treatment of severe hypertension in pregnancy and preterm labor. Nicardipine crosses the pl…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6404534578323364, "bge_max": 0.6404534578323364, "title": "Ondansetron: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu 2006).…"}, {"doc_id": "rituximab-intravenous-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6401717066764832, "bge_max": 0.6401717066764832, "title": "Rituximab (intravenous): Drug information", "rep_snippet": "Other agents are preferred for treating lupus nephritis in pregnant women (Hahn 2012). When treating rheumatoid arthritis, it is recommended to discontinue use and switch to a safer medication prior to conception unless…"}, {"doc_id": "nifedipine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6400731801986694, "bge_max": 0.6400731801986694, "title": "Nifedipine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta (Manninen 1991; Silberschmidt 2008). An increase in perinatal asphyxia, cesarean delivery, prematurity,…"}, {"doc_id": "cyproheptadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6393778920173645, "bge_max": 0.6393778920173645, "title": "Cyproheptadine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Per the product labeling, an increased risk of congenital abnormalities was not observed following maternal use of cyproheptadine…"}, {"doc_id": "rilpivirine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6375218033790588, "bge_max": 0.6375218033790588, "title": "Rilpivirine: Drug information", "rep_snippet": "Pregnancy Implications  Rilpivirine has moderate to high placental transfer. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretrovir…"}, {"doc_id": "insulin-detemir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6374093294143677, "bge_max": 0.6374093294143677, "title": "Insulin detemir: Drug information", "rep_snippet": "Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Insulin requirements tend to fall during the fir…"}, {"doc_id": "triprolidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.636817991733551, "bge_max": 0.636817991733551, "title": "Triprolidine: Drug information", "rep_snippet": "Pregnancy Implications  Information related to the use of triprolidine in pregnancy is limited (Aldridge 2014; Gilboa 2009). Antihistamines may be used for the treatment of rhinitis in pregnant women, although agents oth…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363129615783691, "bge_max": 0.6363129615783691, "title": "Lurasidone: Drug information", "rep_snippet": "Pregnancy Implications  Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Sympto…"}, {"doc_id": "levocetirizine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6363075971603394, "bge_max": 0.6363075971603394, "title": "Levocetirizine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies; therefore, the manufacturer classifies levocetirizine as pregnancy category B. The use of antihistamines for the treatment of…"}, {"doc_id": "glycerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6362746357917786, "bge_max": 0.6362746357917786, "title": "Glycerin: Drug information", "rep_snippet": "Pregnancy Implications  Glycerin suppositories are generally considered safe to use during pregnancy (Cullen, 2007; Wald, 2003)."}, {"doc_id": "propylthiouracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.636227011680603, "bge_max": 0.636227011680603, "title": "Propylthiouracil: Drug information", "rep_snippet": "[US Boxed Warning]: Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimeste…"}, {"doc_id": "rimantadine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6352302432060242, "bge_max": 0.6352302432060242, "title": "Rimantadine: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in animal reproduction studies. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complic…"}, {"doc_id": "peramivir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.635165810585022, "bge_max": 0.635165810585022, "title": "Peramivir: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events were observed in some animal reproduction studies. Information related to the use of peramivir in pregnancy is limited (Hernandez 2011; Sorbello 2012). Based on information from one…"}, {"doc_id": "methyl-salicylate-and-menthol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6341525912284851, "bge_max": 0.6341525912284851, "title": "Methyl salicylate and menthol: Drug information", "rep_snippet": "Pregnancy Implications  There are no adequate or well controlled studies in pregnant women. Use of the topical patch during the last 3 months of pregnancy is contraindicated by the manufacturer due to increased risk to t…"}, {"doc_id": "trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.633554220199585, "bge_max": 0.633554220199585, "title": "Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information", "rep_snippet": "The pharmacokinetics of sulfamethoxazole and trimethoprim are similar to nonpregnant values in early pregnancy (Ylikorkala 1973). Sulfamethoxazole and trimethoprim are recommended for the prophylaxis or treatment of Pneu…"}, {"doc_id": "mifepristone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6328004598617554, "bge_max": 0.6328004598617554, "title": "Mifepristone: Drug information", "rep_snippet": "• Intrauterine device: When used for the termination of pregnancy, remove any intrauterine device before treatment begins. Consider the possibility of ectopic pregnancy in women who become pregnant with an IUD in place.…"}, {"doc_id": "neratinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6326151490211487, "bge_max": 0.6326151490211487, "title": "Neratinib: Drug information", "rep_snippet": "Pregnancy Implications  Based on the mechanism of action and data from animal reproduction studies, use of neratinib in pregnancy may cause fetal harm. Women of reproductive potential should have a pregnancy test prior t…"}, {"doc_id": "pyrazinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6325585842132568, "bge_max": 0.6325585842132568, "title": "Pyrazinamide: Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have not been observed in animal reproduction studies. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to…"}, {"doc_id": "sertraline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6325463056564331, "bge_max": 0.6325463056564331, "title": "Sertraline: Drug information", "rep_snippet": "Pregnancy Implications  Sertraline crosses the human placenta. Available studies evaluating teratogenic effects following maternal use of sertraline in the first trimester have not shown an overall increased risk of majo…"}, {"doc_id": "black-widow-spider-latrodectus-mactans-antivenom-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6325170993804932, "bge_max": 0.6325170993804932, "title": "Black widow spider (Latrodectus mactans) antivenom: Drug information", "rep_snippet": "Pregnancy Implications  Animal reproduction studies have not been conducted. Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Rus…"}]}
{"qid": "Q21", "query": "CAP inpatient severe penicillin allergy — dosing and monitoring for levofloxacin; QT cautions.", "candidates": [{"doc_id": "levofloxacin-systemic-drug-information", "bm25_top3": 22.967194964934144, "bm25_max": 28.428352915697122, "bge_top3": null, "bge_max": null, "title": "Levofloxacin (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Levofloxacin (systemic): Pediatric drug information\")  Acute bacterial rhinosinusitis (off-label use): Oral, IV: 10 to 20 mg/kg/day divided every 12 to 24 hours for 10…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 28.0152596880082, "bm25_max": 28.0152596880082, "bge_top3": null, "bge_max": null, "title": "Vancomycin: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Infants >3 months, Children, and Adolescents: IV: Note: In children ≥5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out. Also c…"}, {"doc_id": "ampicillin-drug-information", "bm25_top3": 27.484070014115424, "bm25_max": 27.484070014115424, "bge_top3": 0.6918896436691284, "bge_max": 0.6918896436691284, "title": "Ampicillin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ampicillin: Pediatric drug information\")  Usual dosage range: Infants, Children, and Adolescents:  Oral: 50 to 100 mg/kg/day divided every 6 hours (maximum: 2 to 4 g/da…"}, {"doc_id": "ceftriaxone-drug-information", "bm25_top3": 21.725739829334294, "bm25_max": 26.921545465058948, "bge_top3": 0.7067168951034546, "bge_max": 0.7067168951034546, "title": "Ceftriaxone: Drug information", "rep_snippet": "Community-acquired pneumonia (CAP) (IDSA/PIDS [Bradley 2011]) (off-label dose): Infants >3 months and Children: IV: 50 to 100 mg/kg/day once daily or divided every 12 hours (maximum: 2,000 mg daily). Note: May consider a…"}, {"doc_id": "penicillin-g-intravenous-and-short-acting-intramuscular-drug-information", "bm25_top3": 25.639009390213324, "bm25_max": 25.639009390213324, "bge_top3": 0.7189385890960693, "bge_max": 0.7189385890960693, "title": "Penicillin G (intravenous and short-acting intramuscular): Drug information", "rep_snippet": "Other susceptible organisms: Infants, Children, and Adolescents: 300,000 units/kg/day divided every 4 to 6 hours; maximum daily dose: 24 million units/day (Tunkel 2004)  Meningococcal disease: IV: Infants, Children, and…"}, {"doc_id": "cefazolin-drug-information", "bm25_top3": 25.381682215074512, "bm25_max": 25.381682215074512, "bge_top3": 0.6842002868652344, "bge_max": 0.6842002868652344, "title": "Cefazolin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cefazolin: Pediatric drug information\")  Usual dosage range: IM, IV: Infants >1 month, Children, and Adolescents: 25 to 100 mg/kg/day divided every 6 to 8 hours; maximu…"}, {"doc_id": "azithromycin-systemic-drug-information", "bm25_top3": 19.03166723999288, "bm25_max": 19.03166723999288, "bge_top3": null, "bge_max": null, "title": "Azithromycin (systemic): Drug information", "rep_snippet": "Pharyngitis (including susceptible group A streptococci), tonsillitis (as an alternative agent in penicillin-allergic patients): Oral: 12 mg/kg (maximum: 500 mg) on day 1 followed by 6 mg/kg (maximum: 250 mg) once daily…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 17.262543341334077, "bm25_max": 17.790587004069454, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product  Caplet, oral:  Benadryl Allergy and Cold [DSC], Benadryl…"}, {"doc_id": "linezolid-drug-information", "bm25_top3": 17.786248799827828, "bm25_max": 17.786248799827828, "bge_top3": null, "bge_max": null, "title": "Linezolid: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Linezolid: Pediatric drug information\")  Usual dosage: Oral, IV:  Children ≤11 years: 10 mg/kg (maximum: 600 mg/dose) every 8 hours  Children ≥12 years and Adolescents:…"}, {"doc_id": "ceftazidime-and-avibactam-drug-information", "bm25_top3": 17.75091336542748, "bm25_max": 17.75091336542748, "bge_top3": null, "bge_max": null, "title": "Ceftazidime and avibactam: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported i…"}, {"doc_id": "artemether-and-lumefantrine-drug-information", "bm25_top3": 17.506195882640785, "bm25_max": 17.506195882640785, "bge_top3": null, "bge_max": null, "title": "Artemether and lumefantrine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "moxifloxacin-systemic-drug-information", "bm25_top3": 17.094465388579867, "bm25_max": 17.094465388579867, "bge_top3": null, "bge_max": null, "title": "Moxifloxacin (systemic): Drug information", "rep_snippet": "Dosing: Adult  Acute bacterial rhinosinusitis: Oral, IV: 400 mg every 24 hours for 10 days (manufacturer’s labeling) or 5 to 7 days (Chow 2012). Note: Recommended in patients with beta-lactam allergy; may also be used if…"}, {"doc_id": "amiloride-and-hydrochlorothiazide-drug-information", "bm25_top3": 16.707766238880918, "bm25_max": 16.707766238880918, "bge_top3": null, "bge_max": null, "title": "Amiloride and hydrochlorothiazide: Drug information", "rep_snippet": "• Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with ac…"}, {"doc_id": "clindamycin-systemic-drug-information", "bm25_top3": 16.148566510560418, "bm25_max": 16.47048038910207, "bge_top3": null, "bge_max": null, "title": "Clindamycin (systemic): Drug information", "rep_snippet": "Osteomyelitis due to MRSA (off-label use): IV, Oral: 10 to 13 mg/kg/dose every 6 to 8 hours for a minimum of 4 to 6 weeks (maximum: 40 mg/kg/day) (IDSA [Liu 2011])  Pharyngitis, group A streptococci (IDSA recommendations…"}, {"doc_id": "pindolol-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": 16.3352436169556, "bm25_max": 16.3352436169556, "bge_top3": null, "bge_max": null, "title": "Pindolol and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "• Ocular: Conjunctival xerosis (dryness of eye surface) has been reported with use of beta blockers; therapy discontinuation may be indicated if severe. Hydrochlorothiazide may cause acute transient myopia and acute angl…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": 15.994970149067612, "bm25_max": 15.994970149067612, "bge_top3": 0.6803815364837646, "bge_max": 0.6803815364837646, "title": "Cefuroxime: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.  • Hypersen…"}, {"doc_id": "phenylephrine-and-pramoxine-drug-information", "bm25_top3": 15.648485480701757, "bm25_max": 15.648485480701757, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and pramoxine: Drug information", "rep_snippet": "Administration  Cleanse affected area by patting or blotting with cleansing wipe, and gently dry before applying cream. Apply externally or in the lower portion of the anal canal only. For application in the lower anal c…"}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": 14.97230052454503, "bm25_max": 14.97230052454503, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "If used in combination with amiodarone (or in patients who discontinued amiodarone just prior to initiating sofosbuvir/velpatasvir), inpatient cardiac monitoring for the first 48 hours of coadministration, then outpatien…"}, {"doc_id": "sofosbuvir-velpatasvir-and-voxilaprevir-drug-information", "bm25_top3": 14.97230052454503, "bm25_max": 14.97230052454503, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir, velpatasvir, and voxilaprevir: Drug information", "rep_snippet": "If used in combination with amiodarone (or in patients who discontinued amiodarone just prior to initiating sofosbuvir/velpatasvir), inpatient cardiac monitoring for the first 48 hours of coadministration, then outpatien…"}, {"doc_id": "amoxicillin-and-clavulanate-drug-information", "bm25_top3": 14.810019528320371, "bm25_max": 14.810019528320371, "bge_top3": 0.6927599906921387, "bge_max": 0.6927599906921387, "title": "Amoxicillin and clavulanate: Drug information", "rep_snippet": "Use  Pneumonia, community-acquired: Extended-release tablets only: Treatment of patients with community-acquired pneumonia (CAP) caused by confirmed or suspected beta-lactamase-producing pathogens (ie, Haemophilus influe…"}, {"doc_id": "telithromycin-drug-information", "bm25_top3": 14.524648956040755, "bm25_max": 14.524648956040755, "bge_top3": null, "bge_max": null, "title": "Telithromycin: Drug information", "rep_snippet": "Dosing: Adult  Note: Ketek has been discontinued in the United States for more than 1 year.  Community-acquired pneumonia (CAP): Oral: 800 mg once daily for 7-10 days"}, {"doc_id": "cefpodoxime-drug-information", "bm25_top3": 14.499935135158317, "bm25_max": 14.499935135158317, "bge_top3": null, "bge_max": null, "title": "Cefpodoxime: Drug information", "rep_snippet": "Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Pneumonia, community acquired: Children ≥12 years of age and Adolescents: Oral: Refer to adult dosing.  Rhinosinusitis, acute maxillary:  Infants ≥…"}, {"doc_id": "penicilloyl-polylysine-drug-information", "bm25_top3": 11.102459415206742, "bm25_max": 11.102459415206742, "bge_top3": null, "bge_max": null, "title": "Penicilloyl-polylysine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Allergic reactions: Rare systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should…"}, {"doc_id": "ceftibuten-drug-information", "bm25_top3": 10.32230749254062, "bm25_max": 10.32230749254062, "bge_top3": 0.6909062266349792, "bge_max": 0.6909062266349792, "title": "Ceftibuten: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Penicillin allergy: Use with caution in patients with a history of penicillin allergy; if a hypersensitivity reaction occurs, discontinue therapy and institut…"}, {"doc_id": "cefprozil-drug-information", "bm25_top3": 9.938739231429555, "bm25_max": 9.938739231429555, "bge_top3": 0.6803677678108215, "bge_max": 0.6803677678108215, "title": "Cefprozil: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and trea…"}, {"doc_id": "influenza-virus-vaccine-live-attenuated-drug-information", "bm25_top3": 9.491864778466066, "bm25_max": 9.491864778466066, "bge_top3": 0.6883399486541748, "bge_max": 0.6883399486541748, "title": "Influenza virus vaccine (live attenuated): Drug information", "rep_snippet": "• Chicken egg protein: Manufactured with chicken egg protein. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the ACIP and NACI regarding influenza vaccination to per…"}, {"doc_id": "cefadroxil-drug-information", "bm25_top3": 7.6092303934560945, "bm25_max": 7.6092303934560945, "bge_top3": 0.67729651927948, "bge_max": 0.67729651927948, "title": "Cefadroxil: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute…"}, {"doc_id": "influenza-virus-vaccine-inactivated-drug-information", "bm25_top3": 7.276106237293327, "bm25_max": 7.276106237293327, "bge_top3": null, "bge_max": null, "title": "Influenza virus vaccine (inactivated): Drug information", "rep_snippet": "• Chicken egg protein: Most products are manufactured with chicken egg protein (expressed as ovalbumin content when content is disclosed on prescribing information). The ovalbumin content may vary from season to season a…"}, {"doc_id": "solifenacin-drug-information", "bm25_top3": 7.212533115624161, "bm25_max": 7.212533115624161, "bge_top3": null, "bge_max": null, "title": "Solifenacin: Drug information", "rep_snippet": "• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment required; use is not recommended in patients with severe hepatic impairment (Child-Pugh class C)…"}, {"doc_id": "cefdinir-drug-information", "bm25_top3": 7.140460588043068, "bm25_max": 7.140460588043068, "bge_top3": 0.6769382357597351, "bge_max": 0.6769382357597351, "title": "Cefdinir: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticar…"}, {"doc_id": "penicillamine-drug-information", "bm25_top3": 6.138641406511372, "bm25_max": 6.138641406511372, "bge_top3": null, "bge_max": null, "title": "Penicillamine: Drug information", "rep_snippet": "• Hepatotoxicity: Monitor liver function tests periodically due to rare reports of intrahepatic cholestasis or toxic hepatitis. More frequent monitoring is required during the first year of therapy in patients with Wilso…"}, {"doc_id": "griseofulvin-drug-information", "bm25_top3": 5.9421310723052585, "bm25_max": 5.9421310723052585, "bge_top3": null, "bge_max": null, "title": "Griseofulvin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hematologic effects: Leukopenia has been reported (rare); discontinue therapy if granulocytopenia occurs.  • Hepatic effects: May cause jaundice and elevated…"}, {"doc_id": "cephalexin-drug-information", "bm25_top3": 5.903326527183804, "bm25_max": 5.903326527183804, "bge_top3": null, "bge_max": null, "title": "Cephalexin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Allergic reactions (eg, rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": 5.809353233690487, "bm25_max": 5.809353233690487, "bge_top3": null, "bge_max": null, "title": "Sotalol: Drug information", "rep_snippet": "• Proarrhythmic effects: [US Boxed Warning]: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsades de pointes). Do not initiate if baseline QTc interval is >450…"}, {"doc_id": "gentamicin-systemic-drug-information", "bm25_top3": 5.780080699198223, "bm25_max": 5.780080699198223, "bge_top3": null, "bge_max": null, "title": "Gentamicin (systemic): Drug information", "rep_snippet": "Monitoring Parameters  Urinalysis, urine output, BUN, serum creatinine, plasma gentamicin levels (as appropriate to dosing method). Levels are typically obtained before and after the third dose in conventional dosing. He…"}, {"doc_id": "cefditoren-drug-information", "bm25_top3": 5.639038243169871, "bm25_max": 5.639038243169871, "bge_top3": null, "bge_max": null, "title": "Cefditoren: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.  • Penicill…"}, {"doc_id": "alfuzosin-drug-information", "bm25_top3": 5.638518960380992, "bm25_max": 5.638518960380992, "bge_top3": null, "bge_max": null, "title": "Alfuzosin: Drug information", "rep_snippet": "• Cardiovascular disease: Use with caution in patients with histories of tachyarrhythmia or with certain cardiovascular conditions, such as myocardial ischemia.  • Hepatic impairment: Use with caution in patients with mi…"}, {"doc_id": "granisetron-drug-information", "bm25_top3": 5.425809203471712, "bm25_max": 5.425809203471712, "bge_top3": null, "bge_max": null, "title": "Granisetron: Drug information", "rep_snippet": "• Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomag…"}, {"doc_id": "cefaclor-drug-information", "bm25_top3": 5.2889416414597274, "bm25_max": 5.2889416414597274, "bge_top3": 0.6937927603721619, "bge_max": 0.6937927603721619, "title": "Cefaclor: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Anaphylactic reactions have occurred. If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures…"}, {"doc_id": "furosemide-drug-information", "bm25_top3": 5.2732690728108835, "bm25_max": 5.2732690728108835, "bge_top3": null, "bge_max": null, "title": "Furosemide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor I & O (inpatient setting) and weight daily; blood pressure, orthostasis; serum electrolytes, renal function; monitor hearing with high doses or rapid IV administration"}, {"doc_id": "ranolazine-drug-information", "bm25_top3": 4.699129724587351, "bm25_max": 4.699129724587351, "bge_top3": null, "bge_max": null, "title": "Ranolazine: Drug information", "rep_snippet": "Monitoring Parameters  Baseline and follow up ECG to evaluate QT interval; monitor renal function periodically in patients with moderate to severe renal impairment, particularly for increases in serum creatinine accompan…"}, {"doc_id": "beano-alpha-galactosidase-drug-information", "bm25_top3": 4.587539610066063, "bm25_max": 4.587539610066063, "bge_top3": null, "bge_max": null, "title": "Beano (alpha-galactosidase): Drug information", "rep_snippet": "Dietary Considerations  Must be taken just before or with initial bite of food to be effective. Although made from safe, food-grade mold, there is no evidence that individuals with an allergy to penicillin or molds would…"}, {"doc_id": "kanamycin-united-states-not-available-drug-information", "bm25_top3": 4.544433316208064, "bm25_max": 4.544433316208064, "bge_top3": null, "bge_max": null, "title": "Kanamycin (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Serum creatinine and BUN every 2-3 days; peak and trough concentrations; hearing  Some penicillin derivatives may accelerate the degradation of aminoglycosides in vitro. This may be clinically-sign…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": 4.2144190259257215, "bm25_max": 4.2144190259257215, "bge_top3": null, "bge_max": null, "title": "Ertapenem: Drug information", "rep_snippet": "Use  Moderate-to-severe infections:  Acute pelvic infections: For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and postsurgical gynecologic infections caused by Strepto…"}, {"doc_id": "sevoflurane-drug-information", "bm25_top3": 3.1932697410977386, "bm25_max": 3.1932697410977386, "bge_top3": null, "bge_max": null, "title": "Sevoflurane: Drug information", "rep_snippet": "Use  Anesthesia: Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery"}, {"doc_id": "nafcillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7372747659683228, "bge_max": 0.7372747659683228, "title": "Nafcillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "ampicillin-and-sulbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7332465052604675, "bge_max": 0.7332465052604675, "title": "Ampicillin and sulbactam: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "penicillin-g-procaine-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7180525064468384, "bge_max": 0.7180525064468384, "title": "Penicillin G procaine (intermediate-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7165641188621521, "bge_max": 0.7165641188621521, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients o…"}, {"doc_id": "penicillin-g-benzathine-long-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7146735787391663, "bge_max": 0.7146735787391663, "title": "Penicillin G benzathine (long-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin th…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7129004001617432, "bge_max": 0.7129004001617432, "title": "Dicloxacillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have been reported in patients on pen…"}, {"doc_id": "oxacillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.709082305431366, "bge_max": 0.709082305431366, "title": "Oxacillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin…"}, {"doc_id": "piperacillin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6948038935661316, "bge_max": 0.7082796096801758, "title": "Piperacillin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients o…"}, {"doc_id": "penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7073270082473755, "bge_max": 0.7073270082473755, "title": "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "penicillin-v-potassium-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7029891014099121, "bge_max": 0.7029891014099121, "title": "Penicillin V potassium (oral): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "measles-mumps-rubella-and-varicella-virus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.702818751335144, "bge_max": 0.702818751335144, "title": "Measles, mumps, rubella, and varicella virus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "piperacillin-and-tazobactam-sodium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.70103919506073, "bge_max": 0.70103919506073, "title": "Piperacillin and tazobactam sodium: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic/anaphylactoid) reactions have been reported…"}, {"doc_id": "ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7006244659423828, "bge_max": 0.7006244659423828, "title": "Ticarcillin and clavulanate potassium (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concern related to adverse effects:  • Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin the…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.697088897228241, "bge_max": 0.697088897228241, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lact…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-combination-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.695725679397583, "bge_max": 0.695725679397583, "title": "Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "amoxicillin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6947256922721863, "bge_max": 0.6947256922721863, "title": "Amoxicillin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6926754713058472, "bge_max": 0.6926754713058472, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lact…"}, {"doc_id": "filgrastim-including-biosimilars-of-filgrastim-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6902616024017334, "bge_max": 0.6902616024017334, "title": "Filgrastim (including biosimilars of filgrastim): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse reactions:  • Allergic reactions: Serious allergic reactions (including anaphylaxis) have been reported, usually with the initial exposure; may be managed symptomatically…"}, {"doc_id": "live-attenuated-cholera-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6854696273803711, "bge_max": 0.6854696273803711, "title": "Live attenuated cholera vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "hepatitis-b-immune-globulin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6842530369758606, "bge_max": 0.6842530369758606, "title": "Hepatitis B immune globulin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be a…"}, {"doc_id": "levofloxacin-united-states-not-available-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6839315891265869, "bge_max": 0.6839315891265869, "title": "Levofloxacin (United States: Not available) (oral inhalation): Drug information", "rep_snippet": "• Hepatotoxicity: Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported with systemically administered levofloxacin (generally within 2 weeks). Elderly patients…"}, {"doc_id": "ranibizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6833270788192749, "bge_max": 0.6833270788192749, "title": "Ranibizumab: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniqu…"}, {"doc_id": "telavancin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.683184027671814, "bge_max": 0.683184027671814, "title": "Telavancin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported after first or subsequent doses; some ha…"}, {"doc_id": "gadoversetamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6830052137374878, "bge_max": 0.6830052137374878, "title": "Gadoversetamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "gadodiamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6830052137374878, "bge_max": 0.6830052137374878, "title": "Gadodiamide: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "gadofosveset-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6830052137374878, "bge_max": 0.6830052137374878, "title": "Gadofosveset: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medicat…"}, {"doc_id": "tetanus-immune-globulin-human-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6803270578384399, "bge_max": 0.6803270578384399, "title": "Tetanus immune globulin (human): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be a…"}, {"doc_id": "cefoxitin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6799298524856567, "bge_max": 0.6799298524856567, "title": "Cefoxitin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angi…"}, {"doc_id": "avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6797276735305786, "bge_max": 0.6797276735305786, "title": "Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from strategic national stockpile in consultation with local health department): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6797256469726562, "bge_max": 0.6797256469726562, "title": "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "nebivolol-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6794586777687073, "bge_max": 0.6794586777687073, "title": "Nebivolol and valsartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactic reactions: Use nebivolol with caution with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more…"}, {"doc_id": "diphtheria-tetanus-toxoids-and-acellular-pertussis-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6785242557525635, "bge_max": 0.6785242557525635, "title": "Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "meropenem-and-vaborbactam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6780614852905273, "bge_max": 0.6780614852905273, "title": "Meropenem and vaborbactam: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis and serious skin reactions, have been reported with beta-lactam antibact…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-recombinant-hepatitis-b-and-inactivated-poliovirus-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6775455474853516, "bge_max": 0.6775455474853516, "title": "Diphtheria, tetanus toxoids, acellular pertussis, recombinant hepatitis B, and inactivated poliovirus vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-and-haemophilus-influenzae-type-b-conjugate-vaccine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6775455474853516, "bge_max": 0.6775455474853516, "title": "Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b conjugate vaccine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be av…"}, {"doc_id": "levobunolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6774923801422119, "bge_max": 0.6774923801422119, "title": "Levobunolol: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse events:  • Anaphylactic reactions: Instill with caution in patients with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6767568588256836, "bge_max": 0.6767568588256836, "title": "Alirocumab: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypersensitivity reactions: Hypersensitivity reactions, including some severe reactions requiring hospitalization (eg, hypersensitivity vasculitis), have been…"}]}
{"qid": "Q22", "query": "Oral candidiasis — dosing and swish/swallow instructions for nystatin suspension.", "candidates": [{"doc_id": "nystatin-oral-drug-information", "bm25_top3": 40.67843265427184, "bm25_max": 53.00841988403144, "bge_top3": 0.7726044853528341, "bge_max": 0.7869009375572205, "title": "Nystatin (oral): Drug information", "rep_snippet": "Dosing: Adult  Oral candidiasis: Suspension (swish and swallow): 400,000-600,000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing  Intestinal infections: Oral t…"}, {"doc_id": "cetylpyridinium-drug-information", "bm25_top3": 19.857355345914318, "bm25_max": 29.018772567397583, "bge_top3": 0.6946874856948853, "bge_max": 0.6946874856948853, "title": "Cetylpyridinium: Drug information", "rep_snippet": "Dosing: Adult  Antiseptic (OTC labeling): Oral: Swish 20 mL thoroughly between teeth for 30 seconds then spit; use twice daily; may be used before or after brushing; do not swallow."}, {"doc_id": "artificial-saliva-drug-information", "bm25_top3": 17.394981598204332, "bm25_max": 28.573447909259205, "bge_top3": 0.658435583114624, "bge_max": 0.658435583114624, "title": "Artificial saliva: Drug information", "rep_snippet": "Dosing: Adult  Mucositis (due to high-dose chemotherapy or radiation therapy): Oral:  Caphosol, NeutraSal: Swish and spit 4 to 10 doses daily (use for the duration of chemo- or radiation therapy).  SalivaMax, SalivateRx:…"}, {"doc_id": "clotrimazole-oral-drug-information", "bm25_top3": 28.147164285960407, "bm25_max": 28.147164285960407, "bge_top3": null, "bge_max": null, "title": "Clotrimazole (oral): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Clotrimazole (oral): Pediatric drug information \")  Oropharyngeal candidiasis (treatment): Children ≥3 years and Adolescents: Refer to adult dosing."}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 26.949501181184992, "bm25_max": 26.949501181184992, "bge_top3": null, "bge_max": null, "title": "Vancomycin: Drug information", "rep_snippet": "Dosage Forms Considerations  First-Vancomycin oral solution and Vancomycin+SyrSpend SF oral suspension are compounding kits. Refer to manufacturer’s labeling for compounding instructions."}, {"doc_id": "nystatin-topical-drug-information", "bm25_top3": 20.7304524839015, "bm25_max": 26.191155697966, "bge_top3": 0.688543438911438, "bge_max": 0.688543438911438, "title": "Nystatin (topical): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nystatin (topical): Pediatric drug information\")  Fungal infections (cutaneous and mucocutaneous): Infants, Children, and Adolescents: Topical: Refer to adult dosing."}, {"doc_id": "diphenhydramine-systemic-drug-information", "bm25_top3": 25.65218029612508, "bm25_max": 25.65218029612508, "bge_top3": null, "bge_max": null, "title": "Diphenhydramine (systemic): Drug information", "rep_snippet": "Dosage Forms Considerations  Dicopanol FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "anidulafungin-drug-information", "bm25_top3": 18.803175742835673, "bm25_max": 19.145168391333122, "bge_top3": null, "bge_max": null, "title": "Anidulafungin: Drug information", "rep_snippet": "Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high incidence of invasive candidiasis) (alternative therapy; off-label use): IV: Initial dose: 200 mg on day 1; subsequent do…"}, {"doc_id": "glycopyrrolate-glycopyrronium-oral-inhalation-drug-information", "bm25_top3": 19.085470872633252, "bm25_max": 19.085470872633252, "bge_top3": null, "bge_max": null, "title": "Glycopyrrolate (glycopyrronium) (oral inhalation): Drug information", "rep_snippet": "Administration  Inhalation: For oral inhalation only.  Dry powder inhaler (capsule): Do not swallow capsules. Administer at the same time each day; use only with the Neohaler device. Do not remove capsules from blister u…"}, {"doc_id": "carbamide-peroxide-drug-information", "bm25_top3": 18.636163923973584, "bm25_max": 18.636163923973584, "bge_top3": null, "bge_max": null, "title": "Carbamide peroxide: Drug information", "rep_snippet": "Dosing: Adult  Ear wax removal: Otic: Instill 5 to 10 drops twice daily up to 4 days.  Mouth, gum, or dental irritation: Oral: Use up to 4 times daily after meals and at bedtime. For direct application, place several dro…"}, {"doc_id": "colesevelam-drug-information", "bm25_top3": 18.01751482723731, "bm25_max": 18.01751482723731, "bge_top3": 0.6697692275047302, "bge_max": 0.6697692275047302, "title": "Colesevelam: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Colesevelam: Pediatric drug information\")  Heterozygous familial hypercholesterolemia: Children 10 to 17 years (males and postmenarchal females): Oral: 3.75 g once dail…"}, {"doc_id": "ciclopirox-drug-information", "bm25_top3": 17.71913292054814, "bm25_max": 17.71913292054814, "bge_top3": null, "bge_max": null, "title": "Ciclopirox: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciclopirox: Pediatric drug information\")  Tinea pedis, tinea corporis: Topical:  Cream and suspension: Children >10 years and Adolescents: Refer to adult dosing.  Gel:…"}, {"doc_id": "nitazoxanide-drug-information", "bm25_top3": 17.69294093004563, "bm25_max": 17.69294093004563, "bge_top3": null, "bge_max": null, "title": "Nitazoxanide: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Nitazoxanide: Pediatric drug information\")  Diarrhea, infectious caused by Cryptosporidium parvum or Giardia lamblia: Oral:  Children 1 to 3 years: Oral suspension: 100…"}, {"doc_id": "cefuroxime-drug-information", "bm25_top3": 17.281420119462588, "bm25_max": 17.281420119462588, "bge_top3": null, "bge_max": null, "title": "Cefuroxime: Drug information", "rep_snippet": "Administration  Oral suspension: Administer with food. Shake well before use.  Oral tablet: May administer with or without food. Swallow tablet whole (crushed tablet has strong, persistent, bitter taste).  IM: Inject dee…"}, {"doc_id": "cyclobenzaprine-drug-information", "bm25_top3": 15.073458080026228, "bm25_max": 15.073458080026228, "bge_top3": null, "bge_max": null, "title": "Cyclobenzaprine: Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Cyclobenzaprine and Active-Cyclobenzaprine creams are compounded from kits. Refer to manufacturer’s labeling for compounding instructions.  Tabradol FusePaq is a compounding kit for t…"}, {"doc_id": "midazolam-drug-information", "bm25_top3": 14.849602714146563, "bm25_max": 14.849602714146563, "bge_top3": null, "bge_max": null, "title": "Midazolam: Drug information", "rep_snippet": "Dosage Forms Considerations  Midazolam+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "ursodeoxycholic-acid-ursodiol-drug-information", "bm25_top3": 14.849602714146563, "bm25_max": 14.849602714146563, "bge_top3": null, "bge_max": null, "title": "Ursodeoxycholic acid (ursodiol): Drug information", "rep_snippet": "Dosage Forms Considerations  Ursodiol+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 14.652180296125081, "bm25_max": 14.652180296125081, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "Dosage Forms Considerations  Deprizine FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "gabapentin-drug-information", "bm25_top3": 14.591448740211803, "bm25_max": 14.591448740211803, "bge_top3": null, "bge_max": null, "title": "Gabapentin: Drug information", "rep_snippet": "Dosage Forms Considerations  Gralise is the extended release formulation.  Fanatrex FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions.…"}, {"doc_id": "amlodipine-drug-information", "bm25_top3": 14.501303068510108, "bm25_max": 14.501303068510108, "bge_top3": null, "bge_max": null, "title": "Amlodipine: Drug information", "rep_snippet": "Dosage Forms Considerations  AmLODIPine Bes+SyrSpend SF oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "atenolol-drug-information", "bm25_top3": 14.501303068510108, "bm25_max": 14.501303068510108, "bge_top3": null, "bge_max": null, "title": "Atenolol: Drug information", "rep_snippet": "Dosage Forms Considerations  Atenolol+SyrSpend SF PH4 oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions."}, {"doc_id": "triamcinolone-neomycin-gramicidin-and-nystatin-topical-united-states-not-available-drug-information", "bm25_top3": 13.678985206102215, "bm25_max": 13.678985206102215, "bge_top3": null, "bge_max": null, "title": "Triamcinolone, neomycin, gramicidin, and nystatin (topical) (United States: Not available): Drug information", "rep_snippet": "Contraindications  Hypersensitivity to triamcinolone, neomycin, gramicidin, nystatin, or any component of the formulation; tuberculosis and most viral skin lesions (including herpes simplex, vaccinia, varicella), fungal…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": 11.588305282169692, "bm25_max": 11.588305282169692, "bge_top3": null, "bge_max": null, "title": "Tramadol: Drug information", "rep_snippet": "Dosage Forms Considerations  ConZip extended release capsules are formulated as a biphasic product, providing immediate and extended release components:  100 mg: 25 mg (immediate release) and 75 mg (extended release)  20…"}, {"doc_id": "baclofen-drug-information", "bm25_top3": 11.329857113222651, "bm25_max": 11.329857113222651, "bge_top3": null, "bge_max": null, "title": "Baclofen: Drug information", "rep_snippet": "Dosage Forms Considerations  EnovaRX-Baclofen and Equipto-Baclofen creams are compounded from kits. Refer to manufacturer’s labeling for compounding instructions.  First-Baclofen suspension is a compounding kit. Refer to…"}, {"doc_id": "oseltamivir-drug-information", "bm25_top3": 10.973257588774374, "bm25_max": 10.973257588774374, "bge_top3": null, "bge_max": null, "title": "Oseltamivir: Drug information", "rep_snippet": "Medication Safety Issues  Sound-alike/look-alike issues:  Tamiflu may be confused with Tambocor, Thera-Flu  Other safety concerns:  Oseltamivir (Tamiflu) oral suspension is available in a 6 mg/mL concentration. Instructi…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 10.221241241306739, "bm25_max": 10.221241241306739, "bge_top3": null, "bge_max": null, "title": "Omeprazole: Drug information", "rep_snippet": "Administration  Administer 30 to 60 minutes before meals; may take with antacids. If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (ACG [Katz 2013]; Hersc…"}, {"doc_id": "candesartan-drug-information", "bm25_top3": 10.195267747869021, "bm25_max": 10.195267747869021, "bge_top3": null, "bge_max": null, "title": "Candesartan: Drug information", "rep_snippet": "Administration  Administer without regard to meals. An oral suspension may be prepared for children unable to swallow tablets (refer to Extemporaneously Prepared information)."}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 9.949408289277216, "bm25_max": 9.949408289277216, "bge_top3": null, "bge_max": null, "title": "Lansoprazole: Drug information", "rep_snippet": "Dosage Forms Considerations  First-Lansoprazole suspension is a compounding kit. Refer to manufacturer’s labeling for compounding instructions."}, {"doc_id": "axitinib-drug-information", "bm25_top3": 9.838170224349255, "bm25_max": 9.838170224349255, "bge_top3": null, "bge_max": null, "title": "Axitinib: Drug information", "rep_snippet": "Administration  Oral: Swallow tablet whole with a glass of water. May be taken with or without food. If a dose is missed or vomited, do not make up; resume dosing with the next scheduled dose. A suspension may be prepare…"}, {"doc_id": "sevelamer-drug-information", "bm25_top3": 8.622169881918175, "bm25_max": 8.622169881918175, "bge_top3": 0.6791784763336182, "bge_max": 0.6791784763336182, "title": "Sevelamer: Drug information", "rep_snippet": "Administration  Administer with meals.  Powder for oral suspension: May prepare an oral suspension in water using the directed amount of water appropriate for the packet size or may premix the entire content of the packe…"}, {"doc_id": "naproxen-drug-information", "bm25_top3": 8.495106451739737, "bm25_max": 8.495106451739737, "bge_top3": null, "bge_max": null, "title": "Naproxen: Drug information", "rep_snippet": "Administration  Oral: Administer with food, milk, or antacids to decrease GI adverse effects.  Suspension: Shake suspension well before administration.  Tablet, delayed or extended release: Swallow tablet whole; do not b…"}, {"doc_id": "simethicone-drug-information", "bm25_top3": 8.308812347286612, "bm25_max": 8.308812347286612, "bge_top3": 0.6907268762588501, "bge_max": 0.6907268762588501, "title": "Simethicone: Drug information", "rep_snippet": "Administration  Oral: Chewable tablet: Chew thoroughly and swallow  Oral suspension (drops): Shake well before using; may mix with 30 mL water, infant formula, or other liquids. Fill enclosed dropper to recommended dosag…"}, {"doc_id": "aprepitant-drug-information", "bm25_top3": 8.227299718446755, "bm25_max": 8.227299718446755, "bge_top3": null, "bge_max": null, "title": "Aprepitant: Drug information", "rep_snippet": "Administration  IV: Infuse over 30 minutes approximately one-half hour (30 minutes) prior to chemotherapy. Use only non-DEHP tubing for administration. Administration information is for aprepitant IV (Cinvanti); refer to…"}, {"doc_id": "mercaptopurine-drug-information", "bm25_top3": 8.172200279921693, "bm25_max": 8.172200279921693, "bge_top3": null, "bge_max": null, "title": "Mercaptopurine: Drug information", "rep_snippet": "Suspension: Shake well for at least 30 seconds to ensure suspension is mixed thoroughly (suspension is viscous). Measure dose with an oral dosing syringe (a 1 mL and a 5 mL oral dosing syringe are supplied by the manufac…"}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 7.797120982097262, "bm25_max": 7.797120982097262, "bge_top3": null, "bge_max": null, "title": "Deferasirox: Drug information", "rep_snippet": "Tablets for suspension (Exjade): Administer tablets by making an oral suspension; do not chew or swallow tablets whole. Completely disperse tablets in water, orange juice, or apple juice (use 105 mL for total doses <1 g;…"}, {"doc_id": "nitisinone-drug-information", "bm25_top3": 6.508542282225024, "bm25_max": 6.508542282225024, "bge_top3": null, "bge_max": null, "title": "Nitisinone: Drug information", "rep_snippet": "Administration  Capsules: Administer at least 1 hour prior to, or 2 hours after a meal. Capsules may be opened and contents suspended in a small quantity of water, formula, or apple sauce; administer immediately.  Suspen…"}, {"doc_id": "hydrogen-peroxide-drug-information", "bm25_top3": 6.116176601407613, "bm25_max": 6.116176601407613, "bge_top3": null, "bge_max": null, "title": "Hydrogen peroxide: Drug information", "rep_snippet": "Removal of oral secretions: Solution (3%): Mix with equal amounts of water; swish around mouth over affected area for at least 1 minute, then spit out.  Mouth, gum, or dental irritation:  Oral rinse (1.4%): Swish around…"}, {"doc_id": "posaconazole-drug-information", "bm25_top3": 5.007332871063923, "bm25_max": 5.007332871063923, "bge_top3": null, "bge_max": null, "title": "Posaconazole: Drug information", "rep_snippet": "Use  Prophylaxis of invasive Aspergillus and Candida infections: Suspension and delayed-release tablets (13 years and older) and injection (18 years and older): Prophylaxis of invasive Aspergillus and Candida infections…"}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 4.565857888158964, "bm25_max": 4.565857888158964, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Oropharyngeal/Esophageal candidiasis (oral solution): Treatment of oropharyngeal and esophageal candidiasis  Canadian labeling: Oral capsules: Additional indications (not in US labeling):  Candidiasis, oral and/or esopha…"}, {"doc_id": "amphotericin-b-deoxycholate-conventional-drug-information", "bm25_top3": 4.450135569997165, "bm25_max": 4.450135569997165, "bge_top3": null, "bge_max": null, "title": "Amphotericin B deoxycholate (conventional): Drug information", "rep_snippet": "Use: Off-Label  Candidiasis, endophthalmitis (intravitreal); Candidiasis, esophageal (non-HIV-infected patients); Candidiasis, esophageal, in HIV-infected patients (adolescents and adults); Candidiasis, esophageal, in HI…"}, {"doc_id": "ketoconazole-topical-drug-information", "bm25_top3": 4.447942029595277, "bm25_max": 4.447942029595277, "bge_top3": null, "bge_max": null, "title": "Ketoconazole (topical): Drug information", "rep_snippet": "Use: Off-Label  Cream: Susceptible fungal infections in the oral cavity including candidiasis, oral thrush, and chronic mucocutaneous candidiasis"}, {"doc_id": "rufinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6992567181587219, "bge_max": 0.6992567181587219, "title": "Rufinamide: Drug information", "rep_snippet": "Administration  Oral: Administer with food. Tablets may be swallowed whole, split in half, or crushed. Oral suspension should be administered using the provided adapter and calibrated oral syringe; shake well before each…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6801637411117554, "bge_max": 0.6801637411117554, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Administration  Administer prepared suspension orally. Not to be taken in dry form. Suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration a…"}, {"doc_id": "buspirone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6765796542167664, "bge_max": 0.6765796542167664, "title": "Buspirone: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food, but must be consistent."}, {"doc_id": "glycerin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761847138404846, "bge_max": 0.6761847138404846, "title": "Glycerin: Drug information", "rep_snippet": "Dosing: Adult  Constipation: Rectal: One adult suppository once daily as needed or as directed  Mouth/throat irritation: Oral: Apply a one-inch strip directly to tongue and oral cavity as needed"}, {"doc_id": "dofetilide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Dofetilide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "ledipasvir-and-sofosbuvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Ledipasvir and sofosbuvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "sofosbuvir-and-velpatasvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Sofosbuvir and velpatasvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "cariprazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Cariprazine: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "eplerenone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Eplerenone: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "bictegravir-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Bictegravir, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "brexpiprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Brexpiprazole: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "rifaximin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Rifaximin: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "olmesartan-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Olmesartan and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "daclatasvir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6750782132148743, "bge_max": 0.6750782132148743, "title": "Daclatasvir: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food."}, {"doc_id": "amiloride-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6741801500320435, "bge_max": 0.6741801500320435, "title": "Amiloride and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6741801500320435, "bge_max": 0.6741801500320435, "title": "Tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "tiagabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6741801500320435, "bge_max": 0.6741801500320435, "title": "Tiagabine: Drug information", "rep_snippet": "Administration  Oral: Administer with food."}, {"doc_id": "flavocoxid-united-states-note-fda-has-issued-a-warning-against-use-of-this-product-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6718282103538513, "bge_max": 0.6718282103538513, "title": "Flavocoxid (United States – Note: FDA has issued a warning against use of this product): Drug information", "rep_snippet": "Administration  Oral: Administer with or without meals."}, {"doc_id": "cetylpyridinium-and-benzocaine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6691563129425049, "bge_max": 0.6691563129425049, "title": "Cetylpyridinium and benzocaine (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Antiseptic/anesthetic: Oral: Dissolve in mouth as needed for sore throat  Antiseptic/anesthetic (dental use): Oral: Dissolve in mouth as needed for pain"}, {"doc_id": "acetaminophen-paracetamol-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6690638661384583, "bge_max": 0.6690638661384583, "title": "Acetaminophen (paracetamol) and codeine: Drug information", "rep_snippet": "Administration  Oral solution or suspension: Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur).…"}, {"doc_id": "raltegravir-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6688399910926819, "bge_max": 0.6688399910926819, "title": "Raltegravir: Drug information", "rep_snippet": "Administration  May be administered without regard to meals.  Chewable tablets: May be chewed or swallowed whole; the 100 mg chewable tablet may be divided into equal halves.  Film-coated tablets: Must be swallowed whole…"}, {"doc_id": "antiseptic-mouthwash-dental-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.66881263256073, "bge_max": 0.66881263256073, "title": "Antiseptic mouthwash (dental): Drug information", "rep_snippet": "Dosing: Adult  Plaque/gingivitis prevention: Oral: Rinse full strength for 30 seconds with 20 mL morning and night"}, {"doc_id": "barium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6663525104522705, "bge_max": 0.6663525104522705, "title": "Barium: Drug information", "rep_snippet": "Administration  Oral, rectal: Refer to individual product labeling for dosage and administration information."}, {"doc_id": "clidinium-and-chlordiazepoxide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6646972894668579, "bge_max": 0.6646972894668579, "title": "Clidinium and chlordiazepoxide: Drug information", "rep_snippet": "Administration  Oral: Administer before meals and at bedtime."}, {"doc_id": "rupatadine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.663796067237854, "bge_max": 0.663796067237854, "title": "Rupatadine (United States: Not available): Drug information", "rep_snippet": "Administration  Oral: Administer with or without food. For solution, insert oral syringe (provided with packaging) into perforated stopper. Turn bottle upside down to allow syringe to fill with appropriate dose. Wash ora…"}, {"doc_id": "phenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6632689833641052, "bge_max": 0.6632689833641052, "title": "Phenytoin: Drug information", "rep_snippet": "Medication Guide and/or Vaccine Information Statement (VIS)  An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:  Dilantin che…"}, {"doc_id": "pirfenidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6629630923271179, "bge_max": 0.6629630923271179, "title": "Pirfenidone: Drug information", "rep_snippet": "Administration  Oral: Administer with food at the same time each day."}, {"doc_id": "netupitant-and-palonosetron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618168354034424, "bge_max": 0.6618168354034424, "title": "Netupitant and palonosetron: Drug information", "rep_snippet": "Administration  Oral: May administer with or without food."}, {"doc_id": "lamivudine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618168354034424, "bge_max": 0.6618168354034424, "title": "Lamivudine and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Administration  Oral: May administer with or without food."}, {"doc_id": "magnesium-citrate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6613870859146118, "bge_max": 0.6613870859146118, "title": "Magnesium citrate: Drug information", "rep_snippet": "Dosing: Adult  Laxative: Oral: Solution: 195-300 mL given once or in divided doses"}, {"doc_id": "miconazole-oral-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6612844467163086, "bge_max": 0.6612844467163086, "title": "Miconazole (oral): Drug information", "rep_snippet": "Dosing: Adult  Oropharyngeal candidiasis: Buccal tablet: 50 mg (1 tablet) applied to the upper gum region once daily for 14 days"}, {"doc_id": "trimebutine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6611398458480835, "bge_max": 0.6611398458480835, "title": "Trimebutine (United States: Not available): Drug information", "rep_snippet": "Administration  Oral: Administer before meals."}, {"doc_id": "nevirapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6610369682312012, "bge_max": 0.6610369682312012, "title": "Nevirapine: Drug information", "rep_snippet": "Administration  Oral: May be administered with or without food; may be administered with an antacid or didanosine. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especi…"}, {"doc_id": "rilpivirine-emtricitabine-and-tenofovir-alafenamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6606591939926147, "bge_max": 0.6606591939926147, "title": "Rilpivirine, emtricitabine, and tenofovir alafenamide: Drug information", "rep_snippet": "Administration  Oral: Administer with a meal."}, {"doc_id": "vigabatrin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6602542400360107, "bge_max": 0.6602542400360107, "title": "Vigabatrin: Drug information", "rep_snippet": "Administration  Administer without regard to meals.  Oral solution: Mix with water immediately prior to administration. Administer using an oral syringe (provided)."}, {"doc_id": "megestrol-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6593683958053589, "bge_max": 0.6593683958053589, "title": "Megestrol acetate: Drug information", "rep_snippet": "Administration  Oral: Shake suspension well before use.  The 625 mg/5 mL suspension may be administered without regard to meals."}, {"doc_id": "cefixime-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6592493653297424, "bge_max": 0.6592493653297424, "title": "Cefixime: Drug information", "rep_snippet": "Administration  May be administered with or without food. Shake oral suspension well before use. Chewable tablets must be chewed or crushed before swallowing."}, {"doc_id": "magnesium-carbonate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591840386390686, "bge_max": 0.6591840386390686, "title": "Magnesium carbonate: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "chlorzoxazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591840386390686, "bge_max": 0.6591840386390686, "title": "Chlorzoxazone: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "methyltestosterone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6591840386390686, "bge_max": 0.6591840386390686, "title": "Methyltestosterone: Drug information", "rep_snippet": "Administration  Administer orally."}, {"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6582635045051575, "bge_max": 0.6582635045051575, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Administration  Oral: Administer in single or divided doses with or without food."}]}
{"qid": "Q23", "query": "Seizure maintenance — therapeutic trough range and toxicity signs for valproic acid (monitoring labs).", "candidates": [{"doc_id": "valproate-drug-information", "bm25_top3": 30.096798632218455, "bm25_max": 32.197314186544304, "bge_top3": 0.7046372592449188, "bge_max": 0.719673216342926, "title": "Valproate: Drug information", "rep_snippet": "Epilepsy: Although seizure control may improve at levels >100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100 to 150 mcg/mL (SI: 700 to 1,050 micromole/L)  Mania: Clinical response seen with trough leve…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 23.254347268479282, "bm25_max": 23.965735555972593, "bge_top3": null, "bge_max": null, "title": "Voriconazole: Drug information", "rep_snippet": "Monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment (and prolonged prophylaxis); endophthalmitis; meningitis or osteoarticular infections due to Exserohi…"}, {"doc_id": "streptomycin-drug-information", "bm25_top3": 23.30477252929055, "bm25_max": 23.30477252929055, "bge_top3": null, "bge_max": null, "title": "Streptomycin: Drug information", "rep_snippet": "Reference Range  Therapeutic: Peak: 20 to 30 mcg/mL; Trough: <5 mcg/mL (Edson 1991); Toxic: Peak: >50 mcg/mL; Trough: >10 mcg/mL"}, {"doc_id": "imipenem-and-cilastatin-drug-information", "bm25_top3": 22.511258338071688, "bm25_max": 22.511258338071688, "bge_top3": null, "bge_max": null, "title": "Imipenem and cilastatin: Drug information", "rep_snippet": "• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.…"}, {"doc_id": "vancomycin-drug-information", "bm25_top3": 21.376331275342405, "bm25_max": 21.376331275342405, "bge_top3": null, "bge_max": null, "title": "Vancomycin: Drug information", "rep_snippet": "Monitoring Parameters  Intravenous: Periodic renal function tests, CBC; serum trough vancomycin concentrations in select patients (eg, aggressive dosing, life-threatening infection, seriously ill, unstable renal function…"}, {"doc_id": "carnitine-supplements-levocarnitine-drug-information", "bm25_top3": 16.970932838987707, "bm25_max": 18.739287482791347, "bge_top3": 0.6749553084373474, "bge_max": 0.6749553084373474, "title": "Carnitine supplements (Levocarnitine): Drug information", "rep_snippet": "Monitoring Parameters  Carnitine concentrations (initially, weekly, and monthly for IV therapy)  Metabolic disorders: Monitor blood chemistry, vital signs, and plasma carnitine levels (maintain between 35 to 60 μmol/L).…"}, {"doc_id": "ethosuximide-drug-information", "bm25_top3": 16.637286560563965, "bm25_max": 16.637286560563965, "bge_top3": 0.6943042278289795, "bge_max": 0.6943042278289795, "title": "Ethosuximide: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; trough serum concentrations, CBC, platelets, liver enzymes (periodic), urinalysis (periodic); signs of rash; suicidality (eg, suicidal thoughts, depression, behavioral changes)"}, {"doc_id": "lamotrigine-drug-information", "bm25_top3": 16.001481154899782, "bm25_max": 16.501548918072338, "bge_top3": 0.6582935452461243, "bge_max": 0.6582935452461243, "title": "Lamotrigine: Drug information", "rep_snippet": "Regimens containing carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, and without valproic acid: Initial: Weeks 1 and 2: 50 mg once daily; Weeks 3 and 4: 100 mg once daily; Week 5: 200 mg…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 14.789384990501734, "bm25_max": 14.789384990501734, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whene…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": 14.727854769862091, "bm25_max": 14.727854769862091, "bge_top3": 0.6688529849052429, "bge_max": 0.6688529849052429, "title": "Apalutamide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor thyroid function (eg, TSH) as clinically necessary. Monitor for signs/symptoms of seizure and dermatologic toxicity. Assess for fall and fracture risk. Monitor adherence."}, {"doc_id": "itraconazole-drug-information", "bm25_top3": 13.506501034140888, "bm25_max": 14.345143060862046, "bge_top3": null, "bge_max": null, "title": "Itraconazole: Drug information", "rep_snippet": "Reference Range  Invasive aspergillosis:  Timing of concentrations: Obtain trough after steady state has been reached (4 to 7 days after therapy initiation); the need for continued or repeat monitoring is a patient speci…"}, {"doc_id": "bupropion-drug-information", "bm25_top3": 13.407852614400142, "bm25_max": 13.407852614400142, "bge_top3": null, "bge_max": null, "title": "Bupropion: Drug information", "rep_snippet": "Reference Range  Therapeutic levels have not been well established and are not routinely recommended. Studies have suggested optimal antidepressant response may occur at trough bupropion plasma concentrations <100 µg/L (…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 13.287937254281772, "bm25_max": 13.287937254281772, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Monitoring Parameters  IV: Serum calcium, sodium and phosphorus levels; renal function; after IV phosphate repletion, repeat serum phosphorus level should be checked 2-4 hours later  Oral: Bowel cleansing: Baseline and p…"}, {"doc_id": "nelarabine-drug-information", "bm25_top3": 12.987223820378254, "bm25_max": 12.987223820378254, "bge_top3": null, "bge_max": null, "title": "Nelarabine: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential, liver and kidney function; monitor closely for neurologic toxicity (severe somnolence, seizure, peripheral neuropathy, confusion, ataxia, paresthesia, hypoesthesia, coma, or…"}, {"doc_id": "melphalan-drug-information", "bm25_top3": 12.894635338180528, "bm25_max": 12.894635338180528, "bge_top3": null, "bge_max": null, "title": "Melphalan: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelet count, serum electrolytes, renal/liver function tests, serum uric acid; signs/symptoms of hypersensitivity reaction, pulmonary toxicity, and gastrointestinal toxi…"}, {"doc_id": "everolimus-drug-information", "bm25_top3": 11.626575280355434, "bm25_max": 12.877952800526192, "bge_top3": null, "bge_max": null, "title": "Everolimus: Drug information", "rep_snippet": "Initial: 4.5 mg/m2 once daily; round to nearest tablet (tablet or tablet for oral suspension) size; continue until disease progression or unacceptable toxicity.  If trough <5 ng/mL: Increase dose by 2.5 mg daily (tablets…"}, {"doc_id": "kanamycin-united-states-not-available-drug-information", "bm25_top3": 12.558753205644773, "bm25_max": 12.558753205644773, "bge_top3": null, "bge_max": null, "title": "Kanamycin (United States: Not available): Drug information", "rep_snippet": "Reference Range  Therapeutic: Peak: 15-30 mcg/mL; Trough: 5-10 mcg/mL; Toxic: Peak: >35 mcg/mL; Trough: >10 mcg/mL"}, {"doc_id": "factor-xiii-a-subunit-recombinant-human-drug-information", "bm25_top3": 12.317593899077838, "bm25_max": 12.317593899077838, "bge_top3": null, "bge_max": null, "title": "Factor XIII A-subunit, recombinant human: Drug information", "rep_snippet": "Monitoring Parameters  Factor XIII trough levels in conjunction with clinical response to assess efficacy; factor XIII inhibitory antibodies if inadequate clinical response and/or factor XIII trough levels are suboptimal…"}, {"doc_id": "factor-xiii-concentrate-from-human-plasma-drug-information", "bm25_top3": 11.955298813414085, "bm25_max": 11.955298813414085, "bge_top3": null, "bge_max": null, "title": "Factor XIII, concentrate from human plasma: Drug information", "rep_snippet": "Monitoring Parameters  Factor XIII trough levels in conjunction with clinical response to assess efficacy (ie, approximately every 28 days for prophylaxis, during and after surgery for perioperative management of surgica…"}, {"doc_id": "ertapenem-drug-information", "bm25_top3": 11.84632616998963, "bm25_max": 11.84632616998963, "bge_top3": null, "bge_max": null, "title": "Ertapenem: Drug information", "rep_snippet": "• Valproic acid and derivatives: Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibi…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 11.537740148076125, "bm25_max": 11.537740148076125, "bge_top3": null, "bge_max": null, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Use  Note: Not approved in the US  Dravet syndrome: Adjunctive treatment of refractory generalized tonic-clonic seizures in conjunction with clobazam and valproic acid in patients with severe myoclonic epilepsy in infanc…"}, {"doc_id": "oxcarbazepine-drug-information", "bm25_top3": 11.36729060932242, "bm25_max": 11.439761215632622, "bge_top3": 0.6760482788085938, "bge_max": 0.6760482788085938, "title": "Oxcarbazepine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; serum sodium as deemed necessary (particularly during first 3 months of therapy); symptoms of CNS depression (dizziness, headache, somnolence); hypersensitivity reactions. Additi…"}, {"doc_id": "daptomycin-drug-information", "bm25_top3": 11.298477128053388, "bm25_max": 11.298477128053388, "bge_top3": null, "bge_max": null, "title": "Daptomycin: Drug information", "rep_snippet": "Reference Range  Trough concentrations at steady-state:  4 mg/kg once daily: 5.9 ± 1.6 mcg/mL  6 mg/kg once daily: 6.7 ± 1.6 mcg/mL  Note: Routine trough monitoring is not recommended. Trough concentrations are not predi…"}, {"doc_id": "cyclosporine-ciclosporin-systemic-drug-information", "bm25_top3": 11.12484293557334, "bm25_max": 11.12484293557334, "bge_top3": null, "bge_max": null, "title": "Cyclosporine (ciclosporin) (systemic): Drug information", "rep_snippet": "Reference Range  Reference ranges are method dependent and specimen dependent; use the same analytical method consistently  Method-dependent and specimen-dependent: Trough levels should be obtained:  Oral: 12 hours after…"}, {"doc_id": "omacetaxine-drug-information", "bm25_top3": 10.815254355570893, "bm25_max": 10.815254355570893, "bge_top3": null, "bge_max": null, "title": "Omacetaxine: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelets (weekly during induction and initial maintenance cycles, then every 2 weeks or as clinically indicated after initial maintenance cycles); blood glucose (frequent…"}, {"doc_id": "enzalutamide-drug-information", "bm25_top3": 10.714821609649611, "bm25_max": 10.714821609649611, "bge_top3": 0.6595829725265503, "bge_max": 0.6595829725265503, "title": "Enzalutamide: Drug information", "rep_snippet": "Monitoring Parameters  Monitor for signs/symptoms of seizure, loss of consciousness, dizziness, and hallucinations; CBC with differential and liver function tests (baseline and periodic); additional INR monitoring (if on…"}, {"doc_id": "idarubicin-drug-information", "bm25_top3": 10.620538404898173, "bm25_max": 10.620538404898173, "bge_top3": null, "bge_max": null, "title": "Idarubicin: Drug information", "rep_snippet": "Monitoring Parameters  CBC with differential and platelet count (frequently), cardiac function (LVEF; prior and during treatment), serum electrolytes, renal function (serum creatinine; prior to and during treatment), uri…"}, {"doc_id": "haloperidol-drug-information", "bm25_top3": 10.567606223335677, "bm25_max": 10.567606223335677, "bge_top3": null, "bge_max": null, "title": "Haloperidol: Drug information", "rep_snippet": "Reference Range  Schizophrenia: Therapeutic drug monitoring is not routinely warranted; a clear correlation between plasma concentrations and therapeutic response has not been demonstrated. Clinical studies suggest a the…"}, {"doc_id": "sirolimus-drug-information", "bm25_top3": 10.434932723212459, "bm25_max": 10.434932723212459, "bge_top3": null, "bge_max": null, "title": "Sirolimus: Drug information", "rep_snippet": "High immunologic risk: Loading dose: Up to 15 mg on day 1; maintenance: 5 mg/day; obtain trough concentration between days 5 to 7 and adjust accordingly. Continue concurrent cyclosporine/sirolimus/corticosteroid therapy…"}, {"doc_id": "pegademase-bovine-drug-information", "bm25_top3": 10.416257200152256, "bm25_max": 10.416257200152256, "bge_top3": null, "bge_max": null, "title": "Pegademase bovine: Drug information", "rep_snippet": "Reference Range  Plasma ADA activity: Recommended maintenance trough level: 15-35 micromole/hour/mL  Red cell dATP: After 2 months of maintenance therapy, levels should decrease to ≤0.005-0.015 micromole/mL (normal dATP…"}, {"doc_id": "flecainide-drug-information", "bm25_top3": 10.1756312418688, "bm25_max": 10.1756312418688, "bge_top3": null, "bge_max": null, "title": "Flecainide: Drug information", "rep_snippet": "Reference Range  Therapeutic: Trough concentration: 0.2 to 1 mcg/mL. Note: Pediatric patients may respond at the lower end of the recommended therapeutic range (0.2 to 0.5 mcg/mL) but up to 0.8 mcg/mL may be required."}, {"doc_id": "rufinamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.701509952545166, "bge_max": 0.701509952545166, "title": "Rufinamide: Drug information", "rep_snippet": "Monitoring Parameters  Seizure (frequency and duration); serum levels of concurrent anticonvulsants; suicidality (eg, suicidal thoughts, depression, behavioral changes); rash (may indicate multi-organ hypersensitivity re…"}, {"doc_id": "perampanel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6978611946105957, "bge_max": 0.6978611946105957, "title": "Perampanel: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency/duration; suicidality (eg, suicidal thoughts, depression, behavioral changes) during therapy and for at least 1 month after discontinuation; weight"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6936428546905518, "bge_max": 0.6936428546905518, "title": "Trimipramine: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure thre…"}, {"doc_id": "eslicarbazepine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6934985518455505, "bge_max": 0.6934985518455505, "title": "Eslicarbazepine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency; liver enzymes (baseline); serum sodium and chloride as deemed necessary during maintenance treatment, particularly in patients receiving other medications known to decrease sodiu…"}, {"doc_id": "tiagabine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6915867924690247, "bge_max": 0.6915867924690247, "title": "Tiagabine: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency, liver function tests (periodically), suicidality (eg, suicidal thoughts, depression, behavioral changes)"}, {"doc_id": "varenicline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6878769993782043, "bge_max": 0.6878769993782043, "title": "Varenicline: Drug information", "rep_snippet": "• Seizures: Seizures have been reported in patients with or without a history of seizures. Seizures generally occurred within the first month of therapy. Consider the risks against the benefits before initiating in patie…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6872332096099854, "bge_max": 0.6872332096099854, "title": "Desipramine: Drug information", "rep_snippet": "• Seizure disorder: Use with extreme caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seiz…"}, {"doc_id": "molindone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6860358715057373, "bge_max": 0.6860358715057373, "title": "Molindone: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients at risk of seizures.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, ad…"}, {"doc_id": "risperidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6842922568321228, "bge_max": 0.6842922568321228, "title": "Risperidone: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6769566535949707, "bge_max": 0.6769566535949707, "title": "Etelcalcetide: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients with a history of seizure disorder; seizure threshold is lowered by significant decreases in serum calcium. Monitor corrected serum calcium levels closely.  Concurrent dru…"}, {"doc_id": "cariprazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6767674088478088, "bge_max": 0.6767674088478088, "title": "Cariprazine: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures or with conditions that potentially lower the seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predis…"}, {"doc_id": "lurasidone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6759001016616821, "bge_max": 0.6759001016616821, "title": "Lurasidone: Drug information", "rep_snippet": "• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures or conditions that lower the seizure threshold such as Alzheimer disease. Elderly patients may be at increased risk…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6727737188339233, "bge_max": 0.6727737188339233, "title": "Levomilnacipran: Drug information", "rep_snippet": "• Seizure disorders: Use caution with a previous seizure disorder.  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, addit…"}, {"doc_id": "topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6717497706413269, "bge_max": 0.6717497706413269, "title": "Topiramate: Drug information", "rep_snippet": "Monitoring Parameters  Seizure frequency, hydration status; electrolytes (recommended monitoring includes serum bicarbonate at baseline and periodically during treatment), serum creatinine; monitor for symptoms of acute…"}, {"doc_id": "dronabinol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6706323027610779, "bge_max": 0.6706323027610779, "title": "Dronabinol: Drug information", "rep_snippet": "Monitoring Parameters  Monitor heart rate and blood pressure. Monitor for CNS adverse effects, seizures (including worsened seizure control), new or worsening psychiatric symptoms, development of worsening nausea, vomiti…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6700757145881653, "bge_max": 0.6700757145881653, "title": "Amitriptyline: Drug information", "rep_snippet": "• Renal impairment: Use with caution in patients with renal impairment.  • Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoho…"}, {"doc_id": "benzhydrocodone-and-acetaminophen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.669821560382843, "bge_max": 0.669821560382843, "title": "Benzhydrocodone and acetaminophen: Drug information", "rep_snippet": "Monitoring Parameters  Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction."}, {"doc_id": "promethazine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6649068593978882, "bge_max": 0.6649068593978882, "title": "Promethazine and codeine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of symptoms; respiratory and mental status; blood pressure; heart rate; signs of misuse, abuse, and addiction."}, {"doc_id": "promethazine-phenylephrine-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6649068593978882, "bge_max": 0.6649068593978882, "title": "Promethazine, phenylephrine, and codeine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of symptoms; respiratory and mental status; blood pressure; heart rate; signs of misuse, abuse, and addiction."}, {"doc_id": "lorazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6634227633476257, "bge_max": 0.6634227633476257, "title": "Lorazepam: Drug information", "rep_snippet": "Monitoring Parameters  Respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety  Long-term therapy: CBC, liver function tests, LDH  High-dose or continuous IV use or IV use in patients with…"}, {"doc_id": "carisoprodol-aspirin-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6618616580963135, "bge_max": 0.6618616580963135, "title": "Carisoprodol, aspirin, and codeine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of symptoms; respiratory and mental status, blood pressure, heart rate; signs of misuse, abuse, and addiction."}, {"doc_id": "methoxy-polyethylene-glycol-epoetin-beta-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6596752405166626, "bge_max": 0.6596752405166626, "title": "Methoxy polyethylene glycol-epoetin beta: Drug information", "rep_snippet": "Monitoring Parameters  Hemoglobin levels (at least weekly until stable, then at least monthly); iron stores (transferrin saturation and serum ferritin) at baseline and during therapy; premonitory neurologic symptoms of s…"}, {"doc_id": "clozapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6596099138259888, "bge_max": 0.6596099138259888, "title": "Clozapine: Drug information", "rep_snippet": "• Seizures: [US Boxed Warning]: Seizures have been associated with clozapine use in a dose-dependent manner. Initiate treatment with no more than 12.5 mg, titrate gradually using divided dosing. Use with caution in patie…"}, {"doc_id": "pentobarbital-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6581379175186157, "bge_max": 0.6581379175186157, "title": "Pentobarbital: Drug information", "rep_snippet": "Monitoring Parameters  Respiratory status (for conscious sedation, includes pulse oximetry), cardiovascular status, CNS status; cardiac monitor and blood pressure monitor required; clinical signs of propylene glycol toxi…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6574159264564514, "bge_max": 0.6574159264564514, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Liver function tests (periodic); blood pressure; suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased)"}, {"doc_id": "ezogabine-retigabine-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6560239791870117, "bge_max": 0.6560239791870117, "title": "Ezogabine (retigabine) (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Seizures; electrolytes, bilirubin, QT interval (in patients with risk factors for QT prolongation), renal and hepatic function; urologic symptoms; observe patient for excessive sedation, confusion,…"}, {"doc_id": "tranexamic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6557830572128296, "bge_max": 0.6557830572128296, "title": "Tranexamic acid: Drug information", "rep_snippet": "Monitoring Parameters  Ophthalmic examination (visual acuity, color vision, eye-ground, and visual fields) at baseline and regular intervals during the course of therapy in patients being treated for longer than several…"}, {"doc_id": "ethotoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6555313467979431, "bge_max": 0.6555313467979431, "title": "Ethotoin: Drug information", "rep_snippet": "Use  Seizures: Control of generalized tonic-clonic (grand mal) and complex-partial (psychomotor) seizures"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6552407741546631, "bge_max": 0.6552407741546631, "title": "Ranitidine: Drug information", "rep_snippet": "Monitoring Parameters  AST, ALT, serum creatinine; occult blood with GI bleeding, signs/symptoms of peptic ulcer disease; when used to prevent stress-related GI bleeding, measure the intragastric pH and try to maintain p…"}, {"doc_id": "bupropion-and-naltrexone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.655064046382904, "bge_max": 0.655064046382904, "title": "Bupropion and naltrexone: Drug information", "rep_snippet": "Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure…"}, {"doc_id": "guaifenesin-and-codeine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6548394560813904, "bge_max": 0.6548394560813904, "title": "Guaifenesin and codeine: Drug information", "rep_snippet": "Monitoring Parameters  Relief of symptoms; respiratory and mental status; signs of misuse, abuse, and addiction."}, {"doc_id": "efavirenz-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.654376745223999, "bge_max": 0.654376745223999, "title": "Efavirenz: Drug information", "rep_snippet": "Monitoring Parameters  Serum transaminases; cholesterol and triglycerides (prior to therapy and periodically during); signs and symptoms of infection; psychiatric effects"}, {"doc_id": "salsalate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6541261672973633, "bge_max": 0.6541261672973633, "title": "Salsalate: Drug information", "rep_snippet": "Monitoring Parameters  Signs and symptoms of GI bleeding; BP; renal function; urinary pH; plasma salicylate, CBC, and chemistry profile periodically during long term therapy."}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6537799835205078, "bge_max": 0.6537799835205078, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure thre…"}, {"doc_id": "vitamin-b6-pyridoxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6532089114189148, "bge_max": 0.6532089114189148, "title": "Vitamin B6 (pyridoxine): Drug information", "rep_snippet": "Monitoring Parameters  For treatment of isoniazid or gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity"}, {"doc_id": "diazepam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6529621481895447, "bge_max": 0.6529621481895447, "title": "Diazepam: Drug information", "rep_snippet": "Monitoring Parameters  Heart rate, respiratory rate, blood pressure, and mental status; liver enzymes and CBC with long-term therapy; clinical signs of propylene glycol toxicity (for continuous high-dose and/or long dura…"}, {"doc_id": "liposomal-bupivacaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6529499888420105, "bge_max": 0.6529499888420105, "title": "Liposomal bupivacaine: Drug information", "rep_snippet": "Monitoring Parameters  Cardiovascular and respiratory (adequacy of ventilation) vital signs, state of consciousness; signs of CNS toxicity, pain relief."}, {"doc_id": "methotrexate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6529099941253662, "bge_max": 0.6529099941253662, "title": "Methotrexate: Drug information", "rep_snippet": "Reference Range  Therapeutic levels: Variable; Toxic concentration: Variable; therapeutic range is dependent upon therapeutic approach.  High-dose regimens produce drug levels that are between 0.1 to 1 micromole/L 24 to…"}, {"doc_id": "minoxidil-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6528668403625488, "bge_max": 0.6528668403625488, "title": "Minoxidil (systemic): Drug information", "rep_snippet": "Valproate Products: May increase the serum concentration of Minoxidil (Systemic). Risk C: Monitor therapy  Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy"}, {"doc_id": "aripiprazole-lauroxil-long-acting-injectable-aristada-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6528048515319824, "bge_max": 0.6528048515319824, "title": "Aripiprazole lauroxil (long-acting injectable [Aristada]): Drug information", "rep_snippet": "• Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate motor disturbances (APA [Lehman 2004; Rabins 2007]).  • Seizures: Use with caution in patients at risk of seizures, i…"}, {"doc_id": "felbamate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6526737809181213, "bge_max": 0.6526737809181213, "title": "Felbamate: Drug information", "rep_snippet": "Monitoring Parameters  Serum levels of concomitant anticonvulsant therapy; liver function tests (baseline and periodically thereafter); CBC (baseline, frequently during therapy, and for a significant period after discont…"}, {"doc_id": "chloroprocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6522085070610046, "bge_max": 0.6522085070610046, "title": "Chloroprocaine: Drug information", "rep_snippet": "Monitoring Parameters  Cardiovascular and respiratory status; mental status; vital signs; signs of CNS toxicity"}]}
{"qid": "Q24", "query": "Hypothyroidism — conversion and administration timing for levothyroxine; interactions with food/iron/calcium.", "candidates": [{"doc_id": "calcium-carbonate-drug-information", "bm25_top3": 37.277235358807154, "bm25_max": 37.277235358807154, "bge_top3": null, "bge_max": null, "title": "Calcium carbonate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer with food."}, {"doc_id": "calcium-glubionate-drug-information", "bm25_top3": 37.12425899351149, "bm25_max": 37.12425899351149, "bge_top3": null, "bge_max": null, "title": "Calcium glubionate: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "calcium-and-vitamin-d-drug-information", "bm25_top3": 37.12425899351149, "bm25_max": 37.12425899351149, "bge_top3": null, "bge_max": null, "title": "Calcium and vitamin D: Drug information", "rep_snippet": "Food Interactions  Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption. Management: Administer preferably with…"}, {"doc_id": "levothyroxine-drug-information", "bm25_top3": 34.01147080509623, "bm25_max": 36.783167345731, "bge_top3": 0.7392017245292664, "bge_max": 0.7554028034210205, "title": "Levothyroxine: Drug information", "rep_snippet": "Food Interactions  Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula), soy, g…"}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 35.43728472799656, "bm25_max": 35.43728472799656, "bge_top3": 0.6830213665962219, "bge_max": 0.6830213665962219, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases the absorption and bioavailability of etidronate. Management: Administer on an empty stomach with a full glass of water 2 hours before or after food/supplements with calcium, iron, or ma…"}, {"doc_id": "polysaccharide-iron-complex-drug-information", "bm25_top3": 35.185838141779826, "bm25_max": 35.185838141779826, "bge_top3": null, "bge_max": null, "title": "Polysaccharide-iron complex: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "ferrous-sulfate-drug-information", "bm25_top3": 35.185838141779826, "bm25_max": 35.185838141779826, "bge_top3": null, "bge_max": null, "title": "Ferrous sulfate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "polysaccharide-iron-complex-vitamin-b12-and-folic-acid-drug-information", "bm25_top3": 34.820176636470705, "bm25_max": 34.820176636470705, "bge_top3": 0.6821112036705017, "bge_max": 0.6821112036705017, "title": "Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "polysaccharide-iron-complex-and-folic-acid-drug-information", "bm25_top3": 34.820176636470705, "bm25_max": 34.820176636470705, "bge_top3": 0.6821112036705017, "bge_max": 0.6821112036705017, "title": "Polysaccharide-iron complex and folic acid: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "calcium-polystyrene-sulfonate-united-states-not-available-drug-information", "bm25_top3": 33.78883698289153, "bm25_max": 33.78883698289153, "bge_top3": null, "bge_max": null, "title": "Calcium polystyrene sulfonate (United States: Not available): Drug information", "rep_snippet": "Sorbitol: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis. Risk X: Avoid combination  Thyroid Produc…"}, {"doc_id": "multiple-vitamins-pediatric-drug-information", "bm25_top3": 30.11655422114812, "bm25_max": 30.11655422114812, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (pediatric): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "multiple-vitamins-drug-information", "bm25_top3": 30.11655422114812, "bm25_max": 30.11655422114812, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "dolutegravir-and-rilpivirine-drug-information", "bm25_top3": 27.22621960672965, "bm25_max": 28.49098338011628, "bge_top3": null, "bge_max": null, "title": "Dolutegravir and rilpivirine: Drug information", "rep_snippet": "Administration  Administer with a meal; a protein supplement drink alone does not replace a meal. Administer 4 hours before or 6 hours after cation-containing antacids or laxatives, sucralfate, oral supplements containin…"}, {"doc_id": "dolutegravir-abacavir-and-lamivudine-drug-information", "bm25_top3": 28.18989085887496, "bm25_max": 28.18989085887496, "bge_top3": null, "bge_max": null, "title": "Dolutegravir, abacavir, and lamivudine: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food. If patient is on concomitant therapy with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin an additional daily single-component d…"}, {"doc_id": "ferric-citrate-drug-information", "bm25_top3": 25.2456728084747, "bm25_max": 25.2456728084747, "bge_top3": 0.6901423931121826, "bge_max": 0.6901423931121826, "title": "Ferric citrate: Drug information", "rep_snippet": "Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours. Separation of doses is not required with pare…"}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 24.59957955421327, "bm25_max": 24.59957955421327, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Food Interactions  Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.  Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with…"}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": 24.35035368340707, "bm25_max": 24.35035368340707, "bge_top3": null, "bge_max": null, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Dietary Considerations  Administration with food decreases nausea, administer with food. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis."}, {"doc_id": "ferrous-gluconate-drug-information", "bm25_top3": 24.185838141779826, "bm25_max": 24.185838141779826, "bge_top3": null, "bge_max": null, "title": "Ferrous gluconate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "ferrous-fumarate-drug-information", "bm25_top3": 24.185838141779826, "bm25_max": 24.185838141779826, "bge_top3": null, "bge_max": null, "title": "Ferrous fumarate: Drug information", "rep_snippet": "Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron sal…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 22.48666363996481, "bm25_max": 22.48666363996481, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Food Interactions  Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of…"}, {"doc_id": "clodronate-united-states-not-available-drug-information", "bm25_top3": 21.6665476033497, "bm25_max": 21.6665476033497, "bge_top3": null, "bge_max": null, "title": "Clodronate (United States: Not available): Drug information", "rep_snippet": "Food Interactions  All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids,…"}, {"doc_id": "etidronate-drug-information", "bm25_top3": 21.196338766292037, "bm25_max": 21.196338766292037, "bge_top3": null, "bge_max": null, "title": "Etidronate: Drug information", "rep_snippet": "Food Interactions  Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6-8 oz) 2 hours befor…"}, {"doc_id": "sucroferric-oxyhydroxide-drug-information", "bm25_top3": 21.011966779891576, "bm25_max": 21.011966779891576, "bge_top3": 0.680635929107666, "bge_max": 0.680635929107666, "title": "Sucroferric oxyhydroxide: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Levothyroxine: Sucroferric Oxyhydroxide may decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral…"}, {"doc_id": "orlistat-drug-information", "bm25_top3": 20.93206282771851, "bm25_max": 20.93206282771851, "bge_top3": null, "bge_max": null, "title": "Orlistat: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amiodarone: Orlistat may decrease the serum concentration of Amiodarone. Risk C: Monitor therapy  Anticonvulsants: Orlistat may decrease…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": 20.60366227122843, "bm25_max": 20.60366227122843, "bge_top3": 0.6951322754224142, "bge_max": 0.71687912940979, "title": "Liothyronine: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy  Amiodarone: May diminish the therap…"}, {"doc_id": "liotrix-drug-information", "bm25_top3": 16.545961866695787, "bm25_max": 20.60366227122843, "bge_top3": 0.7334425846735636, "bge_max": 0.7394250631332397, "title": "Liotrix: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy  Amiodarone: May diminish the therap…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 20.60366227122843, "bm25_max": 20.60366227122843, "bge_top3": 0.695193886756897, "bge_max": 0.6978877782821655, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy  Amiodarone: May diminish the therap…"}, {"doc_id": "famciclovir-drug-information", "bm25_top3": 19.902892120005056, "bm25_max": 19.902892120005056, "bge_top3": null, "bge_max": null, "title": "Famciclovir: Drug information", "rep_snippet": "Food Interactions  Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals."}, {"doc_id": "multiple-vitamins-prenatal-drug-information", "bm25_top3": 19.11655422114812, "bm25_max": 19.11655422114812, "bge_top3": null, "bge_max": null, "title": "Multiple vitamins (prenatal): Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "vitamin-b-complex-drug-information", "bm25_top3": 19.11655422114812, "bm25_max": 19.11655422114812, "bge_top3": null, "bge_max": null, "title": "Vitamin B complex: Drug information", "rep_snippet": "Food Interactions  Iron absorption is inhibited by eggs and milk."}, {"doc_id": "entacapone-drug-information", "bm25_top3": 18.161911073287584, "bm25_max": 18.161911073287584, "bge_top3": null, "bge_max": null, "title": "Entacapone: Drug information", "rep_snippet": "Food Interactions  Entacapone has been reported to chelate iron and decreasing serum iron levels were noted in clinical trials; however, clinically significant anemia has not been observed."}, {"doc_id": "deferiprone-drug-information", "bm25_top3": 18.008767164108963, "bm25_max": 18.008767164108963, "bge_top3": null, "bge_max": null, "title": "Deferiprone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Antacids: May decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or…"}, {"doc_id": "isoniazid-drug-information", "bm25_top3": 17.54139157110192, "bm25_max": 17.54139157110192, "bge_top3": null, "bge_max": null, "title": "Isoniazid: Drug information", "rep_snippet": "Food Interactions  Administration with food significantly reduces bioavailability. Management: Avoid administration with food.  Isoniazid may decrease folic acid absorption and alters pyridoxine metabolism. Management: I…"}, {"doc_id": "dolutegravir-drug-information", "bm25_top3": 16.21999619860174, "bm25_max": 17.528563403947604, "bge_top3": null, "bge_max": null, "title": "Dolutegravir: Drug information", "rep_snippet": "Administration  Administer without regard to meals. Administer 2 hours before or 6 hours after cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Al…"}, {"doc_id": "telotristat-ethyl-drug-information", "bm25_top3": 17.447030905862547, "bm25_max": 17.447030905862547, "bge_top3": null, "bge_max": null, "title": "Telotristat ethyl: Drug information", "rep_snippet": "Food Interactions  Administration with food results in higher exposure to telotristat ethyl and telotristat."}, {"doc_id": "amiodarone-drug-information", "bm25_top3": 17.123095526269235, "bm25_max": 17.123095526269235, "bge_top3": 0.6905112862586975, "bge_max": 0.6905112862586975, "title": "Amiodarone: Drug information", "rep_snippet": "Food Interactions  Food increases the rate and extent of absorption of amiodarone. Grapefruit juice increases bioavailability of oral amiodarone by 50% and decreases the conversion of amiodarone to N-DEA (active metaboli…"}, {"doc_id": "ofloxacin-systemic-drug-information", "bm25_top3": 16.238734068473015, "bm25_max": 16.238734068473015, "bge_top3": null, "bge_max": null, "title": "Ofloxacin (systemic): Drug information", "rep_snippet": "Administration  Administer with or without food. Do not take within 2 hours of sucralfate, didanosine, iron, zinc, or antacids containing magnesium, calcium, or aluminum."}, {"doc_id": "imatinib-drug-information", "bm25_top3": 13.774673128109622, "bm25_max": 13.774673128109622, "bge_top3": 0.6836057901382446, "bge_max": 0.6836057901382446, "title": "Imatinib: Drug information", "rep_snippet": "• Gastric surgery: Imatinib exposure may be reduced in patients who have had gastric surgery (eg, bypass, major gastrectomy, or resection); monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010).  •…"}, {"doc_id": "boceprevir-united-states-not-available-drug-information", "bm25_top3": 13.70422033954538, "bm25_max": 13.70422033954538, "bge_top3": null, "bge_max": null, "title": "Boceprevir (United States: Not available): Drug information", "rep_snippet": "Dietary Considerations  Take with food. The type or timing of a meal is not important as long as dose is taken with food."}, {"doc_id": "gemifloxacin-united-states-not-available-drug-information", "bm25_top3": 12.172741634757536, "bm25_max": 12.172741634757536, "bge_top3": null, "bge_max": null, "title": "Gemifloxacin (United States: Not available): Drug information", "rep_snippet": "Administration  Oral: May be administered with or without food. Do not administer with dairy products (eg, milk, yogurt) or calcium-fortified juices alone; however, may be administered with a meal that contains these pro…"}, {"doc_id": "delafloxacin-drug-information", "bm25_top3": 11.387346676470052, "bm25_max": 11.387346676470052, "bge_top3": null, "bge_max": null, "title": "Delafloxacin: Drug information", "rep_snippet": "Administration  Oral: Administer with or without food. Administer at least 2 hours before or 6 hours after antacids containing magnesium or aluminum, sucralfate, metal cations (eg, iron), multivitamins containing zinc or…"}, {"doc_id": "digoxin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7025496363639832, "bge_max": 0.7025496363639832, "title": "Digoxin: Drug information", "rep_snippet": "• Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result due to significant reduction in digoxin clearance (Burk 2010). In patients with hyperthyroidism, lower digoxin…"}, {"doc_id": "latanoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7013640403747559, "bge_max": 0.7013640403747559, "title": "Latanoprost and timolol (United States: Not available): Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "apalutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6975362300872803, "bge_max": 0.6975362300872803, "title": "Apalutamide: Drug information", "rep_snippet": "• Thyroid dysfunction: Hypothyroidism and elevated thyroid stimulating hormone (TSH) have been reported with apalutamide; the median onset was ~4 months (there were no grade 3 or 4 hypothyroid events). Thyroid replacemen…"}, {"doc_id": "propylthiouracil-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6900255680084229, "bge_max": 0.6972973346710205, "title": "Propylthiouracil: Drug information", "rep_snippet": "Use  Hyperthyroidism: Treatment of hyperthyroidism in patients with Graves' disease or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate…"}, {"doc_id": "propranolol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6958893537521362, "bge_max": 0.6958893537521362, "title": "Propranolol: Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6928933262825012, "bge_max": 0.6928933262825012, "title": "Lithium: Drug information", "rep_snippet": "• Hypothyroidism: May cause hypothyroidism, generally within 6 to 18 months of initiating treatment. Women may be at an increased risk. If hypothyroidism develops and symptoms of bipolar disorder are well-controlled, con…"}, {"doc_id": "sotalol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6924710273742676, "bge_max": 0.6924710273742676, "title": "Sotalol: Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "ferumoxytol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6892042756080627, "bge_max": 0.6892042756080627, "title": "Ferumoxytol: Drug information", "rep_snippet": "Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult d…"}, {"doc_id": "methimazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.683406412601471, "bge_max": 0.6878495216369629, "title": "Methimazole: Drug information", "rep_snippet": "Dosing: Adult  Hyperthyroidism: Oral: Initial: 15 to 60 mg/day depending on severity of disease; usual maintenance dose: 5 to 15 mg/day. Note: The manufacturer suggests dividing the daily dose into 3 equal administration…"}, {"doc_id": "buprenorphine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6866505146026611, "bge_max": 0.6866505146026611, "title": "Buprenorphine: Drug information", "rep_snippet": "• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.  Concurrent drug therapy issues:"}, {"doc_id": "nivolumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.684041440486908, "bge_max": 0.684041440486908, "title": "Nivolumab: Drug information", "rep_snippet": "• Thyroid disorders: Immune-mediated hyperthyroidism and hypothyroidism/thyroiditis have occurred, mostly grades 1 and 2 hyper-/hypothyroidism (one patient receiving nivolumab in combination with ipilimumab experienced g…"}, {"doc_id": "axitinib-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6836081743240356, "bge_max": 0.6836081743240356, "title": "Axitinib: Drug information", "rep_snippet": "Monitoring Parameters  Hepatic function (ALT, AST, and bilirubin; baseline and periodic), thyroid function (baseline and periodic), urinalysis (for proteinuria; baseline and periodically); blood pressure, signs/symptoms…"}, {"doc_id": "pasireotide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6835715174674988, "bge_max": 0.6835715174674988, "title": "Pasireotide: Drug information", "rep_snippet": "• Hypocortisolism: Suppression of the adrenocorticotropic hormone (ACTH) from therapy may lead to hypocortisolism in Cushing disease. Monitor all patients for signs or symptoms of hypocortisolism (eg, anorexia, fatigue,…"}, {"doc_id": "phentermine-and-topiramate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6827978491783142, "bge_max": 0.6827978491783142, "title": "Phentermine and topiramate: Drug information", "rep_snippet": "• Hyperthermia: Topiramate may be associated (rarely) with severe oligohidrosis and hyperthermia; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patien…"}, {"doc_id": "durvalumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6818705797195435, "bge_max": 0.6818705797195435, "title": "Durvalumab: Drug information", "rep_snippet": "• Thyroid disorders: Immune-related thyroid disorders have occurred in patients receiving durvalumab. Monitor thyroid function at baseline and periodically during treatment; monitor for clinical signs/symptoms of thyroid…"}, {"doc_id": "carbidopa-levodopa-and-entacapone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6805921792984009, "bge_max": 0.6805921792984009, "title": "Carbidopa, levodopa, and entacapone: Drug information", "rep_snippet": "Dietary Considerations  Distribute protein intake throughout the day to avoid fluctuations in levodopa absorption. Separate dosing of iron supplements and multivitamins with minerals."}, {"doc_id": "fosphenytoin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6788967847824097, "bge_max": 0.6788967847824097, "title": "Fosphenytoin: Drug information", "rep_snippet": "• Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Due…"}, {"doc_id": "cortisone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6782191395759583, "bge_max": 0.6782191395759583, "title": "Cortisone acetate: Drug information", "rep_snippet": "• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.  Concurrent drug therapy issue…"}]}
{"qid": "Q25", "query": "GERD — standard dose and omeprazole interaction with clopidogrel (CYP2C19) relevance.", "candidates": [{"doc_id": "aspirin-and-omeprazole-drug-information", "bm25_top3": 30.407998548866722, "bm25_max": 38.9606183101401, "bge_top3": 0.654836118221283, "bge_max": 0.6699199080467224, "title": "Aspirin and omeprazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "omeprazole-drug-information", "bm25_top3": 32.93814534720374, "bm25_max": 37.744840414905056, "bge_top3": 0.6304609576861063, "bge_max": 0.6454031467437744, "title": "Omeprazole: Drug information", "rep_snippet": "Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy  Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. Risk X: Avoid combination  C…"}, {"doc_id": "clopidogrel-drug-information", "bm25_top3": 31.043339660092776, "bm25_max": 32.411293960868264, "bge_top3": 0.6416863799095154, "bge_max": 0.6484447121620178, "title": "Clopidogrel: Drug information", "rep_snippet": "Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy  Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum con…"}, {"doc_id": "omeprazole-and-sodium-bicarbonate-drug-information", "bm25_top3": 29.29424404762263, "bm25_max": 31.421820600561382, "bge_top3": 0.634392261505127, "bge_max": 0.6486279368400574, "title": "Omeprazole and sodium bicarbonate: Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "omeprazole-clarithromycin-and-amoxicillin-copackaged-drug-information", "bm25_top3": 27.452036385319055, "bm25_max": 31.33725164542788, "bge_top3": 0.6339336335659027, "bge_max": 0.6458870768547058, "title": "Omeprazole, clarithromycin, and amoxicillin (copackaged): Drug information", "rep_snippet": "Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding c…"}, {"doc_id": "lansoprazole-amoxicillin-and-clarithromycin-copackaged-drug-information", "bm25_top3": 25.553324214372147, "bm25_max": 28.235917069312382, "bge_top3": null, "bge_max": null, "title": "Lansoprazole, amoxicillin, and clarithromycin (copackaged): Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": 24.554376231347973, "bm25_max": 27.238723717719992, "bge_top3": 0.6413416266441345, "bge_max": 0.6413416266441345, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 24.99121397258007, "bm25_max": 24.99121397258007, "bge_top3": 0.6201103329658508, "bge_max": 0.6201103329658508, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": 23.40714090204763, "bm25_max": 23.40714090204763, "bge_top3": 0.6221334934234619, "bge_max": 0.6221334934234619, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "cilostazol-drug-information", "bm25_top3": 22.01609327137438, "bm25_max": 22.01609327137438, "bge_top3": null, "bge_max": null, "title": "Cilostazol: Drug information", "rep_snippet": "Dosing: Adult  Intermittent claudication: Oral: 100 mg twice daily. Note: The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either…"}, {"doc_id": "voriconazole-drug-information", "bm25_top3": 11.591295211786935, "bm25_max": 19.078324033881124, "bge_top3": 0.6455096006393433, "bge_max": 0.6455096006393433, "title": "Voriconazole: Drug information", "rep_snippet": "Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this com…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": 11.501713411251886, "bm25_max": 18.812890449565963, "bge_top3": 0.6168178021907806, "bge_max": 0.6242318749427795, "title": "Dexlansoprazole: Drug information", "rep_snippet": "• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": 18.5675518722703, "bm25_max": 18.5675518722703, "bge_top3": 0.6313910484313965, "bge_max": 0.6313910484313965, "title": "Fluconazole: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "lansoprazole-drug-information", "bm25_top3": 18.078570321716278, "bm25_max": 18.078570321716278, "bge_top3": 0.6051892042160034, "bge_max": 0.6051892042160034, "title": "Lansoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends e…"}, {"doc_id": "pantoprazole-drug-information", "bm25_top3": 17.235917069312382, "bm25_max": 17.235917069312382, "bge_top3": 0.6124954223632812, "bge_max": 0.6203566789627075, "title": "Pantoprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": 16.989238607210225, "bm25_max": 16.989238607210225, "bge_top3": 0.6134054660797119, "bge_max": 0.6134054660797119, "title": "Fluvoxamine: Drug information", "rep_snippet": "Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Risk D:…"}, {"doc_id": "rabeprazole-drug-information", "bm25_top3": 11.40471182033331, "bm25_max": 15.314037322930265, "bge_top3": 0.6064428687095642, "bge_max": 0.6064428687095642, "title": "Rabeprazole: Drug information", "rep_snippet": "• Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": 11.018083220640913, "bm25_max": 14.325161218941332, "bge_top3": 0.6229051947593689, "bge_max": 0.6272498965263367, "title": "Esomeprazole: Drug information", "rep_snippet": "Clopidogrel: Esomeprazole may diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information re…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": 9.144710481506657, "bm25_max": 14.003565929284772, "bge_top3": 0.6138948798179626, "bge_max": 0.6138948798179626, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination  Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. Risk C:…"}, {"doc_id": "stiripentol-united-states-not-available-drug-information", "bm25_top3": 9.083167519552244, "bm25_max": 13.880480005375947, "bge_top3": 0.622881293296814, "bge_max": 0.622881293296814, "title": "Stiripentol (United States: Not available): Drug information", "rep_snippet": "Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": 13.782852754959702, "bm25_max": 13.782852754959702, "bge_top3": 0.6148130297660828, "bge_max": 0.6148130297660828, "title": "Fluoxetine: Drug information", "rep_snippet": "Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine. Risk X: Avoid combination  Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease s…"}, {"doc_id": "etravirine-drug-information", "bm25_top3": 4.015156810008886, "bm25_max": 4.015156810008886, "bge_top3": null, "bge_max": null, "title": "Etravirine: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C19 (weak…"}, {"doc_id": "luliconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6331793069839478, "bge_max": 0.6331793069839478, "title": "Luliconazole: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 5…"}, {"doc_id": "pioglitazone-and-glimepiride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6241330206394196, "bge_max": 0.6285829544067383, "title": "Pioglitazone and glimepiride: Drug information", "rep_snippet": "• CYP2C9 genotype: Systemic exposure of glimepiride is increased in patients with CYP2C9*3 allele (Niemi 2002).  Concurrent drug therapy issues:  • Drug-drug interactions: Potentially significant interactions may exist,…"}, {"doc_id": "repaglinide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6246106624603271, "bge_max": 0.6246106624603271, "title": "Repaglinide: Drug information", "rep_snippet": "Clopidogrel: May increase the serum concentration of Repaglinide. Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg…"}, {"doc_id": "mirabegron-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6146143078804016, "bge_max": 0.6146143078804016, "title": "Mirabegron: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. Risk C: Monitor therapy  Anticholinergic…"}, {"doc_id": "brivaracetam-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080458164215088, "bge_max": 0.6080458164215088, "title": "Brivaracetam: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential"}, {"doc_id": "nilutamide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080458164215088, "bge_max": 0.6080458164215088, "title": "Nilutamide: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential"}, {"doc_id": "carisoprodol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080458164215088, "bge_max": 0.6080458164215088, "title": "Carisoprodol: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential"}, {"doc_id": "methsuximide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6080458164215088, "bge_max": 0.6080458164215088, "title": "Methsuximide: Drug information", "rep_snippet": "Metabolism/Transport Effects  Substrate of CYP2C19 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6060590744018555, "bge_max": 0.6060590744018555, "title": "Dabigatran: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Dabigatran Ete…"}, {"doc_id": "tamoxifen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6048254370689392, "bge_max": 0.6048254370689392, "title": "Tamoxifen: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "pioglitazone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6047082543373108, "bge_max": 0.6047082543373108, "title": "Pioglitazone: Drug information", "rep_snippet": "Drug Interactions  (For additional information: Launch drug interactions program)  Abiraterone Acetate: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). Risk C: Monitor therapy  Alph…"}]}
{"qid": "Q26", "query": "Depression — time to effect, black box warnings, and dose range for sertraline; tapering guidance.", "candidates": [{"doc_id": "sertraline-drug-information", "bm25_top3": 24.502527298413373, "bm25_max": 33.56257974232778, "bge_top3": 0.6644225517908732, "bge_max": 0.6824319362640381, "title": "Sertraline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "olanzapine-and-fluoxetine-drug-information", "bm25_top3": 30.977238873027208, "bm25_max": 30.977238873027208, "bge_top3": 0.648825466632843, "bge_max": 0.648825466632843, "title": "Olanzapine and fluoxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant and antipsychotic therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms.…"}, {"doc_id": "ibuprofen-drug-information", "bm25_top3": 30.53380868570475, "bm25_max": 30.53380868570475, "bge_top3": null, "bge_max": null, "title": "Ibuprofen: Drug information", "rep_snippet": "Recurrent pericarditis: 600 mg every 8 hours (range: 1,200 to 2,400 mg) for weeks to months until complete symptom resolution followed by a gradual tapering of the dose by 200 to 400 mg every 1 to 2 weeks (ESC [Adler 201…"}, {"doc_id": "perindopril-and-amlodipine-drug-information", "bm25_top3": 21.302760810669458, "bm25_max": 21.302760810669458, "bge_top3": null, "bge_max": null, "title": "Perindopril and amlodipine: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "tranylcypromine-drug-information", "bm25_top3": 21.184853081348813, "bm25_max": 21.184853081348813, "bge_top3": 0.6869760751724243, "bge_max": 0.6869760751724243, "title": "Tranylcypromine: Drug information", "rep_snippet": "Dosing: Adult  Major depression: Oral: Initial: 10 mg/day; if symptoms do not improve after 2 weeks, increase dose by 10 mg/day increments at 1- to 3-week intervals; usual dosage range 30 to 60 mg/day in divided doses (A…"}, {"doc_id": "amitriptyline-drug-information", "bm25_top3": 20.906045539894727, "bm25_max": 20.906045539894727, "bge_top3": 0.6669007539749146, "bge_max": 0.6669007539749146, "title": "Amitriptyline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "lisinopril-and-hydrochlorothiazide-drug-information", "bm25_top3": 20.89311050030851, "bm25_max": 20.89311050030851, "bge_top3": null, "bge_max": null, "title": "Lisinopril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal impairment: Use lisinopril with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Cumulative effects of hydroc…"}, {"doc_id": "trandolapril-and-verapamil-drug-information", "bm25_top3": 20.75279329866759, "bm25_max": 20.75279329866759, "bge_top3": null, "bge_max": null, "title": "Trandolapril and verapamil: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "selegiline-drug-information", "bm25_top3": 20.466438032915953, "bm25_max": 20.466438032915953, "bge_top3": 0.6575589179992676, "bge_max": 0.663143515586853, "title": "Selegiline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant or antiparkinsonian therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptom…"}, {"doc_id": "acetaminophen-paracetamol-diphenhydramine-and-phenylephrine-drug-information", "bm25_top3": 20.416054784215504, "bm25_max": 20.416054784215504, "bge_top3": null, "bge_max": null, "title": "Acetaminophen (paracetamol), diphenhydramine, and phenylephrine: Drug information", "rep_snippet": "• Pediatric: Use with caution in children; may cause excitability. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient's age, the product should not be administered wit…"}, {"doc_id": "moexipril-and-hydrochlorothiazide-drug-information", "bm25_top3": 20.096223539797595, "bm25_max": 20.096223539797595, "bge_top3": null, "bge_max": null, "title": "Moexipril and hydrochlorothiazide: Drug information", "rep_snippet": "• Renal impairment: Use ACE inhibitors with caution in preexisting renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Cumulative effects of hyd…"}, {"doc_id": "quinapril-and-hydrochlorothiazide-drug-information", "bm25_top3": 19.80149300377074, "bm25_max": 19.80149300377074, "bge_top3": null, "bge_max": null, "title": "Quinapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Black patients: Effectiveness of ACE inhibitors is less in black patients than in non-black patients. In addition, ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.  • Pregn…"}, {"doc_id": "enalapril-and-hydrochlorothiazide-drug-information", "bm25_top3": 19.67324901439407, "bm25_max": 19.67324901439407, "bge_top3": null, "bge_max": null, "title": "Enalapril and hydrochlorothiazide: Drug information", "rep_snippet": "• Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pregnancy: [US Boxed Warn…"}, {"doc_id": "onabotulinumtoxina-botox-drug-information", "bm25_top3": 19.513831664368908, "bm25_max": 19.513831664368908, "bge_top3": null, "bge_max": null, "title": "OnabotulinumtoxinA (Botox): Drug information", "rep_snippet": "Dose may be increased up to twice the previous dose if the response from the initial dose lasted ≤2 months; maximum dose per site: 5 units. Tolerance may occur if treatments are given more often than every 3 months, but…"}, {"doc_id": "budesonide-and-formoterol-drug-information", "bm25_top3": 19.48733797199277, "bm25_max": 19.48733797199277, "bge_top3": null, "bge_max": null, "title": "Budesonide and formoterol: Drug information", "rep_snippet": "• Pediatric: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimete…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": 19.187308580336, "bm25_max": 19.187308580336, "bge_top3": null, "bge_max": null, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially fo…"}, {"doc_id": "clomipramine-drug-information", "bm25_top3": 19.022996138455674, "bm25_max": 19.022996138455674, "bge_top3": 0.659457802772522, "bge_max": 0.659457802772522, "title": "Clomipramine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "tetrabenazine-drug-information", "bm25_top3": 18.74043576727814, "bm25_max": 18.74043576727814, "bge_top3": 0.6664363145828247, "bge_max": 0.6664363145828247, "title": "Tetrabenazine: Drug information", "rep_snippet": "Dosing: Adjustment for Toxicity  For toxicity/adverse reaction, including akathisia, restlessness, parkinsonism, insomnia, depression, suicidality, anxiety, sedation (intolerable): Suspend upward dosage titration and red…"}, {"doc_id": "amitriptyline-and-chlordiazepoxide-drug-information", "bm25_top3": 18.555543237032754, "bm25_max": 18.555543237032754, "bge_top3": 0.6664119362831116, "bge_max": 0.6833356618881226, "title": "Amitriptyline and chlordiazepoxide: Drug information", "rep_snippet": "Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior t…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": 17.75640821213092, "bm25_max": 17.75640821213092, "bge_top3": null, "bge_max": null, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "• Black patients: ACE inhibitors' effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.  • Pregnancy: [Canadian Box…"}, {"doc_id": "cilazapril-and-hydrochlorothiazide-united-states-not-available-drug-information", "bm25_top3": 17.286297922972956, "bm25_max": 17.286297922972956, "bge_top3": null, "bge_max": null, "title": "Cilazapril and hydrochlorothiazide (United States: Not available): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "flunisolide-oral-inhalation-drug-information", "bm25_top3": 12.997891095445691, "bm25_max": 12.997891095445691, "bge_top3": null, "bge_max": null, "title": "Flunisolide (oral inhalation): Drug information", "rep_snippet": "• Pediatric: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize th…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 12.734788276179813, "bm25_max": 12.734788276179813, "bge_top3": null, "bge_max": null, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "• Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimiz…"}, {"doc_id": "mometasone-nasal-drug-information", "bm25_top3": 9.8404840253177, "bm25_max": 9.8404840253177, "bge_top3": null, "bge_max": null, "title": "Mometasone (nasal): Drug information", "rep_snippet": "• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users or in p…"}, {"doc_id": "cromolyn-sodium-cromoglicate-systemic-drug-information", "bm25_top3": 8.995541237673201, "bm25_max": 8.995541237673201, "bge_top3": null, "bge_max": null, "title": "Cromolyn (sodium cromoglicate) (systemic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Severe anaphylactic reactions may occur rarely  Dosage form specific issues:  • Use with caution in patients with hepatic or renal impairment; do…"}, {"doc_id": "dabrafenib-drug-information", "bm25_top3": 8.841414585622033, "bm25_max": 8.841414585622033, "bge_top3": null, "bge_max": null, "title": "Dabrafenib: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Cardiomyopathy: Cardiomyopathy may occur when used as a single agent or in combination with trametinib. The median time to onset of cardiomyopathy in patients…"}, {"doc_id": "sofosbuvir-drug-information", "bm25_top3": 8.623549968674377, "bm25_max": 8.623549968674377, "bge_top3": null, "bge_max": null, "title": "Sofosbuvir: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "trabectedin-drug-information", "bm25_top3": 8.216705628171821, "bm25_max": 8.216705628171821, "bge_top3": null, "bge_max": null, "title": "Trabectedin: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia commonly occur; neutropenic fever and neutropenic sepsis (with fatalities) have been report…"}, {"doc_id": "fluticasone-nasal-drug-information", "bm25_top3": 8.194579532291652, "bm25_max": 8.194579532291652, "bge_top3": null, "bge_max": null, "title": "Fluticasone (nasal): Drug information", "rep_snippet": "• Pediatrics: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowes…"}, {"doc_id": "nortriptyline-drug-information", "bm25_top3": 8.022996138455673, "bm25_max": 8.022996138455673, "bge_top3": 0.663595974445343, "bge_max": 0.6711333394050598, "title": "Nortriptyline: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "protriptyline-drug-information", "bm25_top3": 8.022996138455673, "bm25_max": 8.022996138455673, "bge_top3": 0.6946454048156738, "bge_max": 0.6946454048156738, "title": "Protriptyline: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "amoxapine-drug-information", "bm25_top3": 8.022996138455673, "bm25_max": 8.022996138455673, "bge_top3": 0.6556626558303833, "bge_max": 0.6571054458618164, "title": "Amoxapine: Drug information", "rep_snippet": "Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when poss…"}, {"doc_id": "cobimetinib-drug-information", "bm25_top3": 8.009384824744508, "bm25_max": 8.009384824744508, "bge_top3": null, "bge_max": null, "title": "Cobimetinib: Drug information", "rep_snippet": "• Rhabdomyolysis: Rhabdomyolysis and creatine phosphokinase (CPK) elevations may occur with cobimetinib. The median time to first occurrence of grade 3 or 4 CPK elevations was 16 days (range: 12 days to 11 months), with…"}, {"doc_id": "disulfiram-drug-information", "bm25_top3": 7.864674652497939, "bm25_max": 7.864674652497939, "bge_top3": null, "bge_max": null, "title": "Disulfiram: Drug information", "rep_snippet": "Phenytoin: Disulfiram may increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible. Phenytoin dose adjustment will likely be necessary when starting and/o…"}, {"doc_id": "trimipramine-drug-information", "bm25_top3": 7.555543237032754, "bm25_max": 7.555543237032754, "bge_top3": 0.675126701593399, "bge_max": 0.7007651925086975, "title": "Trimipramine: Drug information", "rep_snippet": "Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior t…"}, {"doc_id": "quinapril-drug-information", "bm25_top3": 7.538703844251273, "bm25_max": 7.538703844251273, "bge_top3": null, "bge_max": null, "title": "Quinapril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 7.235087686065967, "bm25_max": 7.235087686065967, "bge_top3": null, "bge_max": null, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "• Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawin…"}, {"doc_id": "benazepril-drug-information", "bm25_top3": 6.906413542479914, "bm25_max": 6.906413542479914, "bge_top3": null, "bge_max": null, "title": "Benazepril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "trandolapril-drug-information", "bm25_top3": 6.906413542479914, "bm25_max": 6.906413542479914, "bge_top3": null, "bge_max": null, "title": "Trandolapril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "perindopril-drug-information", "bm25_top3": 6.858838539251902, "bm25_max": 6.858838539251902, "bge_top3": null, "bge_max": null, "title": "Perindopril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "ramipril-drug-information", "bm25_top3": 6.858838539251902, "bm25_max": 6.858838539251902, "bge_top3": null, "bge_max": null, "title": "Ramipril: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "cilazapril-united-states-not-available-drug-information", "bm25_top3": 6.570648437573677, "bm25_max": 6.570648437573677, "bge_top3": null, "bge_max": null, "title": "Cilazapril (United States: Not available): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "dabigatran-drug-information", "bm25_top3": 6.192883576772575, "bm25_max": 6.192883576772575, "bge_top3": null, "bge_max": null, "title": "Dabigatran: Drug information", "rep_snippet": "Reference Range  Routine coagulation testing is not required or necessary for DOACs. There are currently no FDA-approved assays or calibration reagents available.  In clinical situations when assessment of the anticoagul…"}, {"doc_id": "cromolyn-sodium-cromoglicate-oral-inhalation-drug-information", "bm25_top3": 6.098890963847985, "bm25_max": 6.098890963847985, "bge_top3": null, "bge_max": null, "title": "Cromolyn (sodium cromoglicate) (oral inhalation): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Anaphylaxis: Severe anaphylactic reactions may occur rarely  • Bronchospasm: May occur with cough after inhalation; if this occurs, treat with a fast-acting b…"}, {"doc_id": "levomilnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.701827347278595, "bge_max": 0.701827347278595, "title": "Levomilnacipran: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 20 mg once daily for 2 days; increase to 40 mg once daily; may then be increased in increments of 40 mg at intervals of 2 or more days; Maintenance: 40-120 mg once daily; Maximum…"}, {"doc_id": "mirtazapine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.692670464515686, "bge_max": 0.692670464515686, "title": "Mirtazapine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: Initial: 15 mg nightly, may titrate dose up no more frequently than every 1 to 2 weeks to a maximum of 45 mg/day; dosage range: 15 to 45 mg daily  Discontinuation of…"}, {"doc_id": "isocarboxazid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6774562001228333, "bge_max": 0.6894237995147705, "title": "Isocarboxazid: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 10 mg 2 times/day; may increase by 10 mg/day every 2 to 4 days to 40 mg/day by the end of the first week (divided into 2 to 4 doses). After first week, may increase by up to 20 m…"}, {"doc_id": "desvenlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6860930919647217, "bge_max": 0.6860930919647217, "title": "Desvenlafaxine: Drug information", "rep_snippet": "Dosing: Adult  Major depressive disorder (MDD): Oral: 50 mg once daily; doses up to 400 mg once daily have been studied and have shown to be effective; however, the manufacturer states there is no additional benefit at d…"}, {"doc_id": "methylphenidate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6704900860786438, "bge_max": 0.6704900860786438, "title": "Methylphenidate: Drug information", "rep_snippet": "Extended and sustained release tablets (Metadate ER, Ritalin-SR): May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the t…"}, {"doc_id": "escitalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6687933802604675, "bge_max": 0.6687933802604675, "title": "Escitalopram: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "desipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.668279230594635, "bge_max": 0.668279230594635, "title": "Desipramine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "vortioxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6676462292671204, "bge_max": 0.6676462292671204, "title": "Vortioxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "maprotiline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6578978002071381, "bge_max": 0.6666393280029297, "title": "Maprotiline: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "phenelzine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6625944972038269, "bge_max": 0.665488600730896, "title": "Phenelzine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "doxepin-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6652418375015259, "bge_max": 0.6652418375015259, "title": "Doxepin (systemic): Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "moclobemide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6651579141616821, "bge_max": 0.6651579141616821, "title": "Moclobemide (United States: Not available): Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "imipramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6566878358523051, "bge_max": 0.6645494699478149, "title": "Imipramine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "citalopram-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6644572019577026, "bge_max": 0.6644572019577026, "title": "Citalopram: Drug information", "rep_snippet": "Premature Ejaculation (off-label use): Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability up to 40 mg/day (Althof 2014; Safarinejad 2006). Additional data may be necessary to further de…"}, {"doc_id": "duloxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6636440753936768, "bge_max": 0.6636440753936768, "title": "Duloxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "amitriptyline-and-perphenazine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6628080606460571, "bge_max": 0.6628080606460571, "title": "Amitriptyline and perphenazine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "nefazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6625581979751587, "bge_max": 0.6625581979751587, "title": "Nefazodone: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral: Initial: 100 mg twice daily; alternatively depression treatment guidelines suggest starting doses of 50 to 100 mg daily (APA, 2010; Bauer 2013). Based on response and tolerability, gradua…"}, {"doc_id": "paroxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.660494327545166, "bge_max": 0.660494327545166, "title": "Paroxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "fluoxetine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6581108570098877, "bge_max": 0.6581108570098877, "title": "Fluoxetine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "trazodone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6569967269897461, "bge_max": 0.6569967269897461, "title": "Trazodone: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "acetaminophen-paracetamol-and-tramadol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6558971405029297, "bge_max": 0.6558971405029297, "title": "Acetaminophen (paracetamol) and tramadol: Drug information", "rep_snippet": "• Respiratory depression: [US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose increase. Carbon dioxid…"}, {"doc_id": "fluvoxamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6553665995597839, "bge_max": 0.6553665995597839, "title": "Fluvoxamine: Drug information", "rep_snippet": "Discontinuation of therapy: Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporti…"}, {"doc_id": "milnacipran-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6504874229431152, "bge_max": 0.6504874229431152, "title": "Milnacipran: Drug information", "rep_snippet": "Dosing: Adult  Fibromyalgia: Oral: 50 mg twice daily.  Titration schedule: 12.5 mg once on day 1, then 12.5 mg twice daily on days 2-3, 25 mg twice daily on days 4-7, then 50 mg twice daily thereafter. Dose may be increa…"}, {"doc_id": "liothyronine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6490909457206726, "bge_max": 0.6490909457206726, "title": "Liothyronine: Drug information", "rep_snippet": "Suppression test (T3): Oral: 75 to 100 mcg once daily for 7 days. Radioactive iodide uptake is determined before and after administration.  Antidepressant augmentation (off-label use): Oral: Initial: 25 mcg/day; may be i…"}, {"doc_id": "venlafaxine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6487486362457275, "bge_max": 0.6487486362457275, "title": "Venlafaxine: Drug information", "rep_snippet": "Dosing: Adult  Depression: Oral:  Immediate-release tablets: Initial: 37.5 to 75 mg/day, administered in 2 or 3 divided doses; may increase in ≤75 mg/day increments at intervals of ≥4 days as tolerated; usual dosage: 75…"}]}
{"qid": "Q27", "query": "Asthma rescue — dosing and spacer/technique notes for albuterol HFA; maximum puffs/day.", "candidates": [{"doc_id": "fluticasone-oral-inhalation-drug-information", "bm25_top3": 39.45972262668116, "bm25_max": 42.782057146733365, "bge_top3": 0.702365497748057, "bge_max": 0.71767657995224, "title": "Fluticasone (oral inhalation): Drug information", "rep_snippet": "US labeling: Note: Dosing based on previous asthma therapy and asthma severity. May increase dose after 2 weeks of therapy in patients who are not adequately controlled.  Metered dose inhaler: Initial (patients with no p…"}, {"doc_id": "ipratropium-and-albuterol-drug-information", "bm25_top3": 30.044761651916087, "bm25_max": 39.99977732011353, "bge_top3": 0.6896898150444031, "bge_max": 0.6896898150444031, "title": "Ipratropium and albuterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Oral inhalation:  Metered dose inhaler (MDI): One inhalation 4 times daily (maximum: 6 inhalations/day)  Nebulization solution: Initial: 1 vial (3 mL) (ipratropium bromide 0.5 mg/albuterol 2.5 mg) ev…"}, {"doc_id": "oxycodone-and-naloxone-drug-information", "bm25_top3": 38.68182400657187, "bm25_max": 38.68182400657187, "bge_top3": null, "bge_max": null, "title": "Oxycodone and naloxone: Drug information", "rep_snippet": "Currently on other oral opioids: Discontinue all other around-the-clock opioids. Initiate oxycodone/naloxone at the lowest available strength; adequate rescue medication should be provided. Maximum single dose: Oxycodone…"}, {"doc_id": "beclomethasone-oral-inhalation-drug-information", "bm25_top3": 33.750641774092315, "bm25_max": 37.5207739652716, "bge_top3": 0.7024985551834106, "bge_max": 0.7080588340759277, "title": "Beclomethasone (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation (doses should be titrated to the lowest effective dose once asthma is controlled):  US labeling: Metered-dose inhaler:  QVAR/QVAR RediHaler: Note: Dosing based on previous asthma therapy…"}, {"doc_id": "fluticasone-and-salmeterol-drug-information", "bm25_top3": 32.362752024574014, "bm25_max": 33.330475124271615, "bge_top3": 0.6970367431640625, "bge_max": 0.6995068788528442, "title": "Fluticasone and salmeterol: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Fluticasone and salmeterol: Pediatric drug information\")  Asthma: Inhalation: Note: The recommended starting dose is based upon asthma severity; may increase dose after…"}, {"doc_id": "prednisolone-systemic-drug-information", "bm25_top3": 32.2989410121498, "bm25_max": 32.67018064563051, "bge_top3": 0.7058759927749634, "bge_max": 0.7165800929069519, "title": "Prednisolone (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisolone (systemic): Pediatric drug information\")  Dose depends upon condition being treated and response of patient; dosage for infants and children should be base…"}, {"doc_id": "doxorubicin-conventional-drug-information", "bm25_top3": 32.54894253561136, "bm25_max": 32.54894253561136, "bge_top3": null, "bge_max": null, "title": "Doxorubicin (conventional): Drug information", "rep_snippet": "Postoperative: 90 mg/m2 administered as a continuous infusion over 24 hours on weeks 13, 22, and 31 (in combination with methotrexate, cisplatin, and ifosfamide) (Bacci 2003)  MAP regimen: Adults ≤40 years:  Preoperative…"}, {"doc_id": "salmeterol-drug-information", "bm25_top3": 31.096273154671035, "bm25_max": 31.096273154671035, "bge_top3": 0.6828508973121643, "bge_max": 0.6828508973121643, "title": "Salmeterol: Drug information", "rep_snippet": "Dosing: Adult  Note: Do not use for the relief of acute bronchospasm.  Asthma/Bronchospasm (maintenance and prevention): Inhalation: One inhalation twice daily (~12 hours apart); maximum: 1 inhalation twice daily. Note:…"}, {"doc_id": "methylprednisolone-drug-information", "bm25_top3": 29.848604525280354, "bm25_max": 29.848604525280354, "bge_top3": null, "bge_max": null, "title": "Methylprednisolone: Drug information", "rep_snippet": "Status asthmaticus (previous NAEPP guidelines; still used by some clinicians): Children: IV: Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours; Note: See NAEPP 2007 guidelines for asthma exacerbations (e…"}, {"doc_id": "ranitidine-drug-information", "bm25_top3": 29.59490282644096, "bm25_max": 29.59490282644096, "bge_top3": null, "bge_max": null, "title": "Ranitidine: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ranitidine: Pediatric drug information\")  Duodenal ulcer:  Oral:  Treatment:  Infants, Children, and Adolescents ≤16 years: 4 to 8 mg/kg/day divided twice daily; maximu…"}, {"doc_id": "ceftazidime-drug-information", "bm25_top3": 29.385607326230197, "bm25_max": 29.385607326230197, "bge_top3": null, "bge_max": null, "title": "Ceftazidime: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ceftazidime: Pediatric drug information\")  General dosing, susceptible infections: IM, IV:  Manufacturer's labeling: Infants and Children: 30 to 50 mg/kg/dose every 8 h…"}, {"doc_id": "ciclesonide-oral-inhalation-drug-information", "bm25_top3": 25.63088229549765, "bm25_max": 27.884168464412202, "bge_top3": 0.7175449132919312, "bge_max": 0.7175449132919312, "title": "Ciclesonide (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Note: Titrate to the lowest effective dose once asthma stability is achieved:  US labeling (metered dose inhaler [MDI]):  Prior therapy with bronchodilators alone: Initial: 80 mcg twice…"}, {"doc_id": "albuterol-salbutamol-drug-information", "bm25_top3": 22.82711057250218, "bm25_max": 24.705276074609, "bge_top3": 0.6822414100170135, "bge_max": 0.6881952285766602, "title": "Albuterol (salbutamol): Drug information", "rep_snippet": "Pregnancy Implications  Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported fo…"}, {"doc_id": "metoclopramide-drug-information", "bm25_top3": 23.116267029894416, "bm25_max": 23.116267029894416, "bge_top3": null, "bge_max": null, "title": "Metoclopramide: Drug information", "rep_snippet": "IV: 10 to 20 mg as a single dose (AHS [Orr 2016]; EFNS [Evers 2009]).  Prevention of radiation therapy-induced nausea and vomiting (minimal emetic risk) (off-label use): Oral: 20 mg as rescue therapy; if rescue therapy i…"}, {"doc_id": "formoterol-drug-information", "bm25_top3": 22.241591415785138, "bm25_max": 22.76831502690831, "bge_top3": 0.6736226677894592, "bge_max": 0.6736226677894592, "title": "Formoterol: Drug information", "rep_snippet": "Dosing: Adult  Note: Foradil Aerolizer is no longer available in the US.  Asthma: Inhalation: Note: For asthma control, long-acting beta2-agonists (LABAs) should be used in combination with inhaled corticosteroids and no…"}, {"doc_id": "methotrexate-drug-information", "bm25_top3": 19.928378146648132, "bm25_max": 22.112071565439393, "bge_top3": null, "bge_max": null, "title": "Methotrexate: Drug information", "rep_snippet": "Dosing: Adult  Note: Methotrexate doses between 100 to 500 mg/m2 may require leucovorin calcium rescue. Doses >500 mg/m2 require leucovorin calcium rescue (refer to Dosing – Adjustment for Toxicity for leucovorin calcium…"}, {"doc_id": "formoterol-and-mometasone-drug-information", "bm25_top3": 21.297382620388788, "bm25_max": 21.297382620388788, "bge_top3": 0.6990033984184265, "bge_max": 0.7125223875045776, "title": "Formoterol and mometasone: Drug information", "rep_snippet": "• Appropriate use: Do not use for acute bronchospasm. Short-acting beta-2 agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do not initiate in patients with significantl…"}, {"doc_id": "ondansetron-drug-information", "bm25_top3": 20.774089730887916, "bm25_max": 20.774089730887916, "bge_top3": null, "bge_max": null, "title": "Ondansetron: Drug information", "rep_snippet": "American Society of Clinical Oncology Antiemetic Guideline recommendations (ASCO [Hesketh 2017]): Give before each fraction throughout radiation therapy for high emetic risk (with dexamethasone; continue for at least 24…"}, {"doc_id": "sulindac-drug-information", "bm25_top3": 20.332771021802834, "bm25_max": 20.332771021802834, "bge_top3": null, "bge_max": null, "title": "Sulindac: Drug information", "rep_snippet": "Dosing: Adult  Acute gouty arthritis: 200 mg twice daily for 7 days (maximum: 400 mg/day)  Ankylosing spondylitis: 150 mg twice daily (maximum: 400 mg/day)  Bursitis/tendinitis of the shoulder: 200 mg twice daily for 7 t…"}, {"doc_id": "levalbuterol-drug-information", "bm25_top3": 20.093134439739803, "bm25_max": 20.093134439739803, "bge_top3": 0.6845817963282267, "bge_max": 0.6934590339660645, "title": "Levalbuterol: Drug information", "rep_snippet": "• Asthma: Optimize anti-inflammatory treatment before initiating maintenance treatment with levalbuterol. Do not use as a component of long-term therapy without an anti-inflammatory agent. Only the mildest form of asthma…"}, {"doc_id": "tramadol-drug-information", "bm25_top3": 20.032128308030344, "bm25_max": 20.032128308030344, "bge_top3": null, "bge_max": null, "title": "Tramadol: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral: Note: Doses should be titrated to appropriate analgesic effect; use the lowest effective dose for the shortest period of time:  Immediate release: 50 to 100 mg every 4 to 6 hours (ma…"}, {"doc_id": "benzonatate-drug-information", "bm25_top3": 18.603124795064733, "bm25_max": 18.603124795064733, "bge_top3": 0.6701058149337769, "bge_max": 0.6701058149337769, "title": "Benzonatate: Drug information", "rep_snippet": "Dosing: Adult  Cough: Oral: 100 to 200 mg 3 times/day as needed for cough (maximum single dose: 200 mg; maximum dose: 600 mg/day)"}, {"doc_id": "tinidazole-drug-information", "bm25_top3": 18.399682526615848, "bm25_max": 18.399682526615848, "bge_top3": null, "bge_max": null, "title": "Tinidazole: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Tinidazole: Pediatric drug information\")  Amebiasis, intestinal: Oral: Children >3 years and Adolescents: 50 mg/kg/day for 3 days (maximum dose: 2 g/day)  Amebiasis, li…"}, {"doc_id": "theophylline-drug-information", "bm25_top3": 17.745415206089373, "bm25_max": 17.90431184213984, "bge_top3": null, "bge_max": null, "title": "Theophylline: Drug information", "rep_snippet": "Children 1 year to Adolescents 15 years and weight ≤45 kg: Initial: 12 to 14 mg/kg/day in divided doses every 4 to 6 hours (maximum: 300 mg/day); if tolerated, after 3 days increase to 16 mg/kg/day in divided doses every…"}, {"doc_id": "selenium-drug-information", "bm25_top3": 17.851677249601398, "bm25_max": 17.851677249601398, "bge_top3": null, "bge_max": null, "title": "Selenium: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Selenium: Pediatric drug information\")  IV: Parenteral nutrition additive (Vanek 2012):  Infants: 1 to 3 mcg/kg/day (maximum not stated)  Children and adolescents: 1 to…"}, {"doc_id": "prednisone-drug-information", "bm25_top3": 15.49734871572402, "bm25_max": 15.49734871572402, "bge_top3": null, "bge_max": null, "title": "Prednisone: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Prednisone: Pediatric drug information\")  General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Children and Adolescents: Oral: Refer to adult dosing…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 14.525525689221794, "bm25_max": 14.525525689221794, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Metronidazole (systemic): Pediatric drug information\")  Note: Some clinicians recommend using adjusted body weight in obese children. Dosing weight = IBW + 0.45 (TBW-IB…"}, {"doc_id": "fluticasone-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.736034095287323, "bge_max": 0.736034095287323, "title": "Fluticasone and vilanterol: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Note: Recommended starting dose is determined according to asthma severity. For patients not adequately controlled on the lower combination dose, consider the higher dose combination. R…"}, {"doc_id": "zileuton-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7350262403488159, "bge_max": 0.7350262403488159, "title": "Zileuton: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral:  Immediate release: 600 mg 4 times daily  Extended release: 1,200 mg twice daily"}, {"doc_id": "cromolyn-sodium-cromoglicate-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.713799238204956, "bge_max": 0.713799238204956, "title": "Cromolyn (sodium cromoglicate) (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  Asthma: Nebulization solution: Initial: 20 mg 4 times/day; usual dose: 20 mg 3 to 4 times/day  Note: For chronic control of asthma, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/…"}, {"doc_id": "tiotropium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7120007276535034, "bge_max": 0.7120007276535034, "title": "Tiotropium: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Inhalation: Spiriva Respimat (1.25 mcg/actuation): Metered-dose inhaler: Two inhalations (2.5 mcg) once daily (maximum: 2 inhalations per 24 hours). Note: Maximum benefits may take up to 4 to 8 wee…"}, {"doc_id": "reslizumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7021852135658264, "bge_max": 0.7021852135658264, "title": "Reslizumab: Drug information", "rep_snippet": "Dosing: Adult  Asthma: IV: 3 mg/kg once every 4 weeks."}, {"doc_id": "ephedrine-and-guaifenesin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7002858519554138, "bge_max": 0.7002858519554138, "title": "Ephedrine and guaifenesin: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral: Ephedrine 12.5 to 25 mg/guaifenesin 200 to 400 mg every 4 hours as needed. Maximum: Ephedrine 150 mg/guaifenesin 2400 mg per 24 hours."}, {"doc_id": "terbutaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6956604719161987, "bge_max": 0.6956604719161987, "title": "Terbutaline: Drug information", "rep_snippet": "Dosing: Adult  Asthma/bronchospasm:  Oral: 5 mg 3 times daily (approximately every 6 hours); reduce dose to 2.5 mg 3 times daily if side effects occur; maximum: 15 mg/24 hours  SubQ:  Manufacturer's labeling: 0.25 mg/dos…"}, {"doc_id": "dyphylline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6850318312644958, "bge_max": 0.6850318312644958, "title": "Dyphylline: Drug information", "rep_snippet": "Dosing: Adult  Bronchoconstriction (asthma, COPD): Oral: Up to 15 mg/kg 4 times daily, individualize dosage"}, {"doc_id": "zafirlukast-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6845589280128479, "bge_max": 0.6845589280128479, "title": "Zafirlukast: Drug information", "rep_snippet": "Dosing: Adult  Asthma: Oral: 20 mg twice daily  Chronic urticaria (off-label use): Oral: 20 mg twice daily (Bagenstose, 2004)"}, {"doc_id": "glycopyrrolate-glycopyrronium-and-formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6845187544822693, "bge_max": 0.6845187544822693, "title": "Glycopyrrolate (glycopyrronium) and formoterol: Drug information", "rep_snippet": "Dosing: Adult  COPD (maintenance): Oral inhalation: Two inhalations (glycopyrrolate 9 mcg/formoterol 4.8 mcg per inhalation) twice daily; (maximum: 2 inhalations twice daily)."}, {"doc_id": "budesonide-and-formoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.684511661529541, "bge_max": 0.684511661529541, "title": "Budesonide and formoterol: Drug information", "rep_snippet": "Dosing: Adult  Note: If asthma or COPD symptoms occur in the period between doses, an inhaled, short-acting beta2-agonist should be taken for immediate relief.  Asthma: Inhalation:  Starting dose is based on asthma sever…"}, {"doc_id": "flunisolide-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6822882294654846, "bge_max": 0.6822882294654846, "title": "Flunisolide (nasal): Drug information", "rep_snippet": "Dosing: Adult  Rhinitis (seasonal/perennial): Intranasal: Two sprays (50 mcg) in each nostril twice daily (total daily dose: 200 mcg/day); may increase to 2 sprays in each nostril 3 times daily (total daily dose: 300 mcg…"}, {"doc_id": "brompheniramine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.681329071521759, "bge_max": 0.681329071521759, "title": "Brompheniramine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory tract conditions: Oral: Note: These are general dosage guidelines; also refer to product specific dosing. All dosing is presented in terms of brompheniramine maleate and phenylephrine hyd…"}, {"doc_id": "arformoterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6799368858337402, "bge_max": 0.6799368858337402, "title": "Arformoterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Nebulization: 15 mcg twice daily; maximum: 30 mcg daily"}, {"doc_id": "iloprost-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6792995929718018, "bge_max": 0.6792995929718018, "title": "Iloprost: Drug information", "rep_snippet": "Dosing: Adult  Pulmonary arterial hypertension (PAH): Inhalation: Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose. Administer 6-9 times daily (dosing at intervals ≥2 hours while awake according to individual…"}, {"doc_id": "triamcinolone-nasal-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6769989132881165, "bge_max": 0.6769989132881165, "title": "Triamcinolone (nasal): Drug information", "rep_snippet": "Dosing: Adult  Allergic rhinitis/upper respiratory symptoms: Intranasal: Two sprays (110 mcg) in each nostril once daily; once symptoms controlled reduce to 1 spray (55 mcg) in each nostril once daily (maximum: 2 sprays…"}, {"doc_id": "hydrocodone-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6761990785598755, "bge_max": 0.6761990785598755, "title": "Hydrocodone and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Cough and upper respiratory tract symptoms: Oral: Note: Dosage units vary based on product formulation (extended release vs. immediate release); use caution when verifying dose with product formulation.  E…"}, {"doc_id": "olodaterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6760350465774536, "bge_max": 0.6760350465774536, "title": "Olodaterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation: Two inhalations once daily (maximum: 2 inhalations per day.)"}, {"doc_id": "codeine-and-chlorpheniramine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6758489012718201, "bge_max": 0.6758489012718201, "title": "Codeine and chlorpheniramine: Drug information", "rep_snippet": "Dosing: Adult  Cough and upper respiratory symptoms: Oral: 10 mL every 12 hours; maximum dose: 20 mL per 24 hours"}, {"doc_id": "ipratropium-oral-inhalation-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6757204532623291, "bge_max": 0.6757204532623291, "title": "Ipratropium (oral inhalation): Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation:  Metered-dose inhaler (MDI): 2 inhalations (34 mcg) 4 times daily; maximum dose: 12 inhalations (204 mcg)/day  Nebulization solution: 0.5 mg (500 mcg, one unit-dose vial) every 6 to 8 hou…"}, {"doc_id": "ketotifen-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6754087209701538, "bge_max": 0.6754087209701538, "title": "Ketotifen (Systemic) (United States: Not available) (systemic): Drug information", "rep_snippet": "Dosing: Pediatric  Atopic asthma (prophylactic treatment): Oral:  Infants and Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg/dose twice daily (maxim…"}, {"doc_id": "promethazine-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.674206554889679, "bge_max": 0.674206554889679, "title": "Promethazine and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Upper respiratory symptoms: Oral: 5 mL (promethazine 6.25 mg/phenylephrine 5 mg) every 4 to 6 hours; maximum: 30 mL (promethazine 37.5 mg/phenylephrine 30 mg)/24 hours"}, {"doc_id": "metaproterenol-orciprenaline-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6740627288818359, "bge_max": 0.6740627288818359, "title": "Metaproterenol (orciprenaline): Drug information", "rep_snippet": "Dosing: Adult  Asthma/Bronchospasm: Oral: 20 mg 3 or 4 times daily Note: Oral bronchodilators are not recommended for routine use in the management of acute asthma or long-term daily maintenance treatment due to a slower…"}, {"doc_id": "fenoterol-and-ipratropium-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6721916198730469, "bge_max": 0.6721916198730469, "title": "Fenoterol and ipratropium (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Note: Initiate therapy under medical supervision (eg, hospital setting). May consider home administration in exceptional cases (eg, severe symptoms or experienced patients requiring higher doses) when rapi…"}, {"doc_id": "fluticasone-umeclidinium-and-vilanterol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6712616682052612, "bge_max": 0.6712616682052612, "title": "Fluticasone, umeclidinium, and vilanterol: Drug information", "rep_snippet": "Dosing: Adult  COPD: Inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day)"}, {"doc_id": "acetaminophen-paracetamol-dextromethorphan-and-phenylephrine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6700268983840942, "bge_max": 0.6700268983840942, "title": "Acetaminophen (paracetamol), dextromethorphan, and phenylephrine: Drug information", "rep_snippet": "Dosing: Adult  Note: When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose.  Cold and flu…"}]}
{"qid": "Q28", "query": "Bacterial conjunctivitis — dosing and contact lens precautions for ofloxacin ophthalmic solution.", "candidates": [{"doc_id": "ofloxacin-ophthalmic-drug-information", "bm25_top3": 33.68285883166826, "bm25_max": 49.576724028243106, "bge_top3": 0.716676930586497, "bge_max": 0.7440736889839172, "title": "Ofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ofloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic: Children ≥1 year and Adolescents: Refer to adult dosing.  Corneal ulcer: Oph…"}, {"doc_id": "ciprofloxacin-ophthalmic-drug-information", "bm25_top3": 36.428816967441165, "bm25_max": 43.99460158434674, "bge_top3": 0.7046405076980591, "bge_max": 0.7144625186920166, "title": "Ciprofloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ciprofloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic:  Solution: Children ≥1 year and Adolescents: Refer to adult dosing.  Oin…"}, {"doc_id": "moxifloxacin-ophthalmic-drug-information", "bm25_top3": 39.30430495624899, "bm25_max": 39.30430495624899, "bge_top3": 0.7116969525814056, "bge_max": 0.7202739119529724, "title": "Moxifloxacin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Moxifloxacin (ophthalmic): Pediatric drug information\")  Bacterial conjunctivitis: Ophthalmic:  Children ≥4 months and Adolescents (Moxeza): Refer to adult dosing.  Neo…"}, {"doc_id": "sulfacetamide-ophthalmic-drug-information", "bm25_top3": 34.320903470925224, "bm25_max": 35.795775913757105, "bge_top3": 0.6962713003158569, "bge_max": 0.6962713003158569, "title": "Sulfacetamide (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, other superficial ocular infections: Note: Taper dose by increasing dosage time interval as condition responds; usual duration of treatment: 7 to 10 days:  Ophthalmic solution: Instill 1 to…"}, {"doc_id": "betaxolol-ophthalmic-drug-information", "bm25_top3": 35.76374682498162, "bm25_max": 35.76374682498162, "bge_top3": 0.7305649518966675, "bge_max": 0.7305649518966675, "title": "Betaxolol (ophthalmic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "bepotastine-ophthalmic-drug-information", "bm25_top3": 35.72684598683335, "bm25_max": 35.72684598683335, "bge_top3": 0.6946170330047607, "bge_max": 0.7058072090148926, "title": "Bepotastine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 10 minutes before reinserting.…"}, {"doc_id": "ketorolac-ophthalmic-drug-information", "bm25_top3": 34.74402124386574, "bm25_max": 34.92250665482666, "bge_top3": null, "bge_max": null, "title": "Ketorolac (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Postoperative ocular inflammation following cataract extraction (0.5% solution): Ophthalmic: Instill 1 drop into affected eye(s) 4 times daily beginning 24 hours after surgery; continue for 2 weeks  Postop…"}, {"doc_id": "olopatadine-ophthalmic-drug-information", "bm25_top3": 34.22218147272585, "bm25_max": 34.22218147272585, "bge_top3": 0.6804189682006836, "bge_max": 0.6804189682006836, "title": "Olopatadine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Other warnings/precautions:  • Contact lens: Not for use to treat contact lens-related irritation. Solution contains benzalkonium chloride; remove lens prior to administration and wait at least 10 m…"}, {"doc_id": "azelastine-ophthalmic-drug-information", "bm25_top3": 30.22937691036143, "bm25_max": 33.644651320636314, "bge_top3": 0.701770007610321, "bge_max": 0.7055650949478149, "title": "Azelastine (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Azelastine (ophthalmic): Pediatric drug information\")  Allergic conjunctivitis: Children ≥3 years and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "ketotifen-ophthalmic-drug-information", "bm25_top3": 31.919193023109727, "bm25_max": 33.644651320636314, "bge_top3": 0.6849084794521332, "bge_max": 0.6885647773742676, "title": "Ketotifen (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Ketotifen (ophthalmic): Pediatric drug information\")  Allergic conjunctivitis: Children ≥3 years and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "cromolyn-sodium-cromoglicate-ophthalmic-drug-information", "bm25_top3": 30.69544476425323, "bm25_max": 33.49519092223103, "bge_top3": 0.685543417930603, "bge_max": 0.685543417930603, "title": "Cromolyn (sodium cromoglicate) (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Cromolyn (sodium cromoglicate) (ophthalmic): Pediatric drug information\")  Conjunctivitis and keratitis: Ophthalmic: Children ≥4 years and Adolescents: Refer to adult d…"}, {"doc_id": "cetirizine-ophthalmic-drug-information", "bm25_top3": 32.53793561022576, "bm25_max": 32.53793561022576, "bge_top3": 0.698459267616272, "bge_max": 0.698459267616272, "title": "Cetirizine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride, which may be absorbed by contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting. N…"}, {"doc_id": "cysteamine-ophthalmic-drug-information", "bm25_top3": 32.037964133715064, "bm25_max": 32.037964133715064, "bge_top3": null, "bge_max": null, "title": "Cysteamine (ophthalmic): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Intracranial hypertension/papilledema: Intracranial hypertension (pseudotumor cerebri) and/or papilledema have been reported with oral cysteamine treatment; m…"}, {"doc_id": "travoprost-drug-information", "bm25_top3": 31.42154453502743, "bm25_max": 31.42154453502743, "bge_top3": 0.7010986804962158, "bge_max": 0.7010986804962158, "title": "Travoprost: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  • Ocular effects: May permanently change…"}, {"doc_id": "epinastine-drug-information", "bm25_top3": 30.649873836357642, "bm25_max": 30.649873836357642, "bge_top3": 0.7197026312351227, "bge_max": 0.7390844821929932, "title": "Epinastine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  Special populations:  • Contact lens wea…"}, {"doc_id": "besifloxacin-drug-information", "bm25_top3": 23.607326680656374, "bm25_max": 29.009079137855576, "bge_top3": 0.7436591386795044, "bge_max": 0.7577288150787354, "title": "Besifloxacin: Drug information", "rep_snippet": "Dosing: Adult  Bacterial conjunctivitis: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily (4 to 12 hours apart) for 7 days"}, {"doc_id": "brinzolamide-and-timolol-united-states-not-available-drug-information", "bm25_top3": 28.92682293754416, "bm25_max": 28.92682293754416, "bge_top3": null, "bge_max": null, "title": "Brinzolamide and timolol (United States: Not available): Drug information", "rep_snippet": "• Contact lens wearers: Formulation contains benzalkonium chloride which may be absorbed by soft contact lenses and discolor lenses; remove lens prior to administration and wait 15 minutes before reinserting.  Other warn…"}, {"doc_id": "netarsudil-drug-information", "bm25_top3": 28.60591526036103, "bm25_max": 28.60591526036103, "bge_top3": 0.734665036201477, "bge_max": 0.734665036201477, "title": "Netarsudil: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.  Special populations:  • Contact lens wea…"}, {"doc_id": "gatifloxacin-drug-information", "bm25_top3": 24.634139380374222, "bm25_max": 28.456743862879996, "bge_top3": 0.7234037518501282, "bge_max": 0.731903076171875, "title": "Gatifloxacin: Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Gatifloxacin: Pediatric drug information\")  Bacterial conjunctivitis: Children ≥1 year and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "tobramycin-and-dexamethasone-drug-information", "bm25_top3": 27.542162050797476, "bm25_max": 27.542162050797476, "bge_top3": 0.7078250646591187, "bge_max": 0.7078250646591187, "title": "Tobramycin and dexamethasone: Drug information", "rep_snippet": "• Ocular herpes simplex: Use with extreme caution in patients with a history of ocular herpes simplex; use of corticosteroids may prolong the course and exacerbate severity of infection.  Special populations:  • Contact…"}, {"doc_id": "carteolol-ophthalmic-drug-information", "bm25_top3": 27.25155404853678, "bm25_max": 27.25155404853678, "bge_top3": null, "bge_max": null, "title": "Carteolol (ophthalmic): Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "dorzolamide-and-timolol-drug-information", "bm25_top3": 26.87577293774146, "bm25_max": 26.87577293774146, "bge_top3": null, "bge_max": null, "title": "Dorzolamide and timolol: Drug information", "rep_snippet": "• Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.  Other warnings/precaution…"}, {"doc_id": "latanoprost-and-timolol-united-states-not-available-drug-information", "bm25_top3": 25.45865456573127, "bm25_max": 25.45865456573127, "bge_top3": null, "bge_max": null, "title": "Latanoprost and timolol (United States: Not available): Drug information", "rep_snippet": "• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid st…"}, {"doc_id": "brimonidine-and-timolol-drug-information", "bm25_top3": 24.066516974580026, "bm25_max": 24.066516974580026, "bge_top3": null, "bge_max": null, "title": "Brimonidine and timolol: Drug information", "rep_snippet": "• Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.  • Pediatric: Safety and efficacy h…"}, {"doc_id": "phenylephrine-and-ketorolac-injection-drug-information", "bm25_top3": 23.57085521644355, "bm25_max": 23.57085521644355, "bge_top3": null, "bge_max": null, "title": "Phenylephrine and ketorolac injection: Drug information", "rep_snippet": "Use  Ophthalmic surgical irrigation: Added to an ophthalmic irrigation solution to prevent intraoperative miosis and to reduce postoperative ocular pain during cataract surgery or intraocular lens replacement"}, {"doc_id": "alcaftadine-drug-information", "bm25_top3": 23.158852461313284, "bm25_max": 23.158852461313284, "bge_top3": 0.7008129358291626, "bge_max": 0.7008129358291626, "title": "Alcaftadine: Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinsertin…"}, {"doc_id": "emedastine-drug-information", "bm25_top3": 23.019924224760913, "bm25_max": 23.019924224760913, "bge_top3": 0.7076727151870728, "bge_max": 0.7076727151870728, "title": "Emedastine: Drug information", "rep_snippet": "Warnings/Precautions  Special populations:  • Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove contact lenses prior to use and wait ≥10 minutes before reinserting.…"}, {"doc_id": "nedocromil-drug-information", "bm25_top3": 19.409544830772052, "bm25_max": 22.277673254575387, "bge_top3": 0.7142802675565084, "bge_max": 0.7506740689277649, "title": "Nedocromil: Drug information", "rep_snippet": "Warnings/Precautions  Dosage form specific issues:  • Ophthalmic solution: Contains benzalkonium chloride, which may be absorbed by contact lenses; users of contact lenses should not wear them during periods of symptomat…"}, {"doc_id": "natamycin-drug-information", "bm25_top3": 19.21176741720936, "bm25_max": 19.21176741720936, "bge_top3": null, "bge_max": null, "title": "Natamycin: Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Epithelial ulceration: Suspension may adhere to epithelial ulcers; retention of the suspension in the fornices occurs regularly.  Special populations:  • Contact lens we…"}, {"doc_id": "lifitegrast-drug-information", "bm25_top3": 17.59203608875461, "bm25_max": 17.59203608875461, "bge_top3": null, "bge_max": null, "title": "Lifitegrast: Drug information", "rep_snippet": "Warnings/Precautions  Special Populations:  • Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting."}, {"doc_id": "framycetin-united-states-not-available-drug-information", "bm25_top3": 17.367299075712758, "bm25_max": 17.367299075712758, "bge_top3": null, "bge_max": null, "title": "Framycetin (United States: Not available): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Superinfection: Prolonged use may result in fungal or bacterial superinfection.  Special populations:  • Contact lens wearers: Formulation contains benzalkoni…"}, {"doc_id": "loteprednol-drug-information", "bm25_top3": 17.030666590490465, "bm25_max": 17.030666590490465, "bge_top3": 0.6802210807800293, "bge_max": 0.6802210807800293, "title": "Loteprednol: Drug information", "rep_snippet": "• Herpes simplex: Corticosteroids should not be used to treat ocular herpes simplex; may exacerbate the severity of the infection. Use extreme caution in patients with history of herpes simplex.  Special populations:  •…"}, {"doc_id": "metipranolol-drug-information", "bm25_top3": 14.218035293774385, "bm25_max": 14.218035293774385, "bge_top3": null, "bge_max": null, "title": "Metipranolol: Drug information", "rep_snippet": "• Peripheral vascular disease (PVD): Use with caution in patients with PVD (including Raynaud's).  • Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS de…"}, {"doc_id": "lodoxamide-tromethamine-drug-information", "bm25_top3": 14.130630318982647, "bm25_max": 14.130630318982647, "bge_top3": null, "bge_max": null, "title": "Lodoxamide tromethamine: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Irritation: May cause discomfort or transient burning or stinging upon instillation.  • Ocular effects: May cause temporary blurred vision or other visual dis…"}, {"doc_id": "homatropine-drug-information", "bm25_top3": 13.863898617611746, "bm25_max": 13.863898617611746, "bge_top3": null, "bge_max": null, "title": "Homatropine: Drug information", "rep_snippet": "• Contact lens wearers: Some strengths may contain benzalkonium chloride which may be adsorbed by contact lenses (Chapman 1990); remove contacts prior to administration and wait 15 minutes before reinserting.  Other warn…"}, {"doc_id": "dorzolamide-drug-information", "bm25_top3": 13.328435397715936, "bm25_max": 13.328435397715936, "bge_top3": null, "bge_max": null, "title": "Dorzolamide: Drug information", "rep_snippet": "Administration  Ophthalmic: If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lens prior to administration and wait 15 minutes before reinserting. Avoid…"}, {"doc_id": "ivermectin-topical-drug-information", "bm25_top3": 12.810207588118484, "bm25_max": 12.810207588118484, "bge_top3": null, "bge_max": null, "title": "Ivermectin (topical): Drug information", "rep_snippet": "Warnings/Precautions  Other warnings/precautions:  • Appropriate use:  Topical lotion: For topical use on scalp and scalp hair only; avoid contact with eyes. Wash hands after application.  Topical cream: Not for oral, op…"}, {"doc_id": "levobunolol-drug-information", "bm25_top3": 11.923434124281936, "bm25_max": 11.923434124281936, "bge_top3": null, "bge_max": null, "title": "Levobunolol: Drug information", "rep_snippet": "Administration  For topical ophthalmic use only. Wash hands before and after use. Some solutions contain benzalkonium chloride; remove contact lens prior to administration. Wait 15 minutes before reinserting. Do not touc…"}, {"doc_id": "neomycin-polymyxin-b-and-dexamethasone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6925158798694611, "bge_max": 0.7014197111129761, "title": "Neomycin, polymyxin B, and dexamethasone: Drug information", "rep_snippet": "• Ocular herpes simplex: Use with extreme caution in patients with a history of ocular herpes simplex; frequent slit lamp microscopy is recommended.  Dosage-forms specific issues:  • Ophthalmic suspension: May contain be…"}, {"doc_id": "fusidic-acid-united-states-not-available-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6927425265312195, "bge_max": 0.6992861032485962, "title": "Fusidic acid (United States: Not available) (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ophthalmic infections/conjunctivitis: Ophthalmic: Instill 1 drop into the conjunctival sac of each eye every 12 hours for 7 days; reassess if infection has not resolved after 7 days"}, {"doc_id": "rimexolone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6977455615997314, "bge_max": 0.6977455615997314, "title": "Rimexolone: Drug information", "rep_snippet": "• Contact lens wearers: Some preparations contain benzalkonium chloride which may be adsorbed by contact lenses.  Other warnings/precautions:  • Appropriate use: Patients should be re-evaluated if symptoms fail to improv…"}, {"doc_id": "trimethoprim-and-polymyxin-b-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6975933909416199, "bge_max": 0.6975933909416199, "title": "Trimethoprim and polymyxin B: Drug information", "rep_snippet": "Dosing: Adult  Conjunctivitis, blepharoconjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013;…"}, {"doc_id": "bacitracin-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.685271292924881, "bge_max": 0.6905106902122498, "title": "Bacitracin (ophthalmic): Drug information", "rep_snippet": "Dosing: Pediatric  (For additional information see \"Bacitracin (ophthalmic): Pediatric drug information\")  Ophthalmic infection: Children and Adolescents: Ophthalmic: Refer to adult dosing."}, {"doc_id": "tetrahydrozoline-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6857212781906128, "bge_max": 0.6864514350891113, "title": "Tetrahydrozoline (ophthalmic): Drug information", "rep_snippet": "Dosing: Adult  Ocular decongestant: Ophthalmic: Instill 1 to 2 drops in the affected eye(s) up to 4 times daily"}, {"doc_id": "fluorescein-and-benoxinate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6863112449645996, "bge_max": 0.6863112449645996, "title": "Fluorescein and benoxinate: Drug information", "rep_snippet": "Dosage Forms  Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  Solution, ophthalmic:  Altafluor, Flurox: Fluorescein sodium 0.25% and benoxinate hyd…"}, {"doc_id": "nepafenac-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6851657629013062, "bge_max": 0.6851657629013062, "title": "Nepafenac: Drug information", "rep_snippet": "Administration  Ophthalmic: For topical ophthalmic use only; shake well prior to use. Remove contact lenses prior to using solutions containing benzalkonium chloride. To avoid contamination, do not touch tip of container…"}, {"doc_id": "atropine-ophthalmic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6814591288566589, "bge_max": 0.6814591288566589, "title": "Atropine (ophthalmic): Drug information", "rep_snippet": "Dosage form specific issues:  • Benzalkonium chloride: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses.  Other warnings/precautions:  • Appropriate use: To avoid precipitating…"}, {"doc_id": "loteprednol-and-tobramycin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6808614730834961, "bge_max": 0.6808614730834961, "title": "Loteprednol and tobramycin: Drug information", "rep_snippet": "• Ocular herpes simplex: Corticosteroids should not be used to treat ocular herpes simplex; use extreme caution in patients with a history of ocular herpes simplex.  Special populations:  • Contact lens wearers: Some pre…"}, {"doc_id": "brinzolamide-and-brimonidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6798208951950073, "bge_max": 0.6798208951950073, "title": "Brinzolamide and brimonidine: Drug information", "rep_snippet": "Administration  Shake bottle well prior to administration. If using additional topical ophthalmic preparations, separate administration by at least 5 minutes. Remove contact lenses prior to administration and wait 15 min…"}, {"doc_id": "naphazoline-ophthalmic-nasal-decongestant-preparation-is-not-available-in-united-states-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6797443628311157, "bge_max": 0.6797443628311157, "title": "Naphazoline (ophthalmic [nasal decongestant preparation is not available in United States]): Drug information", "rep_snippet": "Warnings/Precautions  Disease-related concerns:  • Cardiovascular disease: Use with caution in patients with cardiovascular abnormalities or hypertension.  • Diabetes: Use with caution in patients with diabetes mellitus.…"}]}
{"qid": "Q29", "query": "Hyperkalemia risk — spironolactone in CKD stage 3: starting dose and potassium monitoring frequency.", "candidates": [{"doc_id": "hydrochlorothiazide-and-spironolactone-drug-information", "bm25_top3": 23.850305508517145, "bm25_max": 24.913933760828925, "bge_top3": 0.6765785813331604, "bge_max": 0.6805931329727173, "title": "Hydrochlorothiazide and spironolactone: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • CNS effects: Somnolence and dizziness have been reported with use; advise patients to use caution when driving or operating machinery until response to initia…"}, {"doc_id": "potassium-phosphate-drug-information", "bm25_top3": 24.609334537871725, "bm25_max": 24.609334537871725, "bge_top3": null, "bge_max": null, "title": "Potassium phosphate: Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Extravasation: Vesicant/irritant (may depend on concentration); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.…"}, {"doc_id": "spironolactone-drug-information", "bm25_top3": 23.135413384839516, "bm25_max": 23.7134952226302, "bge_top3": 0.6795550982157389, "bge_max": 0.6873471736907959, "title": "Spironolactone: Drug information", "rep_snippet": "Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. Risk C: Monitor therapy  Cipr…"}, {"doc_id": "calcium-polystyrene-sulfonate-united-states-not-available-drug-information", "bm25_top3": 22.485161133957284, "bm25_max": 22.485161133957284, "bge_top3": 0.6813117265701294, "bge_max": 0.6813117265701294, "title": "Calcium polystyrene sulfonate (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Hyperkalemia: Initiate treatment if potassium level >6 mmol/L (6 mEq/L); discontinue when potassium ≤5 mmol/L (5 mEq/L).  Oral: Usual dose: 15 g 3 to 4 times daily; dose should be based on clinical present…"}, {"doc_id": "sevelamer-drug-information", "bm25_top3": 14.395307994535935, "bm25_max": 19.829901857152507, "bge_top3": 0.6982875466346741, "bge_max": 0.6982875466346741, "title": "Sevelamer: Drug information", "rep_snippet": "Monitoring Parameters  Serum chemistries, including bicarbonate and chloride  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progress…"}, {"doc_id": "alfacalcidol-united-states-not-available-drug-information", "bm25_top3": 16.536425525780466, "bm25_max": 19.445581927173812, "bge_top3": 0.6940934360027313, "bge_max": 0.7165257930755615, "title": "Alfacalcidol (United States: Not available): Drug information", "rep_snippet": "Monitoring Parameters  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral a…"}, {"doc_id": "lanthanum-carbonate-drug-information", "bm25_top3": 15.916754608608516, "bm25_max": 18.275666874225205, "bge_top3": 0.6847690343856812, "bge_max": 0.6847690343856812, "title": "Lanthanum carbonate: Drug information", "rep_snippet": "Monitoring Parameters  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral a…"}, {"doc_id": "doxercalciferol-drug-information", "bm25_top3": 15.4080854801552, "bm25_max": 17.55233285081098, "bge_top3": 0.6918609738349915, "bge_max": 0.6918609738349915, "title": "Doxercalciferol: Drug information", "rep_snippet": "Monitoring Parameters  Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral a…"}, {"doc_id": "eplerenone-drug-information", "bm25_top3": 12.940570709574876, "bm25_max": 16.133021397229648, "bge_top3": 0.680833617846171, "bge_max": 0.6839128732681274, "title": "Eplerenone: Drug information", "rep_snippet": "• Renal impairment: Risk of hyperkalemia is increased with declining renal function. Use with caution in patients with mild renal impairment; based on indication and degree of impairment use may be contraindicated (refer…"}, {"doc_id": "trimethoprim-drug-information", "bm25_top3": 15.345654705381964, "bm25_max": 15.345654705381964, "bge_top3": null, "bge_max": null, "title": "Trimethoprim: Drug information", "rep_snippet": "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for mor…"}, {"doc_id": "calcitriol-systemic-drug-information", "bm25_top3": 13.681939299877035, "bm25_max": 15.312794907137643, "bge_top3": 0.693875253200531, "bge_max": 0.7111823558807373, "title": "Calcitriol (systemic): Drug information", "rep_snippet": "CKD stage 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: monitor based on baseline level and CKD progression  CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months  CKD stag…"}, {"doc_id": "triamterene-drug-information", "bm25_top3": 12.050637874464124, "bm25_max": 15.064443351580522, "bge_top3": 0.7001820802688599, "bge_max": 0.7101352214813232, "title": "Triamterene: Drug information", "rep_snippet": "• Potassium supplements: Avoid potassium supplements, potassium-containing salt substitutes, a diet rich in potassium, or other drugs that can cause hyperkalemia.  • Drug-drug interactions: Potentially significant intera…"}, {"doc_id": "cinacalcet-drug-information", "bm25_top3": 15.008008520421804, "bm25_max": 15.008008520421804, "bge_top3": 0.6807394027709961, "bge_max": 0.6807394027709961, "title": "Cinacalcet: Drug information", "rep_snippet": "Reference Range  CKD K/DOQI guidelines definition of stages; chronic disease is kidney damage or GFR <60 mL/minute/1.73 m2 for ≥3 months:  Stage 2: GFR 60 to 89 mL/minute/1.73 m2 (kidney damage with mild decrease GFR)  S…"}, {"doc_id": "paricalcitol-drug-information", "bm25_top3": 12.20004384658426, "bm25_max": 14.740825031329617, "bge_top3": 0.685937374830246, "bge_max": 0.6880923509597778, "title": "Paricalcitol: Drug information", "rep_snippet": "Use  IV: Prevention and treatment of secondary hyperparathyroidism associated with stage 5 chronic kidney disease (CKD)  Oral: Prevention and treatment in adults and pediatric patients 10 years and older with secondary h…"}, {"doc_id": "etelcalcetide-drug-information", "bm25_top3": 13.405844558411186, "bm25_max": 13.405844558411186, "bge_top3": 0.70009446144104, "bge_max": 0.70009446144104, "title": "Etelcalcetide: Drug information", "rep_snippet": "Reference Range  Target goals of PTH, calcium, and phosphorus in adult CKD patients on hemodialysis (ie, CKD stage 5), per clinical practice guidelines:  Corrected serum calcium: CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.3…"}, {"doc_id": "calcifediol-drug-information", "bm25_top3": 11.915168452119865, "bm25_max": 13.145142967283448, "bge_top3": 0.6734121143817902, "bge_max": 0.6748976111412048, "title": "Calcifediol: Drug information", "rep_snippet": "Reference Range  Corrected total serum calcium (K/DOQI 2003): CKD stages 3 and 4: 8.4 to 10.2 mg/dL (2.1 to 2.6 mmol/L); CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.37 mmol/L); KDIGO guidelines recommend maintaining normal r…"}, {"doc_id": "calcium-acetate-drug-information", "bm25_top3": 11.695160483712128, "bm25_max": 11.994252011822564, "bge_top3": null, "bge_max": null, "title": "Calcium acetate: Drug information", "rep_snippet": "Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for…"}, {"doc_id": "enoxaparin-drug-information", "bm25_top3": 11.608529040473421, "bm25_max": 11.608529040473421, "bge_top3": 0.7025173902511597, "bge_max": 0.7025173902511597, "title": "Enoxaparin: Drug information", "rep_snippet": "• Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfuncti…"}, {"doc_id": "tolvaptan-drug-information", "bm25_top3": 11.44921038827276, "bm25_max": 11.44921038827276, "bge_top3": null, "bge_max": null, "title": "Tolvaptan: Drug information", "rep_snippet": "• Hepatic impairment: Avoid use in patients with liver disease, including those with cirrhosis, since the ability to recover from further liver injury may be impaired. In addition, patients with cirrhosis have a higher r…"}, {"doc_id": "flurbiprofen-systemic-drug-information", "bm25_top3": 11.05707367290891, "bm25_max": 11.05707367290891, "bge_top3": null, "bge_max": null, "title": "Flurbiprofen (systemic): Drug information", "rep_snippet": "• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Moni…"}, {"doc_id": "simvastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Simvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "alirocumab-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Alirocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "ezetimibe-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Ezetimibe: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "pitavastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Pitavastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "fluvastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Fluvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "rosuvastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Rosuvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "lovastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Lovastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "atorvastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Atorvastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "evolocumab-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Evolocumab: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "pravastatin-drug-information", "bm25_top3": 8.398548669502649, "bm25_max": 8.398548669502649, "bge_top3": null, "bge_max": null, "title": "Pravastatin: Drug information", "rep_snippet": "Reference Range  Treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <160 mg…"}, {"doc_id": "cholestyramine-resin-drug-information", "bm25_top3": 8.35738289876522, "bm25_max": 8.35738289876522, "bge_top3": null, "bge_max": null, "title": "Cholestyramine resin: Drug information", "rep_snippet": "Reference Range  Lipid treatment goals:  American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]): Adults:  Low risk (no risk factors):  Non-HDL-C: <…"}, {"doc_id": "hydrochlorothiazide-and-triamterene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7059195339679718, "bge_max": 0.7095452547073364, "title": "Hydrochlorothiazide and triamterene: Drug information", "rep_snippet": "• Hyperkalemia: [US Boxed Warning]: Hyperkalemia can occur with triamterene; patients at risk include those with renal impairment, diabetes (even without evidence of renal impairment), the elderly, and the severely ill.…"}, {"doc_id": "recombinant-human-parathyroid-hormone-1-84-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6992387771606445, "bge_max": 0.6992387771606445, "title": "Recombinant human parathyroid hormone (1-84): Drug information", "rep_snippet": "Warnings/Precautions  Concerns related to adverse effects:  • Hypercalcemia: Severe hypercalcemia has been reported; the risk is highest during initiation of therapy and dose escalation. Monitor serum calcium concentrati…"}, {"doc_id": "valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6976966261863708, "bge_max": 0.6976966261863708, "title": "Valsartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use with caution with these…"}, {"doc_id": "losartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6907644271850586, "bge_max": 0.6907644271850586, "title": "Losartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, wi…"}, {"doc_id": "amiloride-and-hydrochlorothiazide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6892448663711548, "bge_max": 0.6892448663711548, "title": "Amiloride and hydrochlorothiazide: Drug information", "rep_snippet": "Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy mod…"}, {"doc_id": "amiloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6892448663711548, "bge_max": 0.6892448663711548, "title": "Amiloride: Drug information", "rep_snippet": "Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy mod…"}, {"doc_id": "irbesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6856446266174316, "bge_max": 0.6856446266174316, "title": "Irbesartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, wi…"}, {"doc_id": "potassium-chloride-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6802511811256409, "bge_max": 0.6834296584129333, "title": "Potassium chloride: Drug information", "rep_snippet": "• Acid/base disorders: Use with caution in patients with acid/base alterations or acid/base correction; hyperosmolality or acidosis (or correction of alkalosis) is associated with hyperkalemia (shift of intracellular pot…"}, {"doc_id": "tacrolimus-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6829803586006165, "bge_max": 0.6829803586006165, "title": "Tacrolimus (systemic): Drug information", "rep_snippet": "• Gastrointestinal perforation: Gastrointestinal perforation may occur; all reported cases were considered to be a complication of transplant surgery or accompanied by infection, diverticulum, or malignant neoplasm.  • H…"}, {"doc_id": "sodium-citrate-potassium-citrate-and-citric-acid-oral-solution-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6828311085700989, "bge_max": 0.6828311085700989, "title": "Sodium citrate, potassium citrate, and citric acid (oral solution): Drug information", "rep_snippet": "Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy modification  H…"}, {"doc_id": "potassium-citrate-tablet-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6828311085700989, "bge_max": 0.6828311085700989, "title": "Potassium citrate (tablet): Drug information", "rep_snippet": "Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy modification  H…"}, {"doc_id": "potassium-citrate-and-citric-acid-powder-or-solution-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6828311085700989, "bge_max": 0.6828311085700989, "title": "Potassium citrate and citric acid (powder or solution): Drug information", "rep_snippet": "Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy modification  H…"}, {"doc_id": "perindopril-and-indapamide-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6819490194320679, "bge_max": 0.6819490194320679, "title": "Perindopril and indapamide (United States: Not available): Drug information", "rep_snippet": "• Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal impairment, diabetes mellitus, elderly patients, intercurrent events (in particular, dehydration), acute cardiac decompen…"}, {"doc_id": "lithium-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6816060543060303, "bge_max": 0.6816060543060303, "title": "Lithium: Drug information", "rep_snippet": "• Hypercalcemia: Hypercalcemia with or without hyperparathyroidism has been reported. Risks are greater in women and possibly in older patients; symptom onset does not appear to be related to therapy duration (Lehmann 20…"}, {"doc_id": "sacubitril-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6805718541145325, "bge_max": 0.6805718541145325, "title": "Sacubitril and valsartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, hypoaldosteronism, high potassium diet, concomitant use of aliskiren (contraindicated), potassium-sparing diuretics, potassium supplem…"}, {"doc_id": "amlodipine-and-olmesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6802945733070374, "bge_max": 0.6802945733070374, "title": "Amlodipine and olmesartan: Drug information", "rep_snippet": "Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy  Prostacyclin Analogues: May enhance the hypotensive effect of Blo…"}, {"doc_id": "amlodipine-and-valsartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6802945733070374, "bge_max": 0.6802945733070374, "title": "Amlodipine and valsartan: Drug information", "rep_snippet": "Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy  Prostacyclin Analogues: May enhance the hypotensive effect of Blo…"}, {"doc_id": "telmisartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6771012544631958, "bge_max": 0.6771012544631958, "title": "Telmisartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, wi…"}, {"doc_id": "candesartan-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.6741176247596741, "bge_max": 0.6741176247596741, "title": "Candesartan: Drug information", "rep_snippet": "• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, wi…"}]}
{"qid": "Q30", "query": "Osteoporosis — alendronate weekly dosing and administration (upright 30 min, empty stomach, water only).", "candidates": [{"doc_id": "fexofenadine-drug-information", "bm25_top3": 30.478680377001275, "bm25_max": 30.478680377001275, "bge_top3": null, "bge_max": null, "title": "Fexofenadine: Drug information", "rep_snippet": "Administration  Orally disintegrating tablet: Administer on an empty stomach. Remove tablet from individual blister and place immediately on tongue; tablet will disintegrate with or without water (do not administer with…"}, {"doc_id": "alendronate-and-cholecalciferol-drug-information", "bm25_top3": 28.42523196800084, "bm25_max": 28.42523196800084, "bge_top3": 0.797769159078598, "bge_max": 0.8335347175598145, "title": "Alendronate and cholecalciferol: Drug information", "rep_snippet": "Administration  Alendronate must be taken with plain water (6-8 oz) first thing in the morning and ≥30 minutes before the first food, beverage, or other medication of the day. Do not take with mineral water or with other…"}, {"doc_id": "doxylamine-and-pyridoxine-drug-information", "bm25_top3": 27.951050402732143, "bm25_max": 27.951050402732143, "bge_top3": null, "bge_max": null, "title": "Doxylamine and pyridoxine: Drug information", "rep_snippet": "Administration  Administer on an empty stomach with a glass of water. Swallow tablets whole, do not chew crush or split."}, {"doc_id": "fexofenadine-and-pseudoephedrine-drug-information", "bm25_top3": 25.881528277564115, "bm25_max": 26.51441555077783, "bge_top3": null, "bge_max": null, "title": "Fexofenadine and pseudoephedrine: Drug information", "rep_snippet": "Dietary Considerations  Doses should be administered on an empty stomach with water."}, {"doc_id": "loperamide-and-simethicone-drug-information", "bm25_top3": 25.877257592422758, "bm25_max": 25.877257592422758, "bge_top3": null, "bge_max": null, "title": "Loperamide and simethicone: Drug information", "rep_snippet": "Administration  Administer with plenty of clear fluids to prevent dehydration. Administer non-chewable tablets with a full glass of water and on an empty stomach (1 hour before or 2 hours after a meal)."}, {"doc_id": "alendronate-drug-information", "bm25_top3": 23.812147149540177, "bm25_max": 25.382827313149175, "bge_top3": 0.7604486346244812, "bge_max": 0.7641494274139404, "title": "Alendronate: Drug information", "rep_snippet": "Food Interactions  All food and beverages interfere with absorption. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice, coffee, and mineral water) and food may r…"}, {"doc_id": "efavirenz-emtricitabine-and-tenofovir-disoproxil-fumarate-drug-information", "bm25_top3": 24.913553815579043, "bm25_max": 24.913553815579043, "bge_top3": null, "bge_max": null, "title": "Efavirenz, emtricitabine, and tenofovir disoproxil fumarate: Drug information", "rep_snippet": "Administration  Administer on an empty stomach; dosing at bedtime may improve tolerability of CNS symptoms."}, {"doc_id": "etidronate-and-calcium-united-states-not-available-drug-information", "bm25_top3": 24.405287746908833, "bm25_max": 24.566500425389364, "bge_top3": 0.7400118708610535, "bge_max": 0.7400118708610535, "title": "Etidronate and calcium (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases the absorption and bioavailability of etidronate. Management: Administer on an empty stomach with a full glass of water 2 hours before or after food/supplements with calcium, iron, or ma…"}, {"doc_id": "magaldrate-and-simethicone-drug-information", "bm25_top3": 23.88312428343732, "bm25_max": 23.88312428343732, "bge_top3": null, "bge_max": null, "title": "Magaldrate and simethicone: Drug information", "rep_snippet": "Administration  Administer on empty stomach."}, {"doc_id": "tegaserod-united-states-available-via-fda-emergency-access-protocol-only-drug-information", "bm25_top3": 23.31599883918694, "bm25_max": 23.31599883918694, "bge_top3": null, "bge_max": null, "title": "Tegaserod (United States: Available via FDA emergency access protocol only): Drug information", "rep_snippet": "Dietary Considerations  Take on an empty stomach, 30 minutes before meals."}, {"doc_id": "moexipril-and-hydrochlorothiazide-drug-information", "bm25_top3": 22.157499552759692, "bm25_max": 22.157499552759692, "bge_top3": null, "bge_max": null, "title": "Moexipril and hydrochlorothiazide: Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach 1 hour prior to a meal."}, {"doc_id": "etidronate-drug-information", "bm25_top3": 21.42731410918607, "bm25_max": 21.42731410918607, "bge_top3": null, "bge_max": null, "title": "Etidronate: Drug information", "rep_snippet": "Administration  Administer tablet on an empty stomach with a full glass of plain water (6 to 8 oz) 2 hours before food. Patients should be instructed to stay upright (not to lie down) after taking the medication. If gast…"}, {"doc_id": "risedronate-drug-information", "bm25_top3": 20.972714866378187, "bm25_max": 20.972714866378187, "bge_top3": 0.7367362777392069, "bge_max": 0.7669497728347778, "title": "Risedronate: Drug information", "rep_snippet": "Administration  Oral: Note: Avoid administration of oral calcium supplements, antacids, magnesium supplements/laxatives, and iron preparations within 30 minutes of risedronate administration.  Immediate release tablet: R…"}, {"doc_id": "trospium-drug-information", "bm25_top3": 20.136806853415184, "bm25_max": 20.136806853415184, "bge_top3": 0.7113519310951233, "bge_max": 0.7113519310951233, "title": "Trospium: Drug information", "rep_snippet": "Administration  Immediate release: Administer with water on an empty stomach at least 1 hour prior to meals.  Extended release: Administer in the morning with water on an empty stomach at least 1 hour before a meal."}, {"doc_id": "l-lysine-drug-information", "bm25_top3": 20.123634343314666, "bm25_max": 20.123634343314666, "bge_top3": null, "bge_max": null, "title": "L-Lysine: Drug information", "rep_snippet": "Administration  Administer with water on an empty stomach."}, {"doc_id": "ferrous-fumarate-drug-information", "bm25_top3": 18.989000521246368, "bm25_max": 18.989000521246368, "bge_top3": null, "bge_max": null, "title": "Ferrous fumarate: Drug information", "rep_snippet": "Administration  Should be administered with water or juice on an empty stomach."}, {"doc_id": "carbinoxamine-drug-information", "bm25_top3": 18.690870350381502, "bm25_max": 18.690870350381502, "bge_top3": null, "bge_max": null, "title": "Carbinoxamine: Drug information", "rep_snippet": "Administration  Administer orally on an empty stomach with water. Shake suspension well before administering dose."}, {"doc_id": "methylnaltrexone-drug-information", "bm25_top3": 17.353552888853738, "bm25_max": 17.353552888853738, "bge_top3": null, "bge_max": null, "title": "Methylnaltrexone: Drug information", "rep_snippet": "Administration  SubQ: Administer by subcutaneous injection into the upper arm, abdomen, or thigh. Rotate injection sites with each dose.  Tablet: Oral: Administer with water on an empty stomach at least 30 minutes before…"}, {"doc_id": "ferrous-sulfate-drug-information", "bm25_top3": 17.190516815779958, "bm25_max": 17.190516815779958, "bge_top3": null, "bge_max": null, "title": "Ferrous sulfate: Drug information", "rep_snippet": "Administration  Oral: Do not chew or crush extended-release preparations; administer with water or juice on an empty stomach."}, {"doc_id": "entecavir-drug-information", "bm25_top3": 15.936255127847993, "bm25_max": 15.936255127847993, "bge_top3": null, "bge_max": null, "title": "Entecavir: Drug information", "rep_snippet": "Administration  Administer on an empty stomach (2 hours before or after a meal). Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe. Oral solution and tablet are bioequiv…"}, {"doc_id": "sucralfate-drug-information", "bm25_top3": 15.245440695642937, "bm25_max": 15.745690158202681, "bge_top3": 0.7246624231338501, "bge_max": 0.7246624231338501, "title": "Sucralfate: Drug information", "rep_snippet": "Dietary Considerations  Take with water on an empty stomach."}, {"doc_id": "didanosine-drug-information", "bm25_top3": 13.14218624522465, "bm25_max": 15.37875099652993, "bge_top3": null, "bge_max": null, "title": "Didanosine: Drug information", "rep_snippet": "Administration  Oral: Pediatric powder for oral solution: Administer on an empty stomach at least 30 minutes before or 2 hours after eating. Shake well prior to use.  Oral: Videx EC: Administer on an empty stomach at lea…"}, {"doc_id": "ivermectin-systemic-drug-information", "bm25_top3": 15.075213673435549, "bm25_max": 15.075213673435549, "bge_top3": null, "bge_max": null, "title": "Ivermectin (systemic): Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach with water.  Pediculosis pubis and scabies treatment: To increase bioavailability in the epidermis, ivermectin is recommended to be taken with food (CDC [Workowski 201…"}, {"doc_id": "nimodipine-drug-information", "bm25_top3": 14.817168569823853, "bm25_max": 14.817168569823853, "bge_top3": null, "bge_max": null, "title": "Nimodipine: Drug information", "rep_snippet": "Administration  For enteral administration ONLY. Life-threatening adverse events have occurred when administered parenterally. Administer on an empty stomach at least 1 hour before or 2 hours after meals.  Oral:  US labe…"}, {"doc_id": "thyroid-extract-desiccated-thyroid-drug-information", "bm25_top3": 14.674130996471057, "bm25_max": 14.674130996471057, "bge_top3": null, "bge_max": null, "title": "Thyroid extract (desiccated thyroid): Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach (eg, 30 to 60 minutes prior to breakfast) to increase absorption."}, {"doc_id": "nilotinib-drug-information", "bm25_top3": 14.345348434420863, "bm25_max": 14.345348434420863, "bge_top3": null, "bge_max": null, "title": "Nilotinib: Drug information", "rep_snippet": "Administration  Oral: Administer twice daily with doses ~12 hours apart. Administer on an empty stomach, at least 1 hour before or 2 hours after food. Capsules should be swallowed whole with water. If unable to swallow w…"}, {"doc_id": "ferrous-gluconate-drug-information", "bm25_top3": 14.07301850070726, "bm25_max": 14.07301850070726, "bge_top3": null, "bge_max": null, "title": "Ferrous gluconate: Drug information", "rep_snippet": "Administration  Oral: Should be administered with water or juice on an empty stomach (Liu 2012). Administration of iron preparations to premature infants with vitamin E deficiency may cause increased red cell hemolysis a…"}, {"doc_id": "dicloxacillin-drug-information", "bm25_top3": 13.739129846046819, "bm25_max": 13.739129846046819, "bge_top3": null, "bge_max": null, "title": "Dicloxacillin: Drug information", "rep_snippet": "Food Interactions  Food decreases drug absorption rate and serum concentration. Management: Administer around-the-clock on an empty stomach with a large glass of water 1 hour before or 2 hours after meals."}, {"doc_id": "eltrombopag-drug-information", "bm25_top3": 13.731294237182063, "bm25_max": 13.731294237182063, "bge_top3": null, "bge_max": null, "title": "Eltrombopag: Drug information", "rep_snippet": "Administration  Administer on an empty stomach, 1 hour before or 2 hours after a meal. Swallow tablets whole; do not crush and mix with food or liquids. Prepare the suspension with cool or cold water only (do not use hot…"}, {"doc_id": "cloxacillin-united-states-not-available-drug-information", "bm25_top3": 13.703698782821288, "bm25_max": 13.703698782821288, "bge_top3": null, "bge_max": null, "title": "Cloxacillin (United States: Not available): Drug information", "rep_snippet": "Food Interactions  Food decreases cloxacillin absorption; serum levels are reduced by ~50%. Management: Administer with water on an empty stomach 1 hour before or 2 hours after meals."}, {"doc_id": "doxycycline-drug-information", "bm25_top3": 13.205227145850916, "bm25_max": 13.205227145850916, "bge_top3": null, "bge_max": null, "title": "Doxycycline: Drug information", "rep_snippet": "Administration  Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.  Oral: In general, administer with meals to decrease GI upset; however, some man…"}, {"doc_id": "sodium-phosphate-drug-information", "bm25_top3": 12.77102447495156, "bm25_max": 12.77102447495156, "bge_top3": null, "bge_max": null, "title": "Sodium phosphate: Drug information", "rep_snippet": "Dietary Considerations  Bowel cleansing: Should be taken on an empty stomach with clear liquids; a clear liquid diet should be used for 12 hours prior to and during tablet administration. Clear liquids may include water,…"}, {"doc_id": "estramustine-drug-information", "bm25_top3": 12.716651531486598, "bm25_max": 12.716651531486598, "bge_top3": null, "bge_max": null, "title": "Estramustine: Drug information", "rep_snippet": "Administration  Estramustine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.  Administer on an empty stomach, at least 1 hour before or 2 hours after eating. Ad…"}, {"doc_id": "linaclotide-drug-information", "bm25_top3": 12.631923849297912, "bm25_max": 12.631923849297912, "bge_top3": null, "bge_max": null, "title": "Linaclotide: Drug information", "rep_snippet": "Dietary Considerations  Administer at least 30 minutes before the first meal of the day on an empty stomach. Loose stools and greater stool frequency may occur after administration with a high-fat breakfast."}, {"doc_id": "abiraterone-drug-information", "bm25_top3": 12.574455600118949, "bm25_max": 12.574455600118949, "bge_top3": null, "bge_max": null, "title": "Abiraterone: Drug information", "rep_snippet": "Administration  Oral: Administer abiraterone orally on an empty stomach, at least 1 hour before and 2 hours after food. No food should be consumed for at least 2 hours before or for at least 1 hour after the abiraterone…"}, {"doc_id": "albendazole-drug-information", "bm25_top3": 12.014677630101783, "bm25_max": 12.014677630101783, "bge_top3": null, "bge_max": null, "title": "Albendazole: Drug information", "rep_snippet": "Administration  Administer with a high-fat meal if treating a systemic infection (to increase absorption). Administration on an empty stomach may be appropriate for treating an intraluminal infection with no systemic inv…"}, {"doc_id": "zinc-acetate-drug-information", "bm25_top3": 11.672236473986342, "bm25_max": 11.672236473986342, "bge_top3": null, "bge_max": null, "title": "Zinc acetate: Drug information", "rep_snippet": "Administration  Oral: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals, and at least 1 hour separated from beverages other than water. Gastric irritation is most commonly associated with mor…"}, {"doc_id": "liotrix-drug-information", "bm25_top3": 11.488619830708096, "bm25_max": 11.488619830708096, "bge_top3": null, "bge_max": null, "title": "Liotrix: Drug information", "rep_snippet": "Dietary Considerations  Take once a day on an empty stomach 30-60 minutes before meals."}, {"doc_id": "norfloxacin-united-states-not-available-drug-information", "bm25_top3": 11.0880320847888, "bm25_max": 11.274642788153045, "bge_top3": null, "bge_max": null, "title": "Norfloxacin (United States: not available): Drug information", "rep_snippet": "Administration  Oral: Hold antacids, sucralfate, or multivitamins/supplements containing iron, zinc, magnesium, or aluminum for at least 2 hours before or after giving norfloxacin; do not administer together. Administer…"}, {"doc_id": "metronidazole-systemic-drug-information", "bm25_top3": 11.264296420134087, "bm25_max": 11.264296420134087, "bge_top3": null, "bge_max": null, "title": "Metronidazole (systemic): Drug information", "rep_snippet": "Administration  IV: Infuse intravenously over 30 to 60 minutes. Avoid contact of drug solution with equipment containing aluminum.  Oral: Immediate-release tablets and capsules may be administered with food to minimize s…"}, {"doc_id": "moexipril-drug-information", "bm25_top3": 11.157499552759692, "bm25_max": 11.157499552759692, "bge_top3": null, "bge_max": null, "title": "Moexipril: Drug information", "rep_snippet": "Administration  Oral: Administer on an empty stomach 1 hour prior to a meal."}, {"doc_id": "deferasirox-drug-information", "bm25_top3": 10.955770389500222, "bm25_max": 11.098294986633135, "bge_top3": null, "bge_max": null, "title": "Deferasirox: Drug information", "rep_snippet": "Dietary Considerations  Tablets for oral suspension: Bioavailability increased variably when taken with food; take on empty stomach 30 minutes before a meal.  Granules and Tablets: Bioavailability decreased slightly (not…"}, {"doc_id": "sorafenib-drug-information", "bm25_top3": 10.95917284268993, "bm25_max": 10.95917284268993, "bge_top3": null, "bge_max": null, "title": "Sorafenib: Drug information", "rep_snippet": "Administration  Administer on an empty stomach (1 hour before or 2 hours after eating)."}, {"doc_id": "equine-conjugated-estrogens-and-medroxyprogesterone-acetate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7786000370979309, "bge_max": 0.7786000370979309, "title": "Equine conjugated estrogens and medroxyprogesterone acetate: Drug information", "rep_snippet": "Dietary Considerations  Administration with food decreases nausea, administer with food. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis."}, {"doc_id": "ibandronate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7414524753888448, "bge_max": 0.7651110887527466, "title": "Ibandronate: Drug information", "rep_snippet": "Administration  Oral: Administer 60 minutes before the first food or drink of the day (other than water) and prior to taking any oral medications or supplements (eg, calcium, antacids, vitamins). Ibandronate should be ta…"}, {"doc_id": "abaloparatide-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7590318918228149, "bge_max": 0.7590318918228149, "title": "Abaloparatide: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: SubQ: 80 mcg once daily"}, {"doc_id": "teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7332030534744263, "bge_max": 0.7540692090988159, "title": "Teriparatide (recombinant human parathyroid hormone [1-34]): Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis (men, postmenopausal women, glucocorticoid induced): SubQ: 20 mcg once daily; Note: Initial administration should occur under circumstances in which the patient may sit or lie down, in the eve…"}, {"doc_id": "bazedoxifene-and-conjugated-equine-estrogens-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.753103494644165, "bge_max": 0.753103494644165, "title": "Bazedoxifene and conjugated equine estrogens: Drug information", "rep_snippet": "Dosing: Adult  Menopause (moderate-to-severe vasomotor symptoms), prevention of postmenopausal osteoporosis: Females: Oral: One tablet daily"}, {"doc_id": "flavocoxid-united-states-note-fda-has-issued-a-warning-against-use-of-this-product-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7474068403244019, "bge_max": 0.7474068403244019, "title": "Flavocoxid (United States – Note: FDA has issued a warning against use of this product): Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis: Oral: 250 to 500 mg (with or without zinc) every 12 hours"}, {"doc_id": "raloxifene-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7398744225502014, "bge_max": 0.7464762926101685, "title": "Raloxifene: Drug information", "rep_snippet": "Dosing: Adult  Osteoporosis: Females: Oral: 60 mg once daily  Risk reduction for invasive breast cancer: Females (postmenopausal): Oral: 60 mg once daily.  Duration of therapy for breast cancer risk reduction: 5 years; m…"}, {"doc_id": "esomeprazole-and-naproxen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7453629970550537, "bge_max": 0.7453629970550537, "title": "Esomeprazole and naproxen: Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: Oral: One tablet (naproxen 375 mg/esomeprazole 20 mg or naproxen 500 mg/esomeprazole 20 mg) twice daily  Note: If a total daily dose of esomepr…"}, {"doc_id": "ibuprofen-and-famotidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.736682116985321, "bge_max": 0.736682116985321, "title": "Ibuprofen and famotidine: Drug information", "rep_snippet": "Dosing: Adult  Osteoarthritis, rheumatoid arthritis: Oral: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) 3 times daily."}, {"doc_id": "estradiol-and-levonorgestrel-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7346360683441162, "bge_max": 0.7346360683441162, "title": "Estradiol and levonorgestrel: Drug information", "rep_snippet": "Dosing: Adult  Note: Patients should be treated with the lowest effective dose and for the shortest duration, consistent with treatment goals.  Treatment of moderate to severe vasomotor symptoms associated with menopause…"}, {"doc_id": "tolmetin-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7316677570343018, "bge_max": 0.7316677570343018, "title": "Tolmetin: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Osteoarthritis/RA: Oral: Initial: 400 mg 3 times daily; adjust dose according to patient response after 1 to 2 weeks; Maintenance: 6…"}, {"doc_id": "ethinyl-estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7253022789955139, "bge_max": 0.7253022789955139, "title": "Ethinyl estradiol and norethindrone: Drug information", "rep_snippet": "Postmenopausal indications: General dosing guidelines: When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals. Reevaluate patient…"}, {"doc_id": "metaxalone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7238374948501587, "bge_max": 0.7238374948501587, "title": "Metaxalone: Drug information", "rep_snippet": "Dosing: Adult  Musculoskeletal conditions: Oral: 800 mg 3 to 4 times daily"}, {"doc_id": "dimethyl-fumarate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7223544120788574, "bge_max": 0.7223544120788574, "title": "Dimethyl fumarate: Drug information", "rep_snippet": "Dosing: Adult  Multiple sclerosis (relapsing): Oral: Initial: 120 mg twice daily; after 7 days, increase to the maintenance dose: 240 mg twice daily"}, {"doc_id": "magnesium-carbonate-calcium-carbonate-and-folic-acid-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7201119065284729, "bge_max": 0.7201119065284729, "title": "Magnesium carbonate, calcium carbonate, and folic acid: Drug information", "rep_snippet": "Dosing: Adult  Prevention or treatment of nutritional deficiencies: Oral: 1-3 tablets 3 times/day with meals"}, {"doc_id": "conjugated-equine-estrogens-systemic-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7200232744216919, "bge_max": 0.7200232744216919, "title": "Conjugated equine estrogens (systemic): Drug information", "rep_snippet": "Hypoestrogenism (female) due to hypogonadism: Oral: 0.3 or 0.625 mg/day given cyclically*; dose may be titrated in 6- to 12-month intervals; progestin treatment should be added to maintain bone mineral density once skele…"}, {"doc_id": "difenoxin-and-atropine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7198706269264221, "bge_max": 0.7198706269264221, "title": "Difenoxin and atropine: Drug information", "rep_snippet": "Dosing: Adult  Diarrhea: Oral: Initial: 2 tablets, then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, up to 8 tablets in a 24-hour period; if no improvement after 48 hours, continued administr…"}, {"doc_id": "riluzole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7184550762176514, "bge_max": 0.7184550762176514, "title": "Riluzole: Drug information", "rep_snippet": "Dosing: Adult  Amyotrophic lateral sclerosis (ALS): Oral: 50 mg twice daily."}, {"doc_id": "omeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7181176543235779, "bge_max": 0.7181176543235779, "title": "Omeprazole: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral: 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks. Up to 40 mg once daily has been used in patients with ulcers refractive to other therapies (eg, H2 antag…"}, {"doc_id": "nizatidine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7161850333213806, "bge_max": 0.7161850333213806, "title": "Nizatidine: Drug information", "rep_snippet": "Dosing: Adult  Duodenal ulcer: Oral:  Treatment: 300 mg once daily at bedtime or 150 mg twice daily for up to 8 weeks  Maintenance of healing: 150 mg once daily at bedtime  Gastric ulcer, benign: Oral: 150 mg twice daily…"}, {"doc_id": "dexlansoprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7155443429946899, "bge_max": 0.7155443429946899, "title": "Dexlansoprazole: Drug information", "rep_snippet": "Dosing: Adult  Note: Doses >30 mg do not provide additional benefit during maintenance phase.  Erosive esophagitis: Oral:  Healing: 60 mg once daily for up to 8 weeks  Maintenance: 30 mg once daily  Gastroesophageal refl…"}, {"doc_id": "norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7145808339118958, "bge_max": 0.7145808339118958, "title": "Norethindrone: Drug information", "rep_snippet": "Endometriosis: Females: Oral: Norethindrone acetate: 5 mg/day for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporar…"}, {"doc_id": "vitamin-d2-ergocalciferol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7133370041847229, "bge_max": 0.7133370041847229, "title": "Vitamin D2 (ergocalciferol): Drug information", "rep_snippet": "Dosing: Adult  Note: 1 mcg = 40 units  Osteoporosis prevention (off-label use): Adults ≥50 years: 800 to 1000 units/day (NOF guidelines, 2014)  Vitamin D deficiency treatment (off-label dose): (Holick, 2011): Oral: 6000…"}, {"doc_id": "estradiol-and-norgestimate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7113139629364014, "bge_max": 0.7113139629364014, "title": "Estradiol and norgestimate: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: For use in women with a uterus. When treating postmenopausal women, use estrogens for the shortest duration possible at the lowest effective dose consistent with treatment goals.…"}, {"doc_id": "fluconazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7111883759498596, "bge_max": 0.7111883759498596, "title": "Fluconazole: Drug information", "rep_snippet": "Alternate recommendations: 100 to 200 mg daily for 7 to 14 days for moderate-to-severe disease; in patients with recurrent infection, chronic therapy of 100 mg 3 times weekly is recommended, if required (IDSA [Pappas 201…"}, {"doc_id": "denosumab-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7107498049736023, "bge_max": 0.7107498049736023, "title": "Denosumab: Drug information", "rep_snippet": "Treatment of osteoporosis in men or in postmenopausal women: SubQ: 60 mg as a single dose, once every 6 months  Bone destruction caused by rheumatoid arthritis (off-label use): SubQ: 60 mg or 180 mg as a single one time…"}, {"doc_id": "fenoprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7106404900550842, "bge_max": 0.7106404900550842, "title": "Fenoprofen: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Osteoarthritis, rheumatoid arthritis: Oral: 400 to 600 mg 3 to 4 times daily; adjust dose based on patient response; maximum dose: 3…"}, {"doc_id": "estropipate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7105569839477539, "bge_max": 0.7105569839477539, "title": "Estropipate: Drug information", "rep_snippet": "Hypoestrogenism (female) due to hypogonadism: Oral: 1.5 to 9 mg daily for the first 3 weeks of a theoretical cycle, followed by a rest period of 8 to 10 days. Repeat if bleeding does not occur by the end of the rest peri…"}, {"doc_id": "esomeprazole-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7101202607154846, "bge_max": 0.7101202607154846, "title": "Esomeprazole: Drug information", "rep_snippet": "Dosing: Adult  Note: All dosing is expressed in terms of esomeprazole base, regardless of the salt associated with the dosing information. Esomeprazole strontium 24.65 mg is equivalent to 20 mg of esomeprazole base; esom…"}, {"doc_id": "hydrocodone-and-ibuprofen-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.709254264831543, "bge_max": 0.709254264831543, "title": "Hydrocodone and ibuprofen: Drug information", "rep_snippet": "Dosing: Adult  Pain management: Oral: One tablet (hydrocodone 2.5 mg to 10 mg/ibuprofen 200 mg) every 4 to 6 hours as needed; (maximum: 5 tablets [hydrocodone 12.5 to 50 mg/ibuprofen 1,000 mg] per 24 hours). Note: Short-…"}, {"doc_id": "methenamine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.709224283695221, "bge_max": 0.709224283695221, "title": "Methenamine: Drug information", "rep_snippet": "Administration  Restrict alkalinizing foods and medications to maintain urine pH ≤5.5.  Hippurate: Administer twice daily (morning and night).  Mandelate: Administer 4 times daily (after each meal and at bedtime)."}, {"doc_id": "estradiol-and-norethindrone-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7091854810714722, "bge_max": 0.7091854810714722, "title": "Estradiol and norethindrone: Drug information", "rep_snippet": "Dosing: Adult  General dosing guidelines: Females: These combination products are indicated for women with a uterus. When treating postmenopausal women, use for the shortest duration possible at the lowest effective dose…"}, {"doc_id": "ursodeoxycholic-acid-ursodiol-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7087310552597046, "bge_max": 0.7087310552597046, "title": "Ursodeoxycholic acid (ursodiol): Drug information", "rep_snippet": "Dosing: Adult  Gallstone dissolution (Actigall): Oral: 8-10 mg/kg/day in 2-3 divided doses; use beyond 24 months is not established  Gallstone prevention (Actigall): Oral: 300 mg twice daily  Primary biliary cirrhosis (U…"}, {"doc_id": "meclofenamate-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7071165442466736, "bge_max": 0.7071165442466736, "title": "Meclofenamate: Drug information", "rep_snippet": "Dosing: Adult  Note: Use the lowest effective dose for the shortest possible duration.  Osteoarthritis and rheumatoid arthritis: Oral: 200 to 400 mg daily in 3 to 4 equally divided doses; initiate at lower dosage then in…"}, {"doc_id": "glycerin-and-lidocaine-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7069766521453857, "bge_max": 0.7069766521453857, "title": "Glycerin and lidocaine: Drug information", "rep_snippet": "Dosing: Adult  Anorectal disorders: Topical: Apply to the affected area ≤6 times daily (morning, evening, and after each bowel movement)."}, {"doc_id": "zucapsaicin-united-states-not-available-drug-information", "bm25_top3": null, "bm25_max": null, "bge_top3": 0.7063847184181213, "bge_max": 0.7063847184181213, "title": "Zucapsaicin (United States: Not available): Drug information", "rep_snippet": "Dosing: Adult  Pain relief in osteoarthritis of knee: Topical: Apply a pea-sized amount to 3 locations around affected knee 3 times daily; allow at least 4 hours between applications (maximum: 3 applications/day). Therap…"}]}
